[
  {
    "title": "Futures: Rally Looks Strong As 2024 Kicks Off; What To Do",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-2024-tesla-deliveries-due/",
    "time_published": "20240101T193700",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Market Rally Strong Heading Into 2024: Tesla Deliveries Due Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-technologytrends2024-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.106809,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.163117",
        "ticker_sentiment_score": "0.024947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "-0.031392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.016434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.139106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.253706",
        "ticker_sentiment_score": "0.034788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.076734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.028402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.163117",
        "ticker_sentiment_score": "0.064293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "-0.025177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "-0.015711",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Could Start Off 2024 With a Bang",
    "url": "https://www.fool.com/investing/2024/01/01/why-eli-lilly-could-start-off-2024-with-a-bang/",
    "time_published": "20240101T121500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Investors shouldn't assume Eli Lilly's stock has peaked.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.270091,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.480056",
        "ticker_sentiment_score": "0.320178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Techs Skid To Start 2024; Two Weight-Loss Stocks Flash Buy Signals",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-techs-slump-to-start-2024-celsius-eli-lilly-flash-buy-signals/",
    "time_published": "20240102T214700",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Techs Slump To Start 2024. Celsius, Eli Lilly Flash Buy Signals Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/Skifall-EG-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.0584,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "-0.003766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "0.159344",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.153666",
        "ticker_sentiment_score": "-0.137704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "-0.114986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.330152",
        "ticker_sentiment_score": "-0.057055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.129941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New Year Resolution Stocks: Can Getting Fitter Be A Winner On The Stock Market? - Anheuser-Busch InBev  ( NYSE:BUD ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/entertainment/24/01/36456513/new-year-resolution-stocks-can-getting-fitter-be-a-winner-on-the-stock-market",
    "time_published": "20240102T175811",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "As another holiday season fades into memory, and we return to our desks - perhaps a little flabbier and a little hungover - will investors think about carrying over their New Year resolutions into their stock portfolios?",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Strong-Woman-Exercising-With-Battle-Rope.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.143826,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BUD",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.063366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.022267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.022267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLNT",
        "relevance_score": "0.420316",
        "ticker_sentiment_score": "0.072538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why This IBD Stock Of The Day Just Struck A Bullish Pose",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-strikes-a-bullish-pose-after-closing-a-recent-takeover/",
    "time_published": "20240102T170800",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Strikes A Bullish Pose After Closing A Recent Takeover Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-2-2024LLY.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.107357,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.677874",
        "ticker_sentiment_score": "0.0787",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Up 57% in 2023: Will the Uptrend Continue?",
    "url": "https://www.zacks.com/stock/news/2204399/eli-lilly-lly-stock-up-57-in-2023-will-the-uptrend-continue",
    "time_published": "20240102T134300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.243868,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.598368",
        "ticker_sentiment_score": "0.380988",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RIGL",
        "relevance_score": "0.203643",
        "ticker_sentiment_score": "0.133485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.044317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AQST",
        "relevance_score": "0.203643",
        "ticker_sentiment_score": "0.070763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.033004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Losses Widen; Why Tesla's Slide May Be Bullish",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-losses-broaden-bitcoin-skids-why-teslas-slide-may-be-bullish/",
    "time_published": "20240103T221600",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Market Losses Widen. Why Tesla's Slide May Be Bullish Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-elonmusk-grumpy-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.036382,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "-0.138269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "-0.110765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "-0.01356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "-0.110765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.317527",
        "ticker_sentiment_score": "-0.061006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.105474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.138464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.152493",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "-0.038652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.249653",
        "ticker_sentiment_score": "-0.140816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ate too much during the holidays? Now be on guard for the weight-loss scams",
    "url": "https://www.marketwatch.com/story/ate-too-much-during-the-holidays-now-be-on-guard-for-the-weight-loss-scams-e0799b8b",
    "time_published": "20240103T184200",
    "authors": [
      "Lukas I. Alpert"
    ],
    "summary": "Weight-loss drugs like Ozempic and Wegovy have been all the rage lately, but with the holiday season wrapping up, so are weight-loss scams. Experts say now is the time when ads promoting \"miracle\" weight-loss cures start popping up in droves, looking to take advantage of people who have made New ...",
    "banner_image": "https://images.mktw.net/im-815160/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.152881,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.142144",
        "ticker_sentiment_score": "0.013073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.142144",
        "ticker_sentiment_score": "0.013073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Research Reports for Amazon.com, Berkshire Hathaway & Eli Lilly",
    "url": "https://www.zacks.com/research-daily/2204956/top-research-reports-for-amazoncom-berkshire-hathaway-eli-lilly",
    "time_published": "20240103T173700",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Berkshire Hathaway Inc. (BRK.B) and Eli Lilly and Company (LLY).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.269929,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.372257",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.352939",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.107515",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Is Jumping Today While the Overall Market Is Slumping",
    "url": "https://www.fool.com/investing/2024/01/03/why-eli-lilly-stock-is-jumping-today-while-the-ove/",
    "time_published": "20240103T172011",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Here's how the big pharma stock is swimming against the current.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760035/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.165653,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.822443",
        "ticker_sentiment_score": "0.223974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.108366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold",
    "url": "https://www.fool.com/investing/2024/01/03/missed-out-eli-lilly-best-pharmaceutical-stock/",
    "time_published": "20240103T160850",
    "authors": [
      "Justin Pope"
    ],
    "summary": "The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its rival instead.",
    "banner_image": "https://media.ycharts.com/charts/14da68206118d21fd87def9a5d059da6.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.225488,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.308965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.465196",
        "ticker_sentiment_score": "0.240351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sitting on gains of 1,200% - it would have been irresponsible not to take some profits",
    "url": "https://www.cnbc.com/2024/01/03/sitting-on-gains-of-1200-percent-it-would-have-been-irresponsible-not-to-take-profits.html",
    "time_published": "20240103T160847",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107353758-17042961141704296107-32728997393-1080pnbcnews.jpg?v=1704296114&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.22172,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.195968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.367412",
        "ticker_sentiment_score": "0.239968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.367412",
        "ticker_sentiment_score": "0.239968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.100694",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1000 In This Stock 20 Years Ago, You Would Have $9,000 Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/01/36472515/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-9-000-today",
    "time_published": "20240103T160027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 20 years by 4.17% on an annualized basis producing an average annual return of 11.54%. Currently, Eli Lilly has a market capitalization of $580.10 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.158543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.375984",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Weakens After Economic Data; Tesla Hits Nasdaq",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-as-fed-minutes-loom-tesla-hits-nasdaq/",
    "time_published": "20240103T155600",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "Dow Jones Falls As Fed Minutes Loom. Tesla Hits Nasdaq Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/stock-tesla-store-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.016843,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.161207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.068032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.110408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.161207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.251032",
        "ticker_sentiment_score": "0.007865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.001233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.001233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.25909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.25909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LW",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.161207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2204917/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
    "time_published": "20240103T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default108.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.254969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.523044",
        "ticker_sentiment_score": "0.181048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Sees a More Significant Dip Than Broader Market: Some Facts to Know",
    "url": "https://www.zacks.com/stock/news/2205914/eli-lilly-lly-sees-a-more-significant-dip-than-broader-market-some-facts-to-know",
    "time_published": "20240104T224517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Eli Lilly (LLY) closed at $614.50, marking a -0.52% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default181.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.223926,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.478198",
        "ticker_sentiment_score": "0.334743",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bulls, Bears Duel Ahead Of Jobs Report; 6 Stocks To Watch",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-bulls-bears-duel-ahead-of-jobs-report-spot-bitcoin-etfs/",
    "time_published": "20240104T213800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Bulls, Bears Duel Ahead Of Jobs Report. 6 Stocks To Watch Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/Bear.Bull_.NYSE_.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.069233,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.09245",
        "ticker_sentiment_score": "0.031714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.213584",
        "ticker_sentiment_score": "0.019936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.183662",
        "ticker_sentiment_score": "0.021055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.213584",
        "ticker_sentiment_score": "0.001713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "-0.011738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213584",
        "ticker_sentiment_score": "0.052874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.183662",
        "ticker_sentiment_score": "-0.099095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.123052",
        "ticker_sentiment_score": "0.042128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.272451",
        "ticker_sentiment_score": "0.140486",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Indexes Mixed After Jobs Data Surprise; Chip Glut Shock Hits EV Plays As Apple Sells Off On Second Downgrade",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-in-bumpy-new-year-rally-chip-glut-hits-ev-plays-as-apple-gets-second-downgrade/",
    "time_published": "20240104T204500",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Indexes Mixed After Jobs Data Surprise. Chip Glut Shock Hits EV Plays As Apple Sells Off On Second Downgrade Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-apple-iphone14colors-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999763"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.002415,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.100159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "-0.311501",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "-0.274083",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "-0.160875",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.039477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIOT",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.100159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "-0.223527",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.019962",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: Buy The Dip - There's A Lot More Upside To Come, Says Marc Chaikin - Boise Cascade  ( NYSE:BCC ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36497683/exclusive-buy-the-dip-theres-a-lot-more-upside-to-come-says-marc-chaikin",
    "time_published": "20240104T192933",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Stocks have experienced a shaky beginning in 2024, with initial losses followed by slight gains on Thursday. However, Marc Chaikin, founder and CEO of Chaikin Analytics, believes that this does not signify an end to the rally that began in late October.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/MarcChaikin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.103974,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.089327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCC",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.120912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.097381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.167166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why WW International Stock Just Dropped 11%",
    "url": "https://www.fool.com/investing/2024/01/04/why-ww-international-stock-just-dropped-11/",
    "time_published": "20240104T192443",
    "authors": [
      "Rich Smith"
    ],
    "summary": "WW's revenue was sliding even before Ozempic came on the scene. Now Eli Lilly has a new weight loss drug -- and an easy way to order it.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760189/gettyimages-663845678.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.053965,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.592742",
        "ticker_sentiment_score": "-0.113305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WW",
        "relevance_score": "0.492659",
        "ticker_sentiment_score": "-0.187446",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly launches home delivery of obesity drug Zepbound, warns on cosmetic use",
    "url": "https://www.marketwatch.com/story/eli-lilly-launches-digital-health-services-for-patients-with-obesity-migraine-and-diabetes-94c32500",
    "time_published": "20240104T192300",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Eli Lilly & Co. on Thursday announced the launch of new digital health services that could help smooth patient access to the obesity drug Zepbound and other medications - but also warned against the use of some of its most-popular drugs for cosmetic weight loss.",
    "banner_image": "https://images.mktw.net/im-735118/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.181354,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.630386",
        "ticker_sentiment_score": "0.218019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36495250/eli-lilly-launches-website-to-help-patients-with-home-delivery-options-for-weight-loss-medicines",
    "time_published": "20240104T172102",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Drugmaker Eli Lilly And Co LLY announced on Thursday a new website that allows patients to get a weight loss drug prescription through a telehealth provider.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/June-20--2023--Brazil--In-This-Photo-Ill.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.177967,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.81619",
        "ticker_sentiment_score": "0.535051",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.020784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Beefs Up Weight-Loss Marketing Efforts As Knockoffs Battles Continues",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-rises-lilly-launches-direct-to-consumer-website-for-weight-loss-drugs/",
    "time_published": "20240104T155500",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Eli Lilly Stock Rises: Lilly Launches Direct-To-Consumer Website For Weight-Loss Drugs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.148341,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.777664",
        "ticker_sentiment_score": "0.17987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.122046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With LLY - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36492031/check-out-what-whales-are-doing-with-lly",
    "time_published": "20240104T151640",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.07853,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.672712",
        "ticker_sentiment_score": "-0.059707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks For Your January 2024 Watchlist",
    "url": "https://stockmarket.com/featured/2-biotech-stocks-for-your-january-2024-watchlist-2024-01-04",
    "time_published": "20240104T144143",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The biotechnology sector is an innovative and dynamic area of the stock market, primarily focused on using biological systems and organisms to develop new products and technologies. Companies in this sector engage in a wide range of activities.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/12/LLY-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      }
    ],
    "overall_sentiment_score": 0.282774,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.458446",
        "ticker_sentiment_score": "0.359762",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.399204",
        "ticker_sentiment_score": "0.272594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Best Stocks to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/01/04/the-best-stocks-to-invest-1000-in-right-now/",
    "time_published": "20240104T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's not too late to get in on these market beaters.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759414/pharmacist-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.270989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.276491",
        "ticker_sentiment_score": "0.36389",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.168099",
        "ticker_sentiment_score": "0.264564",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.3796",
        "ticker_sentiment_score": "0.27009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect\u2122",
    "url": "https://www.prnewswire.com/news-releases/lilly-launches-end-to-end-digital-healthcare-experience-through-lillydirect-302025738.html",
    "time_published": "20240104T123000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced LillyDirect\u2122, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.346773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.55727",
        "ticker_sentiment_score": "0.487883",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.168999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Reverse Goldilocks - why this bank is souring on stocks, for now",
    "url": "https://www.marketwatch.com/story/reverse-goldilocks-why-this-bank-is-souring-on-stocks-for-now-a109f4ba",
    "time_published": "20240104T114700",
    "authors": [
      "Steve Goldstein"
    ],
    "summary": "This bank is raising dry powder as they see a tough period for stocks as well as riskier corporate bonds ...",
    "banner_image": "https://images.mktw.net/im-01461765?width=700&height=609",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.029505,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.086919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.113951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "-0.20928",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.039824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURV",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.039824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "-0.232413",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.093576",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2205421/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240104T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.199856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.060733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.060733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.042489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.060733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option?",
    "url": "https://www.fool.com/investing/2024/01/04/everyone-is-talking-about-eli-lilly-is-it-a-good-l/",
    "time_published": "20240104T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly shares advanced in the double digits last year.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759865%2Fgettyimages-1199696916.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.230327,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.053861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.693907",
        "ticker_sentiment_score": "0.323484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rise; Cathie Wood Buys Tesla",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-losses-broaden-cathie-wood-buys-tesla-sells-bitcoin-stock-coinbase/",
    "time_published": "20240104T025400",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Market Losses Broaden. Cathie Wood Buys Tesla, Sells Bitcoin Stock Coinbase Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.012157,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.164356",
        "ticker_sentiment_score": "-0.129879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "-0.110203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "-0.013364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "-0.110203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.410402",
        "ticker_sentiment_score": "0.04251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "-0.10417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.131823",
        "ticker_sentiment_score": "0.131849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "-0.150818",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.260073",
        "ticker_sentiment_score": "0.040517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.228533",
        "ticker_sentiment_score": "-0.122188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JPMorgan Healthcare, CES Show, Bank Earnings, Inflation Data",
    "url": "https://www.investors.com/research/investing-action-plan/jpmorgan-healthcare-ces-show-bank-earnings-inflation-data-investing-action-plan/",
    "time_published": "20240105T222900",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "The big benchmarks launched the New Year by posting their first weekly slip since October. The Dow trimmed less than 1% while the Nasdaq lopped off 3%. Chips faltered, but solar stocks and auto retailers were the hardest hit industries. Big Pharma names had a good week, as Merck ( MRK ) led the ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-marketgrowth-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.173993,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CELH",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDFC",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.013892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.021094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WIT",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.064744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.1163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.021094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.018562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.133922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.018562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.107238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AYI",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.091327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.024866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.109444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.133922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.064744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.084607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market At Key Levels, Here's What To Do; Nvidia Nears Breakout",
    "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-at-key-levels-bitcoin-etf-nvidia-near-buy-point-on-100-billion-forecast/",
    "time_published": "20240105T221800",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Market At Key Levels, Here's What To Do. Nvidia Nears Breakout Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-nvidia-ceojensenhuang-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.05755,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "-0.040301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.196725",
        "ticker_sentiment_score": "-0.004762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.278063",
        "ticker_sentiment_score": "-0.031214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "0.064925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.039211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.141227",
        "ticker_sentiment_score": "0.049142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.094929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "0.053951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.066588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.007278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "0.084005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "0.064925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "0.026688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/",
    "time_published": "20240105T180100",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.130124,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.404098",
        "ticker_sentiment_score": "0.232614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.141762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.106572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.060388",
        "ticker_sentiment_score": "0.337437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Omega  ( OMGA )  Up 95% on Obesity Drug Deal With Novo Nordisk",
    "url": "https://www.zacks.com/stock/news/2206517/omega-omga-up-95-on-obesity-drug-deal-with-novo-nordisk",
    "time_published": "20240105T175500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.249163,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.181114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.135412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.156185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.356733",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Weight-Loss Drug Boom: Philanthropy Powerhouse Emerges As Lilly Endowment Comes Closer To Gates Foundation - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36514235/weight-loss-drug-boom-philanthropy-powerhouse-emerges-as-lilly-endowment-comes-closer-to-gates-fo",
    "time_published": "20240105T175137",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Lilly Endowment, the principal stakeholder in pharmaceutical giant Eli Lilly & Co. LLY, has witnessed an exceptional surge in its assets, reaching an estimated $60 billion amid the soaring success of the company's weight-loss drug, Mounjaro, which bolstered Eli Lilly's stocks by almost 60% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-and-other-drugs-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.210521,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.868543",
        "ticker_sentiment_score": "0.34658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Skids To Start 2024: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-skids-to-start-2024-as-tesla-apple-stumble-mobileye-crashes-weekly-review/",
    "time_published": "20240105T172600",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-BullBearMarket-88-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.004903,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MARA",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "0.031073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.043033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.182736",
        "ticker_sentiment_score": "-0.254609",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.10812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.097219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "-0.020511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.10812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAG",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.048948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03072",
        "ticker_sentiment_score": "0.092757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LW",
        "relevance_score": "0.091977",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.10812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.10812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "0.031073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMPL",
        "relevance_score": "0.091977",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.03072",
        "ticker_sentiment_score": "-0.282869",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.212514",
        "ticker_sentiment_score": "0.010321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.043033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.182736",
        "ticker_sentiment_score": "-0.026343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPE",
        "relevance_score": "0.091977",
        "ticker_sentiment_score": "-0.085615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "-0.019092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.036136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "0.031073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dry January Investing: Trading Pints For Portfolio Growth - Merck & Co  ( NYSE:MRK ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36513620/dry-january-investing-trading-pints-for-portfolio-growth",
    "time_published": "20240105T172022",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Around 15% of Americans said they were planning to participate this year in Dry January - a month of abstinence from alcohol - according to a survey by Morning Consult. Most cite the health benefits from taking a break from the bottle, but it has its financial benefits too.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/wall-street-beer-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.214335,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.294132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.072032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAP",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.072032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.339557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.115142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVS or LLY: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2206412/nvs-or-lly-which-is-the-better-value-stock-right-now",
    "time_published": "20240105T164006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.504108,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.51906",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Starts Website to Help Access Tirzepatide Drugs",
    "url": "https://www.zacks.com/stock/news/2206369/lilly-lly-starts-website-to-help-access-tirzepatide-drugs",
    "time_published": "20240105T153600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.203265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.510838",
        "ticker_sentiment_score": "0.022707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LFMD",
        "relevance_score": "0.204647",
        "ticker_sentiment_score": "0.052019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.270523",
        "ticker_sentiment_score": "0.064996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.207108",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.137278",
        "ticker_sentiment_score": "0.300003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  Up on $1.1B Research Deals With 2 Biotechs",
    "url": "https://www.zacks.com/stock/news/2206370/novo-nordisk-nvo-up-on-11b-research-deals-with-2-biotechs",
    "time_published": "20240105T153500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.228746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.164749",
        "ticker_sentiment_score": "0.15357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.244928",
        "ticker_sentiment_score": "0.091398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.322549",
        "ticker_sentiment_score": "0.162148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.467318",
        "ticker_sentiment_score": "0.323723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals",
    "url": "https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-llys-new-digital-pharmacy-nvo-abbvs-fresh-rd-deals",
    "time_published": "20240105T152500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.143344,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.076649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.240803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.154026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.125188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "-0.119302",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge - Apple  ( NASDAQ:AAPL ) , Coinbase Glb  ( NASDAQ:COIN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36510120/short-sellers-nightmare-195b-evaporates-in-2023s-market-surge",
    "time_published": "20240105T142522",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "In a year when equity markets rallied strongly, short sellers - traders who position for losses on assets - had an extremely tough time in 2023. Data published on Friday by S3 Partners showed that short sellers in the U.S. and Canada were down $194.9 billion in 2023 - down 20.4% on an average ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/bear-chart-shutter3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.019588,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.042676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.435133",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.042676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.289687",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FRC",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "-0.272366",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.042676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/",
    "time_published": "20240105T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.069333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.037838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.084592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.150269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.153696",
        "ticker_sentiment_score": "0.053027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.006781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.079056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.008781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.001871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.017905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEAM",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.057997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLNN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.020246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.08972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.011896",
        "ticker_sentiment_score": "-0.115274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.042606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.064761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.059429",
        "ticker_sentiment_score": "0.106048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "7 Stocks Are Taking Off Already - And The Year Just Started",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-stocks-are-taking-off-already-and-the-year-just-started/",
    "time_published": "20240105T130000",
    "authors": [
      "MATT KRANTZ",
      "Investor's Business Daily"
    ],
    "summary": "The calendar just flipped to 2024 - and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated in 2023.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-cranesmoney-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.227189,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "0.332128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.521465",
        "ticker_sentiment_score": "0.232629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.162601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "QS, PTON, LLY, WBA, TSLA: Top 5 Trending Stocks Today - Peloton Interactive  ( NASDAQ:PTON ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36503974/quantumscape-peloton-eli-lilly-walgreens-tesla-why-these-5-stocks-are-on-investors-radars-today",
    "time_published": "20240105T015754",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34. The S&P 500 and Nasdaq fell 0.34% and 0.56% to 4,688.68 and 14,510.30 respectively. These are the top stocks that gained the attention of retail traders and investors throughout the day:",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Stocks-Photo-by-Phongphan-on-Shutterstoc_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.2372,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "-0.106164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QS",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.301866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.35905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PTON",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.271955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.089775",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Rally At Key Level; Nvidia Leads 6 Stocks To Watch",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-at-key-levels-nvidia-leads-6-stocks-near-buy-points/",
    "time_published": "20240106T224600",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Market Rally At Key Levels. Nvidia Leads 6 Stocks Near Buy Points Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-nvidia-ceojensenhuang-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.055121,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.02665",
        "ticker_sentiment_score": "-0.050722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.079832",
        "ticker_sentiment_score": "-0.040916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.286741",
        "ticker_sentiment_score": "0.002141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.066721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.02665",
        "ticker_sentiment_score": "0.038808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "-0.094682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.158868",
        "ticker_sentiment_score": "0.051729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.079832",
        "ticker_sentiment_score": "0.068036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.079832",
        "ticker_sentiment_score": "0.007196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.066721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.184901",
        "ticker_sentiment_score": "-0.004546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.13266",
        "ticker_sentiment_score": "0.047474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.158868",
        "ticker_sentiment_score": "0.080575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.106305",
        "ticker_sentiment_score": "-0.060459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.158868",
        "ticker_sentiment_score": "0.025606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia And Spotify Lead Five Stocks Near Buy Points",
    "url": "https://www.investors.com/news/nvidia-spotify-lead-five-stocks-near-buy-points/",
    "time_published": "20240106T161200",
    "authors": [
      "JED GRAHAM",
      "Investor's Business Daily"
    ],
    "summary": "Nvidia ( NVDA ) , one of the Magnificent Seven stocks, and digital audio streaming leader Spotify ( SPOT ) head this weekend's watchlist of stocks near buy points.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-nvidia-hq-04-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.141748,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.173176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.32231",
        "ticker_sentiment_score": "0.198665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.294446",
        "ticker_sentiment_score": "0.241706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.173176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.03014",
        "ticker_sentiment_score": "0.070517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.03014",
        "ticker_sentiment_score": "0.068427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.34974",
        "ticker_sentiment_score": "0.242228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.090247",
        "ticker_sentiment_score": "-0.130828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.237551",
        "ticker_sentiment_score": "0.119502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.041072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.073016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.004022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Healthcare Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/01/06/2-top-healthcare-stocks-to-buy-right-now/",
    "time_published": "20240106T151500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's always a good time to invest in these excellent stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759940/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.236189,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.322374",
        "ticker_sentiment_score": "0.211863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MFCSF",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.087754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.243008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.51159",
        "ticker_sentiment_score": "0.344214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alphabet Unit In Drug Discovery Deals With Eli Lilly, Novartis",
    "url": "https://www.investors.com/news/technology/alphabet-isomorphic-labs-in-drug-discovery-deals-with-eli-lilly-novartis/",
    "time_published": "20240107T202600",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Isomorphic Labs, a unit of Google-parent Alphabet ( GOOGL ) , on Sunday announced strategic research collaborations with Eli Lilly ( LLY ) and Novartis ( NVS ) . The Lilly and Novartis collaborations will focus on small-molecule treatments and multiple targets.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/01/Stock-AIbiotech-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.103625,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.696319",
        "ticker_sentiment_score": "0.241613",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.125025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.185545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How To Buy Hot And Promising - But Uncertain - Biotech Stocks",
    "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/",
    "time_published": "20240108T173400",
    "authors": [
      "Investor's Business Daily",
      "MATTHEW GALGANI"
    ],
    "summary": "A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-petridishmolecule-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.070153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.200529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.200529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.400052",
        "ticker_sentiment_score": "0.433085",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.070153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.430266",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AAPL: Are AAPL, MSFT, and GOOGL Solid 2024 Buys?",
    "url": "https://stocknews.com/news/aapl-msft-googl-lly-nvs-are-aapl-msft-and-googl-solid-2024-buys/",
    "time_published": "20240108T162405",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "The Magnificent Seven stocks, which include Apple Inc. ( AAPL ) , Microsoft Corporation ( MSFT ) and Alphabet Inc. ( GOOGL ) , concluded a stellar year, outperforming the S&P 500 index. Vanguard Mega Cap Growth Index Fund ETF Shares ( MGK ) secured a 6.9% gain over the past six months, surpassing ...",
    "banner_image": "https://stocknews.com/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.355517,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.420556",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.20494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.178648",
        "ticker_sentiment_score": "0.356535",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.025734",
        "ticker_sentiment_score": "0.060904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall As Boeing Tumbles",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-boeing-plunges-on-737-max-woes-can-market-rally-hold-key-levels/",
    "time_published": "20240108T112800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures Fall As Boeing Plunges On 737 Max Woes. Can Market Rally Hold Key Levels? Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/Biz05-airshow-022216-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.026516,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.073849",
        "ticker_sentiment_score": "-0.059431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.073849",
        "ticker_sentiment_score": "-0.097112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.024648",
        "ticker_sentiment_score": "-0.137676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.289178",
        "ticker_sentiment_score": "0.02146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.049271",
        "ticker_sentiment_score": "0.05937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.024648",
        "ticker_sentiment_score": "0.038323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.049271",
        "ticker_sentiment_score": "-0.094177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.147066",
        "ticker_sentiment_score": "0.049267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.073849",
        "ticker_sentiment_score": "0.060439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.073849",
        "ticker_sentiment_score": "0.007117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.049271",
        "ticker_sentiment_score": "0.05937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.171224",
        "ticker_sentiment_score": "-0.004301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.122769",
        "ticker_sentiment_score": "0.045676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.171224",
        "ticker_sentiment_score": "0.049832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.122769",
        "ticker_sentiment_score": "-0.126965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.195222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech ETFs Stage Solid Comeback at the Start of 2024",
    "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024",
    "time_published": "20240109T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.147642,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.06769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.071668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.140918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Simple Tricks That Every Investor Should Use  ( but Most Don't ) ",
    "url": "https://www.fool.com/investing/2024/01/09/3-simple-tricks-that-every-investor-should-use-but/",
    "time_published": "20240109T151500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Having a few tricks up your sleeve can increase your returns over time.",
    "banner_image": "https://media.ycharts.com/charts/48e06246cfdd0fa2187cc0683cfa221e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.233827,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.032509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.123385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36552329/pfizers-aggressive-stance-in-obesity-drugs-ceo-albert-bourla-confirms-bold-bet-despite-prior-drug",
    "time_published": "20240109T124231",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, at the JP Morgan Healthcare Conference, Pfizer Inc PFE CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning obesity market despite setbacks involving a terminated weight-loss drug candidate due to severe side effects.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/09/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.014279,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.089198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.00444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.089198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.056545",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly  ( LLY )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2208495/why-eli-lilly-lly-outpaced-the-stock-market-today",
    "time_published": "20240110T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) closed the most recent trading day at $630.19, moving +0.75% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default327.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.252041,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.673811",
        "ticker_sentiment_score": "0.351443",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Options: A Look at What the Big Money is Thinking - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36581006/eli-lillys-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240110T174609",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 50 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.085924,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.645091",
        "ticker_sentiment_score": "-0.113283",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What is Wegovy worth to your employer? Companies wrestle with obesity drugs' costs, long-term value.",
    "url": "https://www.marketwatch.com/story/what-is-wegovy-worth-to-your-employer-companies-wrestle-with-obesity-drugs-costs-long-term-value-520b37c4",
    "time_published": "20240110T140000",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Amid mounting evidence of obesity drugs' long-term health benefits, thorny questions persist about their value to employers ...",
    "banner_image": "https://images.mktw.net/im-520633/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.138036,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.16144",
        "ticker_sentiment_score": "0.102609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.201021",
        "ticker_sentiment_score": "0.163011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36572555/bring-on-the-competition-in-obesity-drugs-novo-nordisk-ceo-optimistic-about-prolonged-patient-adh",
    "time_published": "20240110T114313",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S NVO, shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are likely to continue with Wegovy for more extended periods compared to older treatments commonly used.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/wegovy-company.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.266805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.044989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.002294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.445569",
        "ticker_sentiment_score": "0.124314",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Doesn't Expect Eli Lilly Stock to Move Much Higher in 2024. Here's Why Analysts Could Be Wrong.",
    "url": "https://www.fool.com/investing/2024/01/10/wall-street-doesnt-expect-eli-lilly-stock-to-move/",
    "time_published": "20240110T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly's sizzle might not fizzle in the new year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760650/stock-charts-on-screen-analysts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.164182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.759979",
        "ticker_sentiment_score": "0.161885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.020019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/news/24/01/36602710/fda-finds-no-evidence-weight-loss-drugs-cause-suicidal-thoughts",
    "time_published": "20240111T215505",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "Following a preliminary review, the U.S. Food and Drug Administration found no evidence that weight-loss drugs cause suicidal thoughts.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/man-3011213-1280.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.117571,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "-0.071299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "-0.081664",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36594746/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lillys-dominance",
    "time_published": "20240111T164037",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Pharmaceutical companies, including Amgen Inc AMGN and Pfizer Inc PFE, are strategically positioning themselves to tap into the burgeoning obesity market. The pursuit involves developing innovative drugs or engaging in strategic acquisitions to compete with established players such as Novo ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/aapharma_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.164763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.084786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.252282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.252282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.531326",
        "ticker_sentiment_score": "0.077283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.185632",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "60% Of This Year's Top Stocks Are In This Sector  ( It's Not Tech ) ",
    "url": "https://www.investors.com/etfs-and-funds/etfs/sp500-this-years-top-stocks-are-in-this-sector-not-tech/",
    "time_published": "20240111T130000",
    "authors": [
      "Investor's Business Daily",
      "MATT KRANTZ"
    ],
    "summary": "Just when it looked like technology stocks took over the S&P 500 - another sector is on the rise. Health care stocks, like Viatris ( VTRS ) , Catalent ( CTLT ) and Moderna ( MRNA ) , are dominating the ranks of top-performing stocks this year so far, says an Investor's Business Daily analysis of ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-doctormoney-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.242038,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNPR",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.074964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.192664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "0.201769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.180302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.164515",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.111881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.141481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Skyrocketed 59% in 2023",
    "url": "https://www.fool.com/investing/2024/01/11/why-eli-lilly-stock-skyrocketed-59-in-2023/",
    "time_published": "20240111T104900",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760865/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.163735,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.722311",
        "ticker_sentiment_score": "0.243335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.155496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Making All The Right Moves; 4 Stocks In Buy Zones",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-making-the-right-moves-nvidia-microsoft-lead-tesla-breaks-down/",
    "time_published": "20240112T221400",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Market Rally Making The Right Moves. Nvidia, Microsoft Lead, Tesla Breaks Down Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.057794,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.081902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.212248",
        "ticker_sentiment_score": "0.143681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.070598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "-0.1804",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212248",
        "ticker_sentiment_score": "0.119715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.126024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03068",
        "ticker_sentiment_score": "-0.011302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.071779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "-0.086306",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Two Health Care Leaders Scale New Highs On Big Wins",
    "url": "https://www.investors.com/stock-lists/new-highs/lly-stock-is-at-a-new-high-after-a-new-website-launch/",
    "time_published": "20240112T204900",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "LLY stock is at a high after a website launch Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-EliLilly-01-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.232753,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.645887",
        "ticker_sentiment_score": "0.223424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.645887",
        "ticker_sentiment_score": "0.255609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns - Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/news/24/01/36615264/evolving-landscape-for-alzheimers-blood-tests-gains-momentum-amid-inaccuracy-concerns",
    "time_published": "20240112T181714",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A new era in Alzheimer's diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medicine pioneered blood tests capable of detecting sticky amyloid plaques, a key Alzheimer's indicator.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/dementia-Photo-by-Gerd-Altmann-via-Pixab.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.0975,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.144892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.096036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LH",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.193429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.252164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts",
    "url": "https://www.zacks.com/stock/news/2209351/fda-finds-no-link-between-obesity-drugs-and-suicidal-thoughts",
    "time_published": "20240112T124700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.101797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.104048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.056869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.110461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.149399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.250732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong",
    "url": "https://www.fool.com/investing/2024/01/13/after-surging-53-in-2023-this-pharmaceutical-stock/",
    "time_published": "20240113T153000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "The rise of Ozempic and Wegovy helped Novo Nordisk stock surge over 50% last year.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760592%2Fblood-pressure-doctor-senior-citizen.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.200507,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.245835",
        "ticker_sentiment_score": "0.111819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.584467",
        "ticker_sentiment_score": "0.200302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/01/13/3-unstoppable-stocks-to-buy-in-2024/",
    "time_published": "20240113T124800",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks appear to be on a clear path to continued growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761021/scientists-in-a-lab-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.25543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.266343",
        "ticker_sentiment_score": "0.049266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.349945",
        "ticker_sentiment_score": "0.133208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.143626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.308614",
        "ticker_sentiment_score": "0.308668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:DKK",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.270178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:NOK",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.270178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Fall: Market Rally Stellar; Four Stocks In Buy Zones",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stellar-market-rally/",
    "time_published": "20240114T231900",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Futures Fall: Market Rally Stellar. Four Stocks In Buy Zones Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.053334,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.404312",
        "ticker_sentiment_score": "0.14192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.236438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.090714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.156739",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.079619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.136213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "-0.056152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.054082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "-0.086608",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 9 Stocks Are Running To Start 2024",
    "url": "https://www.investors.com/news/sp-500-these-9-stocks-are-running-to-start-2024/",
    "time_published": "20240114T130000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "The S&P 500 index is up just a fraction in 2024 so far, but a number of big caps are off to a strong start. Nvidia ( NVDA ) , the No. 1 S&P 500 stock performer in 2023, is leading the way again. That is, excluding Juniper Networks ( JNPR ) , which spiked last week as Hewlett Packard Enterprise ( ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/05/Stock-nvidia-hq-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.172108,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.177567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.109733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.128431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.149398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "0.098631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.096737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.107239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.105371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.246327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.028285",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024",
    "url": "https://www.fool.com/investing/2024/01/14/move-over-novo-nordisk-this-is-the-pharmaceutical/",
    "time_published": "20240114T114500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760470%2Fbreast-cancer-awareness-doctor.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.210943,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.40443",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.315391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Fall; Elon Musk Makes This Tesla Threat",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-boeing-apple-in-focus-elon-musk-makes-this-tesla-threat/",
    "time_published": "20240115T234000",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Futures Fall. Elon Musk Makes This Tesla Threat Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-elonmusk-grumpy-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.016993,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.349803",
        "ticker_sentiment_score": "0.12775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.246444",
        "ticker_sentiment_score": "0.21025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.018659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.349803",
        "ticker_sentiment_score": "-0.165023",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.072576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.13589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.027828",
        "ticker_sentiment_score": "-0.054775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.053346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.093256",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Top Healthcare Stocks Declared Dividend Raises in 2023",
    "url": "https://www.fool.com/investing/2024/01/15/these-2-top-healthcare-stocks-declared-dividend-ra/",
    "time_published": "20240115T114600",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760775/medical-professionals-conferring-in-a-hospial-corridor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.200385,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.290262",
        "ticker_sentiment_score": "0.153969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.132101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.150481",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca",
    "url": "https://www.zacks.com/stock/news/2209905/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-amgen-and-astrazeneca",
    "time_published": "20240115T105000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094253,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.085906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.040358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.07059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.149079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Disney board nominates slate of dozen directors that excludes activist investors",
    "url": "https://www.marketwatch.com/story/disney-board-nominates-dozen-nominees-that-does-not-include-activist-investors-ca209b34",
    "time_published": "20240116T232200",
    "authors": [
      "Jon Swartz"
    ],
    "summary": "Walt Disney Co.'s board on Tuesday nominated a slate of 12 directors that notably left out activist investors from Trian Fund Management ( Nelson Peltz, James Rasulo ) and Blackwells Group ( Craig Hatkoff, Jessica Schell, Leah Solivan ) , both of which have been highly critical of Disney Chief ...",
    "banner_image": "https://images.mktw.net/im-76764933/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.018947,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.419153",
        "ticker_sentiment_score": "-0.059125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "-0.026743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "-0.044416",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36647588/unpacking-the-latest-options-trading-trends-in-eli-lilly",
    "time_published": "20240116T183219",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.104602,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.077542",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High",
    "url": "https://www.zacks.com/commentary/2211005/these-stocks-are-showing-relative-strength-as-sp-500-stalls-near-record-high",
    "time_published": "20240116T174900",
    "authors": [
      "Bryan Hayes"
    ],
    "summary": "As investors, our job isn't to predict an unknowable future.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/06/59517.png?v=596080559",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.22225,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.158868",
        "ticker_sentiment_score": "0.168458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Charts turn bullish on health-care stocks as sector takes early lead in 2024",
    "url": "https://www.marketwatch.com/story/charts-turn-bullish-on-health-care-stocks-as-sector-takes-early-lead-in-2024-12272495",
    "time_published": "20240116T162900",
    "authors": [
      "Joseph Adinolfi"
    ],
    "summary": "Health-care stocks are off to a strong start in 2024, and Wall Street analysts are taking notice.",
    "banner_image": "https://images.mktw.net/im-735118/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.342773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCK",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.294849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2210683/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20240116T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default227.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.235186,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.529767",
        "ticker_sentiment_score": "0.170174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly  ( LLY )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2211728/why-eli-lilly-lly-dipped-more-than-broader-market-today",
    "time_published": "20240117T224517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reachead $628.91 at the closing of the latest trading day, reflecting a -0.89% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.210888,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.26377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Balancing Act: The Ultimate Guide To Large-Cap Growth Stocks With Low Risk - Apple  ( NASDAQ:AAPL ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/24/01/36663650/balancing-act-the-ultimate-guide-to-large-cap-growth-stocks-with-low-risk",
    "time_published": "20240117T164342",
    "authors": [
      "Aditi Ganguly"
    ],
    "summary": "The stock market has rebounded from a weak start to the year, with the benchmark S&P 500 index rising by over 1.8% over the past five days. The tech-focused Nasdaq Composite Index has fared better as the tech rally resumes momentum, gaining over 3% in the second trading week of 2024.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Middle-Aged-Hispanic-Business-Manager-Ce.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.202814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "-0.00436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.21961",
        "ticker_sentiment_score": "0.067022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.21961",
        "ticker_sentiment_score": "0.434536",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.053643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Blockbuster Diabetes Drug Mounjaro Set To Enter New Markets Amid Manufacturing Boost - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36662189/eli-lillys-blockbuster-diabetes-drug-mounjaro-set-to-enter-new-markets-amid-manufacturing-boost",
    "time_published": "20240117T153050",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly & Company LLY has unveiled plans to introduce its weight-loss drug Mounjaro ( tirzepatide ) in new countries this year while simultaneously expanding manufacturing capacity,",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.110028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.772528",
        "ticker_sentiment_score": "0.082062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2211196/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240117T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.125875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bull of the Day: Regeneron Pharmaceuticals  ( REGN ) ",
    "url": "https://www.zacks.com/commentary/2211051/bull-of-the-day-regeneron-pharmaceuticals-regn",
    "time_published": "20240117T093000",
    "authors": [
      "Ethan Feller"
    ],
    "summary": "The Biotechnology company enjoys a litany of bullish catalysts on the horizon ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default21.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.242725,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.072522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.231906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.20698",
        "ticker_sentiment_score": "0.072522",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Eli Lilly and Novartis",
    "url": "https://www.zacks.com/stock/news/2211164/zacks-investment-ideas-feature-highlights-eli-lilly-and-novartis",
    "time_published": "20240117T084300",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly and Novartis have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.229073,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.158173",
        "ticker_sentiment_score": "0.167993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Tumbled on Thursday",
    "url": "https://www.fool.com/investing/2024/01/18/why-eli-lilly-stock-tumbled-on-thursday/",
    "time_published": "20240118T233601",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Investors were a bit concerned about an industrywide move.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761845/medical-professionals-conferring-in-a-hospial-corridor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.109739,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "0.07204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.16529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for Eli Lilly, Linde & NextEra Energy",
    "url": "https://www.zacks.com/research-daily/2211986/top-analyst-reports-for-eli-lilly-linde-nextera-energy",
    "time_published": "20240118T174200",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and NextEra Energy, Inc. (NEE).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.229808,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LIN",
        "relevance_score": "0.30569",
        "ticker_sentiment_score": "0.498644",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.280479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.209828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36699634/healthcare-giant-eli-lilly-under-fda-lens-again-for-manufacturing-lapses",
    "time_published": "20240119T182152",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY faces renewed scrutiny as the FDA inspectors reveal additional manufacturing issues at its Branchburg, New Jersey plant. In a recent inspection conducted by the FDA in July, eight deficiencies were identified, ranging from problems in tracking the manufacturing process to ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.110724,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.568148",
        "ticker_sentiment_score": "0.072943",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block",
    "url": "https://www.zacks.com/stock/news/2212548/the-zacks-analyst-blog-highlights-eli-lilly-linde-nextera-energy-honda-motor-arthur-j-gallagher-and-block",
    "time_published": "20240119T094000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.183774,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LIN",
        "relevance_score": "0.413425",
        "ticker_sentiment_score": "0.322251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.349575",
        "ticker_sentiment_score": "0.168288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.034497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.034497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.349575",
        "ticker_sentiment_score": "0.159724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's What Investors Should Expect From Eli Lilly Stock in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/heres-what-investors-should-expect-from-eli-lilly/",
    "time_published": "20240120T212900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "More headlines on the horizon.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761474/investors-watch-a-presentation-around-a-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.243767,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.544246",
        "ticker_sentiment_score": "0.335515",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.110251",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Eli Lilly Be Worth More Than Meta Platforms by 2030?",
    "url": "https://www.fool.com/investing/2024/01/20/will-eli-lilly-be-worth-more-than-meta-platforms/",
    "time_published": "20240120T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It would be quite the accomplishment for the drugmaker.",
    "banner_image": "https://media.ycharts.com/charts/46557cd62ae4e92e49f1f7c9ac145684.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.183138,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.70749",
        "ticker_sentiment_score": "0.240222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.642977",
        "ticker_sentiment_score": "0.280435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Flying Stocks That Could Soar Even More in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/3-high-flying-stocks-that-could-soar-even-more-in/",
    "time_published": "20240120T115000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These big winners could keep the momentum going.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761822/dna-on-monitor-scientists.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.195213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.26179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.056817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.160317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "-0.005924",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be the First Trillion-Dollar Healthcare Stock",
    "url": "https://www.fool.com/investing/2024/01/21/prediction-this-will-be-the-first-trillion-dollar/",
    "time_published": "20240121T160200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This company is currently firing on all cylinders.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761056/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.267579,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.637818",
        "ticker_sentiment_score": "0.397667",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.191225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.213931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166551",
        "ticker_sentiment_score": "0.132619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/01/21/is-it-too-late-to-buy-crispr-therapeutics-stock/",
    "time_published": "20240121T153000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly is now the most valuable healthcare stock in the world.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761255/a-doctor-looking-at-a-tablet-with-another-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.366365",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SGTX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.131851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.080989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.131851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "24 Dividend Growth Stocks to Buy and Hold in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/24-dividend-growth-stocks-to-buy-and-hold-in-2024/",
    "time_published": "20240121T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Dividends are good. Growing dividends are even better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761751/excited-investor-looks-at-financial-charts-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.360211,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IIPR",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.140815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.153863",
        "ticker_sentiment_score": "0.303904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.190566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.092688",
        "ticker_sentiment_score": "0.175204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.391015",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.141351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.225235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.141351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.127185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.391015",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36720412/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-900-today",
    "time_published": "20240122T173044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 20 years by 4.2% on an annualized basis producing an average annual return of 11.72%. Currently, Eli Lilly has a market capitalization of $598.54 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.158543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.375984",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "These 5 Wildly Popular High-Flying Stocks of 2023 Could Be Duds in the Rest of 2024, According to Wall Street",
    "url": "https://www.fool.com/investing/2024/01/22/these-5-wildly-popular-high-flying-stocks-of-2023/",
    "time_published": "20240122T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Analysts have not-so-great expectations going forward for these huge winners.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761848/young-woman-frustrated-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.182612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.124941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.138121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.088872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.102004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.25253",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Sinks As Market Gains: Here's Why",
    "url": "https://www.zacks.com/stock/news/2214575/eli-lilly-lly-stock-sinks-as-market-gains-heres-why",
    "time_published": "20240123T224518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Eli Lilly (LLY) settling at $629.68, representing a -0.19% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default314.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.191838,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.565003",
        "ticker_sentiment_score": "0.229546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly gene therapy allows child born deaf to hear, clinical trial shows",
    "url": "https://www.marketwatch.com/story/eli-lilly-gene-therapy-allows-child-born-deaf-to-hear-clinical-trial-shows-e66d55be",
    "time_published": "20240123T180600",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "An Eli Lilly experimental gene therapy has restored the hearing of a child who was born deaf.",
    "banner_image": "https://images.mktw.net/im-735118/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128958,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.678673",
        "ticker_sentiment_score": "0.216414",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "-0.020406",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Growth Stocks Are Brilliant Buys for the New Year",
    "url": "https://www.fool.com/investing/2024/01/23/these-2-growth-stocks-are-brilliant-buys-for-the/",
    "time_published": "20240123T144500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Business is booming for these stocks, and investors might want to stop and take note.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761836/family-cuddling-on-sofa-at-home.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.260007,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.247418",
        "ticker_sentiment_score": "0.258839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.041901",
        "ticker_sentiment_score": "0.122225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.28696",
        "ticker_sentiment_score": "0.271791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2213920/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240123T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.221904,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.088171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.069906",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2213924/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240123T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.2573,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.127397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.089059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.063784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Monster Stocks to Buy Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/01/23/2-monster-stocks-to-buy-without-any-hesitation/",
    "time_published": "20240123T110000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks both could deliver great rewards over time.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762141%2Fgettyimages-468679176.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.321362,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.204225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.060388",
        "ticker_sentiment_score": "0.065101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.53287",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.013032",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Don't Be Fooled by These 3 Misleading Facts About Eli Lilly Stock",
    "url": "https://www.fool.com/investing/2024/01/23/3-misleading-facts-about-eli-lilly-stock/",
    "time_published": "20240123T065900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Don't let a few disparate facts dominate your view of this company.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761493/investor-considers-papers-while-sitting-near-books.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.007331,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "-0.120877",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Eli Lilly Could Replace Tesla In 'Magnificent Seven' List: 'To Ignore...Is To Reject The Facts' - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36729974/jim-cramer-says-eli-lilly-could-replace-tesla-in-magnificent-seven-list-to-ignore-is-to-reject-t",
    "time_published": "20240123T030212",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has hinted at the possibility of Tesla Inc TSLA being replaced by Eli Lilly and Co LLY in the \"Magnificent Seven\" list of mega-cap stocks.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer-Photo-by-s-bukley-on-Shutters_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.132447,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.24853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.24853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.24853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.24853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.24853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.589793",
        "ticker_sentiment_score": "0.050007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "-0.151246",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.254895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.589793",
        "ticker_sentiment_score": "0.144922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "-0.151246",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36765784/weight-loss-drugs-ozempic-counterfeit-rising-reports-over-patient-safety-related-fake-drugs",
    "time_published": "20240124T192152",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Three individuals sought medical attention for dangerously low blood sugar in the U.S. in the previous year, having taken suspected fake versions of Novo Nordisk A/S's NVO diabetes medication, Ozempic ( semaglutide ) , according to the American Association of Poison Control Centers ( AAPCC ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.316647,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "-0.163204",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.56217",
        "ticker_sentiment_score": "-0.381676",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Stock Of The Day Lilly Is In A Buy Zone. And It's Not Related To Obesity.",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-rallies-into-buy-zone-on-surprising-results-in-treating-deafness/",
    "time_published": "20240124T171200",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Rallies Into Buy Zone On Surprising Results In Treating Deafness Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-24-2024LLY.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.053361,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.55533",
        "ticker_sentiment_score": "0.145116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.063005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.049141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "-0.043919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36759493/eli-lilly-unusual-options-activity",
    "time_published": "20240124T144708",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.011968,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.737428",
        "ticker_sentiment_score": "-0.119866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "-0.117744",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Labs' fourth-quarter sales top estimates amid strong medical-device demand",
    "url": "https://www.marketwatch.com/story/abbott-labs-fourth-quarter-sales-top-estimates-amid-strong-medical-device-demand-4d68669e",
    "time_published": "20240124T125700",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Abbott Laboratories on Wednesday reported fourth-quarter sales that topped expectations amid strength in its medical-device and nutrition segments.",
    "banner_image": "https://images.mktw.net/im-549400/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.162117,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.197008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.111972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.006598",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Famed Obesity And Diabetes Drug, Mounjaro, Comes To UK Patients, Wins Regulatory Clearance For Prefilled Injection Pen - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36790349/eli-lillys-famed-obesity-and-diabetes-drug-mounjaro-comes-to-uk-patients-wins-regulatory-clearanc",
    "time_published": "20240125T211159",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Medicines and Healthcare products Regulatory Agency ( MHRA ) has approved, Thursday, a four-dose version of the diabetes and weight management medicine Mounjaro ( tirzepatide ) . Eli Lilly And Co's LLY Mounjaro will be branded as Mounjaro KwikPen in the U.K.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.181265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.132125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.064744",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johna Norton to Retire as Lilly Executive Vice President of Global Quality",
    "url": "https://www.prnewswire.com/news-releases/johna-norton-to-retire-as-lilly-executive-vice-president-of-global-quality-302043876.html",
    "time_published": "20240125T130000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.196394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.452639",
        "ticker_sentiment_score": "0.230674",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.005853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.138739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.134834",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Tsunami Looms For Market Rally; Seven Stocks To Watch",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-earnings-tsunami-looms-microsoft-apple-lead-7-stocks-to-watch/",
    "time_published": "20240126T214100",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Earnings Tsunami Looms. Microsoft, Apple Lead 7 Stocks To Watch Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.121082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.090942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.210823",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.180785",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.291842",
        "ticker_sentiment_score": "0.108265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.180785",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.180785",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.030817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.169378",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We Might Have Sold But This Stock Still Deserves Attention",
    "url": "https://www.investors.com/research/swing-trading/short-moves-in-eli-lilly-stock-good-for-swing-trading/",
    "time_published": "20240126T211200",
    "authors": [
      "Investor's Business Daily",
      "JUSTIN NIELSEN"
    ],
    "summary": "Eli Lilly Stock Still Deserves Attention Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/wSWING012924.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.159895,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.174729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36802049/eli-lilly-unusual-options-activity",
    "time_published": "20240126T144602",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.026409,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.00799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "-0.131944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "-0.105032",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tesla's Market Cap Dips Below Eli Lilly Following Q4 Revenue Miss: Report - Tesla  ( NASDAQ:TSLA ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/01/36794521/teslas-market-cap-dips-below-eli-lilly-following-q4-revenue-miss-report",
    "time_published": "20240126T005853",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Tesla Inc. TSLA has been surpassed in market value by pharmaceutical giant Eli Lilly LLY, following a 12% single-day plunge in Tesla's stock. What Happened: Tesla's fourth-quarter earnings report, which fell short of revenue and profit expectations, triggered a significant drop in its stock price.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/NeuroImage_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.117845,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.140541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.161825",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.048427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "-0.208128",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "If You Invested $5,000 in Novo Nordisk in 2019, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/01/27/if-you-invested-5000-in-novo-nordisk-in-2019/",
    "time_published": "20240127T160000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The answer may surprise you.",
    "banner_image": "https://media.ycharts.com/charts/67ec276a6508aaf6afdc910fd4bcc2bb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.280356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "-0.01712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.748842",
        "ticker_sentiment_score": "0.459995",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Could Eli Lilly Be a Trillion-Dollar Company by 2030?",
    "url": "https://www.fool.com/investing/2024/01/27/could-eli-lilly-be-a-trillion-dollar-company-by-20/",
    "time_published": "20240127T132500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly is the world's largest healthcare company by market cap, and the 10th most valuable business in the world.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762341%2Fdoctor-showing-patient-a-chart.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.305641,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.766317",
        "ticker_sentiment_score": "0.468276",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.097646",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Monthly Meeting Q&A with Jim Cramer: Everything from health care to industrials to portfolio management",
    "url": "https://www.cnbc.com/2024/01/28/monthly-meeting-qa-with-jim-cramer-everything-from-health-care-to-industrials.html",
    "time_published": "20240128T180102",
    "authors": [
      "Paulina Likos"
    ],
    "summary": "During the January Monthly Meeting, we took questions directly from Investing Club members.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107200470-1677528554271-NUP_200782_00237.jpg?v=1697057003&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.07939,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIDU",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.189076",
        "ticker_sentiment_score": "0.051361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget The Magnificent Seven. Focus On These Fab Five.",
    "url": "https://www.investors.com/news/sp-500-forget-magnificent-seven-focus-on-fab-five/",
    "time_published": "20240128T130000",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "The Magnificent Seven stocks - S&P 500 giants Amazon.com ( AMZN ) , Apple ( AAPL ) , Google parent Alphabet ( GOOGL ) , Meta Platforms ( META ) , Microsoft ( MSFT ) , Nvidia ( NVDA ) and Tesla ( TSLA ) - have been grouped together since the start of the bull market in January 2023.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-AImachinelearning-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.181552,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.321927",
        "ticker_sentiment_score": "0.294393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.060161",
        "ticker_sentiment_score": "-0.1661",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.218425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.526614",
        "ticker_sentiment_score": "0.312372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.210761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.060161",
        "ticker_sentiment_score": "0.107001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.060161",
        "ticker_sentiment_score": "0.100001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.060161",
        "ticker_sentiment_score": "-0.1661",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.176881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.40271",
        "ticker_sentiment_score": "0.274766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.321927",
        "ticker_sentiment_score": "0.083558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "-0.081834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.185532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.246411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.060161",
        "ticker_sentiment_score": "-0.1661",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Why Beam Therapeutics Stock Zoomed 17% Higher Today",
    "url": "https://www.fool.com/investing/2024/01/29/why-beam-therapeutics-stock-zoomed-17-higher-today/",
    "time_published": "20240129T232100",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "JPMorgan Chase becomes the latest institution in the company's bull pen.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763126/person-in-a-lab-looking-through-a-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.226592,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "0.314666",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.162916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2217450/eli-lilly-lly-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240129T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $645, signifying a +0.9% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default37.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      }
    ],
    "overall_sentiment_score": 0.20128,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.598621",
        "ticker_sentiment_score": "0.27535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36830456/eli-lilly-wants-to-expand-access-to-weight-loss-treatments-in-germany-in-talks-with-government",
    "time_published": "20240129T181423",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY is reportedly engaged in discussions with the German government to lift the ban on the public health system covering the costs of weight-loss treatments.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.053268,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.59016",
        "ticker_sentiment_score": "0.038645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.15576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "We're calling up a health care stock from our Bullpen watch list, starting a new position",
    "url": "https://www.cnbc.com/2024/01/29/were-calling-up-a-health-care-stock-from-our-bullpen-watch-list-starting-a-new-position.html",
    "time_published": "20240129T140341",
    "authors": [
      "Jim Cramer"
    ],
    "summary": "Now that expectations have cooled down, we think this pullback is one worth buying.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107250871-1685970222341-gettyimages-1258453480-Port_Trade_Growth_In_Lianyungang.jpeg?v=1698261998&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.209243,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.074809",
        "ticker_sentiment_score": "0.090625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.087033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.153796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "url": "https://www.zacks.com/stock/news/2216951/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
    "time_published": "20240129T135006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default283.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.371141,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.333286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Eli Lilly? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/01/36823514/how-is-the-market-feeling-about-eli-lilly",
    "time_published": "20240129T133016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly's LLY short percent of float has fallen 3.12% since its last report. The company recently reported that it has 4.89 million shares sold short, which is 0.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.47 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.237023,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.081322",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Await Huge Market News",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-microsoft-leads-huge-earnings-wave/",
    "time_published": "20240129T131000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Microsoft Leads Huge Earnings Wave Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.128441,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.450828",
        "ticker_sentiment_score": "0.05364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.235442",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.079524",
        "ticker_sentiment_score": "-0.178319",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.079524",
        "ticker_sentiment_score": "0.004122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.273224",
        "ticker_sentiment_score": "0.063015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.079524",
        "ticker_sentiment_score": "-0.178319",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.119038",
        "ticker_sentiment_score": "-0.043251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.235442",
        "ticker_sentiment_score": "0.001774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.235442",
        "ticker_sentiment_score": "0.029396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.119038",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.158259",
        "ticker_sentiment_score": "0.001322",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy in 2024: The \"Magnificent Seven\" or the \"Terrific 10\"?",
    "url": "https://www.fool.com/investing/2024/01/29/better-buy-the-magnificent-seven-or-terrific-ten/",
    "time_published": "20240129T112600",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "The financial and healthcare sectors make up a massive amount of the market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762431%2Fgettyimages-1419726675-1201x633-65d4be6.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.333127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.101721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.122273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.201917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.120472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.137474",
        "ticker_sentiment_score": "0.163389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.111863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "0.271149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.101721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.122273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.171363",
        "ticker_sentiment_score": "0.256013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.103812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.144218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.137474",
        "ticker_sentiment_score": "0.127343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.303144",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.171363",
        "ticker_sentiment_score": "0.277563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want to Get Richer in 2024? 2 Top Stocks to Buy Now",
    "url": "https://www.fool.com/investing/2024/01/29/want-to-get-richer-in-2024-2-top-stocks-to-buy-now/",
    "time_published": "20240129T101500",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "Both of these companies have revenue drivers to keep the growth going.",
    "banner_image": "https://media.ycharts.com/charts/3229c5917109536bc38e882a3833c516.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.290036,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "-0.099573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.049216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.325637",
        "ticker_sentiment_score": "0.410488",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Stocks to Buy and Hold For at Least 10 Years",
    "url": "https://www.fool.com/investing/2024/01/29/2-unstoppable-stocks-to-buy-and-hold-for-at-least/",
    "time_published": "20240129T082900",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's hard to bet against these companies right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762585/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.372593,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.484697",
        "ticker_sentiment_score": "0.428275",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.573492",
        "ticker_sentiment_score": "0.557749",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.232005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Earnings Expected to Grow: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2217983/eli-lilly-lly-earnings-expected-to-grow-should-you-buy",
    "time_published": "20240130T150056",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.149619,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.127026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.174903",
        "ticker_sentiment_score": "-0.001424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Lilly  ( LLY )  a Buy as Wall Street Analysts Look Optimistic?",
    "url": "https://www.zacks.com/stock/news/2217883/is-lilly-lly-a-buy-as-wall-street-analysts-look-optimistic",
    "time_published": "20240130T143006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/LLY_01302024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.283192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.362254",
        "ticker_sentiment_score": "0.180653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Topped the Market Today",
    "url": "https://www.fool.com/investing/2024/01/31/why-eli-lilly-stock-topped-the-market-today/",
    "time_published": "20240131T231600",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "One of its more recently approved drugs will be launched into a white-hot market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763435/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.265184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.614086",
        "ticker_sentiment_score": "0.456209",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.512093",
        "ticker_sentiment_score": "0.509193",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2218932/eli-lilly-lly-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240131T164800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.138198,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.400691",
        "ticker_sentiment_score": "0.13284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "0.058657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "0.047535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "-0.001617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2218601/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240131T140010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default286.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.219612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.154158",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biogen drops controversial Alzheimer's drug",
    "url": "https://www.marketwatch.com/story/biogen-halts-development-of-controversial-alzheimers-drug-3e03858a",
    "time_published": "20240131T135900",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Biogen is halting the development and commercialization of the Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to concerns about whether its benefits outweighed its risks.",
    "banner_image": "https://images.mktw.net/im-17279099/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.272324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.712214",
        "ticker_sentiment_score": "0.193001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares - AstraZeneca  ( NASDAQ:AZN ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36866023/take-your-ozempic-why-late-entry-of-rival-weight-loss-drugs-wont-floor-novo-eli-sha",
    "time_published": "20240131T134944",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Eli Lilly LLY reports its fourth quarter earnings next week and, as Novo Nordisk NVO did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss solutions.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.187068,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.249005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "-0.039113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "0.119694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.289771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.262369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.092059",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic maker Novo Nordisk reports 62% surge in profit",
    "url": "https://www.marketwatch.com/story/ozempic-maker-novo-nordisk-reports-62-surge-in-profit-584a5064",
    "time_published": "20240131T085200",
    "authors": [
      "Steve Goldstein"
    ],
    "summary": "Novo Nordisk on Wednesday said its fourth-quarter profit surged by nearly two-thirds, driven by the popularity of its weight-loss drugs that have made it Europe's largest company.",
    "banner_image": "https://images.mktw.net/im-809249/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.239467,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.059165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.746902",
        "ticker_sentiment_score": "0.417184",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.038291",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/36889771/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20240201T144710",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.002398,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.764792",
        "ticker_sentiment_score": "-0.102214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.104834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.131693",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "url": "https://www.zacks.com/stock/news/2219391/lilly-lly-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures",
    "time_published": "20240201T141522",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default45.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.126879,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.359707",
        "ticker_sentiment_score": "0.224852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Disney, Caterpillar, McDonald's, Ford: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/disney-stock-caterpillar-mcdonalds-ford-investing-action-plan/",
    "time_published": "20240202T230000",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "Disney Stock, Caterpillar, McDonald's, Ford: Investing Action Plan Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-NYSE-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.115657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.065969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TENB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.021495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.026981",
        "ticker_sentiment_score": "0.028291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.017985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.070764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.065573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.030931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LITE",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.046811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.091947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.020982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.007181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.134289",
        "ticker_sentiment_score": "0.074545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.027839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.0255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLOB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.11074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTWO",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.05579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Hits High In Stock Picker's Market; Five New Buys",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp-500-hit-highs-stock-pickers-market-5-new-buys-tesla-leads-losers/",
    "time_published": "20240202T224900",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "S&P 500 Hits High In Stock Picker's Market. Five New Buys Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe-1.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      }
    ],
    "overall_sentiment_score": 0.098442,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.023029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.172706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.159857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.13103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.027445",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.136577",
        "ticker_sentiment_score": "0.09451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.027445",
        "ticker_sentiment_score": "0.026153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.015541",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.13103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.163539",
        "ticker_sentiment_score": "-0.215236",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.136835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.136835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.163539",
        "ticker_sentiment_score": "0.030049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.136835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.136835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.136835",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Eli Lilly, Danaher & Citigroup",
    "url": "https://www.zacks.com/research-daily/2220146/top-stock-reports-for-eli-lilly-danaher-citigroup",
    "time_published": "20240202T215900",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/af/51929.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260398,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.202381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.158795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABCZF",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.183981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.097043",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look At The Disruption Of Medifast",
    "url": "https://www.forbes.com/sites/gurufocus/2024/02/02/a-closer-look-at-the-disruption-of-medifast/",
    "time_published": "20240202T173126",
    "authors": [
      "GuruFocus"
    ],
    "summary": "The weight loss and nutrition product company is coping with the GLP-1 drug tsunami \u2022 The new diabetes and diet drugs appear to have disrupted the company's extremely profitable business model. Weight loss and wellness product company Medifast Inc. ( MED, Financial ) has experienced a significant ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bd2469f0bee498c099bcba/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.098847,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "-0.170101",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LFMD",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.012375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VALU",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.163211",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MED",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.10894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "-0.170101",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36913823/whats-going-on-with-eli-lilly-stock-today",
    "time_published": "20240202T172909",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY is set to announce its fourth quarter 2023 financial results next week on Tuesday, 6 February. The analysts expect Eli Lilly to report $2.19 per share earnings and sales of $8.932 billion, according to data from Benzinga Pro.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.009466,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.817578",
        "ticker_sentiment_score": "0.163751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ELF Beauty, Palantir, Arm Holdings, Chipotle Headline Busy Earnings Calendar",
    "url": "https://www.investors.com/research/earnings-preview/earnings-calendar-spotlight-sellers-hit-palantir-stock-growth-concerns/",
    "time_published": "20240202T163900",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Earnings Calendar Spotlight: Sellers Hit Palantir Stock Amid Growth Concerns. Expectations High For ELF Beauty Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/EARNwatch020524.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.148699,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "-0.084032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.192228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SFTBF",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "-0.078621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.106054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.106054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.094514",
        "ticker_sentiment_score": "0.099503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.156868",
        "ticker_sentiment_score": "0.106841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.106054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "-0.18159",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "APOS",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "-0.188672",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "4 Large Drug Stocks Trying to Survive the Industry Challenges",
    "url": "https://www.zacks.com/commentary/2220023/4-large-drug-stocks-trying-to-survive-the-industry-challenges",
    "time_published": "20240202T134700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.215569,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.15857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.065458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "0.236489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.118999",
        "ticker_sentiment_score": "0.140653",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.065458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.031019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2220125/abbvie-abbv-q4-earnings-and-revenues-top-estimates",
    "time_published": "20240202T134502",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default188.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.16185,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.402403",
        "ticker_sentiment_score": "0.208814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures: Five Stocks In Buy Areas",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-future-5-stocks-in-buy-areas-as-market-rally-powers-higher/",
    "time_published": "20240204T152900",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Futures: 5 Stocks In Buy Areas As Rally Powers Higher Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe-1.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      }
    ],
    "overall_sentiment_score": 0.065161,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.022946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.162718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.056491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.130352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "-0.14785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.11087",
        "ticker_sentiment_score": "0.082417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.025406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.11087",
        "ticker_sentiment_score": "-0.011089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.130352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "-0.137966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.11087",
        "ticker_sentiment_score": "-0.106411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.18076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.132855",
        "ticker_sentiment_score": "0.025322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.18076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.18076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.18076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.06666",
        "ticker_sentiment_score": "0.105074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.06666",
        "ticker_sentiment_score": "-0.019266",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: 5 Stocks In Buy Areas As Rally Powers Higher",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-future-5-stocks-in-buy-areas-as-market-rally-powers-higher/",
    "time_published": "20240204T135800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Market Powers To Highs Despite This. 5 New Stocks In Buy Areas Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe-1.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      }
    ],
    "overall_sentiment_score": 0.100894,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.023007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.169832",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.15957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.130999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.130076",
        "ticker_sentiment_score": "0.088441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.026127",
        "ticker_sentiment_score": "0.025975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.130076",
        "ticker_sentiment_score": "-0.011893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.130999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "-0.208682",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.136554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.136554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.02778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.136554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.136554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.136554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.078269",
        "ticker_sentiment_score": "0.107195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings, Jobs, And The Magnificent 7 Soar",
    "url": "https://www.forbes.com/sites/bill_stone/2024/02/04/earnings-jobs-and-the-magnificent-7-soar/",
    "time_published": "20240204T120000",
    "authors": [
      "Bill Stone"
    ],
    "summary": "Last week was the busiest of earnings season, with 106 S&P 500 companies reporting. The S&P 500 rose 1.4% for the week, driven primarily by earnings and the Magnificent 7. The 10-year Treasury yield was fractionally lower at 4.0%.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65be6a5b3de8507b84cf569c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.198921,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.320847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.320847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.212136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.306357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.212136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "-0.198994",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.22152",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.22152",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.22152",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "After a 90% Gain, Is It Too Late to Buy Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/02/04/after-a-90-gain-is-it-too-late-to-buy-eli-lilly/",
    "time_published": "20240204T090500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763686%2Fgettyimages-903626078.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.236494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.04908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.554014",
        "ticker_sentiment_score": "0.356177",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.164656",
        "ticker_sentiment_score": "0.052794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Markets Take a Powder; PLTR, NXPI Beat in Q4",
    "url": "https://www.zacks.com/stock/news/2221393/markets-take-a-powder-pltr-nxpi-beat-in-q4",
    "time_published": "20240205T225900",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Market indices were reluctant to drag a stock market higher amid all-time high ranges on the Dow and S&P 500.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/2520.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.12853,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.071056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.153666",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.096598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.078085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.20444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen's Weight-Loss News Just Sent Lilly To A Record High",
    "url": "https://www.investors.com/news/technology/amgen-stock-slumps-as-it-looks-to-take-on-weight-loss-drugs-leaders-lilly-novo/",
    "time_published": "20240205T180800",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Amgen Stock Slumps As It Looks To Take On Weight-Loss Drugs Leaders Lilly, Novo Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-amgen-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.125806,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.267818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.07163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.262422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.087971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Adverum Biotechnologies  ( NASDAQ:ADVM ) , Air Products & Chemicals  ( NYSE:APD ) ",
    "url": "https://www.benzinga.com/news/24/02/36935399/why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in",
    "time_published": "20240205T175650",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Shares of Air Products and Chemicals, Inc. APD fell sharply during Monday's session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/image32.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": -0.043999,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SAN",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.136457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEGY",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.122608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.076688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORZQ",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.199688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NOVA",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "GRRR",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.163916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JT",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.359106",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCTG",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.021801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LXEH",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "NEXI",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.173255",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "COCH",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "SRM",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QLYS",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "GRDI",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.15131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INBS",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.254523",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EXPR",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGML",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "EVBG",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.213384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SJ",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.09661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMAQR",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "-0.298581",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LYG",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "-0.10694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEXPF",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "-0.141338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSTG",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.241858",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BETS",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.157259",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CAMP",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.143831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHEA",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.305224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPWR",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.233339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WRAP",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.247469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DMK",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.199843",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLRX",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.070706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "YTEN",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.280924",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWIN",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MIRA",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.358345",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.359106",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "APD",
        "relevance_score": "0.182851",
        "ticker_sentiment_score": "0.045478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTOG",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "-0.393938",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "RVSN",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.211207",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.189271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tesla's stock dive means the EV maker is now worth less than Broadcom",
    "url": "https://www.marketwatch.com/story/sap-to-stop-using-tesla-for-company-fleet-report-says-54627dbb",
    "time_published": "20240205T170700",
    "authors": [
      "",
      "Steve Goldstein",
      "Tomi Kilgore"
    ],
    "summary": "Tesla's stock dove toward a nine-month low Monday, to fuel a broad selloff in the electric-vehicle sector, after a report that the EV giant was losing a large customer in Germany.",
    "banner_image": "https://images.mktw.net/im-16513349/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.16058,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAP",
        "relevance_score": "0.222157",
        "ticker_sentiment_score": "-0.010455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.489659",
        "ticker_sentiment_score": "-0.375537",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "FSR",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "-0.154475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FHYDF",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.084769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKLA",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.106169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "-0.154475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MULN",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.064919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36936648/whats-going-on-with-eli-lilly-stock-today",
    "time_published": "20240205T165831",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co's LLY shares are trading higher with a session volume of 1.683 million versus an average volume of 3.12 million, according to data from Benzinga Pro. However, there is no news to justify the movement.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.055232,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.59016",
        "ticker_sentiment_score": "0.142134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.134109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.59016",
        "ticker_sentiment_score": "0.076615",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/36935452/in-depth-analysis-eli-lilly-versus-competitors-in-pharmaceuticals-industry",
    "time_published": "20240205T160034",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Eli Lilly LLY against its key ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.152108,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.479258",
        "ticker_sentiment_score": "0.283947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk To Up Production Capacity As Parent Buys Catalent",
    "url": "https://www.investors.com/news/technology/nvo-stock-novo-nordisk-to-up-production-capacity-as-parent-buys-catalent/",
    "time_published": "20240205T153600",
    "authors": [
      "Investor's Business Daily",
      "REINHARDT KRAUSE"
    ],
    "summary": "Shares in Novo Nordisk ( NVO ) rose Monday after its parent, Novo Holdings, said it has agreed to buy contract drug manufacturer Catalent for $11.5 billion in cash. NVO stock has surged the past year on sales of Ozempic, a diabetes medicine, and weight-loss drug Wegovy.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.105909,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.186067",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.478939",
        "ticker_sentiment_score": "0.264237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.664235",
        "ticker_sentiment_score": "0.419711",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.186067",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Est\u00e9e Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday - Estee Lauder Cos  ( NYSE:EL ) , Tyson Foods  ( NYSE:TSN ) , ON Semiconductor  ( NASDAQ:ON ) ",
    "url": "https://www.benzinga.com/news/24/02/36934947/est-e-lauder-posts-upbeat-earnings-joins-on-semiconductor-tyson-foods-and-other-big-stocks-moving-hi",
    "time_published": "20240205T153252",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Shares of The Est\u00e9e Lauder Companies Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/estee_lauder_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.214337,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FDMT",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "-0.233714",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORZQ",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACRXF",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.207188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.582744",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HAYN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.306985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NSSC",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DWAC",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVBG",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.294378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNA",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.310127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.390197",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/02/05/is-it-too-late-to-buy-eli-lilly-stock/",
    "time_published": "20240205T151500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Growth may slow, and its valuation is looking precarious.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763737/investor-looks-at-phone-in-cafe-while-drinking-espresso.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.216411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.324367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More",
    "url": "https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more",
    "time_published": "20240205T150900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090594,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.01809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "-0.072387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.14336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q4 Earnings Report - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36927090/how-to-earn-500-a-month-from-eli-lilly-stock-ahead-of-q4-earnings-report",
    "time_published": "20240205T133602",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Eli Lilly and Company LLY is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 6, 2024. Analysts expect the Indianapolis-based company to report quarterly earnings at $2.19 per share, up from $2.09 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/eli-lilly_shutterstock.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.125892,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.671304",
        "ticker_sentiment_score": "0.396845",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis",
    "url": "https://www.zacks.com/stock/news/2220698/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-abbvie-and-novartis",
    "time_published": "20240205T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.215514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.011097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.152636",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.13715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.030885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.24899",
        "ticker_sentiment_score": "0.156217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.20484",
        "ticker_sentiment_score": "0.234708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.062277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas",
    "url": "https://www.zacks.com/stock/news/2220682/the-zacks-analyst-blog-highlights-eli-lilly-danaher-citigroup-shopify-and-canadian-pacific-kansas",
    "time_published": "20240205T095000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/33/496.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.221674,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.423843",
        "ticker_sentiment_score": "0.162899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.038811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.051533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABCZF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.169296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CP",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.038811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.423843",
        "ticker_sentiment_score": "0.105431",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's quarterly results top expectations despite Enbrel sales decline",
    "url": "https://www.marketwatch.com/story/amgens-quarterly-results-top-expectations-despite-enbrel-sales-decline-3720269d",
    "time_published": "20240206T214300",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Amgen on Tuesday reported fourth quarter profits and sales that topped analyst expectations even as revenues dropped for one of its top-selling drugs.",
    "banner_image": "https://images.mktw.net/im-814193/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.023871,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.190188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.578948",
        "ticker_sentiment_score": "0.127919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism",
    "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-higher-close-for-stocks-palantir-soars-on-ai-optimism",
    "time_published": "20240206T211241",
    "authors": [
      "Karee Venema"
    ],
    "summary": "Stocks opened higher Tuesday as investors attempted to look past Federal Reserve Chair Jerome Powell's hawkish appearance on \"60 Minutes.\" However, the main indexes ran out of steam as the session wore on as more central bankers took the wait-and-see route toward rate cuts.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/HPGpPu8yev3y9BJ9WaSXu7-415-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.29933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.349454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.220181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.349454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday? - Amgen  ( NASDAQ:AMGN ) , BP  ( NYSE:BP ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/36964052/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-whats-driving-markets-tues",
    "time_published": "20240206T192404",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in the days ahead.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.132785,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPOT",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBS",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCK",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.130458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "-0.143048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FMC",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.42926",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly rides the weight-loss-drug wave to a new record high, and is now worth more than $700 billion",
    "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-q4-earnings-glp-drugs-700-billion-2024-2",
    "time_published": "20240206T170000",
    "authors": [
      "Matthew Fox"
    ],
    "summary": "Eli Lilly Rides the Weight-Loss-Drug Wave to Record, Hits $700 Billion - Markets Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.224787,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.555911",
        "ticker_sentiment_score": "0.347831",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street says Big Tech needs to take a breather after huge run. Here's our take",
    "url": "https://www.cnbc.com/2024/02/06/why-wall-street-analysts-think-big-tech-stocks-will-take-a-breather.html",
    "time_published": "20240206T164237",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107306647-1695737403194-gettyimages-1580864430-AFP_33QR73W.jpeg?v=1702925323&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.211554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "0.181956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.134213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.134213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.095197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.134213",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up Its Gains",
    "url": "https://www.fool.com/investing/2024/02/06/why-eli-lilly-stock-jumped-as-much-as-51-today/",
    "time_published": "20240206T164140",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Investors shouldn't worry that Lilly's gains quickly evaporated.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764189/scientists-in-a-lab-monitor-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.245766,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.684999",
        "ticker_sentiment_score": "0.511454",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks In China Flying, Lifting Sentiment In Stock Markets Across The Globe, AI And Weight Loss Drugs Get Hotter - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/markets/24/02/36960189/stocks-in-china-flying-lifting-sentiment-in-stock-markets-across-the-globe-ai-and-weight-loss-drugs",
    "time_published": "20240206T163135",
    "authors": [
      "The Arora Report"
    ],
    "summary": "To gain an edge, this is what you need to know today. Please click here for an enlarged version of the chart of iShares China Large-Cap ETF FXI. Earlier today, NVIDIA Corp NVDA crossed $700. NVDA is in The Arora Report ZYX Buy Model Portfolio.",
    "banner_image": "https://cdn.benzinga.com/files/regularguy-eth-w9codxtsfts-unsplash_19.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.22034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.197234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.197234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.156997",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "-0.238309",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.151858",
        "ticker_sentiment_score": "0.017067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.247528",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.386374",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Earnings Data Deluge",
    "url": "https://www.zacks.com/stock/news/2221920/earnings-data-deluge",
    "time_published": "20240206T160200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "We have a big day of stock market information on deck, most of which doesn't happen until after the opening bell rings this morning. We have a full docket of Fed presidents reporting later today, including Cleveland's Loretta Mester, Minneapolis' Neel Kashkari, Boston's Susan Collins and ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.052206,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CMG",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.3007",
        "ticker_sentiment_score": "0.077165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.3007",
        "ticker_sentiment_score": "0.074298",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Mixed With Dow Jones Pulling Ahead; Palantir Soars After Earnings",
    "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-struggles-dow-jones-leads-nasdaq-palantir-spy-stock/",
    "time_published": "20240206T155300",
    "authors": [
      "Investor's Business Daily",
      "KIMBERLEY KOENIG"
    ],
    "summary": "Stock Market Struggles, Dow Jones Leads, Nasdaq Eases. Palantir Soars Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Palantir-04-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      }
    ],
    "overall_sentiment_score": 0.09589,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.062377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.111245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.111245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.062377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "0.065084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "0.009552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.102795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDNS",
        "relevance_score": "0.051999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "-0.132313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.051999",
        "ticker_sentiment_score": "0.049031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCU",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "-0.090737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.062377",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales",
    "url": "https://www.zacks.com/stock/news/2221913/eli-lilly-lly-q4-earnings-beat-mounjaro-zepbound-drive-sales",
    "time_published": "20240206T154800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.177494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.337951",
        "ticker_sentiment_score": "0.152966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.219099",
        "ticker_sentiment_score": "0.025828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.126284",
        "ticker_sentiment_score": "0.035026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.188437",
        "ticker_sentiment_score": "0.119642",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses",
    "url": "https://www.zacks.com/stock/news/2221907/earnings-fed-speakers-dominate-activity-lilly-beats-spotify-misses",
    "time_published": "20240206T154100",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/60715.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.054458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CMG",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.069326",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.0538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chips Vs. Oil: Nvidia Now Outweighs The S&P 500's Entire Energy Sector",
    "url": "https://www.investors.com/news/sp500-chips-vs-oil-nvidia-now-outweighs-the-sp-500s-entire-energy-sector/",
    "time_published": "20240206T150700",
    "authors": [
      "KIT NORTON",
      "Investor's Business Daily"
    ],
    "summary": "With Nvidia ( NVDA ) surging 40% since the end of 2023, hitting a market cap of more than $1.7 trillion on Monday, the tech stock is now valued more than the S&P 500's entire energy sector, which includes Exxon Mobil ( XOM ) and Chevron ( CVX ) .",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/10/Stock-oilderrick-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.205955,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.100923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.100923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.414369",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.225735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.225735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.346431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.225735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.067306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.412861",
        "ticker_sentiment_score": "0.306878",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.100923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.225735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jumps Over 100 Points; Eli Lilly Posts Upbeat Earnings - Agrify  ( NASDAQ:AGFY ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36957085/dow-jumps-over-100-points-eli-lilly-posts-upbeat-earnings",
    "time_published": "20240206T145204",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.34% to 38,509.84 while the NASDAQ rose 0.21% to 15,629.82. The S&P 500 also rose, gaining, 0.17% to 4,951.38.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/image30.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.016939,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVIV",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.175165",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AGFY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.311293",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.028824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "-0.084219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRTX",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "-0.044273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRSO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "-0.098739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUNW",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.248732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TENX",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.20693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:PAY",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.166607",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024 - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/36955955/eli-lilly-soars-on-diabetes-and-obesity-drug-boom-projects-20-revenue-increase-in-2024",
    "time_published": "20240206T141519",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a recent announcement, Eli Lilly and Co LLY has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.224494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.253218",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's stock leaps toward a record as a 16% jump in prices boosted profit",
    "url": "https://www.marketwatch.com/story/eli-lillys-stock-surges-toward-a-5th-straight-record-after-an-earnings-beat-and-upbeat-outlook-5a298405",
    "time_published": "20240206T133200",
    "authors": [
      "Tomi Kilgore"
    ],
    "summary": "U.S. prices for Lilly's drugs climbed 27%, driven by diabetes treatment Mounjaro, while prices outside the U.S. fell.",
    "banner_image": "https://images.mktw.net/im-84642168/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.168429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.161944",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36954087/investors-cheer-highly-awaited-eli-lilly-earnings-q4-performance-surpass-expectations-thanks-to-s",
    "time_published": "20240206T132936",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Eli Lilly And Co LLY reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.074302,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.68732",
        "ticker_sentiment_score": "-0.019044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Dip; Palantir Soars On Surging AI Demand",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-palantir-soars-on-surging-ai-demand/",
    "time_published": "20240206T131700",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall As Tesla Slides On Downgrade. Palantir Soars On Surging AI Demand Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.205444,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.110092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "0.134443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.130868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.107195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.015246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.117525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.081445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "0.077388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.059783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.130868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "-0.054554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.008044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Tops Q4 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2221562/eli-lilly-lly-tops-q4-earnings-and-revenue-estimates",
    "time_published": "20240206T125503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of 0.81% and 5.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.144094,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.399204",
        "ticker_sentiment_score": "0.207635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARDX",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P, Nasdaq Futures Point To Another Day Of Weakness: What's Going On With Stocks? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36952531/us-stocks-brace-for-another-day-in-the-red-as-rally-loses-steam-analyst-sees-market-pullback-on-thi",
    "time_published": "20240206T123737",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks are poised for another day of weakness, although some positive tech earnings may provide a modest lift to the sector. The market appears to be digesting information following a rally that began after the early January downturn.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nyse-shutter_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": -0.024063,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.208732",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.212156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JJSF",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.348877",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHKP",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.132222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRB",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.176076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WU",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.309859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Veers Higher On Fourth-Quarter Beat",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2023/",
    "time_published": "20240206T123200",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) stock jetted higher early Tuesday after the pharmaceutical company reported adjusted profit of $2.49 per share on $9.35 billion in fourth-quarter sales. On average, analysts surveyed by FactSet expected Lilly to earn $2.30 per share on $8.95 billion in sales.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Eli-Lilly-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.232148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.941495",
        "ticker_sentiment_score": "0.411227",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance",
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-strong-fourth-quarter-2023-financial-results-and-provides-2024-guidance-302053915.html",
    "time_published": "20240206T114500",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "( i ) Lilly defines New Products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound. ( ii ) Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, Emgality, Jardiance, Olumiant, ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.145433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.01102",
        "ticker_sentiment_score": "-0.072984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.331478",
        "ticker_sentiment_score": "0.17446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.01102",
        "ticker_sentiment_score": "-0.014773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.01102",
        "ticker_sentiment_score": "0.118355",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The first Wall Street bank to make a recession call now expects a narrow landing",
    "url": "https://www.marketwatch.com/story/the-first-wall-street-bank-to-make-a-recession-call-now-expects-a-narrow-landing-660b7549",
    "time_published": "20240206T114000",
    "authors": [
      "Barbara Kollmeyer"
    ],
    "summary": "The U.S. economy will land on a \"narrow path\" this year, and avoid a recession, thanks in part to a better consumer picture, says Deutsche Bank.",
    "banner_image": "https://images.mktw.net/im-54030136?width=700&height=559",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.067508,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.138488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.047851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.093878",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ford, Eli Lilly And 3 Stocks To Watch Heading Into Tuesday - Ford Motor  ( NYSE:F ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36947833/ford-eli-lilly-and-3-stocks-to-watch-heading-into-tuesday",
    "time_published": "20240206T070649",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Eli Lilly and Company LLY to report quarterly earnings at $2.19 per share on revenue of $8.93 billion before the opening bell, according to data ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/ford_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.268213,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.412575",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMKR",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "-0.180827",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMI",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.32771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "F",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "0.438952",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.676595",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36947735/eli-lilly-likely-to-report-higher-q4-earnings-here-are-the-recent-forecast-changes-from-wall-street",
    "time_published": "20240206T060540",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Eli Lilly and Company LLY is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 6, 2024. Analysts expect the company to report quarterly earnings at $2.19 per share, up from year-ago earnings of $2.09 per share.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/eli_lilly_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.049154,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.162099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "-0.098155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "-0.016125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PLTR, NVDA, LLY, SYM, TSLA: Top 5 Trending Stocks Today - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/36946343/palantir-nvidia-eli-lilly-symbotic-tesla-why-these-5-stocks-are-on-investors-radars-today",
    "time_published": "20240206T014514",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "U.S. stocks traded lower at the end of trading on Monday with the Dow Jones Industrial Average declining 0.7% to 38,380.12 and the S&P 500 dropping 0.3% to 4,942.81. The Nasdaq ended Monday lower by 0.2% at 15,597.68. These are the top stocks that gained the attention of retail traders and ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Stocks-Photo-by-Phongphan-on-Shutterstoc_7.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.287582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.191244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.47824",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.095762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.082111",
        "ticker_sentiment_score": "0.285316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYM",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.297278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.214982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Triple Threat Of Key Reversals: Warning Shots Fired In High Fliers Nvidia, Eli Lilly, Super Micro Computers - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/technicals/24/02/36964497/triple-threat-of-key-reversals-warning-shots-fired-in-3-high-fliers",
    "time_published": "20240207T234520",
    "authors": [
      "Aaron Bry"
    ],
    "summary": "In a potential warning sign to investors, three high-flying stocks had key reversals on Tuesday. This means the stocks opened to new highs before trading below their previous closing price.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/07/market.man_.up_.shutterstock_139983946.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.183233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.348391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.817578",
        "ticker_sentiment_score": "0.414446",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.398493",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro, Zepbound Performance - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36990258/analysts-boost-eli-lillys-forecast-with-high-hopes-on-mounjaro-zepbound-performance",
    "time_published": "20240207T194942",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Eli Lilly And Co LLY reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.155368,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.09135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.060669",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Stock Getting Closer To Key Technical Benchmark",
    "url": "https://www.investors.com/news/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
    "time_published": "20240207T161100",
    "authors": [
      "GLENN LARKIN",
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.371044,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.661658",
        "ticker_sentiment_score": "0.346743",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat",
    "url": "https://www.zacks.com/stock/news/2222669/etfs-to-buy-as-mounjaro-powers-eli-lillys-q4-earnings-beat",
    "time_published": "20240207T150500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999965"
      }
    ],
    "overall_sentiment_score": 0.229502,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.337427",
        "ticker_sentiment_score": "0.312048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/36982491/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20240207T144556",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.009605,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.702434",
        "ticker_sentiment_score": "-0.173123",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "-0.15371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly Earns IBD Stock Rating Upgrade",
    "url": "https://www.investors.com/ibd-data-stories/eli-lilly-earns-ibd-stock-rating-upgrade/",
    "time_published": "20240207T080000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Wednesday, Eli Lilly ( LLY ) got an upgrade for its IBD SmartSelect Composite Rating from 90 to 96. X The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.225151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "-0.116293",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Getting Closer To Key Technical Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
    "time_published": "20240207T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.362319,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.422149",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/02/06/eli-lilly-lly-q4-2023-earnings-call-transcript/",
    "time_published": "20240207T003018",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "LLY earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.255016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.010751",
        "ticker_sentiment_score": "0.11558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.058669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.116534",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.128229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.007168",
        "ticker_sentiment_score": "0.073354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.078717",
        "ticker_sentiment_score": "0.13047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGTX",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.116534",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.007168",
        "ticker_sentiment_score": "0.110952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.003584",
        "ticker_sentiment_score": "0.138176",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "As tech layoffs mount, support groups on LinkedIn are helping workers find jobs",
    "url": "https://www.marketwatch.com/story/as-tech-layoffs-mount-communities-on-linkedin-are-trying-to-find-jobs-for-affected-workers-f8248c63",
    "time_published": "20240208T223600",
    "authors": [
      "James Rogers"
    ],
    "summary": "\"People will cross-post opportunities within the group that they believe others could benefit from, people in the group are keen to share opportunities for others.\" ...",
    "banner_image": "https://images.mktw.net/im-61045217/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.097431,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.013266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.009091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OKTA",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.075579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.075579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.013266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYCEF",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.008631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.075579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "U",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.075579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.070117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.019914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCU",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.075579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.110632",
        "ticker_sentiment_score": "-0.087675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.070117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRX",
        "relevance_score": "0.110632",
        "ticker_sentiment_score": "-0.095389",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month",
    "url": "https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/",
    "time_published": "20240208T215600",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "Investors are still excited about obesity treatments and weight-management drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764656%2Fgettyimages-663845678-600x400-bf06395.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238796,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.399506",
        "ticker_sentiment_score": "0.12975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "0.101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.227826",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.195563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze",
    "url": "https://www.marketwatch.com/story/viking-therapeutics-may-offer-investors-a-cheap-entry-to-the-weight-loss-drug-craze-8d5d623a",
    "time_published": "20240208T191800",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "Stock is trading at $28 compared with Eli Lilly's $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.",
    "banner_image": "https://images.mktw.net/im-832731/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.196705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.306761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.158504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.218866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy a Stock on its All-Time Highs?",
    "url": "https://www.zacks.com/stock/news/2223610/should-you-buy-a-stock-on-its-all-time-highs",
    "time_published": "20240208T171800",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "There is a stock you love but it's red hot and has gone vertical. Do you dive in or wait for a sell-off?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/53604.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998626"
      }
    ],
    "overall_sentiment_score": 0.197259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.293741",
        "ticker_sentiment_score": "0.209306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.127529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRT",
        "relevance_score": "0.453501",
        "ticker_sentiment_score": "0.188051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.157067",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.293741",
        "ticker_sentiment_score": "0.343094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Foghorn Therapeutics  ( FHTX )  Stock Is Exploding Higher - Foghorn Therapeutics  ( NASDAQ:FHTX ) ",
    "url": "https://www.benzinga.com/news/24/02/37012990/why-foghorn-therapeutics-fhtx-stock-is-exploding-higher",
    "time_published": "20240208T164828",
    "authors": [
      "Henry Khederian"
    ],
    "summary": "Foghorn Therapeutics Inc. FHTX shares are trading higher by 44.8% to $4.52 during Thursday's session after the company announced that Eli Lilly And Co LLY has chosen FHD-909, an oral BRM selective inhibitor, for clinical development. Foghorn says the drug targets BRG1 mutated non-small cell lung ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/doctor-2568481_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.029067,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.291555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FHTX",
        "relevance_score": "0.634282",
        "ticker_sentiment_score": "0.112111",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "-0.132549",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Obesity Drug Update That Sent This Lilly Rival To A Record High",
    "url": "https://www.investors.com/news/technology/vktx-stock-charges-to-a-record-high-on-an-update-for-its-lilly-rivaling-obesity-treatment/",
    "time_published": "20240208T154000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "VKTX Stock Charges To A Record High On An Update For Its Lilly-Rivaling Obesity Treatment Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-DrugsPills-14-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.164289,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.204647",
        "ticker_sentiment_score": "-0.048648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.137278",
        "ticker_sentiment_score": "0.159429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.563489",
        "ticker_sentiment_score": "0.487709",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.270523",
        "ticker_sentiment_score": "0.110119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37011034/whats-going-on-eli-lilly-stock-thursday",
    "time_published": "20240208T153658",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Since Monday, Eli Lilly And Co LLY shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a whopping $690 billion ( roughly ) . Thursday, shares are trading with a session volume of 25.301K compared to an average volume of 3.277 million, as per data from ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.082912,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.753715",
        "ticker_sentiment_score": "0.253242",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.179932",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.192315",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.179932",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.172805",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.172805",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade",
    "url": "https://www.fool.com/investing/2024/02/08/4-reasons-why-2024-could-be-eli-lillys-worst-year/",
    "time_published": "20240208T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly's headwinds in 2024 should only be temporary challenges.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764351/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.139906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.665529",
        "ticker_sentiment_score": "0.343664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual Moves: 'Authentic Stupidity Is A Perfectly Plausible Explanation' - Apple  ( NASDAQ:AAPL ) , Chipotle Mexican Grill  ( NYSE:CMG ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36997732/apple-chipotle-and-eli-lilly-stocks-baffle-jim-cramer-with-recent-unusual-movements",
    "time_published": "20240208T020536",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" expressed skepticism regarding the recent market movements of Apple Inc AAPL, Chipotle Mexican Grill, Inc. CMG, and Eli Lilly And Co LLY.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_10.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.048811,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CMG",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "-0.10424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.04475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.120584",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/37043860/s-p-500-hits-5-000-magnificent-7-tops-13-trillion-commercial-real-estate-cracks-emerge-the-week-",
    "time_published": "20240209T210819",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "The S&P 500 index surged past the 5,000-point threshold by the week's end, setting new record highs on the optimism surrounding artificial intelligence. Both the S&P 500 and the Nasdaq 100 celebrated their 14th positive week out of the last 15, showcasing the resilience of the winter rally.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.157472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.096429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.379435",
        "ticker_sentiment_score": "0.252457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.096429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.096429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "-0.060031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.044833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "-0.060031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "-0.090253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.096429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "-0.003743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "-0.081232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.058219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.180448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "-0.090253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSHZF",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.022857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.058219",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Shares of Eli Lilly Popped This Week",
    "url": "https://www.fool.com/investing/2024/02/09/why-shares-of-eli-lilly-popped-this-week/",
    "time_published": "20240209T193401",
    "authors": [
      "Brett Schafer"
    ],
    "summary": "The pharmaceutical giant is gaining momentum, and investors are excited.",
    "banner_image": "https://media.ycharts.com/charts/6adc7901c4a88659abaceda0365bf270.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.184299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.295235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.13519",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What to think about 'Peak 65'",
    "url": "https://www.marketwatch.com/story/what-to-think-about-peak-65-d23f2413",
    "time_published": "20240209T190600",
    "authors": [
      "Philip van Doorn"
    ],
    "summary": "Also: Strategies to build a retirement nest egg and make it last, and a different way for investors to play the weight-loss-drug craze.",
    "banner_image": "https://images.mktw.net/im-74524387?width=700&height=486",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095345,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.071851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.012989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "-0.025551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.062043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "0.022061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEWOW",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.093845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.045374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.062043",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals",
    "url": "https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-llys-q4-earnings-nvo-nvs-mrks-ma-deals",
    "time_published": "20240209T153600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.080745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.291182",
        "ticker_sentiment_score": "0.088229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.005453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.244354",
        "ticker_sentiment_score": "0.109061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.148121",
        "ticker_sentiment_score": "0.043887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.291182",
        "ticker_sentiment_score": "0.037556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "-0.074089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Foghorn  ( FHTX )  Jumps 55% as Lilly Takes Up FHD-909 Development",
    "url": "https://www.zacks.com/stock/news/2224167/foghorn-fhtx-jumps-55-as-lilly-takes-up-fhd-909-development",
    "time_published": "20240209T150200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.173802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.353562",
        "ticker_sentiment_score": "0.289334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FHTX",
        "relevance_score": "0.28636",
        "ticker_sentiment_score": "0.213203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.28636",
        "ticker_sentiment_score": "0.153793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Tesla Still A Magnificent 7 Stock? Berkshire Hathaway, Broadcom, Eli Lilly Line Up As Contenders - Broadcom  ( NASDAQ:AVGO ) , iShares U.S. Financial Services ETF  ( ARCA:IYG ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/37035036/is-tesla-still-a-magnificent-7-stock-ev-maker-could-get-bumped-by-these-companies",
    "time_published": "20240209T143835",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Tesla's TSLA standing within the Magnificent Seven is in question. What Happened: The Austin, Texas-based electric vehicle ( EV ) company now stands at number nine on the list of biggest companies on the S&P 500 index.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/musk-tesla-red-shutter_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.201139,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.475072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.223963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.102561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.41627",
        "ticker_sentiment_score": "-0.002894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.095426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Philip Johnson to Retire as Lilly Treasurer",
    "url": "https://www.prnewswire.com/news-releases/philip-johnson-to-retire-as-lilly-treasurer-302058585.html",
    "time_published": "20240209T143000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE:LLY ) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.253815,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.616228",
        "ticker_sentiment_score": "0.36808",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.146835",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Warren Buffett And Disney Share A $543 Billion Money-Making Secret",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-warren-buffett-and-disney-share-billion-moneymaking-secret/",
    "time_published": "20240209T130000",
    "authors": [
      "MATT KRANTZ",
      "Investor's Business Daily"
    ],
    "summary": "S&P 500: Warren Buffett And Disney Share $543 Billion Moneymaking Secret Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.4244,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.256351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "-0.083961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.398988",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.165025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.398988",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.281153",
        "ticker_sentiment_score": "0.312127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/09/is-eli-lilly-stock-a-buy-now/",
    "time_published": "20240209T121500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly's valuation is approaching $700 billion.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764145/person-reviewing-a-sample-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.102609,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.726705",
        "ticker_sentiment_score": "0.150642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: NVDA, LLY, CMG, DECK and VRT",
    "url": "https://www.zacks.com/stock/news/2223834/zacks-market-edge-highlights-nvda-lly-cmg-deck-and-vrt",
    "time_published": "20240209T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "NVDA, LLY, CMG, DECK and VRT have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998626"
      }
    ],
    "overall_sentiment_score": 0.208369,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.26224",
        "ticker_sentiment_score": "0.191647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.116942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRT",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.17501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.143426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.26224",
        "ticker_sentiment_score": "0.315243",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains' - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37024300/jim-cramer-says-investors-should-look-beyond-apple-meta-and-other-magnificent-7-sto",
    "time_published": "20240209T023401",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer-Photo-by-a-katz-on-Shuttersto_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.190571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.103261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.103261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.103261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.103261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.103261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.231799",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XPO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.045091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.176937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMS",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Hits Highs As AI Plays Skyrocket: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-hits-highs-as-arm-palantir-cloudflare-skyrocket/",
    "time_published": "20240209T001300",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rally generally advanced with the S&P 500 hitting 5,000 for the first time and the Nasdaq at its best levels in over two years. The Dow Jones held just below its all-time highs while the Russell 2000 rebounded back above key levels.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.088082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDNDF",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "-0.147329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.066999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPD",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.012012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.049042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVGI",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "0.067321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.053795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCB",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.054344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.078802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.069261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QLYS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.004005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.048215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.129876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.089328",
        "ticker_sentiment_score": "0.118465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOSL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.101404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.224249",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.016619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.07722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.151575",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.074739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIOD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.07345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.018656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?",
    "url": "https://www.fool.com/investing/2024/02/10/eli-lilly-just-succeeded-where-others-failed-but-d/",
    "time_published": "20240210T163000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Potentially adding billions of dollars in revenue might move the needle for the pharmaceutical giant, but that could take years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764034/investor-smiles-while-looking-at-tablet-in-airplane.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.168402,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.306325",
        "ticker_sentiment_score": "0.09986",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks That Could Trounce the Market in 2024",
    "url": "https://www.fool.com/investing/2024/02/10/3-stocks-that-could-trounce-the-market-in-2024/",
    "time_published": "20240210T114900",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "These stocks appear to have what it takes to beat the market this year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.285154,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.143278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.154214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.153045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.096768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.179938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?",
    "url": "https://www.fool.com/investing/2024/02/11/novo-nordisk-is-scaling-a-barrier-to-growth-should/",
    "time_published": "20240211T172500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Even more revenue is on the way from additional sales of Wegovy.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764279/tablet-thinking-office.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.161313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.061823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.008959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.416844",
        "ticker_sentiment_score": "0.16777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could This Warren Buffett Advice Help You Become a Millionaire?",
    "url": "https://www.fool.com/investing/2024/02/11/could-this-buffett-advice-help-you-become-rich/",
    "time_published": "20240211T120100",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Both experienced and new investors may benefit from this investment...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764544%2Fbuffett11-tmf.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.333185,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.032999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.032999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.032999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.251183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outlines What Lies Ahead - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37077761/eli-lillys-weight-loss-drug-tripeptide-is-expanding-market-share-analyst-outline-wh",
    "time_published": "20240212T195417",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In support of expectations for Eli Lilly And Company's LLY tripeptide, BMO Capital Markets is tracking weekly Mounjaro, Zepbound, GLP-1 category TRx ( total prescriptions ) , and NRx ( new prescriptions ) . The analyst models $12.78 billion for the fiscal year 2024 tripeptide revenues.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.328248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.23962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs After Q4 Earnings",
    "url": "https://www.zacks.com/stock/news/2224986/a-look-at-pharma-etfs-after-q4-earnings",
    "time_published": "20240212T175900",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.054971,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "0.071368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "0.058563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "-0.003144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "0.110586",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Value Stocks With Monster Yields",
    "url": "https://www.fool.com/investing/2024/02/12/2-value-stocks-with-monster-yields/",
    "time_published": "20240212T141500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two low-priced large-cap stocks sport ginormous yields.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764890%2Fvalue-vs-price.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.15026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.088091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.378777",
        "ticker_sentiment_score": "-0.032375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.088091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "-0.02711",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37068324/novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-w",
    "time_published": "20240212T135745",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The unprecedented demand for weight loss drugs, including Novo Nordisk A/S's NVO Wegovy and Eli Lilly And Co's LLY Zepbound, has created a supply crunch, leaving patients struggling to access these injectable treatments.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.146812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.160399",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.130414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.321378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?",
    "url": "https://www.fool.com/investing/2024/02/12/this-unstoppable-growth-stock-just-announced-more/",
    "time_published": "20240212T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drugmaker continues to impress investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764366/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.449503",
        "ticker_sentiment_score": "0.281777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Short sellers boosted by 'Hedge Fund Nirvana' that sees most heavily-shorted companies suffer",
    "url": "https://www.marketwatch.com/story/short-sellers-boosted-by-hedge-fund-nirvana-that-sees-most-heavily-shorted-companies-suffer-5be59096",
    "time_published": "20240212T124700",
    "authors": [
      "Louis Goss"
    ],
    "summary": "The most heavily shorted stocks have underperformed in 2024 compared to rivals, in a turnaround compared to ...",
    "banner_image": "https://images.mktw.net/im-17674986?width=700&height=488",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.067078,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WHR",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRO",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBWI",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.055727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?",
    "url": "https://www.fool.com/investing/2024/02/12/could-lillys-zepbound-become-worlds-best-seller/",
    "time_published": "20240212T100300",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Everyone is excited about Zepbound, from patients to investors...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764827%2Fgettyimages-three-investors-look-at-a-computer_in-office.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.1742,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.070678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.270324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.070678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday",
    "url": "https://www.cnbc.com/2024/02/13/why-we-would-be-considering-buying-more-eli-lilly-shares-if-they-were-down.html",
    "time_published": "20240213T171555",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107372911-17078386721707838668-33318611669-1080pnbcnews.jpg?v=1707838672&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.306676,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.216215",
        "ticker_sentiment_score": "0.223262",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.134232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.134232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.169681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,000 Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/37099915/if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-6-000-today",
    "time_published": "20240213T170033",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 5 years by 31.12% on an annualized basis producing an average annual return of 43.4%. Currently, Eli Lilly has a market capitalization of $703.02 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.158543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.375984",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Incyte's  ( INCY )  Q4 Earnings & Revenues Fall Shy of Estimates",
    "url": "https://www.zacks.com/stock/news/2225655/incytes-incy-q4-earnings-revenues-fall-shy-of-estimates",
    "time_published": "20240213T163700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.129819,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.094203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.607733",
        "ticker_sentiment_score": "0.117481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.156125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.135857",
        "ticker_sentiment_score": "-0.021199",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2225357/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240213T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.250252,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.522096",
        "ticker_sentiment_score": "0.180854",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment",
    "url": "https://www.marketwatch.com/story/biogens-quarterly-results-miss-expectations-amid-slow-launch-of-alzheimers-treatment-2d5edeaf",
    "time_published": "20240213T122100",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales.",
    "banner_image": "https://images.mktw.net/im-31052601/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069737,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.196613",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.108138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "-0.046896",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2225205/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240213T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.215642,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.032068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.044001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.064698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2225206/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240213T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.331073,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.050334",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.",
    "url": "https://www.fool.com/investing/2024/02/13/move-aside-eli-lilly-and-novo-nordisk-wall-street/",
    "time_published": "20240213T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "There's more for investors to get excited about in the biopharma world than just weight-loss drugs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764848/scientists-happy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.29916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.488445",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.479945",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.427854",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come' - Eli Lilly  ( NYSE:LLY ) , PepsiCo  ( NASDAQ:PEP ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37086294/jim-cramer-warns-weight-loss-drugs-ozempic-wegovy-and-others-could-impact-food-stoc",
    "time_published": "20240213T064658",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has issued a warning to investors about the potential impact of weight loss drugs, such as Ozempic and Wegovy, on the food and beverage industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_11.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.057754,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.056768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.171236",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? - Air Products & Chemicals  ( NYSE:APD ) , Archer-Daniels Midland  ( NYSE:ADM ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/37133520/nearly-half-of-s-p-500-stocks-trade-below-50-day-moving-average-which-one-is-the-cheapest",
    "time_published": "20240214T174915",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "As the S&P 500 index continues to hover near the 5,000-point threshold, not far from its all-time highs, the remarkable surge of over 20% since late October levels created a stark divide with many corporations failing to join the market rally.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/SP500-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.1086,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.337798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.337798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.132281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MKTX",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.07476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.337798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.07476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RL",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHTR",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.07476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock Wednesday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37129173/whats-going-on-with-eli-lilly-stock-wednesday",
    "time_published": "20240214T153513",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Year-to-date, Eli Lilly And Company's LLY shares have gained almost 25%, with its enterprise value surpassing $700 billion, according to data from Benzinga Pro. The shares are trading with a session volume of $13.895K, compared to an average volume of 3.156 million.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.211575,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.353114",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Perfect Stocks to Buy This Valentine's Day",
    "url": "https://www.fool.com/investing/2024/02/14/3-perfect-stocks-to-buy-this-valentines-day/",
    "time_published": "20240214T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks have sweet long-term prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765046/flowers.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.289897,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.252645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.057031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.207879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/02/14/amgen-takes-aim-at-novo-nordisk-and-eli-lilly-but/",
    "time_published": "20240214T075900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It faces both clinical and competitive barriers, but they might not matter.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764673/lab-worker-women-in-stem-science-research.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.190769,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.185662",
        "ticker_sentiment_score": "0.188728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.215529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.062609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.185687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On Eli Lilly Stock Thursday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37160096/uk-becomes-first-major-market-for-eli-lillys-mounjaro-prefilled-pen-for-tackling-obesity",
    "time_published": "20240215T150938",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Pharmaceutical giant Eli Lilly And Co LLY is set to launch its highly-anticipated obesity drug, Mounjaro ( tirzepatide ) , in Britain this week, making the U.K. the fourth European country to introduce the famed medication.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.187575,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "0.121513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "-0.012856",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy",
    "time_published": "20240215T140535",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) . The update comes when the Danish drugmaker is already struggling to meet the demand from adult patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.030964,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.201435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:KMD",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.15199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?",
    "url": "https://www.investors.com/news/technology/will-weight-loss-diabetes-drugs-drive-lly-stock-into-1-trillion-club/",
    "time_published": "20240216T182700",
    "authors": [
      "REINHARDT KRAUSE",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly's ( LLY ) one-two punch of weight-loss and diabetes treatments Zepbound and Mounjaro should drive the biopharma stock higher, said a Morgan Stanley analyst who raised his price target on LLY stock.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.141259,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.895969",
        "ticker_sentiment_score": "0.123305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "-0.0608",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "One of our financial stocks hit a new high: Here's why we're eyeing a small trade",
    "url": "https://www.cnbc.com/2024/02/16/one-of-our-financial-stocks-hit-a-new-high-why-were-eyeing-a-trade.html",
    "time_published": "20240216T163839",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107374842-17080976861708097678-33359188627-1080pnbcnews.jpg?v=1708097685&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.204173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.170304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.170304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.09059",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What The Future Holds For Google's 'Other Bets'",
    "url": "https://www.investors.com/news/technology/other-bets-x-moonshots-future-google-stock/",
    "time_published": "20240216T154800",
    "authors": [
      "Investor's Business Daily",
      "REINHARDT KRAUSE"
    ],
    "summary": "Other Bets And X Moonshots Key Google Stock's Future Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/wGoog_2c201924.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.159278,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.647825",
        "ticker_sentiment_score": "0.257439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "-0.050985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "-0.035944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.050832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVGI",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.147619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "-0.050985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.081926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VWAGY",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "-0.032837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "0.116286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.074076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.034053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.025574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK",
    "url": "https://www.zacks.com/stock/news/2227385/the-zacks-analyst-blog-highlights-mastercard-sap-crowdstrike-eli-lilly-and-ametek",
    "time_published": "20240216T140500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/497.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.222237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.039317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AME",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.039317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.296761",
        "ticker_sentiment_score": "0.172051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAP",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.268534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.151064",
        "ticker_sentiment_score": "0.039317",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Time To Revisit Amphastar As It Calms After A Plunge",
    "url": "https://www.investors.com/stock-lists/sector-leaders/drug-stock-time-to-revisit-amphastar-as-it-settles-after-a-plunge/",
    "time_published": "20240216T130000",
    "authors": [
      "KIMBERLEY KOENIG",
      "Investor's Business Daily"
    ],
    "summary": "Drug stock Amphastar Pharmaceuticals ( AMPH ) has formed a cup base and settled down after a steep sell-off in January. Now, as an IBD Sector Leader, Amphastar stock is about 18% off its all-time high. Amphastar develops injectable, inhalation and intranasal medical and insulin products.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-amphastarpharma-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      }
    ],
    "overall_sentiment_score": 0.162205,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.137582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "-0.084832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Warren Buffett's Empire Nears Trillion-dollar Club As Class A Shares Hit Above $600,000 - Occidental Petroleum  ( NYSE:OXY ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/02/37193641/warren-buffetts-empire-nears-trillion-dollar-club-as-class-a-shares-hit-above-600-000",
    "time_published": "20240217T182642",
    "authors": [
      "Bibhu Pattnaik"
    ],
    "summary": "This week, Berkshire Hathaway ( NYSE: BRK-A ) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. The surge in share price brings Warren Buffett's iconic conglomerate closer to the coveted $1 trillion market valuation, a feat not yet achieved by any ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/17/shutterstock_353934110.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.223416,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.252954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.232025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.509589",
        "ticker_sentiment_score": "0.168757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Where Will Eli Lilly Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/02/18/where-will-eli-lilly-be-in-5-years/",
    "time_published": "20240218T064500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The stock will still be crushing the market in all likelihood.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765320/patient-taking-medicine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.252692,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.377958",
        "ticker_sentiment_score": "0.149182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.086016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.086016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.086016",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/02/19/3-magnificent-growth-stocks-to-buy-right-now/",
    "time_published": "20240219T151500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765520/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.264978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.27676",
        "ticker_sentiment_score": "0.342352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.160365",
        "ticker_sentiment_score": "0.311688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.044696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.387075",
        "ticker_sentiment_score": "0.271117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 ways a 'Magnificent Seven' stock-market bubble could burst",
    "url": "https://www.marketwatch.com/story/3-ways-a-magnificent-seven-stock-market-bubble-could-burst-df8716d2",
    "time_published": "20240220T173300",
    "authors": [
      "William Watts"
    ],
    "summary": "If the megacap tech rally is indeed a bubble, how might it end?",
    "banner_image": "https://images.mktw.net/im-44847525?width=700&height=560",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.101301,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.104925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.104925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.104925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.139804",
        "ticker_sentiment_score": "0.129381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.139804",
        "ticker_sentiment_score": "0.123643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.139804",
        "ticker_sentiment_score": "0.123643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.085872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Best-Performing S&P 500 Stocks Halfway Through Q1",
    "url": "https://www.zacks.com/stock/news/2228329/5-best-performing-sp-500-stocks-halfway-through-q1",
    "time_published": "20240220T130700",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/52792.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.256075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.148091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.135755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.099699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RL",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.113019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.141555",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "8 Companies' Profit Is Expected To Outgrow Even Nvidia's This Year",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-companies-profit-is-expected-to-outgrow-even-nvidia-this-year/",
    "time_published": "20240220T130000",
    "authors": [
      "Investor's Business Daily",
      "MATT KRANTZ"
    ],
    "summary": "Investors are understandably jazzed about Nvidia's upcoming earnings report for last year. Growth should be impressive. But analysts think a surprisingly large number of companies will grow even faster this year.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/11/it01-chips-111616-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.409819,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.460808",
        "ticker_sentiment_score": "0.477789",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.388141",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.012243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.15583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.012243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.012243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.271547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Was Feeling Sickly on Wednesday",
    "url": "https://www.fool.com/investing/2024/02/21/why-eli-lilly-stock-was-feeling-sickly-on-wednesda/",
    "time_published": "20240221T225659",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company's surging popularity has made it expensive in terms of valuation.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766315/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.087313,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.051227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.242681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.051227",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37237588/eli-lilly-unusual-options-activity",
    "time_published": "20240221T150132",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.050296,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.751437",
        "ticker_sentiment_score": "0.047479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.131082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Has More Than an Ozempic Competitor -- Much More",
    "url": "https://www.fool.com/investing/2024/02/21/eli-lilly-has-more-than-an-ozempic-competitor-much/",
    "time_published": "20240221T113900",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly's hottest treatment might be Mounjaro, but the company has a lot more at its disposal.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765536%2Fdoctors-office-checkup-patient-hospital.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.220724,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.467176",
        "ticker_sentiment_score": "0.300582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "-0.05942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "-0.05942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "-0.05942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "0.147153",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade",
    "url": "https://www.investors.com/news/abbott-laboratories-stock-gets-a-healthy-technical-rating-upgrade/",
    "time_published": "20240221T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily",
      "JULIE MAK"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.448462,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.685395",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease - Eli Lilly  ( NYSE:LLY ) , Better Therapeutics  ( NASDAQ:BTTX ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/02/37268309/better-therapeutics-follows-up-wins-including-fda-authorization-for-aspyrerx-in-2023-with-securin",
    "time_published": "20240222T182518",
    "authors": [
      "Faith Ashmore"
    ],
    "summary": "Researchers, scientists and practitioners in the past few decades have begun to look at healthcare from a more holistic perspective, often challenging traditional medicine. The question on the minds of many is how to integrate holistic medicine into American healthcare - at scale.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Screenshot-2024-02-22-at-11-51-01-PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.282137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.208398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BTTX",
        "relevance_score": "0.46898",
        "ticker_sentiment_score": "0.421072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.208398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Start Stock Investing in Your 50s",
    "url": "https://www.zacks.com/stock/news/2230305/how-to-start-stock-investing-in-your-50s",
    "time_published": "20240222T160200",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "Think you're too old to start buying stocks? Think again. Here's some tips.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.186205,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.273297",
        "ticker_sentiment_score": "0.143963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.046452",
        "ticker_sentiment_score": "-0.081777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSM",
        "relevance_score": "0.358798",
        "ticker_sentiment_score": "0.269233",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.273297",
        "ticker_sentiment_score": "0.264543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.399911",
        "ticker_sentiment_score": "0.137556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.273297",
        "ticker_sentiment_score": "0.376233",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.",
    "url": "https://www.fool.com/investing/2024/02/22/1-pharmaceutical-stock-that-looks-unstoppable/",
    "time_published": "20240222T120000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765806%2Fnurse-checking-elderly-patients-blood-pressure-long-term-care-senior-nursing-home-poc.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.307091,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.6979",
        "ticker_sentiment_score": "0.507042",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.131827",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assessing Eli Lilly and Co's Performance Against Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/37287232/assessing-eli-lilly-and-cos-performance-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20240223T160015",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.207499,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.530253",
        "ticker_sentiment_score": "0.293242",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37285613/what-the-options-market-tells-us-about-eli-lilly-and-co",
    "time_published": "20240223T150104",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.028638,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.790287",
        "ticker_sentiment_score": "-0.036237",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.1043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.1043",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-how-outliers-like-biohaven-regeneron-are-trying-to-squeeze-into-the-obesity-space/",
    "time_published": "20240223T133000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/A1MAIN_weightloss_022324.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.012175,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.027602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "-0.03917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.015999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALUR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.05222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.09668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.061293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.158938",
        "ticker_sentiment_score": "0.096962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.025591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Eli Lilly Stock Help You Become a Millionaire?",
    "url": "https://www.fool.com/investing/2024/02/23/could-eli-lilly-stock-help-you-become-millionaire/",
    "time_published": "20240223T111100",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Shares of Eli Lilly have risen by roughly 1,190% over the past 10 years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765978/rich-couple-on-a-boat.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.30401,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.616842",
        "ticker_sentiment_score": "0.438468",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.214295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.214295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: AAPL, COST, WSM, LLY and HLT",
    "url": "https://www.zacks.com/stock/news/2230610/zacks-market-edge-highlights-aapl-cost-wsm-lly-and-hlt",
    "time_published": "20240223T083500",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "AAPL, COST, WSM, LLY and HLT have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/429.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.199463,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.16987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "-0.080945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSM",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "0.252923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.247198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.171849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.352875",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks That Are No-Brainer Buys Right Now",
    "url": "https://www.fool.com/investing/2024/02/24/3-dividend-stocks-that-are-no-brainer-buys-right-n/",
    "time_published": "20240224T120400",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks check off multiple boxes for investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766429/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.279267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CBAY",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.090452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.308614",
        "ticker_sentiment_score": "0.305134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.153058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.349945",
        "ticker_sentiment_score": "0.191869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.239576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Harvard Business Professor on Failing Well",
    "url": "https://www.fool.com/investing/2024/02/24/harvard-business-professor-on-failing-well/",
    "time_published": "20240224T110000",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Why would Eli Lilly put on a failure party?",
    "banner_image": "https://g.foolcdn.com/editorial/images/765894/mfm_18.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.029862,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.044716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EADSF",
        "relevance_score": "0.011716",
        "ticker_sentiment_score": "-0.110904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.046839",
        "ticker_sentiment_score": "-0.113812",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A growing number of stocks are joining the market rally - even as Big Tech still gets the most attention",
    "url": "https://www.marketwatch.com/story/a-growing-number-of-stocks-are-joining-the-market-rally-even-as-big-tech-still-gets-most-of-the-attention-a0231a08",
    "time_published": "20240224T001900",
    "authors": [
      "Joseph Adinolfi"
    ],
    "summary": "Nvidia's blockbuster earnings report helped all 11 of the S&P 500's sectors finish the week in the green for the first time this year.",
    "banner_image": "https://images.mktw.net/im-20169731/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.114012,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.057072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.147807",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.189099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.123246",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Another Reason Why Nvidia Is King Of Tech",
    "url": "https://www.investors.com/research/nvidia-nvda-stock-warren-buffett-berkshire-hathaway-sp500-lly-meta-stock/",
    "time_published": "20240226T183200",
    "authors": [
      "KIMBERLEY KOENIG",
      "Investor's Business Daily"
    ],
    "summary": "Nvidia Stock: Another Reason Why It's The King Of Tech Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-NVIDIA09-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.219213,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.22861",
        "ticker_sentiment_score": "0.243106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.283542",
        "ticker_sentiment_score": "0.284156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.337044",
        "ticker_sentiment_score": "0.331382",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.068861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g",
    "time_published": "20240226T182533",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Autoinjector-with-Amgevita-by-Amgen-Adal.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.137255,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.172847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.333285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors - AstraZeneca  ( NASDAQ:AZN ) , Catalent  ( NYSE:CTLT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/37315592/eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors",
    "time_published": "20240226T163135",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company's shares 30% higher.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.182634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.262817",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "-0.009696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "0.072593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "0.059846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "-0.009696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stocks In A Tizzy As New Weight-Loss Rival Enters The Arena",
    "url": "https://www.investors.com/news/technology/biotech-stocks-diverge-on-new-results-for-weight-loss-drug-in-mash-patients/",
    "time_published": "20240226T155200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Altimmune-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.170267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.472711",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.059975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.059661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.013949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.030348",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2231511/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
    "time_published": "20240226T140014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default114.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.256927,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.523044",
        "ticker_sentiment_score": "0.184155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Warren Buffett's Berkshire Is On Cusp Of Joining The $1 Trillion Club",
    "url": "https://www.investors.com/news/warren-buffett-stock-berkshire-hathaway-on-cusp-of-1-trillion-market-cap/",
    "time_published": "20240226T123000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "The trillion-dollar club is largely the preserve of tech titans such as Apple ( AAPL ) and Nvidia ( NVDA ) , with Meta Platforms ( META ) rejoining that level this year. But Warren Buffett's Berkshire Hathaway ( BRKB ) is knocking on the door. Berkshire Hathaway has a $952.75 billion ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-Buffett-Warren-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.087538,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.034126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.329992",
        "ticker_sentiment_score": "0.034596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.081763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.329992",
        "ticker_sentiment_score": "0.078441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.130867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.034126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.449219",
        "ticker_sentiment_score": "0.224219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.145508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.329992",
        "ticker_sentiment_score": "-0.479514",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.060578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.329992",
        "ticker_sentiment_score": "0.15192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Novo Nordisk and Eli Lilly Stocks Slipped Today",
    "url": "https://www.fool.com/investing/2024/02/27/why-novo-nordisk-and-eli-lilly-stocks-slipped-toda/",
    "time_published": "20240227T230100",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767102/medical-professional-with-hand-on-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.065764,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.572601",
        "ticker_sentiment_score": "0.031781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.005675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.47452",
        "ticker_sentiment_score": "0.028501",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Today: Stocks End Mixed After Disappointing Economic Data",
    "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-end-mixed-after-disappointing-economic-data",
    "time_published": "20240227T210737",
    "authors": [
      "Karee Venema"
    ],
    "summary": "Tuesday marked another choppy day for stocks as investors looked ahead to this week's key inflation update and the impact it may or may not have on the Fed's plans for interest rates.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hbRMDVRhfJobMQLXddLEdj-415-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": -0.004874,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.061894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.079591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.107479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.061894",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia, Eli Lilly, AMD Enjoy High Equity Valuations: Do Higher Rates Put Them In Peril? - Advanced Micro Devices  ( NASDAQ:AMD ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37346557/are-nvidia-eli-lilly-amds-high-equity-valuations-in-peril-from-higher-rates",
    "time_published": "20240227T203553",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Higher long-term rates typically matter a lot to equity valuations. However, according to DataTrek, today's mega-cap stocks are likely to weather the current higher rate environment. Nvidia Corporation NVDA has a price-to-earnings ( P/E ) ratio of 65.8 Eli Lilly And Company LLY even higher ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nvidia-chart-shutter2_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.101636,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Beam, Up 28% Today, Is Planning To Take On Crispr",
    "url": "https://www.investors.com/news/technology/beam-stock-rockets-to-year-high-as-efforts-to-take-on-crispr-deepen/",
    "time_published": "20240227T192800",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Beam Stock Rockets To Year High As Efforts To Take On Crispr Deepen Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-beamtherapeutics-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.12433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.06926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.38104",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.055094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.38104",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley",
    "url": "https://www.zacks.com/research-daily/2232353/top-analyst-reports-for-eli-lilly-procter-gamble-morgan-stanley",
    "time_published": "20240227T163900",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.274776,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.156541",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.317945",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.575696",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results",
    "url": "https://www.investors.com/news/technology/viking-therapeutics-skyrockets-on-weight-loss-drug-trial-results/",
    "time_published": "20240227T125800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Viking Therapeutics ( VKTX ) said Tuesday that its weight-loss drug achieved all goals of its phase two study. Viking stock more than doubled in premarket trade. Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , which already have weight-loss drugs on the market, fell modestly.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/Stock-biotech-12-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.026041,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "-0.217522",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "-0.170661",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "-0.217522",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics' stock doubles after company reports positive results in trial of weight-loss drug",
    "url": "https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767",
    "time_published": "20240227T122200",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "Investors cheer what may be a cheap way to play the current weight-loss drug mania.",
    "banner_image": "https://images.mktw.net/im-832731/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.070779,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.317254",
        "ticker_sentiment_score": "0.12217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.02259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.193723",
        "ticker_sentiment_score": "0.173518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer - Broadcom  ( NASDAQ:AVGO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/37327396/warren-buffetts-berkshire-hathaway-elon-musks-tesla-and-eli-lilly-could-be-next-trillion-dollar-",
    "time_published": "20240227T040558",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "CNBC's Jim Cramer has identified three companies that could potentially join the trillion-dollar club, in the wake of Nvidia Corp's NVDA rapid ascension. What Happened: On Monday, Cramer named Eli Lilly and Co LLY, Berkshire Hathaway Inc BRK BRK, and Tesla Inc TSLA as potential candidates for the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.221406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.227172",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.16921",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.519002",
        "ticker_sentiment_score": "0.212441",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.056728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.131965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.142234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hims & Hers' stock jumps on hopes of a first profitable year, as it floats opportunities in weight loss",
    "url": "https://www.marketwatch.com/story/hims-hers-stock-jumps-on-forecasts-4290103d",
    "time_published": "20240227T005100",
    "authors": [
      "Bill Peters"
    ],
    "summary": "Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations.",
    "banner_image": "https://images.mktw.net/im-30342026/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.18338,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.065268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WW",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.084826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "-0.025719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.263916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Oprah's departure from Weight Watchers' board is the latest bad news for the stock, amid weight-loss-drug frenzy",
    "url": "https://www.marketwatch.com/story/weight-watchers-shares-fall-sharply-after-oprah-winfrey-decides-not-to-stand-for-board-re-election-94b77c0e",
    "time_published": "20240228T223000",
    "authors": [
      "Bill Peters"
    ],
    "summary": "Shares of WW International Inc., better known as Weight Watchers, tumbled after hours on Wednesday, as the weight-loss platform said Oprah Winfrey planned to leave its board and donate her stake in the company after revealing that she used a weight-loss drug.",
    "banner_image": "https://images.mktw.net/im-15938173/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.12256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.016068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WW",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.009963",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say - Viking Therapeutics  ( NASDAQ:VKTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37369830/viking-therapeutics-weight-loss-study-data-outperformed-novo-nordisk-eli-lilly-stud",
    "time_published": "20240228T170535",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Viking Therapeutics Inc VKTX recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo. The San Diego-based company also announced a capital raise of $350 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.19441,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.030048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.23995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.030048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "One down one to go - what we learned from TJX's great quarter and hope to hear from Salesforce",
    "url": "https://www.cnbc.com/2024/02/28/tjxs-quarter-delivers-and-what-cramer-hopes-to-hear-from-salesforce.html",
    "time_published": "20240228T162915",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/105048046-GettyImages-878554390.jpg?v=1709136479&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.122912,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.330654",
        "ticker_sentiment_score": "0.123265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.053508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.330654",
        "ticker_sentiment_score": "0.123265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics' weight-loss drug data makes company takeover target",
    "url": "https://www.marketwatch.com/story/viking-therapeutics-promising-weight-loss-drug-data-makes-the-company-a-takeover-target-5190434e",
    "time_published": "20240228T161800",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "Viking Therapeutics Inc.'s stock rose another 8% Wednesday to extend its week-to-date gains to 145%, as analysts weighed in on its positive weight-loss drug news with some bullish commentary and said the company has become an attractive takeover target.",
    "banner_image": "https://images.mktw.net/im-520633/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.145905,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.186378",
        "ticker_sentiment_score": "0.071138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.140348",
        "ticker_sentiment_score": "0.298538",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.093836",
        "ticker_sentiment_score": "0.164638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss - Eli Lilly and Co  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37367547/large-us-drug-makers-highlight-indian-market-for-their-blockbuster-drugs-including-for-weight-los",
    "time_published": "20240228T154650",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co's LLY CEO, David Ricks, shared the pharmaceutical giant's plans to introduce its obesity drug, tirzepatide, in India as early as next year. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ardelyx-ARDX_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.16621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.33446",
        "ticker_sentiment_score": "0.265542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.270523",
        "ticker_sentiment_score": "0.259582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.204647",
        "ticker_sentiment_score": "-0.017752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic",
    "url": "https://www.zacks.com/stock/news/2233110/the-zacks-analyst-blog-highlights-eli-lilly-the-procter-gamble-morgan-stanley-att-and-medtronic",
    "time_published": "20240228T141200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3d/451.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.215939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.384102",
        "ticker_sentiment_score": "0.13888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.287274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.039287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.030431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.052852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.45283",
        "ticker_sentiment_score": "0.361651",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Weighs In On Palo Alto, Eli Lilly And Salesforce, Says Price Target Bump For This Stock A 'Red Flag' - Eli Lilly and Co  ( NYSE:LLY ) , Salesforce  ( NYSE:CRM ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/37356894/jim-cramer-weighs-in-on-palo-alto-eli-lilly-and-salesforce-says-price-target-bump-for-this-stock-a-",
    "time_published": "20240228T085914",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "During Tuesday's CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer emphasizing heightened threats following a recent breach at UnitedHealth.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_17.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.070275,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "-0.06943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "-0.051147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.067322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.065095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.147166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "0.285591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could These 3 Companies Headline a \"Magnificent Seven\" of Biotech Stocks?",
    "url": "https://www.fool.com/investing/2024/02/29/could-these-3-companies-headline-magnificent-seven/",
    "time_published": "20240229T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These stocks meet many of the criteria long-term investors look for.",
    "banner_image": "https://media.ycharts.com/charts/a0139fd0df9b9ac5ba1cc3d6745e3b8b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.303241,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.442767",
        "ticker_sentiment_score": "0.443683",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.163124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.442767",
        "ticker_sentiment_score": "0.372147",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount",
    "url": "https://www.marketwatch.com/story/viking-therapeutics-takes-advantage-of-soaring-stock-price-to-issue-fresh-shares-at-a-discount-5eb2a7fe",
    "time_published": "20240229T125500",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "Viking Therapeutics has a stock offering starting at $85 - a discount from its Wednesday closing price of $94.50.",
    "banner_image": "https://images.mktw.net/im-454574/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.231491,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "-0.058797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.34081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.050801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "-0.058797",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics: A Teachable Moment About Investing for the Long Term",
    "url": "https://www.fool.com/investing/2024/02/29/viking-therapeutics-a-teachable-moment-about-inves/",
    "time_published": "20240229T124500",
    "authors": [
      "George Budwell"
    ],
    "summary": "The biotherapeutics company's weight loss candidate scored a major win this week.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767179%2Frocket.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.03876,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.14684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.098366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.14684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "-0.056334",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?",
    "url": "https://www.fool.com/investing/2024/02/29/viking-soared-120-percent-is-it-a-buy/",
    "time_published": "20240229T114200",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Viking stock surged in the triple digits in one trading session.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767161%2Fgettyimages-1226994628.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.149498,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.129045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.058149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.163047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.129045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/29/is-viking-therapeutics-a-buy-now/",
    "time_published": "20240229T095300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The stock recently jumped more than 100% overnight thanks to surprising results from its anti-obesity candidate.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767160%2Fbrilliant-scientist-with-tablet-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.271915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.031994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.037096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.376788",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Market Rally At Highs; Here's What To Do Now",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-hits-high-taiwan-semi-jumps/",
    "time_published": "20240301T215300",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Nasdaq Hits Record High, Taiwan Semi Jumps. Here's What To Do Now Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-greenishbull-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.192437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.129721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.116911",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.145853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.082393",
        "ticker_sentiment_score": "0.047008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.027508",
        "ticker_sentiment_score": "0.135793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.218934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.08363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.06972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.013989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.082393",
        "ticker_sentiment_score": "0.052243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.082393",
        "ticker_sentiment_score": "0.079567",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37430818/record-high-s-p-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-sur",
    "time_published": "20240301T210512",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "The U.S. stock market continues its unchallenged bull run, with Wall Street notching yet another week of record-breaking highs for the S&P 500 and Nasdaq 100 indices. This ongoing surge demonstrates the remarkable strength of the bullish sentiment, with stocks marking their 16th positive week out ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/SP500.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.294378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.487477",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.487477",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.487477",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.487477",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37430399/eli-lillys-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-increti",
    "time_published": "20240301T204459",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "BofA Securities says Eli Lilly and Company LLY remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% ( compared to the DRG index's +10% ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_6.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.412925,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.597525",
        "ticker_sentiment_score": "0.545815",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "0.432372",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How investors can ride along as a global commodity market shifts away from China",
    "url": "https://www.marketwatch.com/story/heres-how-investors-can-ride-along-as-a-major-global-commodity-market-shifts-away-from-china-2d122885",
    "time_published": "20240301T175200",
    "authors": [
      "Philip van Doorn"
    ],
    "summary": "China has long dominated the world market for rare earth minerals, which are required components of many devices.",
    "banner_image": "https://images.mktw.net/im-99051667?width=700&height=486",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.092941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.119251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.124097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.255928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.112357",
        "ticker_sentiment_score": "0.088038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "-0.022334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.047489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.149424",
        "ticker_sentiment_score": "-0.008163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.102997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "-0.136767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.124097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.112357",
        "ticker_sentiment_score": "0.164847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.124097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.102997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "-0.068027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.075043",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rally At Highs After Big Earnings, Inflation Data: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rally-at-highs-after-big-earnings-inflation-data-weekly-review/",
    "time_published": "20240301T171100",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Market Rally At High: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/HTI-WALLSTREET-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.072772,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CELH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.070199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRO",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.170246",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOUR",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "-0.07846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "-0.045922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VEEV",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.051869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.009016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.021388",
        "ticker_sentiment_score": "-0.032482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.109933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTST",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.029796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTAP",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.126281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.0854",
        "ticker_sentiment_score": "-0.003141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSTG",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.069585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "-0.061484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.008818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.0854",
        "ticker_sentiment_score": "0.006503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.092845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.043757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "-0.048304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMR",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "-0.003994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.0854",
        "ticker_sentiment_score": "0.146294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDAY",
        "relevance_score": "0.106636",
        "ticker_sentiment_score": "-0.053552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.021388",
        "ticker_sentiment_score": "0.10193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "0.124126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.106636",
        "ticker_sentiment_score": "0.019519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.042762",
        "ticker_sentiment_score": "-0.228129",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.106636",
        "ticker_sentiment_score": "0.037225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "An analyst call on red-hot Broadcom indicates a possible buying opportunity ahead",
    "url": "https://www.cnbc.com/2024/03/01/an-analyst-call-on-red-hot-broadcom-indicates-a-possible-buying-opportunity-ahead.html",
    "time_published": "20240301T164206",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107380684-1709241555094-gettyimages-2040800689-europapress_5784984_dell_technologies_ceo_michael_dell_speak.jpeg?v=1709241804&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.22537,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.142524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.142524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.354319",
        "ticker_sentiment_score": "0.237812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-price-target-increase-weight-loss-drugs-obesity-treatment/",
    "time_published": "20240301T163500",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      }
    ],
    "overall_sentiment_score": 0.126199,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.803345",
        "ticker_sentiment_score": "0.271135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.019112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "-0.16103",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.019112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "0.087193",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Healthcare Stocks That Have Outperformed Nvidia Since 2022",
    "url": "https://www.fool.com/investing/2024/03/01/3-healthcare-stocks-that-have-outperformed-nvidia/",
    "time_published": "20240301T134500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The healthcare sector is no slouch when it comes to top-performing growth stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766658/a-couple-of-investors-looking-at-a-series-of-charts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": 0.267726,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.293741",
        "ticker_sentiment_score": "0.260399",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.261673",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.502508",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRNA",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.100096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $200? 2 Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/03/01/got-200-2-dividend-stocks-to-buy-and-hold-forever/",
    "time_published": "20240301T130000",
    "authors": [
      "Marc Rapport"
    ],
    "summary": "Trust these two real estate stocks to be attractively priced and proven performers.",
    "banner_image": "https://media.ycharts.com/charts/62754a6bac71681cde913b644bbc6635.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24037,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.137007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARE",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "-0.002366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.137007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.137007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.40225",
        "ticker_sentiment_score": "0.120577",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years",
    "url": "https://www.fool.com/investing/2024/03/01/2-stocks-that-could-turn-1000-into-2500-in-5-years/",
    "time_published": "20240301T123100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It will take a lot, but this goal isn't out of reach for these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766641/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.223574,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.441059",
        "ticker_sentiment_score": "0.168395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.132994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 4 Stocks Are the \"Magnificent Seven\" of Healthcare",
    "url": "https://www.fool.com/investing/2024/03/01/these-stocks-are-magnificent-seven-of-healthcare/",
    "time_published": "20240301T065900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Their growth trajectories aren't as meteoric, but they're still notable.",
    "banner_image": "https://media.ycharts.com/charts/13eb85c054da9d0aa6615994f237628d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.27987,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.028625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.154565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.188971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.154565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.083806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.137514",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic, Wegovy And Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/03/37413349/ozempic-wegovy-other-weight-loss-drugs-wont-solve-global-obesity-crisis-affecting-1b-people-who-warn",
    "time_published": "20240301T060757",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "The World Health Organization ( WHO ) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Dorset--Uk--May-25-2020--An-Obese-Couple.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.046192,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.065924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.033773",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Growth Stocks to Buy in March",
    "url": "https://www.fool.com/investing/2024/03/02/3-magnificent-growth-stocks-to-buy-in-march/",
    "time_published": "20240302T143000",
    "authors": [
      "and Prosper Junior Bakiny",
      "David Jagielski",
      "Keith Speights"
    ],
    "summary": "These three stocks have two important common denominators: the same industry and tremendous growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767491/happy-woman-because-the-stock-market-went-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.262052",
        "ticker_sentiment_score": "0.24374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.262052",
        "ticker_sentiment_score": "0.240059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.344473",
        "ticker_sentiment_score": "0.130278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.153986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.060995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Eli Lilly Stock Now?",
    "url": "https://www.fool.com/investing/2024/03/02/is-it-too-late-to-buy-eli-lilly-stock-now/",
    "time_published": "20240302T131500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly stock is having a moment, but the company could easily continue soaring.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766723%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.250494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.539306",
        "ticker_sentiment_score": "0.300425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "0.10883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly",
    "url": "https://www.fool.com/investing/2024/03/03/blockbuster-drug-stock-novo-nordisk-vs-eli-lilly/",
    "time_published": "20240303T175100",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This is a close contest, and it'll go on for at least a few more rounds.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766405/investor-considers-writing-on-glass-wall-while-another-sits-in-the-background.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.294216,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.20537",
        "ticker_sentiment_score": "0.244637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.351273",
        "ticker_sentiment_score": "0.375129",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Better Buy: Eli Lilly vs. Viking Therapeutics",
    "url": "https://www.fool.com/investing/2024/03/03/better-buy-eli-lilly-vs-viking-therapeutics/",
    "time_published": "20240303T143500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two biotechs could eventually go head to head in a fast-growing market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767192/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.18215,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.497609",
        "ticker_sentiment_score": "0.258264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.457977",
        "ticker_sentiment_score": "0.156752",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2235647/eli-lilly-lly-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240304T224518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.199086,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.254963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Two more stock indexes are on track for records: What that means for the bull market",
    "url": "https://www.marketwatch.com/story/two-more-stock-indexes-are-on-track-for-records-what-that-means-for-the-bull-market-044b8b21",
    "time_published": "20240304T183200",
    "authors": [
      "Joseph Adinolfi"
    ],
    "summary": "Both the S&P 400 midcap Index and an ETF that tracks the S&P 500 equal-weight index appeared poised for record closes on Monday, an indication that more stocks are joining a rally that has been criticized for its dependence on Big Tech.",
    "banner_image": "https://images.mktw.net/im-30026221/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999966"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.143078,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.079609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "0.240434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.249461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.249461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.249461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.071764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.081062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.079609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "0.068776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.249461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.249461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.071764",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37460353/eli-lilly-and-co-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240304T160205",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 80 unusual trades. Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.028882,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.771557",
        "ticker_sentiment_score": "0.068128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "-0.096824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "-0.021063",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?",
    "url": "https://www.fool.com/investing/2024/03/04/1-analyst-thinks-eli-lilly-stock-is-going-to-1000/",
    "time_published": "20240304T112500",
    "authors": [
      "Rich Smith"
    ],
    "summary": "There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767709/origami-dollar-folded-into-an-arrow-pointing-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.107831,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.055756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.171272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "-0.083832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You'd Have If You Invested $10,000 in Eli Lilly Stock When Billionaire George Soros First Bought It",
    "url": "https://www.fool.com/investing/2024/03/04/invested-eli-lilly-stock-george-soros/",
    "time_published": "20240304T104800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The tricky part would have been to not sell the pharmaceutical giant's shares when Soros did.",
    "banner_image": "https://media.ycharts.com/charts/12df98e3752c74616e6161b640865a2b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.177895,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.77688",
        "ticker_sentiment_score": "0.278347",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.244166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is the Biggest Company Not in the \"Magnificent Seven\" -- but It Deserves to Be",
    "url": "https://www.fool.com/investing/2024/03/04/big-company-not-in-magnificent-seven-lilly/",
    "time_published": "20240304T095500",
    "authors": [
      "James Brumley"
    ],
    "summary": "It's in a distinctly different business than the \"Magnificent Seven\" companies, but it deserves the same attention.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767518%2F022924-eli-lilly-results.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.305234,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.46341",
        "ticker_sentiment_score": "0.414854",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.139985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.127166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.071754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.104019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News",
    "url": "https://www.investors.com/news/technology/davita-stock-novo-nordisk-weight-loss-drug-dialysis/",
    "time_published": "20240305T154000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-DaVita-01-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.012189,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.157505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.267198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.589793",
        "ticker_sentiment_score": "0.190103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.362065",
        "ticker_sentiment_score": "0.144641",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why",
    "url": "https://www.fool.com/investing/2024/03/05/eli-lilly-and-novo-nordisk-could-just-be-getting/",
    "time_published": "20240305T145300",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767512%2Fstatistic_id271464_diabetics-prevalence-worldwide-2021-2030-and-2045.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.221674,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.41627",
        "ticker_sentiment_score": "0.367741",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.187892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.506613",
        "ticker_sentiment_score": "0.285938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly",
    "url": "https://www.fool.com/investing/2024/03/05/better-weight-loss-drug-stock-viking-therapeutics/",
    "time_published": "20240305T111500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "One is a reigning champion, and the other is a burgeoning contender.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767463/scientists-lab-testing-blood-draw.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.135374,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "0.159272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.152596",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "-0.000999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37474512/jim-cramer-says-nvidia-eli-lilly-novo-nordisk-are-not-overvalued-will-be-ready-to-buy-if-this-ma",
    "time_published": "20240305T063337",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer_2.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248444,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.227008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.264682",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.227008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Meta Platforms Stock Topped the Market Today",
    "url": "https://www.fool.com/investing/2024/03/06/why-meta-platforms-stock-topped-the-market-today/",
    "time_published": "20240306T234100",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Investors were happy that the company had a generally uneventful Wednesday.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768361/young-person-and-older-person-gazing-at-a-laptop-screen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.317375,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.113969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.113969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.465196",
        "ticker_sentiment_score": "0.447362",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nektar  ( NKTR )  Begins Phase IIb Study Rezpeg in Alopecia Areata",
    "url": "https://www.zacks.com/stock/news/2236911/nektar-nktr-begins-phase-iib-study-rezpeg-in-alopecia-areata",
    "time_published": "20240306T173300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.023958,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "0.046072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INDV",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "0.258128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.445179",
        "ticker_sentiment_score": "0.176086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "-0.256197",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Dexcom Pops As It Enters A New CGM Market: Non-Diabetics",
    "url": "https://www.investors.com/news/technology/dexcom-stock-continuous-glucose-monitor-stelo/",
    "time_published": "20240306T152500",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.250101,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.2163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.176098",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.457794",
        "ticker_sentiment_score": "0.179837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.2163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37510490/escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk",
    "time_published": "20240306T143330",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and \"finishing\" of its injector pens.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_7.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.042218,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.035373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "-0.090714",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?",
    "url": "https://www.fool.com/investing/2024/03/06/is-viking-therapeutics-stock-a-better-buy-than-eli/",
    "time_published": "20240306T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768024/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.209691,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.63878",
        "ticker_sentiment_score": "0.405744",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.207258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.603465",
        "ticker_sentiment_score": "0.395508",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37544347/eli-lillys-legal-battle-against-fake-compounded-tirzepatide-products-bacteria-impurities-detected",
    "time_published": "20240307T194755",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY revealed on Thursday that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Basra--Iraq---July-9--2023-Photo-Of-Moun_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.023894,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.641573",
        "ticker_sentiment_score": "0.014692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.015617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending - Cigna Group  ( NYSE:CI ) ",
    "url": "https://www.benzinga.com/news/earnings/24/03/37542349/insurance-coverage-for-weight-loss-drugs-cigna-unveils-efforts-to-limit-health-plansemployers-spend",
    "time_published": "20240307T181842",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Evernorth Health Services, a subsidiary of Cigna Group CI introduced a financial guarantee within its EncircleRx program. The move aims to provide clients with predictability when covering GLP-1s, ultimately empowering companies and health plans to exercise better control over their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-and-other-drugs-for-weight-loss_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281036,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.150868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.150868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Up 7.5% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2237480/lilly-lly-up-75-since-last-earnings-report-can-it-continue",
    "time_published": "20240307T163058",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.117098,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.395669",
        "ticker_sentiment_score": "0.157298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.036966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy Red-Hot Stocks Now or Wait?",
    "url": "https://www.zacks.com/stock/news/2237396/should-you-buy-red-hot-stocks-now-or-wait",
    "time_published": "20240307T153300",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/02/36829.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.123746,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.036922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.540534",
        "ticker_sentiment_score": "0.12672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.189309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.378094",
        "ticker_sentiment_score": "0.170819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.203418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/n37532116/lillys-newest-phase-of-get-better-campaign-challenges-misperceptions-about-obesity-care",
    "time_published": "20240307T130000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company LLY today launched the next phase of its Get Better corporate branding campaign with a new focus on ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.213729,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.597724",
        "ticker_sentiment_score": "0.281047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.142485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data Why Novo Nordisk Stock Is Trading Higher Today - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37531875/novo-nordisks-stock-hits-52-week-high-after-highly-sought-after-obesity-drug-trial-data",
    "time_published": "20240307T124649",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Novo Nordisk A/S NVO is holding its Capital Markets Day. Its executive management and other members of senior management will provide a full review of strategy, operations, and financial targets.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.009544,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.06563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.53784",
        "ticker_sentiment_score": "0.088544",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Jumps On Strong Results For New Obesity Drug",
    "url": "https://www.investors.com/news/technology/novo-nordisk-jumps-on-new-weight-loss-drug/",
    "time_published": "20240307T114400",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Novo Nordisk ( NVO ) said early Thursday that its experimental oral drug amycretin showed a 13.1% weight loss in participants after 12 weeks in a phase 1 trial. Shares of the Danish drug giant jumped, while rival Eli Lilly ( LLY ) fell.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.191122,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "-0.239584",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "-0.067802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.70749",
        "ticker_sentiment_score": "0.132078",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies - Or Could They Get Another Lift? - Eli Lilly and Co  ( NYSE:LLY ) , Walt Disney  ( NYSE:DIS ) ",
    "url": "https://www.benzinga.com/general/entertainment/24/03/37570233/oprah-winfrey-to-spotlight-weight-loss-drugs-in-new-tv-special-will-shame-blame-come-to-dru",
    "time_published": "20240308T215905",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Legendary television mogul Oprah Winfrey recently announced she was stepping down from the board of directors of WeightWatchers. The announcement, along with fourth-quarter financial results, sent shares of WeightWatchers parent WW International WW lower last month.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.118269,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.136821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WW",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.127329",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo's Weight-Loss Blockbuster Wins Another Approval",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cardiovascular-fda/",
    "time_published": "20240308T193100",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": -0.032259,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "0.109844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.073296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "-0.329709",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Ozempic or Tesla? Markets are in no doubt which is hotter | Business",
    "url": "https://www.cnn.com/2024/03/08/business/novo-nordisk-share-price-wegovy/index.html",
    "time_published": "20240308T162300",
    "authors": [
      "Anna Cooban"
    ],
    "summary": "Ozempic or Tesla? Markets are in no doubt which is hotter ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1812475431.jpg?c=16x9&q=h_144,w_256,c_fill",
    "source": "CNN",
    "category_within_source": "Economy",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.034036,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.198439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.256179",
        "ticker_sentiment_score": "-0.003894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNSKF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.068617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.242631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "S&P 500 Soars to New Highs: 5 Best Stocks YTD",
    "url": "https://www.zacks.com/stock/news/2238098/sp-500-soars-to-new-highs-5-best-stocks-ytd",
    "time_published": "20240308T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.180612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.105162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.216301",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.248851",
        "ticker_sentiment_score": "0.130328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.150906",
        "ticker_sentiment_score": "0.12481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.190196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37562337/in-depth-analysis-eli-lilly-and-co-versus-competitors-in-pharmaceuticals-industry",
    "time_published": "20240308T160013",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.193839,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.551009",
        "ticker_sentiment_score": "0.289642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This is Just the Beginning of Mind Medicine",
    "url": "https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/",
    "time_published": "20240308T155933",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, \"Why The Psychedelic Boom Is All but Inevitable\" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.193082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.031875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.097077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.379691",
        "ticker_sentiment_score": "0.301289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Rally Hits Fresh Highs As Nvidia, Bitcoin Soar: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rally-hits-fresh-highs-as-nvidia-novo-nordisk-bitcoin-soar-weekly-review/",
    "time_published": "20240308T155800",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rally suffered a sharp loss Tuesday but quickly rebounded, with the S&P 500 and Nasdaq composite hitting record highs. The Dow Jones fell modestly, but pared losses. Nvidia ( NVDA ) and chipmakers led the advance, while some software names struggled.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/STock-NYSEstockExchange-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.032056,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.073763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGT",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.161391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.095449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.029991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.062488",
        "ticker_sentiment_score": "0.105246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.095245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.096651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.062488",
        "ticker_sentiment_score": "-0.011132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPS",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.102577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.073763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BASE",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.061438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.082144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BURL",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.164906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SE",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.026943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.124593",
        "ticker_sentiment_score": "-0.138354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.01093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.067953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JWN",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.074982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.073763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.165265",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.103957",
        "ticker_sentiment_score": "-0.108494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.134097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVAV",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.102717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.114471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.164906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.102577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.123255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.103521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.123255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.062488",
        "ticker_sentiment_score": "-0.031232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.067571",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Soars to New Highs: 5 Best Stocks YTD",
    "url": "https://www.zacks.com/stock/news/2238098/sp-500-soars-to-new-highs-5-best-stocks-ytd",
    "time_published": "20240308T150500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.180612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.105162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.216301",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.248851",
        "ticker_sentiment_score": "0.130328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.150906",
        "ticker_sentiment_score": "0.12481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.190196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  Up on Upbeat Data From New Obesity Pill Study",
    "url": "https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study",
    "time_published": "20240308T150300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.190026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.256719",
        "ticker_sentiment_score": "0.151479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.256719",
        "ticker_sentiment_score": "0.105076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.01855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.444487",
        "ticker_sentiment_score": "0.34082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2237910/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20240308T140017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.248212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.525907",
        "ticker_sentiment_score": "0.178495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Delays Decision On Eli Lilly's Alzheimer Drug",
    "url": "https://www.investors.com/news/technology/fda-delays-decision-on-eli-lillys-alzheimer-drug/",
    "time_published": "20240308T120800",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.235291,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.766141",
        "ticker_sentiment_score": "-0.265067",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.199339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.614436",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "-0.317406",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab",
    "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-to-convene-advisory-committee-meeting-to-discuss-the-trailblazer-alz-2-study-of-donanemab-302083661.html",
    "time_published": "20240308T114500",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.135527,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.389552",
        "ticker_sentiment_score": "0.246912",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.045139",
        "ticker_sentiment_score": "0.142544",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2237788/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240308T112002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.042552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.060821",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: NVDA, DELL, LLY, CMG and CAVA",
    "url": "https://www.zacks.com/stock/news/2237763/zacks-market-edge-highlights-nvda-dell-lly-cmg-and-cava",
    "time_published": "20240308T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "NVDA, DELL, LLY, CMG and CAVA have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.151223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.03231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.465196",
        "ticker_sentiment_score": "0.11575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.167831",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.150918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.177879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This is Just the Beginning of Mind Medicine",
    "url": "https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/",
    "time_published": "20240308T080000",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, \"Why The Psychedelic Boom Is All but Inevitable\" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png",
    "source": "Money Morning",
    "category_within_source": "GoogleRSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.193082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.031875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.097077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.379691",
        "ticker_sentiment_score": "0.301289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan - Alphabet  ( NASDAQ:GOOG ) , Apple  ( NASDAQ:AAPL ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37552341/retail-traders-ditch-tesla-apple-google-for-pharma-stocks-like-ozempic-maker-novo-nordisk-and-el",
    "time_published": "20240308T052253",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/stock-market-bse-nse_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.121711,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.159718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.159718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.088137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.104868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.104868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.088137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.290033",
        "ticker_sentiment_score": "0.159927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.037937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APOS",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "-0.199911",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.088137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Stocks to Invest $50,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/03/09/the-best-stocks-to-invest-50000-in-right-now/",
    "time_published": "20240309T150000",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "These stalwart companies can help you grow your wealth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768289/investor-gettyimages-694072990.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.414581,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.003805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.34974",
        "ticker_sentiment_score": "0.548612",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.294446",
        "ticker_sentiment_score": "0.479203",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly the Best Pharmaceutical Stock for You?",
    "url": "https://www.fool.com/investing/2024/03/09/is-eli-lilly-the-best-pharmaceutical-stock-for-you/",
    "time_published": "20240309T100700",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly's recently approved weight-loss drug is off to a good start.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768573%2Fgettyimages-1276837766.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.271218,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.037895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.555067",
        "ticker_sentiment_score": "0.35693",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.034028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Flopped on Friday",
    "url": "https://www.fool.com/investing/2024/03/08/why-eli-lilly-stock-flopped-on-friday/",
    "time_published": "20240309T031608",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "An important new drug's potential approval has been pushed back, and the timing is unclear.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768670/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.100099,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.730535",
        "ticker_sentiment_score": "0.190361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study",
    "url": "https://www.prnewswire.com/news-releases/more-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-improvement-in-a-first-of-its-kind-lebrikizumab-study-302084690.html",
    "time_published": "20240310T200000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.175193,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.246582",
        "ticker_sentiment_score": "0.190911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.136412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.0303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Tesla: I Think This Stock Should Replace It in the \"Magnificent Seven\"",
    "url": "https://www.fool.com/investing/2024/03/10/forget-tesla-i-think-this-stock-should-replace-it/",
    "time_published": "20240310T132900",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Tesla doesn't look very magnificent these days. But there's another stock that does.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768602/scientist-smiling-holding-tablet-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.17247,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.191625",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.469935",
        "ticker_sentiment_score": "0.031351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.12536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet the 5 Stocks That Have Contributed Almost All of the S&P 500's 2024 Gains",
    "url": "https://www.fool.com/investing/2024/03/10/5-stocks-contributed-almost-all-market-2024-gains/",
    "time_published": "20240310T100500",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "These companies have contributed the lion's share of the S&P 500's 7% year-to-date gain.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767902%2Fgettyimages-1473086836-1201x686-332c1f1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.204433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.102298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.102298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.097419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.158636",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.013996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.013969",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?",
    "url": "https://www.fool.com/investing/2024/03/10/is-novo-nordisk-a-buy-after-its-new-obesity-candid/",
    "time_published": "20240310T083300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Encouraging results recently pushed the pharma stock up to new heights.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768402%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.217219,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.112083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.130125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.526003",
        "ticker_sentiment_score": "0.344971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Eli Lilly and Co's Latest Options Trends - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37597261/behind-the-scenes-of-eli-lilly-and-cos-latest-options-trends",
    "time_published": "20240311T190111",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 128 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.007185,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.819198",
        "ticker_sentiment_score": "0.040833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "-0.105459",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2238727/the-zacks-analyst-blog-highlights-nvidia-constellation-energy-meta-platforms-advanced-micro-devices-and-eli-lilly",
    "time_published": "20240311T141400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.18251,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.079315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.165376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.267315",
        "ticker_sentiment_score": "0.100265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.108054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.15192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's  ( NVO )  Wegovy Gets FDA Nod to Reduce Heart Risk",
    "url": "https://www.zacks.com/stock/news/2238445/novo-nordisks-nvo-wegovy-gets-fda-nod-to-reduce-heart-risk",
    "time_published": "20240311T105900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.07767,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "0.229078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "-0.028692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.433215",
        "ticker_sentiment_score": "-0.103756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACET",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "-0.028666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Stock Down as FDA Delays Decision on Donanemab",
    "url": "https://www.zacks.com/stock/news/2238437/lilly-lly-stock-down-as-fda-delays-decision-on-donanemab",
    "time_published": "20240311T103400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.050558,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.409742",
        "ticker_sentiment_score": "0.036375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.035593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.089066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.260577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.098991",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers - AnaptysBio  ( NASDAQ:ANAB ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37631577/skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clini",
    "time_published": "20240312T184852",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, AnaptysBio Inc ANAB reported a fourth-quarter 2023 EPS of $ ( 1.59 ) , slightly better than the consensus of $ ( 1.60 ) . The company reported sales of $9.01 million, surpassing the consensus of $2.23 million.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Chem-Lab_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.242434,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.405936",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.078327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37620871/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240312T140118",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 19 unusual trades. Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.002411,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.814341",
        "ticker_sentiment_score": "-0.028518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "-0.10524",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant",
    "url": "https://www.fool.com/investing/2024/03/12/1-big-new-reason-to-buy-novo-nordisk-stock-hand-ov/",
    "time_published": "20240312T114500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The pharma giant could have yet another knockout obesity drug on the way.",
    "banner_image": "https://media.ycharts.com/charts/5c068ae6a3c61bfe2d5aa4e4398ea40e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.18728,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.089984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.089984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.323785",
        "ticker_sentiment_score": "0.129602",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet the Unknown Small-Cap Company That's Been Paying a Dividend for at Least 66 Years Longer Than Coca-Cola, ExxonMobil, and Eli Lilly",
    "url": "https://www.fool.com/investing/2024/03/12/pay-dividend-66-years-longer-coca-cola-exxonmobil/",
    "time_published": "20240312T092100",
    "authors": [
      "Sean Williams"
    ],
    "summary": "A relatively tiny company ($508 million market cap) that most investors have never heard of has been doling out a consecutive dividend for over two centuries -- including 104 years longer than Coca-Cola!",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768822%2Fgetting-paid-dividends-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.171844,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.267926",
        "ticker_sentiment_score": "0.060302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YORW",
        "relevance_score": "0.169437",
        "ticker_sentiment_score": "-0.024071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.299884",
        "ticker_sentiment_score": "0.088436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.299884",
        "ticker_sentiment_score": "0.158856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic - 'Shame, Blame And The Weight Loss Revolution' - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/03/37605412/gary-black-keeping-tabs-on-oprahs-upcoming-tv-special-about-ozempic-shame-blame-and-the-weight-loss",
    "time_published": "20240312T050946",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey's upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.08539,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "-0.088506",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "-0.068821",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Experts hesitate on weight loss ETFs amid the obesity drug boom",
    "url": "https://www.cnbc.com/2024/03/13/weight-loss-etfs-may-sit-out-obesity-drug-mania-experts-say.html",
    "time_published": "20240313T230001",
    "authors": [
      "Anna Gleason"
    ],
    "summary": "While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107385852-1710189287ETF-SEG2-031124.jpg?v=1710189286&w=750&h=422&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.108075,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.509589",
        "ticker_sentiment_score": "0.185424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.509589",
        "ticker_sentiment_score": "0.185424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2240274/eli-lilly-lly-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240313T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.192562,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.580956",
        "ticker_sentiment_score": "0.249981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Teams Up With Amazon To Deliver Weight-Loss Drug",
    "url": "https://www.investors.com/news/technology/eli-lilly-amazon-pharmacy-lillydirect-weight-loss-drug-zepbound/",
    "time_published": "20240313T171932",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.035732,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "-0.041654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.552443",
        "ticker_sentiment_score": "-0.070742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "-0.242397",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.364987",
        "ticker_sentiment_score": "0.088979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "-0.127667",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs - Agilent Technologies  ( NYSE:A ) , Avantor  ( NYSE:AVTR ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37668318/top-7-biotech-winners-of-novo-nordisk-eli-lillys-outsourcing-strategy-for-weight-lo",
    "time_published": "20240313T163538",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Genetic-Research-And-Biotech-Science-Con_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.276455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.114066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.139069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.072735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.107571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.03309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.387674",
        "ticker_sentiment_score": "0.279985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVTR",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.189468",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.34917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/dexcom-stock-buy-zone-diabetes-obesity-continuous-glucose-monitors/",
    "time_published": "20240313T160442",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-13-24DXCM.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.138038,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.053149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.10132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.10132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "-0.23901",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.531326",
        "ticker_sentiment_score": "0.152339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.053149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37662893/pharmaceutical-crime-jumps-50-as-criminals-seek-to-capitalize-rising-tide-of-counterfeit-weight-l",
    "time_published": "20240313T143118",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has intensified.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.134047,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "-0.088767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.130736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Stocks I'd Add to the \"Magnificent Seven\"",
    "url": "https://www.fool.com/investing/2024/03/13/2-no-brainer-stocks-id-add-to-magnificent-seven/",
    "time_published": "20240313T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They fit right in.",
    "banner_image": "https://media.ycharts.com/charts/e88a70f1dbaeb58217edf59cea01b1d9.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.394698,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.22383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.508232",
        "ticker_sentiment_score": "0.4881",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.096535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.167998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.228793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.167998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.126736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.338251",
        "ticker_sentiment_score": "0.465553",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Obesity Drugs On Amazon - Eli Lilly Partners With Amazon's Pharmacy Unit To Deliver Drug Prescriptions, Including Popular Zepbound For Weight Loss - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37657277/obesity-drugs-on-amazon-eli-lilly-partners-with-amazons-pharmacy-unit-to-deliver-drug-prescriptio",
    "time_published": "20240313T124123",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amazon.com's AMZN Amazon Pharmacy has integrated Eli Lilly And Co's LLY LillyDirect into its services, enabling home delivery of select medications for diabetes, obesity, and migraine.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Amazon-Pharmacy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.059333,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.872847",
        "ticker_sentiment_score": "0.152367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.357358",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?",
    "url": "https://www.fool.com/investing/2024/03/13/could-viking-therapeutics-challenge-eli-lilly/",
    "time_published": "20240313T090300",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Viking aims to enter a market that may be worth $100 billion in a few years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769012%2Fgettyimages-doctors-talking.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.185992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.50287",
        "ticker_sentiment_score": "0.280042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.316184",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.131463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "-0.046408",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Tuesday Rally Was Driven By Nvidia, Eli Lilly And Other 'Stocks Reacting Positively To Good Earnings Per Share News' - Costco Wholesale  ( NASDAQ:COST ) , Broadcom  ( NASDAQ:AVGO ) ",
    "url": "https://www.benzinga.com/markets/equities/24/03/37648583/jim-cramer-says-tuesday-rally-was-driven-by-nvidia-eli-lilly-and-other-stocks-reacting-positivel",
    "time_published": "20240313T082542",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "U.S. stocks experienced a rise on Tuesday following consecutive losses for the S&P 500 and Nasdaq. What Happened: This positive turn occurred despite a slightly warmer-than-expected February consumer price index.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Financial-Analyst-Using-Smartphone-With-_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.344907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "-0.245996",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "-0.004381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "-0.245996",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.27628",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37716166/congressional-scrutiny-intensifies-on-chinese-biotech-firms-wuxi-apptec-faces-biotech-exodus",
    "time_published": "20240314T200301",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/US-China-Tatiana-Popova-and-rawf8-by-Shu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": -0.065123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "0.106372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WXXWY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.033926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "-0.06817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.069834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.069834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.083857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amazon  ( AMZN )  Boosts Pharmacy Efforts With Lilly's Partnership",
    "url": "https://www.zacks.com/stock/news/2240963/amazon-amzn-boosts-pharmacy-efforts-with-lillys-partnership",
    "time_published": "20240314T155000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/2657.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.233733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.284696",
        "ticker_sentiment_score": "0.093314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "0.094316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.798255",
        "ticker_sentiment_score": "0.459306",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.284696",
        "ticker_sentiment_score": "0.155542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Partners Amazon to Deliver Drugs Like Zepbound",
    "url": "https://www.zacks.com/stock/news/2240711/lilly-lly-partners-amazon-to-deliver-drugs-like-zepbound",
    "time_published": "20240314T135400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.235264,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.709611",
        "ticker_sentiment_score": "0.264861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.402941",
        "ticker_sentiment_score": "0.151039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.296485",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Investors Worry About Eli Lilly's Latest Regulatory Setback?",
    "url": "https://www.fool.com/investing/2024/03/14/should-investors-worry-about-eli-lillys-latest-reg/",
    "time_published": "20240314T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are good reasons to remain optimistic.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768907/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.155591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.510952",
        "ticker_sentiment_score": "0.288214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 20 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37757358/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-20-years",
    "time_published": "20240315T190025",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 12.84%. Currently, Eli Lilly and Co has a market capitalization of $713.27 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Extend Losses; Adobe Sell-Off Casts Pall On Tech; Ulta Beauty Tumbles",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-adobe-stock/",
    "time_published": "20240315T144448",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Nasdaq, S&P 500 Extend Losses. Adobe Sell-Off Casts Pall On Tech. Ulta Beauty Tumbles Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999921"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.073182,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "-0.128398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "-0.077214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.001903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.080304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.242862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.011581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.242862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.242862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLSK",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "-0.077214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "-0.077214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.103425",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More",
    "url": "https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azns-new-acquisition-fda-updates-for-nvo-lly-and-more",
    "time_published": "20240315T131900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.200599,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.06412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.169378",
        "ticker_sentiment_score": "0.118514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.105455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.210823",
        "ticker_sentiment_score": "0.128918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.083978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.",
    "url": "https://www.fool.com/investing/2024/03/15/can-eli-lilly-stock-double-in-5-years-heres-what/",
    "time_published": "20240315T131500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The company's valuation may be high but that doesn't mean Eli Lilly is anywhere near its peak.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768802/a-doctor-looking-at-a-tablet-with-another-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.261434,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.3645",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.012002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.042051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Move Over, Tesla! These 6 Stocks Could Replace It in the \"Magnificent 7\"",
    "url": "https://www.fool.com/investing/2024/03/15/move-over-tesla-these-6-stocks-could-replace-it-in/",
    "time_published": "20240315T114600",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Tesla is failing to keep pace with the rest of the Magnificent Seven.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769058/brk-4.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.308524,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.202585",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.202585",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.20537",
        "ticker_sentiment_score": "0.246414",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.103554",
        "ticker_sentiment_score": "0.095498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.154785",
        "ticker_sentiment_score": "0.181921",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.154785",
        "ticker_sentiment_score": "0.092116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.255106",
        "ticker_sentiment_score": "0.030308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.093536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.3038",
        "ticker_sentiment_score": "0.258595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.3038",
        "ticker_sentiment_score": "0.237763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?",
    "url": "https://www.fool.com/investing/2024/03/15/pfizer-viking-therapeutics-eli-lilly-novo-nordisk/",
    "time_published": "20240315T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Viking Therapeutics just might be an attractive acquisition target for Pfizer.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769056/big-fish-eating-little-fish.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.143119,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.149347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.16697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.212839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.149347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.823212",
        "ticker_sentiment_score": "0.234987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone",
    "url": "https://markets.businessinsider.com/news/stocks/the-trillion-dollar-crystal-ball-3-companies-next-in-line-for-the-market-milestone-1033169865",
    "time_published": "20240316T180000",
    "authors": [
      "Rick Orford"
    ],
    "summary": "There are only six trillion-dollar stocks worldwide, every one of which is a popular name. And they all rightfully sit at the top of their sectors. There's a certain allure to reaching $1 trillion, and investors are always looking for the next one to breach that valuation.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2022/12/brk-3-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.249159,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.133089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.133089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.219729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.133089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.219729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.161462",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.125025",
        "ticker_sentiment_score": "0.158757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/03/16/eli-lilly-just-had-a-setback-is-its-stock-still-a/",
    "time_published": "20240316T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The drugmaker is caught up in an unexpected situation with regulators.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769169/stressed-investor-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.050877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.151333",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "-0.095282",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Partners With Amazon's Pharmacy Business: Here's Why Both Stocks Should Win From the Deal",
    "url": "https://www.fool.com/investing/2024/03/16/eli-lilly-partners-with-amazons-pharmacy-business/",
    "time_published": "20240316T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The world's biggest drugmaker has joined forces with the world's biggest online pharmacy provider.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769205/older-man-pills-laptop_gettyimages-1183769809.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.322301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.696714",
        "ticker_sentiment_score": "0.476707",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.858597",
        "ticker_sentiment_score": "0.478987",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/",
    "time_published": "20240317T130000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "There's no need for delays in buying these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769331/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.127458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.2256",
        "ticker_sentiment_score": "-0.115588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.165219",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.252288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?",
    "url": "https://www.fool.com/investing/2024/03/17/eli-lilly-taps-amazon-to-deliver-its-weight-manage/",
    "time_published": "20240317T072400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769141%2Finvestor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.237044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.51768",
        "ticker_sentiment_score": "0.326446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.03811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.322193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.043944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37785607/us-prescriptions-race-for-weight-loss-drugs-eli-lillys-zepbound-overtakes-novo-nordisks-wegovy",
    "time_published": "20240318T142139",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co's LLY much-in-demand weight-loss drug Zepbound ( tirzepatide ) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S's NVO rival obesity medicine Wegovy ( semglutide ) for the first time since its launch.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.083401,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.062231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "-0.003071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.212439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "-0.027466",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead",
    "url": "https://www.fool.com/investing/2024/03/18/forget-eli-lilly-buy-this-magnificent-biotech-stoc/",
    "time_published": "20240318T060000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This company's growth story is about to get moving with gusto.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769498/investors-discuss-investment-at-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.169366,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.241596",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.289351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Surpasses Market Returns: Some Facts Worth Knowing",
    "url": "https://www.zacks.com/stock/news/2243059/eli-lilly-lly-surpasses-market-returns-some-facts-worth-knowing",
    "time_published": "20240319T214520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.185834,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.543535",
        "ticker_sentiment_score": "0.280139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Time to be \"Overweight\" Viking Therapeutics",
    "url": "https://www.zacks.com/commentary/2243036/time-to-be-overweight-viking-therapeutics",
    "time_published": "20240319T185800",
    "authors": [
      "Andrew Rocco"
    ],
    "summary": "A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.008889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.113166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.673107",
        "ticker_sentiment_score": "0.048942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.148456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "-0.123249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.008889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On' - Datadog  ( NASDAQ:DDOG ) , Altimmune  ( NASDAQ:ALT ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37812350/cramer-calls-datadog-dynamite-puts-sofi-in-dog-house-what-the-heck-is-going-on",
    "time_published": "20240319T135514",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Marvell Technology, Inc. MRVL reported a mixed quarter. \"We got to wait,\" he added.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/19/datadog_cramer.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.26512,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LNTH",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.312008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.294909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.139368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "0.244588",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "-0.042238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDNT",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.272036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.216086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.204587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:RON",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.262039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover",
    "url": "https://www.investors.com/news/technology/fusion-pharmaceuticals-astrazeneca-acquisition-biotech-stock/",
    "time_published": "20240319T130332",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Fusion Pharmaceuticals Scores $2 Billion AstraZeneca Takeover. Biotech Stock Nearly Doubles Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": -0.024011,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "-0.283901",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "-0.146994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "-0.19295",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2242689/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240319T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default345.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.224118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.532696",
        "ticker_sentiment_score": "0.154837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/03/19/should-you-pick-eli-lilly-stock-after-a-4x-rise-in-three-years/",
    "time_published": "20240319T120031",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company's P/S ratio to ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f933b2ce306ad3e0975eb8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.317785,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.702129",
        "ticker_sentiment_score": "0.562014",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.229058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Did Novo Nordisk Just Get a Jump on Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/03/19/did-novo-nordisk-just-say-checkmate-to-eli-lilly/",
    "time_published": "20240319T113000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "A recent FDA announcement may have just put one company in the lead.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769494%2Fmedicine-pills-fda-approval-stamp.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.260153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.308504",
        "ticker_sentiment_score": "0.189617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.091571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.47452",
        "ticker_sentiment_score": "0.420823",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Is Fusion Pharmaceuticals Stock Trading Higher Today? - AstraZeneca  ( NASDAQ:AZN ) , Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37818128/astrazenecas-2-4b-fusion-pharmaceuticals-acquisition-signals-shift-in-efforts-from-traditional-re",
    "time_published": "20240319T112623",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, AstraZeneca Plc AZN agreed to acquire Fusion Pharmaceuticals Inc FUSN for $21.00 per share in cash plus a non-transferable contingent value right ( CVR ) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AstraZeneca-HQ-in-Cambridge-UK_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.184623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.111362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.281153",
        "ticker_sentiment_score": "0.456567",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.316525",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.201946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2242578/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240319T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.250395,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.125823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.064508",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?",
    "url": "https://www.fool.com/investing/2024/03/19/madrigal-eli-lilly-novo-nordisk-better-stock-buy/",
    "time_published": "20240319T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Madrigal has one key advantage over its two huge potential future rivals.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769602/fda-blocks-in-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.113464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.256798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.25377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.484881",
        "ticker_sentiment_score": "0.272744",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37859130/is-eli-lilly-winning-the-war-on-weight-loss-drugs-zepbound-overtakes-wegovy-in-us-prescriptions",
    "time_published": "20240320T210000",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "Eli Lilly and Co. LLY enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound - the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.111981,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.194942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "-0.1407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.07224",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fusion  ( FUSN )  Up 99% on $2.4B Buyout Offer From AstraZeneca",
    "url": "https://www.zacks.com/stock/news/2243681/fusion-fusn-up-99-on-24b-buyout-offer-from-astrazeneca",
    "time_published": "20240320T172100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.175598,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.273552",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.338119",
        "ticker_sentiment_score": "0.300363",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.233351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?",
    "url": "https://www.investors.com/news/technology/pfizer-stock-buy-now/",
    "time_published": "20240320T170719",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/PFE-evergreen-051419-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.120598,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.125315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.125315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.075008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.075008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.14606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.687052",
        "ticker_sentiment_score": "0.203831",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.059184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.14606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options Frenzy: What You Need to Know - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37847944/eli-lilly-and-cos-options-frenzy-what-you-need-to-know",
    "time_published": "20240320T140206",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.107187,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.76213",
        "ticker_sentiment_score": "0.106972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?",
    "url": "https://www.fool.com/investing/2024/03/20/novo-nordisk-versus-eli-lilly/",
    "time_published": "20240320T123000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The gap has been shrinking between these stocks over the past month.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769568/a-doctor-using-a-stethoscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.119613,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.412861",
        "ticker_sentiment_score": "0.219186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.216856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss",
    "url": "https://www.investors.com/etfs-and-funds/etfs/weight-loss-drugs-feisty-rivals-take-on-eli-lilly-novo-nordisk/",
    "time_published": "20240320T120048",
    "authors": [
      "MATT KRANTZ",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995869"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.296034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.365148",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.274537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.171325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KROS",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.2681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.374312",
        "ticker_sentiment_score": "0.428918",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.242652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MLYS",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.2681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics",
    "url": "https://www.zacks.com/stock/news/2243165/zacks-investment-ideas-feature-highlights-apple-alphabet-eli-lilly-novo-nordisk-and-viking-therapeutics",
    "time_published": "20240320T085400",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.466811",
        "ticker_sentiment_score": "0.006101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.074881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.672533",
        "ticker_sentiment_score": "0.041285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.06704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.466811",
        "ticker_sentiment_score": "0.006101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medicare Will Cover Weight-Loss Drugs - For Some People",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-wegovy-zepbound-eli-lilly-novo-nordisk/",
    "time_published": "20240321T190934",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Weight-Loss Drugs Win Medicare Coverage. Here's What It Means For Novo Nordisk, Eli Lilly Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/Stock-Medical-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.118183,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.554365",
        "ticker_sentiment_score": "0.003392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.297061",
        "ticker_sentiment_score": "-0.0594",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37876911/wegovys-success-medicare-contemplates-covering-novo-nordisks-semaglutide-for-heart-health",
    "time_published": "20240321T172309",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In a significant development, Medicare may extend coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) to certain members with a history of heart disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_7.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.142358,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "-0.061371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.435666",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Two Tailwinds Continue To Fuel Market; 3 Stocks Setting Up Again",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-dovish-fed-nvidia-ai-boom-new-highs/",
    "time_published": "20240322T205833",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Dovish Fed, Nvidia-Led AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Federal-Reserve-fall-12-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.257842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.17094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.342631",
        "ticker_sentiment_score": "0.238243",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.203655",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.062342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.109337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.288282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.159781",
        "ticker_sentiment_score": "0.053405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.105524",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37894869/comparative-study-eli-lilly-and-co-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240322T160014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Eli Lilly and Co LLY and its primary competitors in the Pharmaceuticals industry.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.189915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.48182",
        "ticker_sentiment_score": "0.231327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37892677/ozempic-users-speak-out-over-side-effects-lawsuits-against-novo-nordisk-and-eli-lilly-surge",
    "time_published": "20240322T143416",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.051356,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.354319",
        "ticker_sentiment_score": "-0.213025",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.354319",
        "ticker_sentiment_score": "-0.171064",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.126752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/03/22/with-shares-near-all-time-highs-is-it-a-buy/",
    "time_published": "20240322T143000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769867%2Fgettyimages-1434356176.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.31419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.159365",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.069977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.134156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.573651",
        "ticker_sentiment_score": "0.473332",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.168048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.168048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Learn How The Best Mutual Funds Deliver Benchmark-Beating Returns",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-performing-mutual-funds-2024-beat-benchmarks/",
    "time_published": "20240322T123014",
    "authors": [
      "ADAM SHELL",
      "Investor's Business Daily"
    ],
    "summary": "Best Performing Mutual Funds Top Benchmarks Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/w.Vitrus032524eps-300x127.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.312476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.136201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVMI",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.051195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.050412",
        "ticker_sentiment_score": "0.108971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.136201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LASR",
        "relevance_score": "0.03782",
        "ticker_sentiment_score": "-0.124863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.087165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.136201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.012611",
        "ticker_sentiment_score": "0.164502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.012611",
        "ticker_sentiment_score": "0.046671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.087165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.012611",
        "ticker_sentiment_score": "0.079997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.03782",
        "ticker_sentiment_score": "0.24374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Did Eli Lilly Just One-Up Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/03/22/did-eli-lilly-just-one-up-novo-nordisk/",
    "time_published": "20240322T111500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769751%2Fgettyimages-1434715649.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.400436,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.849481",
        "ticker_sentiment_score": "0.572617",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.434763",
        "ticker_sentiment_score": "0.164846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could Viking Therapeutics Become the Next Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/03/22/could-viking-therapeutics-become-next-eli-lilly/",
    "time_published": "20240322T085500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Viking shares have skyrocketed on its recent good news.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770100%2Fgettyimages-1220595235.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.153814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.123928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.556298",
        "ticker_sentiment_score": "0.243268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.151858",
        "ticker_sentiment_score": "0.02695",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "59% of This Vanguard ETF Is Invested in the \"Magnificent Seven\" Stocks. Is It a No-Brainer Buy Right Now?",
    "url": "https://www.fool.com/investing/2024/03/24/vanguard-etf-magnificent-seven-buy-right-now/",
    "time_published": "20240324T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "If you want to own all of the Magnificent Seven stocks plus other megacap winners, this ETF could be right up your alley.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770060%2Fetf-board-and-person.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999937"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.351336,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.187514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.178665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.218182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.187514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.178665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.043078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.043078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.043078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.178665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.043078",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall With Market At Highs; 3 Stocks Near Buy Points",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-ai-boom-drive/",
    "time_published": "20240325T111338",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures Fall: Fed, AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Federal-Reserve-fall-12-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211205,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.234968",
        "ticker_sentiment_score": "0.161222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.346077",
        "ticker_sentiment_score": "0.228016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.263309",
        "ticker_sentiment_score": "0.192294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.177367",
        "ticker_sentiment_score": "0.059004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.08924",
        "ticker_sentiment_score": "-0.097246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.08924",
        "ticker_sentiment_score": "-0.097246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.118793",
        "ticker_sentiment_score": "0.105486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.059562",
        "ticker_sentiment_score": "0.287018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.148182",
        "ticker_sentiment_score": "0.050944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.118793",
        "ticker_sentiment_score": "-0.134343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.059562",
        "ticker_sentiment_score": "0.105167",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk and Eli Lilly May Finally Have Some Real Competition",
    "url": "https://www.fool.com/investing/2024/03/25/novo-nordisk-and-eli-lilly-may-finally-have-some-r/",
    "time_published": "20240325T102500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769906%2Fgettyimages-1346675569.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.27397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.319725",
        "ticker_sentiment_score": "0.210402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.195287",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.319725",
        "ticker_sentiment_score": "0.210402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.353895",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2245284/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240325T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.127429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.089069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.063944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Stocks to Invest $10,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/03/25/the-best-stocks-to-invest-10000-in-right-now/",
    "time_published": "20240325T075500",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "These elite enterprises can help you grow richer.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770331/investor-gettyimages-1125967385.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.36328,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.179479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.115837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.380978",
        "ticker_sentiment_score": "0.378059",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.132272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Advances While Market Declines: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2246297/eli-lilly-lly-advances-while-market-declines-some-information-for-investors",
    "time_published": "20240326T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.158274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.175739",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.",
    "url": "https://www.investors.com/news/technology/dexcom-shows-market-leadership-with-jump-to-85-rs-rating/",
    "time_published": "20240326T175600",
    "authors": [
      "JAMES DETAR",
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-Diabetes-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.241901,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.180181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LFMD",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.63935",
        "ticker_sentiment_score": "0.28814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.180181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven  ( NYSE:BHVN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff",
    "time_published": "20240326T174838",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.072644,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.120107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.136685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.239247",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly",
    "url": "https://www.cnbc.com/2024/03/26/viking-jumped-25percent-on-weight-loss-pill-data-we-still-prefer-eli-lilly-.html",
    "time_published": "20240326T152355",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107370511-1707341806087-gettyimages-880238778-98622912.jpeg?v=1711380276&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.180571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.08036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.150186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.214901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.08036",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CHMP to Delay Nod on Biogen  ( BIIB ) , Eisai's Alzheimer's Drug",
    "url": "https://www.zacks.com/stock/news/2246241/chmp-to-delay-nod-on-biogen-biib-eisais-alzheimers-drug",
    "time_published": "20240326T152100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.070826,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.052298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.253514",
        "ticker_sentiment_score": "0.165783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "-0.021795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.223693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.349153",
        "ticker_sentiment_score": "0.225126",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Awaits Consumer Confidence Data",
    "url": "https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data",
    "time_published": "20240326T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.097535,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.069557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.080175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.069557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.039322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.176937",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days",
    "url": "https://www.investors.com/news/technology/viking-stock-weight-loss-drug-zepbound-wegovy/",
    "time_published": "20240326T130240",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-drugTest-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.033581,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "-0.104446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "-0.187987",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "-0.315044",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "-0.152404",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "-0.104446",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2245863/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings",
    "time_published": "20240326T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      }
    ],
    "overall_sentiment_score": 0.385942,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.418501",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.271409",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2245797/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240326T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219275,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.088153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?",
    "url": "https://www.fool.com/investing/2024/03/26/best-stock-eli-lilly-novo-nordisk-viking/",
    "time_published": "20240326T095100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "All three of these high-flying stocks could have more room to run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770468/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.192686,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.288063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "0.1832",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.372216",
        "ticker_sentiment_score": "0.150081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Set to Post Fifth Winning Month Amid Volatility",
    "url": "https://www.zacks.com/stock/news/2245743/wall-street-set-to-post-fifth-winning-month-amid-volatility",
    "time_published": "20240326T063300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wall Street is likely to record the fifth consecutive winning month despite volatility.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d3/848.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.099917,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.072406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.08021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.072406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.039322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.176937",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Futures: Small Caps Jump But Nvidia, Growth Leaders Retreat",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-small-caps-power-higher-nvidia-growth-leaders-retreat/",
    "time_published": "20240327T204100",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Small Caps Power Higher While Nvidia, Growth Leaders Retreat Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-bull-tongue-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.103096,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.09456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.337657",
        "ticker_sentiment_score": "-0.100758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "-0.074302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.092805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.075383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EWBC",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.080418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NCLH",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "0.053608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "-0.064357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.143742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.069596",
        "ticker_sentiment_score": "0.080597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.138663",
        "ticker_sentiment_score": "-0.074302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.034831",
        "ticker_sentiment_score": "0.112676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar - Chevron  ( NYSE:CVX ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37966781/us-companies-in-japan-wary-on-market-intervention-as-yen-hits-34-year-low-vs-dollar",
    "time_published": "20240327T175941",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "U.S. commodity exporters and pharmaceutical companies are among the top traders, with Japan casting a cautious eye toward the foreign exchange markets, in the coming days. Top exporters with significant Japanese interests include Exxon Mobil Corp XOM and Chevron Corp CVX.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Japanese-Yen-Bank-Note-With-Stock-Graph-_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.041021,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "-0.058002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "-0.075447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.47126",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.284983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.47126",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.635246",
        "ticker_sentiment_score": "-0.1938",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.531594",
        "ticker_sentiment_score": "-0.06738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking  ( VKTX )  Up 17% on Encouraging Oral Obesity Drug Data",
    "url": "https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data",
    "time_published": "20240327T164200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.163942,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.338913",
        "ticker_sentiment_score": "0.3268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.245835",
        "ticker_sentiment_score": "0.1314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.182347",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.292922",
        "ticker_sentiment_score": "0.310708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-weight-loss-drugs-viking-therapeutics-novo-nordisk/",
    "time_published": "20240327T162253",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-27-2024LLY.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.189317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.550532",
        "ticker_sentiment_score": "0.3418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "-0.032259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVCR",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.108936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.030653",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amazon  ( AMZN )  Expands Same-Day Medication Delivery Service",
    "url": "https://www.zacks.com/stock/news/2246746/amazon-amzn-expands-same-day-medication-delivery-service",
    "time_published": "20240327T142300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amazon (AMZN) expands same-day delivery of prescription medication to New York City and Los Angeles.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/2657.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.190667",
        "ticker_sentiment_score": "0.006074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTTHF",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.074045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.130543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.828466",
        "ticker_sentiment_score": "0.49868",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.252332",
        "ticker_sentiment_score": "0.207383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37959034/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240327T134621",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.078676,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.827318",
        "ticker_sentiment_score": "0.106044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Strong Before Inflation Data; Will Nvidia Peer Forge Base?",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-will-nvidia-ai-chip-ipo-forge-base/",
    "time_published": "20240328T205027",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Market Strong Before Inflation Data. Will Nvidia Peer Forge Base? Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.175286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "-0.070684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.090389",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.245115",
        "ticker_sentiment_score": "0.214774",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.135221",
        "ticker_sentiment_score": "0.074766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.2053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.15234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.135221",
        "ticker_sentiment_score": "0.028776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.135221",
        "ticker_sentiment_score": "0.184368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EWBC",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.135221",
        "ticker_sentiment_score": "-0.019606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.067855",
        "ticker_sentiment_score": "-0.072171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.250408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.266176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.266176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.266176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XIACY",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "-0.034813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.067855",
        "ticker_sentiment_score": "-0.072171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.045267",
        "ticker_sentiment_score": "0.220043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.2053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.022643",
        "ticker_sentiment_score": "0.2053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Biotech Buyout Candidates",
    "url": "https://www.zacks.com/commentary/2247682/2-top-biotech-buyout-candidates",
    "time_published": "20240328T175500",
    "authors": [
      "Andrew Rocco"
    ],
    "summary": "The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.182342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277748",
        "ticker_sentiment_score": "0.202168",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.305633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.136246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.477704",
        "ticker_sentiment_score": "0.429519",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.04075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.29467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Shows Breadth As Leaders Take A Breath: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rally-breadth-leaders-take-a-breath/",
    "time_published": "20240328T145250",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rally was mixed in a holiday-shortened week. The Nasdaq fell modestly while the Russell 2000 rose solidly. Many AI and other growth leaders suffered solid to sharp losses. DraftKings ( DKNG ) fell sharply as the NCAA moved to ban special prop bets following claims regarding a pro ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-BullPortrait-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.04615,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.187949",
        "ticker_sentiment_score": "-0.020614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.028481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.072062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.094638",
        "ticker_sentiment_score": "-0.051824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.094638",
        "ticker_sentiment_score": "-0.021015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLUT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.011055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "-0.01012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "-0.01012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNUT",
        "relevance_score": "0.157073",
        "ticker_sentiment_score": "-0.027108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "-0.037416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.157073",
        "ticker_sentiment_score": "0.012638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NCLH",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "-0.042335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.094638",
        "ticker_sentiment_score": "0.092167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "-0.01012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "-0.042335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.268541",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "0.08374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37984981/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-5-years",
    "time_published": "20240328T143022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 5 years by 30.75% on an annualized basis producing an average annual return of 43.59%. Currently, Eli Lilly and Co has a market capitalization of $741.67 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?",
    "url": "https://www.fool.com/investing/2024/03/28/eli-lilly-vs-berkshire-hathaway-which-stock-will-b/",
    "time_published": "20240328T130500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770397/stock-traders-looking-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208619,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.040012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.594159",
        "ticker_sentiment_score": "0.395934",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.268975",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bull Market Buys: 3 Dividend Stocks to Own for the Long Run",
    "url": "https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/",
    "time_published": "20240328T123000",
    "authors": [
      "Marc Rapport"
    ],
    "summary": "Invest in stability, dividends, and growth with these three accomplished real estate operators.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770757%2Freit-and-stock-chart.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.356204,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.17707",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "T",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.149038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMT",
        "relevance_score": "0.408791",
        "ticker_sentiment_score": "0.153084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.149038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.149038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.298749",
        "ticker_sentiment_score": "0.234734",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?",
    "url": "https://www.investors.com/news/technology/alzheimers-disease-treatments-eli-lilly-donanemab-amyloid-beta/",
    "time_published": "20240328T120021",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/TECHpic-brain-040124-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.036018,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "-0.071189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.13414",
        "ticker_sentiment_score": "0.151708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INMB",
        "relevance_score": "0.02695",
        "ticker_sentiment_score": "-0.070252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "-0.024517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.09074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.041674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.025612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "-0.068762",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: Are These 2 Top Growth Stocks Next?",
    "url": "https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/",
    "time_published": "20240328T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770130/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.213322,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.438836",
        "ticker_sentiment_score": "0.259135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.242099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.219005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be the Next \"Magnificent Seven\" Stock",
    "url": "https://www.fool.com/investing/2024/03/28/this-will-be-next-magnificent-seven-stock/",
    "time_published": "20240328T105000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "This particular company's growth is set to take off...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770699%2Fgettyimages-1191849990.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.336254,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.140213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.140213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.313833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.140213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "-0.018311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.191248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "-0.063004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.653512",
        "ticker_sentiment_score": "0.469235",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "-0.063004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.140213",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy Hand Over Fist in April",
    "url": "https://www.fool.com/investing/2024/03/30/unstoppable-stocks-to-buy-hand-over-fist-in-april/",
    "time_published": "20240330T105000",
    "authors": [
      "and Prosper Junior Bakiny",
      "David Jagielski",
      "Keith Speights"
    ],
    "summary": "These stocks have exceptionally bright prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771014/happy-woman-because-the-stock-market-went-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.166515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.293339",
        "ticker_sentiment_score": "0.024678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.21193",
        "ticker_sentiment_score": "0.117682",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/03/31/have-1500-2-top-growth-stocks-to-buy-right-now/",
    "time_published": "20240331T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Great companies in steadily growing industries can deliver enviable returns through the years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770818/person-looking-thoughtfully-at-screen-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999174"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.162909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.361626",
        "ticker_sentiment_score": "0.193373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.361626",
        "ticker_sentiment_score": "0.229426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Apple, NVIDIA & Eli Lilly",
    "url": "https://www.zacks.com/research-daily/2248263/top-stock-reports-for-apple-nvidia-eli-lilly",
    "time_published": "20240401T183800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.239366,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.225728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "0.029195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.386666",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2248231/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240401T130014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.235146,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.523044",
        "ticker_sentiment_score": "0.153181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Missed the \"Magnificent Seven\"? Try Buying These 3 Forever Stocks Instead",
    "url": "https://www.fool.com/investing/2024/04/01/missed-the-magnificent-seven-try-buying-these-3/",
    "time_published": "20240401T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "All three companies have very long runways for growth ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768661/two-investors-consider-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.297572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.06688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.177046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.206816",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.177046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.128312",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rise In Reaction To 'Good' Inflation Data",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-nvidia-ai-chip-ipo/",
    "time_published": "20240401T113600",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Rise After 'Good' Inflation Data. Nvidia AI Chip Peer Works On Base Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.168314,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XPEV",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "-0.02974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.08282",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.225093",
        "ticker_sentiment_score": "0.166637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.071468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.203432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.150771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.027496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.176455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EWBC",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.184991",
        "ticker_sentiment_score": "0.019752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "-0.02974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.248366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.264658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.264658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.264658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XIACY",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "-0.033494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "-0.02974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.21857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.203432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.203432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
    "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
    "time_published": "20240401T083000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.180009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.125679",
        "ticker_sentiment_score": "0.255601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.248259",
        "ticker_sentiment_score": "0.115038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.28535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.306284",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.286408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.134207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.100054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2249391/eli-lilly-lly-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240402T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Eli Lilly (LLY) settling at $763.96, representing a +0.45% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default349.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.128657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.520477",
        "ticker_sentiment_score": "0.185292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Bends As Yields Jump; Tesla Skids As 5 Stocks Hang Tough",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-slides-tesla-skids-meta-buy-point/",
    "time_published": "20240402T205300",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Market Slides But Holds Key Levels. Tesla Skids As Meta Eyes Buy Point Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-bullBearFrankfurt-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.058028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.141893",
        "ticker_sentiment_score": "-0.053992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.057011",
        "ticker_sentiment_score": "-0.085698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.057011",
        "ticker_sentiment_score": "-0.085698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.197643",
        "ticker_sentiment_score": "0.106808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.305921",
        "ticker_sentiment_score": "0.032325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PVH",
        "relevance_score": "0.085426",
        "ticker_sentiment_score": "-0.082956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.252405",
        "ticker_sentiment_score": "-0.184414",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.169875",
        "ticker_sentiment_score": "0.09468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.057011",
        "ticker_sentiment_score": "0.09494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.197643",
        "ticker_sentiment_score": "0.094691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.113731",
        "ticker_sentiment_score": "-0.051179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca  ( NASDAQ:AZN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38055367/astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in",
    "time_published": "20240402T185401",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AstraZeneca-HQ-in-Cambridge-UK_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.214279,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.093594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.111146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.727604",
        "ticker_sentiment_score": "0.189804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.093594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "-0.124969",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38055169/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-le",
    "time_published": "20240402T184150",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Citi Research has increased the price target for Eli Lilly And Co LLY, reflecting increased anticipated risk-adjusted peak sales for the company's oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.109662,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.72844",
        "ticker_sentiment_score": "0.192565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.362505",
        "ticker_sentiment_score": "0.194362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.246582",
        "ticker_sentiment_score": "0.120995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Verve Therapeutics Stock Trading Lower On Tuesday? - Verve Therapeutics  ( NASDAQ:VERV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38052320/gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patie",
    "time_published": "20240402T161914",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Verve Therapeutics Inc VERV announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Gene-therapy-30281390100-418857d210-o_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.180933,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.356865",
        "ticker_sentiment_score": "0.286711",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.128895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.271777",
        "ticker_sentiment_score": "0.120376",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience",
    "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience-1033215940",
    "time_published": "20240402T160915",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's ( NYSE:LLY ) strategic positioning and technical resilience present a compelling investment opportunity.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.231119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.640349",
        "ticker_sentiment_score": "0.379462",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.008505",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer says Microsoft's unbundling of Teams and Office is good news for this portfolio stock",
    "url": "https://www.cnbc.com/2024/04/02/jim-cramer-microsoft-teams-office-unbundling-good-news-for-salesforce.html",
    "time_published": "20240402T160800",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107356114-1704816779151-gettyimages-1228524873-AFP_8PZ69L.jpeg?v=1712070146&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.139618,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.111864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.326283",
        "ticker_sentiment_score": "0.138622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.082876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38051329/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience",
    "time_published": "20240402T153943",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's LLY strategic positioning and technical resilience present a compelling investment opportunity. Zepbound boasts impressive weight-loss efficacy in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.281184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.575407",
        "ticker_sentiment_score": "0.435661",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.012024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ten Stocks Showing This Bullish Action, Including A Mag 7 Titan",
    "url": "https://www.investors.com/news/meta-platforms-amd-10-stocks-bullish-action/",
    "time_published": "20240402T114500",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.18806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.153314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.239541",
        "ticker_sentiment_score": "0.13668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.227132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.103429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.137013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.239541",
        "ticker_sentiment_score": "0.105097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.297427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.239541",
        "ticker_sentiment_score": "0.068878",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson",
    "url": "https://www.zacks.com/stock/news/2248815/the-zacks-analyst-blog-highlights-apple-nvidia-eli-lilly-american-tower-and-mckesson",
    "time_published": "20240402T093700",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Apple, NVIDIA, Eli Lilly, American Tower and McKesson are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/429.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.23177,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMT",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.040951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "0.203377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.06747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "0.374601",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.040951",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/04/02/is-it-too-late-to-buy-eli-lilly-stock/",
    "time_published": "20240402T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "There's more to the Lilly story than just excellence in one treatment area.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771415%2Fgettyimages-613345556.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.25364,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.50287",
        "ticker_sentiment_score": "0.312039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.190076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.190076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "-0.10048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "-0.10048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Topped the Market Today",
    "url": "https://www.fool.com/investing/2024/04/03/why-eli-lilly-stock-topped-the-market-today/",
    "time_published": "20240403T203102",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "One analyst following the company believes it could grow its revenue meaningfully this year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771731/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.279871,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.549581",
        "ticker_sentiment_score": "0.361821",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.259711",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co  ( NYSE:LLY ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/04/38077966/eli-lilly-struggles-to-keep-pace-with-mounjaro-zepbound-demand-currently-unavailable-on-amazon-p",
    "time_published": "20240403T200742",
    "authors": [
      "Neil Dennis"
    ],
    "summary": "After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.033528,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.493442",
        "ticker_sentiment_score": "-0.157577",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.083065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "-0.18623",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Verve  ( VERV )  Pauses Enrollment in Cholesterol Study, Stock Falls",
    "url": "https://www.zacks.com/stock/news/2250054/verve-verv-pauses-enrollment-in-cholesterol-study-stock-falls",
    "time_published": "20240403T174000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.108569,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "0.278914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.290262",
        "ticker_sentiment_score": "0.221413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.290262",
        "ticker_sentiment_score": "0.201066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "0.158941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/markets/asia/24/04/38075244/novo-nordisks-popular-diabetes-drug-ozempic-starter-kits-face-extended-shortages-in-germany-faces-bi",
    "time_published": "20240403T173747",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic ( semaglutide ) will not be available in Germany during the second quarter.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_9.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.007237,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.076844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.064828",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38071716/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240403T150119",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 41 unusual trades. Delving into the details, we found 26% of traders were bullish, while 73% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.065172,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.799128",
        "ticker_sentiment_score": "0.056879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rally Holds Support; Five Stocks Eye Buy Points",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-holds-support-meta-near-buy-point-tesla-skid/",
    "time_published": "20240403T120900",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Stock Market Rally Holds Support, Meta Near Buy Point. Tesla Skids Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-bullBearFrankfurt-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.029155,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.129795",
        "ticker_sentiment_score": "-0.051452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "-0.085286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "-0.085286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.180943",
        "ticker_sentiment_score": "0.100045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.280762",
        "ticker_sentiment_score": "0.038775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PVH",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "-0.089248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.256179",
        "ticker_sentiment_score": "-0.214866",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "-0.07445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.089337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.09456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.180943",
        "ticker_sentiment_score": "0.088684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "-0.054697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras - Costco Wholesale  ( NASDAQ:COST ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/04/38063177/costco-long-known-for-rotisserie-chicken-and-hot-dogs-counters-junk-food-with-weight-loss-plan-to-he",
    "time_published": "20240403T072117",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Costco Wholesale Corporation COST has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/CostCo_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.233351,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.111226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.165273",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.104601",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.009183",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Create a Stock Portfolio that Pays $100 a Month",
    "url": "https://www.zacks.com/stock/news/2250736/how-to-create-a-stock-portfolio-that-pays-100-a-month",
    "time_published": "20240404T210500",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "Forget buying a CD. Here's how to set yourself up with individual stocks that will net you passive income.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2427.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.226183,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.132652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VICI",
        "relevance_score": "0.425925",
        "ticker_sentiment_score": "0.28991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.408411",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.425925",
        "ticker_sentiment_score": "0.161418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CZR",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.16694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BOWL",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.16694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KEY",
        "relevance_score": "0.326643",
        "ticker_sentiment_score": "0.111634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?",
    "url": "https://www.fool.com/investing/2024/04/04/could-this-1-detail-help-viking-top-lilly-novo/",
    "time_published": "20240404T085500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Viking shares have soared recently on optimism about its program.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771655%2Fgettyimages-1351333930.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.239522,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.302808",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.104156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.130001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.302808",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-pullback-weight-loss-drugs/",
    "time_published": "20240405T163500",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/SOTD-4-5-2024NVO.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.21862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.13511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.187818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.187818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.294962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.138725",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Understanding Eli Lilly and Co's Position In Pharmaceuticals Industry Compared To Competitors - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38111799/understanding-eli-lilly-and-cos-position-in-pharmaceuticals-industry-compared-to-competitors",
    "time_published": "20240405T150016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.181517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.461997",
        "ticker_sentiment_score": "0.274107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38111253/eli-lilly-and-co-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240405T143133",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 22 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.130804,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.821469",
        "ticker_sentiment_score": "0.166043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock",
    "url": "https://www.fool.com/investing/2024/04/06/eli-lillys-wegovy-competitor-is-causing-supply-con/",
    "time_published": "20240406T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Things are going exactly as planned for the biotech giant.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771534/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.16125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.415535",
        "ticker_sentiment_score": "0.140382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.136348",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Modelo maker Constellation Brands is primed for market share gains but we still see one issue with the company",
    "url": "https://www.cnbc.com/2024/04/07/modelo-maker-constellation-brands-is-primed-for-market-share-gains.html",
    "time_published": "20240407T140001",
    "authors": [
      "Paulina Likos"
    ],
    "summary": "Constellation Brands is positioned for market share gains with a strong business outlook despite this one overhang.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107355010-1704487446557-gettyimages-1910383648-img_5772_oyumebml.jpeg?v=1704487567&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.229898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BUD",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.096031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.075754",
        "ticker_sentiment_score": "0.099982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.1879",
        "ticker_sentiment_score": "0.14927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.096031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.150827",
        "ticker_sentiment_score": "0.128593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRD-A",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.096031",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?",
    "url": "https://www.fool.com/investing/2024/04/07/could-this-new-development-soon-buoy-eli-lilly-and/",
    "time_published": "20240407T111500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "New findings could lead to more growth from their prized medicines.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771971/3-investors-gather-around-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.204144,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.253514",
        "ticker_sentiment_score": "0.247556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.300706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthcare ETFs for the Weight-Loss Drug Boom & Beyond",
    "url": "https://www.zacks.com/stock/news/2252191/healthcare-etfs-for-the-weight-loss-drug-boom-beyond",
    "time_published": "20240408T193400",
    "authors": [
      "Neena Mishra"
    ],
    "summary": "We discuss attractive investment opportunities within the healthcare industry.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986413"
      }
    ],
    "overall_sentiment_score": 0.077078,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.155656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.155656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ProfoundBio Discovers The Joys Of Having A Wealthy Owner - Genmab  ( NASDAQ:GMAB ) , ArriVent BioPharma  ( NASDAQ:AVBP ) ",
    "url": "https://www.benzinga.com/markets/penny-stocks/24/04/38145526/profoundbio-discovers-the-joys-of-having-a-wealthy-owner",
    "time_published": "20240408T154357",
    "authors": [
      "The Bamboo Works"
    ],
    "summary": "Cancer treatment maker ProfoundBio announced it will be purchased by Denmark's Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months",
    "banner_image": "https://cdn.benzinga.com/files/profoundbio-0408-01.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.166859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.013305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVBP",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.017092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.189882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.102595",
        "ticker_sentiment_score": "0.023162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUVB",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.007071",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Growth Stocks to Buy Hand Over Fist in April",
    "url": "https://www.fool.com/investing/2024/04/08/2-growth-stocks-to-buy-hand-over-fist-in-april/",
    "time_published": "20240408T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These healthcare companies' target markets substantially overlap.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771856/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.199123,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.427726",
        "ticker_sentiment_score": "0.348689",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.474763",
        "ticker_sentiment_score": "0.163199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: VICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2251804/zacks-market-edge-highlights-vici-properties-keycorp-meta-platforms-exxonmobil-and-eli-lilly",
    "time_published": "20240408T121000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly are part of the Zacks Market Edge blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.232644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.11931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VICI",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.263703",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.370986",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.146458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CZR",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.165811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BOWL",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.165811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KEY",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.099614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market",
    "url": "https://www.fool.com/investing/2024/04/08/this-may-ensure-lilly-weight-loss-leadership/",
    "time_published": "20240408T103000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly's stock has climbed in the triple digits over the past 12 months.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771977%2Fgettyimages-scientist_computer_others-in-background.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.230043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.192971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.041565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.",
    "url": "https://www.fool.com/investing/2024/04/08/viking-therapeutics-is-great-but-you-shouldnt-buy/",
    "time_published": "20240408T095500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Shares of the clinical-stage biotech have skyrocketed on recent good news.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771950%2Fgettyimages-1203044156.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.267497,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318211",
        "ticker_sentiment_score": "0.258078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "0.121577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.060165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.196275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38163261/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240409T134547",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.088238,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.764287",
        "ticker_sentiment_score": "0.102607",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biophytis  ( BPTS )  to Begin Phase II Obesity Study, Stock Up",
    "url": "https://www.zacks.com/stock/news/2252360/biophytis-bpts-to-begin-phase-ii-obesity-study-stock-up",
    "time_published": "20240409T110200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.204153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.193348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BPTS",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.116071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.127728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.067045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "url": "https://www.fool.com/investing/2024/04/09/missed-out-on-eli-lilly-2-stocks-with-catalysts/",
    "time_published": "20240409T103500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These companies are close to launching new products that could supercharge revenue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772200%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.268179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.079945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.070731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.499254",
        "ticker_sentiment_score": "0.217058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.054324",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bull Market and Beyond: 3 Stocks Just Waiting to Soar",
    "url": "https://www.fool.com/investing/2024/04/09/bull-market-and-beyond-3-stocks-waiting-to-soar/",
    "time_published": "20240409T085000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks, a bargain today, are players to hold on to for the long term.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772058%2Fgettyimages-1134003590.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.360038,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.332036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.166308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DNA",
        "relevance_score": "0.168099",
        "ticker_sentiment_score": "0.202699",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.332036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.276491",
        "ticker_sentiment_score": "0.124612",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2253643/eli-lilly-lly-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240410T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.168251,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.511734",
        "ticker_sentiment_score": "0.184077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies - Eli Lilly and Co  ( NYSE:LLY ) , Amphastar Pharma  ( NASDAQ:AMPH ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38190504/amphastar-pharmaceuticals-interested-in-potential-acquisitions-in-endocrinology-foc",
    "time_published": "20240410T192359",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc AMPH highlighted why they remain excited about Baqsimi, the inhaled glucagon product for severe hypoglycemia. Amphastar Pharmaceuticals develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AMPH.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.234364,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.088808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.784481",
        "ticker_sentiment_score": "0.362454",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits' - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/04/38175804/jim-cramer-stands-by-nvidia-and-eli-lilly-despite-market-dips-says-terrific-time-to-take-some-pr",
    "time_published": "20240410T023205",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer, CNBC's market commentator, recently shared his insights on Tuesday's market activity. He believes that stocks like NVIDIA Corp NVDA and Eli Lilly And Co LLY, which experienced a dip, still hold growth potential. What Happened: Cramer observed that despite the losses, these stocks have ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_23.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.143113,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.087503",
        "ticker_sentiment_score": "0.07559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.339745",
        "ticker_sentiment_score": "0.05582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.417304",
        "ticker_sentiment_score": "0.098172",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Roche Holdings Stock Popped Today",
    "url": "https://www.fool.com/investing/2024/04/11/why-roche-holdings-stock-popped-today/",
    "time_published": "20240411T223321",
    "authors": [
      "Rich Smith"
    ],
    "summary": "Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772667/lady-scientist-in-lab-coat-and-goggles-pours-blue-liquid-from-a-test-tube-into-a-beaker.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.254283,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.325149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week",
    "url": "https://www.fool.com/investing/2024/04/12/why-anaptysbio-stock-zoomed-nearly-8-higher-this-w/",
    "time_published": "20240412T230050",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A powerfully bullish new analyst take on the company helped it rally on the market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772787/person-in-a-lab-looking-through-a-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.317385,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.601722",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "-0.089761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.235022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.32313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/trading-ideas/24/04/38225112/novo-nordisks-dominance-in-obesity-diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-out",
    "time_published": "20240412T172239",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_11.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.369005,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390396",
        "ticker_sentiment_score": "0.220104",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.142896",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.614027",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38223582/eli-lilly-suffers-legal-loss-for-its-popular-weight-lossdiabetes-drug-in-lawsuit-against-florida-",
    "time_published": "20240412T155455",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co LLY cannot rely on state law to stop a compounding pharmacy, RXCompoundStore.com, from marketing its version of the drug tirzepatide. Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weightloss.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_10.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.110367,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.657184",
        "ticker_sentiment_score": "-0.022172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.109988",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38222006/novo-nordiskeli-lillys-weight-loss-drugs-does-not-cause-suicidal-behaviors-after-fda-european-med",
    "time_published": "20240412T144031",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The European Medicines Agency's Pharmacovigilance Risk Assessment Committee ( PRAC ) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists ( GLP-1 ) and suicidal or self-injurious thoughts and behaviors.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/12/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.182408,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.257442",
        "ticker_sentiment_score": "0.067972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2254326/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
    "time_published": "20240412T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.226282,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.119414",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks That Could Double or More by 2030",
    "url": "https://www.fool.com/investing/2024/04/13/magnificent-stocks-could-double-or-more-by-2030/",
    "time_published": "20240413T124700",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "There's no guarantee these stocks will double by 2030, but their growth prospects look great.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772646/african-american-young-couple-dancing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.317862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.298113",
        "ticker_sentiment_score": "0.219395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.120138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.151778",
        "ticker_sentiment_score": "-0.107742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.134657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?",
    "url": "https://www.fool.com/investing/2024/04/13/this-vanguard-etf-has-skyrocketed-40-in-12-months/",
    "time_published": "20240413T095100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "You can own a basket of tremendously successful stocks with this ETF.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772431/stock-chart-rocket.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.221527,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.071162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.171645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.147499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.147499",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?",
    "url": "https://www.fool.com/investing/2024/04/15/better-buy-bristol-myers-squibb-or-the-vanguard-sp/",
    "time_published": "20240415T133000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772855%2Fgrowth.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.213272,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.106159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.106159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.361919",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Better Growth Play: Merck or The Vanguard Growth Index Fund?",
    "url": "https://www.fool.com/investing/2024/04/15/better-growth-play-merck-or-the-vanguard-growth-in/",
    "time_published": "20240415T130000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772854%2Fgrowth-stock.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.258783,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.011109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.055011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.011109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.055011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "0.055011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2254978/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240415T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14492,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.032045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.043543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.064047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2256381/eli-lilly-lly-stock-dips-while-market-gains-key-facts",
    "time_published": "20240416T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.216075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.593715",
        "ticker_sentiment_score": "0.443594",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades - Avalo Therapeutics  ( NASDAQ:AVTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278240/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-",
    "time_published": "20240416T182500",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa ( HS ) and additional updates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/pharma-lab-worker-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.220261,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.231274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.126301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVTX",
        "relevance_score": "0.729067",
        "ticker_sentiment_score": "0.434899",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "15 'Wealth Creator' Stocks Make Investors Filthy Rich",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-wealth-creator-stocks-make-investors-filthy-rich/",
    "time_published": "20240416T120000",
    "authors": [
      "Investor's Business Daily",
      "MATT KRANTZ"
    ],
    "summary": "Not sure which S&P 500 stocks are the best to buy for the next 10 years? There's no question where the top place to put your money this past decade was. Fifteen S&P 500 stocks - including Apple ( AAPL ) , Microsoft ( MSFT ) and Alphabet ( GOOGL ) - are the top wealth creators in the past 10 ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/06/Stock-richpeople-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.367033,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "0.442226",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.402128",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.402128",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "0.442226",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.256604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "0.426861",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.256604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.800471",
        "ticker_sentiment_score": "0.590145",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.256604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.132842",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2255749/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240416T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.29041,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.050073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank",
    "url": "https://www.fool.com/investing/2024/04/17/why-eli-lilly-stock-beat-the-market-today-while-re/",
    "time_published": "20240417T225153",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773323/person-in-a-lab-looking-through-a-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.087169,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.498188",
        "ticker_sentiment_score": "-0.025811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.056622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AHCO",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.056622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.107915",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options Frenzy: What You Need to Know - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38299357/eli-lilly-and-cos-options-frenzy-what-you-need-to-know",
    "time_published": "20240417T180135",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 87 trades. If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.154723,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.782378",
        "ticker_sentiment_score": "0.080076",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Mixed Ahead Of Fed Data; Tesla Falls As Shareholder Votes Are Set, While Chip Leader Sinks",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-nvidia-tesla-stock-2/",
    "time_published": "20240417T144300",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "Stocks Mixed Ahead Of Fed Data. Tesla Falls As Shareholder Votes Are Set, While Chip Leader Sinks Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/04/Stock-elonmusk-smile-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999174"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.043071,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.053004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "-0.340092",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "-0.187714",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.242551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLCE",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "-0.126563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.040165",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38291259/eli-lillys-famed-weight-loss-drug-zepbound-works-as-sleep-apnea-treatment-successful-late-stage-s",
    "time_published": "20240417T125955",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Eli Lilly And Co LLY released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea ( OSA ) , a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Zepbound.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.030814,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "-0.095567",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Study",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-weight-loss-drug-sleep-apnea-resmed-stock/",
    "time_published": "20240417T125700",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) stock popped Wednesday - and pushed shares of ResMed ( RMD ) lower - after its weight-loss drug reduced symptoms of sleep apnea in patients with obesity. Patients who received Lilly's tirzepatide on average had a 63% reduction in sleep apnea symptoms.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-drugTest-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.004813,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.766141",
        "ticker_sentiment_score": "0.019925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.766141",
        "ticker_sentiment_score": "0.032271",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38320162/patients-find-weight-loss-drug-zepbound-a-game-changer-but-makers-see-production-delay-until-2025",
    "time_published": "20240418T165052",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S's NVO Wegvoy ( ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/18/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.03366,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "-0.062792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.02601",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Eli Lilly's Sleep Apnea News Actually Help This CPAP Maker?",
    "url": "https://www.investors.com/news/technology/resmed-stock-eli-lilly-obstructive-sleep-apnea-cpaps/",
    "time_published": "20240418T143300",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "ResMed Stock Reverses Higher As Weight-Loss Drugs Seen Bolstering Its Devices Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-ResMed-01-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.152847,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.054941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.521465",
        "ticker_sentiment_score": "0.330111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.134704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.134704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.178018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38316123/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-15-years",
    "time_published": "20240418T143033",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return of 23.13%. Currently, Eli Lilly and Co has a market capitalization of $711.81 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Company News for Apr 18, 2024",
    "url": "https://www.zacks.com/stock/news/2257452/company-news-for-apr-18-2024",
    "time_published": "20240418T125300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article are: ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.038902,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.457556",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.224855",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.279267",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's  ( LLY )  Tirzepatide Meets Goals in Sleep Apnea Studies",
    "url": "https://www.zacks.com/stock/news/2257439/eli-lillys-lly-tirzepatide-meets-goals-in-sleep-apnea-studies",
    "time_published": "20240418T125100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.102534,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.135263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.017174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.011363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.18079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years",
    "url": "https://www.fool.com/investing/2024/04/18/growth-stocks-turn-10k-into-more-than-100k/",
    "time_published": "20240418T091000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks have taken different paths to where they are today, but both have been exceptional investments.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772800/investor-looking-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.134214,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.150874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.357049",
        "ticker_sentiment_score": "0.088389",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo",
    "url": "https://www.zacks.com/stock/news/2257331/the-zacks-analyst-blog-highlights-eli-lilly-linde-caterpillar-salesforce-and-wells-fargo",
    "time_published": "20240418T082000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.172806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LIN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.059311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Even Medical Products Stocks Don't All Look Healthy In This Sick Market",
    "url": "https://www.investors.com/stock-lists/ibd-50/dexcom-dxcm-stock-medical-companies/",
    "time_published": "20240419T183900",
    "authors": [
      "Investor's Business Daily",
      "KIMBERLEY KOENIG"
    ],
    "summary": "Investors often turn to defensive types of stocks including medical companies in times of market turmoil, but even those can produce mixed results. Take IBD 50 medical products stocks such as Dexcom ( DXCM ) , which has wavered in a buy zone but ultimately slipped below its entry point.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.124833,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INSP",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.172044",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.238152",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "-0.295614",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PRCT",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.153094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.287972",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.457566",
        "ticker_sentiment_score": "0.260041",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Shows Bearish Action: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-taiwan-semiconductor-asml-netflix-united-airlines-weekly-review/",
    "time_published": "20240419T165100",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.041784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.148103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.034689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.102009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.123399",
        "ticker_sentiment_score": "0.018007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.105983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.004134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.102972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "-0.127853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.076438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.107278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.101928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.095435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.088742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0156",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38336360/exploring-the-competitive-space-eli-lilly-and-co-versus-industry-peers-in-pharmaceuticals",
    "time_published": "20240419T150021",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.179898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.52759",
        "ticker_sentiment_score": "0.236352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data",
    "url": "https://www.zacks.com/stock/news/2258354/pharma-stock-roundup-jnjs-q1-results-lly-abbv-rhhbys-successful-study-data",
    "time_published": "20240419T131500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.035644,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.054754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.042066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "-0.191191",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week",
    "url": "https://www.investors.com/stock-lists/sector-leaders/dexcom-stock-dxcm-diabetes-insulin/",
    "time_published": "20240419T123000",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.327633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.135154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "0.428074",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.135154",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Relatively Safe Growth Stocks You Can Buy and Hold",
    "url": "https://www.fool.com/investing/2024/04/20/relatively-safe-growth-stocks-you-can-buy-and-hold/",
    "time_published": "20240420T104800",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "Low risk and high-reward potential? These stocks could offer both.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773405/hands-behind-head-young-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      }
    ],
    "overall_sentiment_score": 0.300536,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.356154",
        "ticker_sentiment_score": "0.337205",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.020054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.280846",
        "ticker_sentiment_score": "0.1808",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.040969",
        "ticker_sentiment_score": "0.100232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Advances But Underperforms Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2259608/eli-lilly-lly-advances-but-underperforms-market-key-facts",
    "time_published": "20240422T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.108153,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.249266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38363518/eli-lilly-aims-to-close-supply-demand-gap-for-zepboundmounjaro-as-it-acquires-manufacturing-facil",
    "time_published": "20240422T182141",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly and Company LLY agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. The deal terms were not disclosed.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/22/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.157515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.740156",
        "ticker_sentiment_score": "0.134465",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38356901/changing-frugal-eating-habits-how-novo-nordiskeli-lillys-weight-loss-drugs-reshaping-food-spendin",
    "time_published": "20240422T132138",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers' spending habits, particularly in the food industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/22/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.191229,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SBUX",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.15276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.15276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.15276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "0.194166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.167429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.167429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.15276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.183109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38383934/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20240423T154548",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 54 trades. If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.137445,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.823417",
        "ticker_sentiment_score": "0.149834",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Reports Next Week: Wall Street Expects Earnings Growth",
    "url": "https://www.zacks.com/stock/news/2260247/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth",
    "time_published": "20240423T140101",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.137784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.057509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.022696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Pfizer vs. Viking Therapeutics",
    "url": "https://www.fool.com/investing/2024/04/23/better-buy-pfizer-vs-viking-therapeutics/",
    "time_published": "20240423T131500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two pharma stocks have followed distinct paths of late. Which is the better investment?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773859%2Fhealthcare.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.281154,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.003002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.374191",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.008004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.003002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.44266",
        "ticker_sentiment_score": "0.561378",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Novo Nordisk Stock Today? - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38413220/what-are-pricing-strategies-for-ozempic-and-wegovy-with-potential-medicare-coverage-expansion-sen",
    "time_published": "20240424T181426",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing Novo Nordisk A/S NVO 's pricing strategies, particularly those of its diabetes and obesity medications, Ozempic and Wegovy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/24/Bernie-Sanders-Ozempic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.158001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "-0.203302",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.051789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.088396",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?",
    "url": "https://www.zacks.com/stock/news/2261491/will-healthcare-etfs-lose-momentum-as-q1-earnings-unfold",
    "time_published": "20240424T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b3/30471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.988915"
      }
    ],
    "overall_sentiment_score": 0.094139,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.030354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "-0.00714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.080874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.078127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.007886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Large Drug Stocks to Hold on to Amid Industry Challenges",
    "url": "https://www.zacks.com/commentary/2260758/4-large-drug-stocks-to-hold-on-to-amid-industry-challenges",
    "time_published": "20240424T140900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999491"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221236,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.11349",
        "ticker_sentiment_score": "0.144552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.022772",
        "ticker_sentiment_score": "0.06641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.135985",
        "ticker_sentiment_score": "0.157325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.022772",
        "ticker_sentiment_score": "0.06641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135985",
        "ticker_sentiment_score": "0.157325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Analysts Estimate Pfizer  ( PFE )  to Report a Decline in Earnings: What to Look Out for",
    "url": "https://www.zacks.com/stock/news/2261226/analysts-estimate-pfizer-pfe-to-report-a-decline-in-earnings-what-to-look-out-for",
    "time_published": "20240424T140154",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.10056,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "-0.001426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "-0.045929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Eli Lilly  ( LLY )  Be in Your Portfolio Ahead of Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2261017/should-eli-lilly-lly-be-in-your-portfolio-ahead-of-q1-earnings",
    "time_published": "20240424T132500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.272056,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.427973",
        "ticker_sentiment_score": "0.337137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.241224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.122477",
        "ticker_sentiment_score": "0.191306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.040969",
        "ticker_sentiment_score": "0.032769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Leader Hits Buy Trigger In Market Rebound",
    "url": "https://www.investors.com/research/novo-nordisk-nvo-stock/",
    "time_published": "20240424T132400",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Wednesday's IBD 50 Stocks To Watch pick, weight-loss drug leader Novo Nordisk ( NVO ) , hit an early buy trigger during the recent stock market rebound. That makes Novo Nordisk stock one of the best stocks to watch right now.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.226694,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.079052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.554916",
        "ticker_sentiment_score": "0.356235",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Roche  ( RHHBY )  Q1 Hit by Currency Headwinds, Lower COVID-19 Sales",
    "url": "https://www.zacks.com/stock/news/2261355/roche-rhhby-q1-hit-by-currency-headwinds-lower-covid-19-sales",
    "time_published": "20240424T131100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.002437,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.260238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "-0.251035",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FOREX:CHF",
        "relevance_score": "0.746555",
        "ticker_sentiment_score": "-0.273034",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2260940/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20240424T130014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default214.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.221909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.134534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market",
    "url": "https://www.fool.com/investing/2024/04/24/meet-lilly-secret-weapon-in-weight-loss-market/",
    "time_published": "20240424T104000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly recently announced news that could solve a big problem.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773935%2Fgettyimages-woman-points-at-computer-with-a-pen-to-show-something-to-a-colleague.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.126673,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.087055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.478692",
        "ticker_sentiment_score": "0.161343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.082674",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2260775/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240424T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      }
    ],
    "overall_sentiment_score": 0.258582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.253605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.048656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.048656",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gear Up for Lilly  ( LLY )  Q1 Earnings: Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2262065/gear-up-for-lilly-lly-q1-earnings-wall-street-estimates-for-key-metrics",
    "time_published": "20240425T131526",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.142583,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.346642",
        "ticker_sentiment_score": "0.204806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie",
    "url": "https://www.zacks.com/stock/news/2262167/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-merck-and-abbvie",
    "time_published": "20240425T123300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219201,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128937",
        "ticker_sentiment_score": "0.112011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.010009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.171333",
        "ticker_sentiment_score": "0.209828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.061809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.150189",
        "ticker_sentiment_score": "0.150982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.061809",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Big Pharma Is Taking A Page Out Of Novartis' Playbook",
    "url": "https://www.investors.com/news/technology/biotech-stocks-big-pharma-radiopharmaceuticals-acquisitions/",
    "time_published": "20240425T123000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/TECH1_radiopharma_042624_shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.091352,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "-0.108479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.234194",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "-0.108479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple, Amazon, Big Pharma And The Fed: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/stock-market-apple-amazon-big-pharma-the-fed/",
    "time_published": "20240426T221700",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-FedBldg-flag-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.189522,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.270149",
        "ticker_sentiment_score": "0.056371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.040372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.151018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.032061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.043458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.326415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.10474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.104639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.123387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.043751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.113638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.109307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.067624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.044114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCJ",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.316853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.109307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.096925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.049741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia Leads 7 Stocks Flashing Buy Signals; As Market Roars Back",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nvidia-new-buys-market-roars-fed-apple-super-micro/",
    "time_published": "20240426T212000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Nvidia Leads 7 New Buys As Market Roars. Fed, Apple, Super Micro Loom Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-lion-closeup-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.155746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KLAC",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.05357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APP",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "0.02576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.025087",
        "ticker_sentiment_score": "0.136081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.207017",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.270591",
        "ticker_sentiment_score": "-0.043192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.074084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.174227",
        "ticker_sentiment_score": "-0.052775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.047399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.124939",
        "ticker_sentiment_score": "0.133604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.168945",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HUBB",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "0.049818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "0.147231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.124939",
        "ticker_sentiment_score": "0.011649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.124939",
        "ticker_sentiment_score": "0.15066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.174227",
        "ticker_sentiment_score": "0.178736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GNRC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.047399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERJ",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXRH",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.047399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.168945",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates",
    "url": "https://www.zacks.com/stock/news/2263464/pharma-stock-roundup-mrk-sny-azn-nvs-q1-results-pipeline-regulatory-updates",
    "time_published": "20240426T153400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.158632,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.014231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.207868",
        "ticker_sentiment_score": "0.026596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.068262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.068262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.139467",
        "ticker_sentiment_score": "0.024867",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CPAP Stock Rockets As Quarterly Report Wipes Out Weight-Loss Woes",
    "url": "https://www.investors.com/news/technology/resmed-stock-resmed-earnings-q1-2024-cpaps-weight-loss-drugs/",
    "time_published": "20240426T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "ResMed Stock Hits 8-Month High After Quarterly Beat Wipes Out Weight-Loss Drug Woes Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/Stock-Resmed-bldg-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.234376,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.038661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.729947",
        "ticker_sentiment_score": "0.392607",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/04/26/a-3x-expected-rise-in-mounjaro-sales-is-likely-to-drive-eli-lillys-q1/",
    "time_published": "20240426T130042",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Eli Lilly stock ( NYSE: LLY ) will report its Q1 results on Tuesday, April 30. The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the consensus estimates. All eyes will be on Eli Lilly's diabetes drug - Mounjaro - and its weight-loss ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662b6a87b3af139422324bac/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.254501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.64741",
        "ticker_sentiment_score": "0.414163",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "GSK ADR Trying To Close In On Key Technical Measure",
    "url": "https://www.investors.com/ibd-data-stories/gsk-adr-trying-to-close-in-on-key-technical-measure-2/",
    "time_published": "20240426T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "GSK ADR ( GSK ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, rising from 68 to 72. X This exclusive rating from Investor's Business Daily tracks market leadership with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.238383,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Nvidia, These Unstoppable Stocks Are Better Buys",
    "url": "https://www.fool.com/investing/2024/04/27/forget-nvidia-these-unstoppable-stocks-are-better/",
    "time_published": "20240427T151000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773650/a-couple-meeting-with-an-advisor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.257992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.300605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.137289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMED",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.295358",
        "ticker_sentiment_score": "0.270426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.189594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On",
    "url": "https://www.fool.com/investing/2024/04/27/1-unstoppable-pharmaceutical-stock-investors/",
    "time_published": "20240427T131500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773981%2Fgettyimages-170619155.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.202672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.507932",
        "ticker_sentiment_score": "0.43694",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.068321",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/27/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
    "time_published": "20240427T111500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "You'll get dividends and more with these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774374/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.273184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396888",
        "ticker_sentiment_score": "0.293766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.360171",
        "ticker_sentiment_score": "0.156442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.176676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FCAP",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.086608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.284106",
        "ticker_sentiment_score": "0.173062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week' - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/general/market-summary/24/04/38474759/jim-cramer-weighs-in-ahead-of-apple-amazon-eli-lilly-earnings-we-have-to-run-such-a-ridicu",
    "time_published": "20240427T023316",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has outlined the key events that investors should keep an eye on in the upcoming week. What Happened: Cramer highlighted the significant events scheduled for the week, including earnings reports from Apple Inc. AAPL, Amazon.com Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/26/Photo-Courtesy-of-Scott-Beale-on-Flickr.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.074813,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "-0.004983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.138544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.211366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "-0.004983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "-0.176479",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.056746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.116715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.085316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "-0.176479",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Announced More Good News: Time to Buy?",
    "url": "https://www.fool.com/investing/2024/04/28/eli-lilly-just-announced-more-good-news-time-to-bu/",
    "time_published": "20240428T171700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's no stopping this high-flying biotech.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774345/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.187399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "0.293327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics Incredibly Undervalued?",
    "url": "https://www.fool.com/investing/2024/04/28/is-viking-therapeutics-incredibly-undervalued/",
    "time_published": "20240428T143000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774718%2Fvalue-stock.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.144914,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.051931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.122681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "-0.038132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.051931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.211582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Earnings And Artificial Intelligence Save Stocks Despite Inflation",
    "url": "https://www.forbes.com/sites/bill_stone/2024/04/28/earnings-and-artificial-intelligence-save-stocks-despite-inflation/",
    "time_published": "20240428T110000",
    "authors": [
      "Bill Stone"
    ],
    "summary": "The pace of earnings picked up steam last week, with 159 S&P 500 companies reporting, and will be followed by the busiest week with 175 scheduled to report. After the relative drag from bank and healthcare earnings over the previous weeks, the more diversified company mix boosted earnings ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662d107592feda028773740a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      }
    ],
    "overall_sentiment_score": 0.111837,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.094901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.289462",
        "ticker_sentiment_score": "0.177081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.084905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.024787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.084905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.147216",
        "ticker_sentiment_score": "0.141706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.118021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Markets Up on Tesla, Q1 Earnings; Q1 Beats After the Bell",
    "url": "https://www.zacks.com/stock/news/2264549/markets-up-on-tesla-q1-earnings-q1-beats-after-the-bell",
    "time_published": "20240429T221000",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "It's now the third straight day higher going back to Thursday of last week, and recovered from a quick drop into the red.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/2151.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.226322,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSLA",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.345756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.058859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.049127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.058859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.092489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.058859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.074551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.058859",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in Novo Nordisk  ( NVO )  Ahead of Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2264446/should-you-invest-in-novo-nordisk-nvo-ahead-of-q1-earnings",
    "time_published": "20240429T173300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.319288,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.19049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.201017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.541149",
        "ticker_sentiment_score": "0.315963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much Stock Eli Lilly Repurchased in 2023",
    "url": "https://www.fool.com/investing/2024/04/29/heres-how-much-stock-eli-lilly-repurchased-in-2023/",
    "time_published": "20240429T141500",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Hint: It probably wasn't as much as you might imagine given the company's immensity.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774282/medical-professional-holding-dollar-sign-paperweight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.232104,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.337325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q1 Earnings Report - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38488543/how-to-earn-500-a-month-from-eli-lilly-stock-ahead-of-q1-earnings-report",
    "time_published": "20240429T123214",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Eli Lilly and Company LLY is set to report first-quarter earnings on Tuesday, April 30. Analysts expect the Indianapolis, Indiana-based company's quarterly earnings to be $2.46 per share, up from $1.62 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/29/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.180433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "0.394508",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rise After Market Roars, But Watch For This",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nvidia-leads-new-buys-tesla-stock-runs-elon-musk/",
    "time_published": "20240429T092900",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures Rise: Nvidia Leads New Buys. Tesla Runs Past Resistance On Elon Musk Move Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-lion-closeup-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.160587,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KLAC",
        "relevance_score": "0.141448",
        "ticker_sentiment_score": "0.050601",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APP",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.025368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.023696",
        "ticker_sentiment_score": "0.135094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "-0.206972",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "-0.042152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.078751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.164709",
        "ticker_sentiment_score": "-0.050732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.048207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.131418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.170137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FRBA",
        "relevance_score": "0.023696",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBB",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.050161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.146646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.011358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.1589",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULT",
        "relevance_score": "0.023696",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.15391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.164709",
        "ticker_sentiment_score": "0.172093",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GNRC",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.048207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERJ",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXRH",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.048207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.071005",
        "ticker_sentiment_score": "0.170137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now",
    "url": "https://www.fool.com/investing/2024/04/29/nasdaq-bull-market-best-investing-move/",
    "time_published": "20240429T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Many technology stocks are soaring, and you may be wondering if they've gotten too expensive.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774545%2Fgettyimages-bull-market.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.345083,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.364908",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.024957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.132371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.044763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.024957",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 3 Companies Recently Lifted Guidance",
    "url": "https://www.zacks.com/stock/news/2265464/these-3-companies-recently-lifted-guidance",
    "time_published": "20240430T215100",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bb/14622.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.465555,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.550532",
        "ticker_sentiment_score": "0.445362",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.550532",
        "ticker_sentiment_score": "0.375157",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.47147",
        "ticker_sentiment_score": "0.289738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks Skid Into Fed; Amazon Rises Late As AMD, Super Micro Fall",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp500-skids-into-fed-amazon-amd-super-micro-earnings/",
    "time_published": "20240430T205600",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Stocks Skid Into Fed. Amazon Rises Late As AMD, Super Micro Fall Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999336"
      }
    ],
    "overall_sentiment_score": -0.012142,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "XPEV",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.269445",
        "ticker_sentiment_score": "-0.046731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "-0.082975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOD",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRS",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.03197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.026053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.15173",
        "ticker_sentiment_score": "-0.008112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "-0.059555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.269445",
        "ticker_sentiment_score": "0.020248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNRC",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.091393",
        "ticker_sentiment_score": "0.053948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.15173",
        "ticker_sentiment_score": "0.058426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "-0.350147",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Stock Market Today: Stocks Sell Off Ahead of Fed Decision",
    "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-sell-off-ahead-of-fed-decision",
    "time_published": "20240430T201046",
    "authors": [
      "Karee Venema"
    ],
    "summary": "Stocks opened in negative territory Tuesday, with losses accelerating into the close. Investors were already skittish ahead of tomorrow's Fed decision and this morning's disappointing inflation data did little to calm nerves.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.106387,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.053027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "-0.095216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "-0.077834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "-0.049372",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Americans Swap $5 Burgers For $1,000 Weight Loss Drugs - Is Soda Getting Left Behind Too? Americans Swap $5 Burgers For $1,000 Weight Loss Drugs, Like Ozempic, Wegovy - Is Soda Getting Left Behind Too? - Coca-Cola  ( NYSE:KO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/education/24/04/38532194/americans-swap-5-burgers-for-1-000-weight-loss-drugs-is-soda-getting-left-behind-too",
    "time_published": "20240430T192236",
    "authors": [
      "Aaron Bry"
    ],
    "summary": "A trio of earnings reports Tuesday morning may have given us a glimpse into how Americans' consumption habits are shifting. Eli Lilly LLY, which makes Mounjaro, one of the leading weight-loss drugs in the United States, beat EPS estimates and also raised its 2024 revenue guidance, sending the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/burger-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.042983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.273807",
        "ticker_sentiment_score": "0.184168",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EAT",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.359447",
        "ticker_sentiment_score": "-0.053341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "-0.11423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBRA",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38531968/goldman-scrutinizes-hits-misses-and-growth-trajectory-concerns-for-eli-lilly-and-it",
    "time_published": "20240430T191132",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Eli Lilly And Co LLY reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and 10% due to higher realized prices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.149723,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.151465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.534294",
        "ticker_sentiment_score": "0.00654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dexcom Stock Continues To Post Very Healthy Profits, Returns",
    "url": "https://www.investors.com/news/technology/stocks-with-rising-relative-strength-dexcom-2/",
    "time_published": "20240430T190300",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "JAMES DETAR",
      "Investor's Business Daily"
    ],
    "summary": "Dexcom Stock Posts Healthy Profits, Returns Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-Dexcom-03-company.jpeg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.314944,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "-0.221697",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LFMD",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.174265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.616228",
        "ticker_sentiment_score": "0.404791",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "-0.221697",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/04/30/eli-lilly-lly-q1-2024-earnings-call-transcript/",
    "time_published": "20240430T183016",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "LLY earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.25265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.107168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.123608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.008973",
        "ticker_sentiment_score": "0.075414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.07169",
        "ticker_sentiment_score": "0.092739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004487",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Q1: Another Quarter of Strong Growth",
    "url": "https://www.fool.com/data-news/2024/04/30/eli-lillys-q1-another-quarter-of-strong-growth/",
    "time_published": "20240430T182456",
    "authors": [
      "JesterAI"
    ],
    "summary": "Eli Lilly's earnings exceeded estimates, powered by significant sales growth despite supply issues.",
    "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.397455,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "0.493382",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks Dive On Fears Of Hawkish Fed; Treasury Yields Rise, Bitcoin Tumbles To $60,000: What's Driving Markets Tuesday? - Arch Capital Group  ( NASDAQ:ACGL ) ",
    "url": "https://www.benzinga.com/markets/equities/24/04/38529736/stocks-dive-on-fears-of-hawkish-fed-treasury-yields-rise-bitcoin-tumbles-to-60-000-whats-driving",
    "time_published": "20240430T173513",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Investor apprehension grips Wall Street with major indices showing midday losses on Tuesday in New York trading, ahead of the Federal Reserve's potentially hawkish pivot in Wednesday's meeting. The S&P 500 retraced 0.9% after a 2-day positive streak, with the tech-heavy Nasdaq 100 slightly ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Man-Markets-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.004925,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TT",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPC",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.005059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.076161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.006244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "-0.225719",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.298969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACGL",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "-0.263389",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.201244",
        "ticker_sentiment_score": "-0.032127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "-0.231721",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-eli-lilly-earnings-q1-2024/",
    "time_published": "20240430T162100",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Surges After Weight-Loss Drug Zepbound Obliterates Sales Views Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/SOTD-4-30-2024LLY.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      }
    ],
    "overall_sentiment_score": 0.092769,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.606385",
        "ticker_sentiment_score": "0.116572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "-0.056852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Surges on Demand for Weight-Loss Drugs",
    "url": "https://www.kiplinger.com/investing/stocks/eli-lilly-stock-surges-on-demand-for-weight-loss-drugs",
    "time_published": "20240430T160829",
    "authors": [
      "Joey Solitro"
    ],
    "summary": "Eli Lilly ( LLY ) stock is rallying more than 5% in Thursday's session after the pharmaceutical giant reported strong first-quarter earnings results and raised its full-year outlook. In the three months ended March 31, Eli Lilly's revenue increased 26% from the year-ago period to $8.8 billion.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99992"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.401504,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.565374",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.246579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.129822",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Incyte's  ( INCY )  Q1 Earnings & Revenues Fall Shy of Estimates",
    "url": "https://www.zacks.com/stock/news/2265278/incytes-incy-q1-earnings-revenues-fall-shy-of-estimates",
    "time_published": "20240430T155000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.076129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.053955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.63573",
        "ticker_sentiment_score": "0.098365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.21489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.034242",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q1 Earnings Top, Sales Miss, 2024 View Raised",
    "url": "https://www.zacks.com/stock/news/2265271/eli-lilly-lly-q1-earnings-top-sales-miss-2024-view-raised",
    "time_published": "20240430T154500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998917"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.194861,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.394494",
        "ticker_sentiment_score": "0.238953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.170395",
        "ticker_sentiment_score": "0.239558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.203786",
        "ticker_sentiment_score": "0.235123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.199248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Is Jumping Today",
    "url": "https://www.fool.com/investing/2024/04/30/why-eli-lilly-stock-is-jumping-today/",
    "time_published": "20240430T152600",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Investors are cheering the big-pharma company's improved outlook.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775011/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.37527,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.893234",
        "ticker_sentiment_score": "0.584559",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "FOMC Meeting Samsung Over Takes Apple, AI Demand Indication Ahead From AMD, Amazon And Super Micro - iShares 20+ Year Treasury Bond ETF  ( NASDAQ:TLT ) ",
    "url": "https://www.benzinga.com/markets/24/04/38524946/fomc-meeting-samsung-over-takes-apple-ai-demand-indication-ahead-from-amd-amazon-and-super-micro",
    "time_published": "20240430T151941",
    "authors": [
      "The Arora Report"
    ],
    "summary": "To gain an edge, this is what you need to know today. Please click here for an enlarged chart of 20+ year iShares 20+ Year Treasury Bond ETF TLT. Samsung has quadrupled its net profit due to demand from artificial intelligence. Its high bandwidth memory is flying off the shelves.",
    "banner_image": "https://cdn.benzinga.com/files/nicholas-cappello-wb63zqj5gne-unsplash_4_4.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.225713,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "-0.189753",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.141855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "-0.189753",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "-0.189753",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "-0.189753",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.193852",
        "ticker_sentiment_score": "0.099572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.161094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.099131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.045358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Increases FY24 Outlook, Joins Brinker International, Zebra Technologies, 3M And Other Big Stocks Moving Higher On Tuesday - Eli Lilly and Co  ( NYSE:LLY ) , Brinker International  ( NYSE:EAT ) , 3M  ( NYSE:MMM ) , Zebra Technologies  ( NASDAQ:ZBRA ) ",
    "url": "https://www.benzinga.com/news/24/04/38523584/eli-lilly-increases-fy24-outlook-joins-brinker-international-zebra-technologies-3m-and-other-big-sto",
    "time_published": "20240430T145337",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were lower, with the Dow Jones index falling over 100 points on Tuesday. Shares of Eli Lilly and Company LLY rose sharply during Tuesday's session after the company raised its FY24 revenue guidance.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.431723,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.254038",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ST",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.146324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WGS",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.372572",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CVLT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.347874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WWD",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.280282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETWO",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.522657",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.340795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LXU",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.319501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.199011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMKR",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.421524",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ACIW",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.444589",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HLIT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "THC",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.539271",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CLW",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.395963",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GLW",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.366704",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ATI",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.298135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.07759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EAT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.296946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TREE",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.327791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TKR",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.298135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZBRA",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.451474",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BLND",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.112839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Data Deluge",
    "url": "https://www.zacks.com/stock/news/2265192/earnings-data-deluge",
    "time_published": "20240430T144800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-market indices are in a giving mood. Specifically, the Dow is selling off -175 points at the hour, the S&P 500 is -21 and the Nasdaq is -78 points. Today we close out April, is likely to be the first negative month since October of last year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a5/1022.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      }
    ],
    "overall_sentiment_score": 0.1322,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.278867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.146037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "-0.082631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.023661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.023661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.023661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Retreat As Lilly Pops and Tesla Drops",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-eli-lilly-stock/",
    "time_published": "20240430T144400",
    "authors": [
      "KIMBERLEY KOENIG",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Sinks While Tesla Retreats Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-Tesla-RedSilo-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      }
    ],
    "overall_sentiment_score": 0.035915,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.19499",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SOLV",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.255927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.237087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.14573",
        "ticker_sentiment_score": "0.021508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.120423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "-0.020013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.127471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "-0.023115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.031199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "-0.064021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pre-Markets Sell on Last Trading Day of April",
    "url": "https://www.zacks.com/stock/news/2265160/pre-markets-sell-on-last-trading-day-of-april",
    "time_published": "20240430T141700",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today we close out a month that's likely to be the first negative one since October of last year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2d/65907.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9973"
      }
    ],
    "overall_sentiment_score": 0.127345,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.14304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.14304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.027355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.023021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.023021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.023021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher On Tuesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38521126/eli-lillys-weight-loss-drug-still-going-strong-boosts-annual-forecast",
    "time_published": "20240430T134107",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Eli Lilly And Co LLY reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and 10% due to higher realized prices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.263761,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "0.041802",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Tops Q1 Earnings Estimates",
    "url": "https://www.zacks.com/stock/news/2264689/eli-lilly-lly-tops-q1-earnings-estimates",
    "time_published": "20240430T115505",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of 1.98% and 0.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.155276,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.181105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Jumps On Strong Earnings, Guidance As Zepbound Sales Beat",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q1-2024/",
    "time_published": "20240430T114400",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Eli Lilly ( LLY ) jumped early Tuesday after the pharma behemoth reported adjusted earnings of $2.58 per share on $8.77 billion in first-quarter sales. On average, analysts polled by FactSet expected Lilly to earn $2.47 per share on $8.94 billion in sales.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/stock-Eli-Lilly-02-Shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.120265,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.619618",
        "ticker_sentiment_score": "0.228673",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "-0.144057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq Set To Open Lower Ahead Of Fed Decision: What's Dragging Stock Futures? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38514380/wall-street-on-edge-ahead-of-fed-decision-spotlight-falls-on-amazon-and-amd-earnings-analyst-says-s",
    "time_published": "20240430T105722",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks appear to be on the back foot early on Tuesday, with index futures trading modestly lower in early pre-market activity. Caution reigns supreme as traders anxiously await the Federal Reserve's interest rate decision on Wednesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Wall-Street-illustration.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.028952,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ST",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAP",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSCC",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FFIV",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.222081",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "THC",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.148054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "-0.147805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "-0.11699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum",
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2024-financial-results-and-raises-full-year-revenue-guidance-by-2-billion-highlights-pipeline-momentum-302130768.html",
    "time_published": "20240430T104500",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.191572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.363663",
        "ticker_sentiment_score": "0.197735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.013008",
        "ticker_sentiment_score": "-0.012355",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Round-Trip Fed Gains; Carvana Spikes Late",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-powell-ai-plays-carvana-skyrockets/",
    "time_published": "20240501T205400",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Stock Market Round-Trips Fed Gains As AI Plays Struggle. Carvana Skyrockets Late Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/Stock-Carvana-19-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      }
    ],
    "overall_sentiment_score": -0.017032,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "-0.019555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.139413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.100025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.103073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "-0.232671",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "POWL",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.148562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "-0.078553",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.061167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.172327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFM",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "-0.010664",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots' - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38563149/eli-lilly-on-its-way-to-1-trillion-market-cap-analysts-say-its-a-have-in-a-sea-of-h",
    "time_published": "20240501T192650",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY \"could be on its way to becoming a $1 trillion market cap company,\" according to analysts at Cantor Fitzgerald. The assessment comes on the heels of an earnings report that shows first-quarter revenue of $8.77 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/01/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.273555,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.461699",
        "ticker_sentiment_score": "-0.035975",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook",
    "url": "https://www.zacks.com/stock/news/2266174/etfs-to-buy-as-eli-lilly-beats-q1-earnings-lifts-outlook",
    "time_published": "20240501T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99998"
      }
    ],
    "overall_sentiment_score": 0.1901,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.279539",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going With Pfizer Stock On Wednesday? - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38554240/pfizer-embraces-direct-to-consumer-model-for-covid-antiviral-says-comirnaty-revenues-continue-to-",
    "time_published": "20240501T143835",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Pfizer Inc. PFE reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54. The company witnesses a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/01/Pfizer-shutterstock2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.04049,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.013458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.551622",
        "ticker_sentiment_score": "0.149321",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks",
    "url": "https://www.fool.com/investing/2024/05/01/50-of-billionaire-stanley-druckenmillers-portfolio/",
    "time_published": "20240501T140000",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "The billionaire's family fund is surprisingly concentrated.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774965%2Fartificial-intelligence-investing-algorithms.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.250066,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "-0.059196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.452881",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.487709",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.253817",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.166574",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Company News for May 1, 2024",
    "url": "https://www.zacks.com/stock/news/2265595/company-news-for-may-1-2024",
    "time_published": "20240501T092100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: PYPL, LLY, MMM, GLW.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.298007,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.387675",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.417006",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GLW",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.662425",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.156644",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Joins Rank Of Stocks With 95-Plus Composite Rating",
    "url": "https://www.investors.com/ibd-data-stories/eli-lilly-joins-rank-of-stocks-with-95-plus-composite-rating-3/",
    "time_published": "20240501T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Eli Lilly ( LLY ) saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 89 to 98. X The new score means the company is now outperforming 98% of all stocks in terms of the most important fundamental and technical stock-picking criteria.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.287598,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "-0.122784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?",
    "url": "https://www.fool.com/investing/2024/05/02/1-wall-street-analyst-thinks-eli-lilly-stock-is-go/",
    "time_published": "20240502T232300",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company seems to be going from strength to strength lately.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775445/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.394751,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.544862",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38596771/weigh-loss-competition-heats-up-in-britain-online-pharmacies-slash-prices-for-wegovy-and-mounjaro",
    "time_published": "20240502T200146",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk A/S's NVO Wegovy and Eli Lilly And Co LLY Mounjaro as initial supply shortages ease, a move driven by growing competition among retailers.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/Ozempic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14075,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.127533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.168364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Earnings Season: 3 Companies Boosting Guidance",
    "url": "https://www.zacks.com/stock/news/2267373/earnings-season-3-companies-boosting-guidance",
    "time_published": "20240502T185900",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/57606.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.43188,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.388488",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.335014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.430088",
        "ticker_sentiment_score": "0.273328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38588563/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240502T151945",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.142203,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.791632",
        "ticker_sentiment_score": "0.262814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition - Catalent  ( NYSE:CTLT ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/05/38575293/demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-",
    "time_published": "20240502T094844",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Novo Nordisk A/S NVO is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase comes despite supply constraints and competition from Eli Lilly & Co. LLY.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/Ozempic-and-other-drugs-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.116438,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.148545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.162779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly Stock Remains a Screaming Buy",
    "url": "https://www.fool.com/investing/2024/05/02/heres-why-eli-lilly-stock-remains-a-screaming-buy/",
    "time_published": "20240502T094500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The biggest healthcare company in the world could grow much larger over the next decade.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775234/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.146329,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.73822",
        "ticker_sentiment_score": "0.188468",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "0.020001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen Stock Zoomed Nearly 12% Higher Today",
    "url": "https://www.fool.com/investing/2024/05/03/why-amgen-stock-zoomed-nearly-12-higher-today/",
    "time_published": "20240503T221534",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775812/medical-professional-holding-dollar-sign-paperweight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.337486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.231231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.585052",
        "ticker_sentiment_score": "0.404777",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.231231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA  ( NYSE:FIX ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38619689/pharma-stock-roundup-lly-nvo-pfe-q1-results-jnjs-new-plan-to-resolve-talc-claims",
    "time_published": "20240503T200026",
    "authors": [
      "Zacks"
    ],
    "summary": "The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely resolve its talc-related lawsuits.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/christina-victoria-craft-zhys6xn7sue-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.127813,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.27317",
        "ticker_sentiment_score": "0.172176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.02327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "0.211201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "-0.086207",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rallies-fed-jobs-report-apple/",
    "time_published": "20240503T171800",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rallied for the week, with Friday's weaker-than-expected jobs report bolstering a relatively dovish Federal Reserve and Fed chief Jerome Powell on Wednesday. The S&P 500 and Nasdaq tested key levels. Apple ( AAPL ) soared on a record buyback and earnings that were better than ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/Stock-NYSE-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.019613,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "XPEV",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEN",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.106072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.027632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.015047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.122221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.013582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "-0.015523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.05416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.092699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTST",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "0.009351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "0.10427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.059575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "0.056179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "-0.016434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHAK",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFM",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.15427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXRH",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.028699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.056596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.028699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.125874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "0.009968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.058097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNRC",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.010997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.010096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.122221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.087864",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q1 Earnings Top, Stock Up on Obesity Drug Update",
    "url": "https://www.zacks.com/stock/news/2268117/amgen-amgn-q1-earnings-top-stock-up-on-obesity-drug-update",
    "time_published": "20240503T154800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is \"very encouraged\" by interim data from the phase II study on obesity candidate MariTide.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.178125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.165849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.15669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.163419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.057977",
        "ticker_sentiment_score": "0.197001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's what's driving Friday's stock action in Apple, Coterra and Eli Lilly",
    "url": "https://www.cnbc.com/2024/05/03/heres-whats-driving-fridays-moves-in-apple-coterra-and-eli-lilly.html",
    "time_published": "20240503T153158",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107374404-1708024054818-gettyimages-2013247027-js2_0524_hk5bxrx4.jpeg?v=1714748643&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Earnings",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.242832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.216765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.160125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.160125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims",
    "url": "https://www.zacks.com/stock/news/2268082/pharma-stock-roundup-lly-nvo-pfe-q1-results-jnjs-new-plan-to-resolve-talc-claims",
    "time_published": "20240503T152900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.115606,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.267926",
        "ticker_sentiment_score": "0.164976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.202648",
        "ticker_sentiment_score": "0.003265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.169437",
        "ticker_sentiment_score": "0.188599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.169437",
        "ticker_sentiment_score": "-0.033654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38616660/comparative-study-eli-lilly-and-co-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240503T150017",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Eli Lilly and Co LLY in comparison to its major competitors within the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.121746,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.472959",
        "ticker_sentiment_score": "0.162826",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-apple-amgen-aapl-amgn-stock/",
    "time_published": "20240503T144100",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Surges, Led By Amgen, Apple. Nvidia Jumps Above Key Level Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-bull-20-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.232682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.026809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.319204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.074693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.279653",
        "ticker_sentiment_score": "0.283304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.043073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.238609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.155187",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.088545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.155187",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.250183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.228899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.140678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making",
    "url": "https://www.fool.com/investing/2024/05/04/move-over-mounjaro-eli-lilly-has-another-blockbust/",
    "time_published": "20240504T123000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F775313%2Fgettyimages-1379960412.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.395213,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.618922",
        "ticker_sentiment_score": "0.568349",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.370204",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How Dividend Investors Can Profit As AI Changes Everything",
    "url": "https://www.forbes.com/sites/michaelfoster/2024/05/04/how-dividend-investors-can-profit--as-ai-changes-everything/",
    "time_published": "20240504T120000",
    "authors": [
      "Michael Foster"
    ],
    "summary": "If you've been following the AI space lately ( and honestly, who hasn't? ) , you've probably seen stories about tech investors feeling a bit shortchanged on the profits they're getting. That's actually good news for the rest of us-a sign the market is maturing and ripe to be tapped for income.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/60803617d7b099e7fee76763/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.252136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.242391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "-0.034987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.256317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.028219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "-0.030778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.204341",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/05/04/eli-lilly-raised-its-outlook-is-the-stock-a-buy-no/",
    "time_published": "20240504T092600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The anti-obesity medication stock is way up, and there could be more fuel in the tank.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775225/investor-dark-room-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.087955,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.567746",
        "ticker_sentiment_score": "0.214476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.095189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.049006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.052796",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years",
    "url": "https://www.fool.com/investing/2024/05/05/3-super-safe-dividend-stocks-that-have-been-making/",
    "time_published": "20240505T184900",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks have rock-solid businesses and they have impressive track records for paying dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774677/a-rich-person-counting-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.420887,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.293423",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.410426",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TD",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.439669",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Artificial Intelligence Plays Paying Up To 9.1%",
    "url": "https://www.forbes.com/sites/brettowens/2024/05/05/3-high-yield-artificial-intelligence-plays-paying-up-to-91/",
    "time_published": "20240505T160100",
    "authors": [
      "Brett Owens"
    ],
    "summary": "Stock market rallies climb walls of worry. Well, we have no shortage of such worries today! A few days ago, Bloomberg lamented there was \"no relief in sight for bonds\". This was ironic because relief-the catalyst for the next big bond rally-is hidden in plain sight.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6633b9330b71c08c9bb7dc33/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.312918,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.220061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.041525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.056145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.082412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.12297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSTZ",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.230018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.056145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.15028",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.185835",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in May",
    "url": "https://www.fool.com/investing/2024/05/05/3-no-brainer-stocks-to-buy-in-may/",
    "time_published": "20240505T105500",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These great stocks are great picks for investors as spring winds down.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775632/person-pleasantly-surprised-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.30299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.271489",
        "ticker_sentiment_score": "0.364937",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.036643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.039621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.014494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.020745",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Jumped by 4% Today",
    "url": "https://www.fool.com/investing/2024/05/06/why-eli-lilly-stock-jumped-by-4-today/",
    "time_published": "20240506T230654",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company's payout is far from the only reason investors like the stock these days, but it certainly helps.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776129/medical-professional-working-at-a-computer-terminal.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.323623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.656549",
        "ticker_sentiment_score": "0.388287",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $2,200 Today - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38655435/100-invested-in-this-stock-15-years-ago-would-be-worth-2-200-today",
    "time_published": "20240506T210044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 15 years by 10.37% on an annualized basis producing an average annual return of 22.64%. Currently, Eli Lilly and Co has a market capitalization of $728.91 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38647415/this-is-what-whales-are-betting-on-eli-lilly-and-co",
    "time_published": "20240506T154549",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Eli Lilly and Co LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.142103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.830107",
        "ticker_sentiment_score": "0.282235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Reliance on International Sales: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2268816/lilly-lly-reliance-on-international-sales-what-investors-need-to-know",
    "time_published": "20240506T131800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Examine the evolution of Lilly's (LLY) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default323.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.206461,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.245835",
        "ticker_sentiment_score": "0.063722",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2268511/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240506T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.203781,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.135357",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Stocks That Could Make You Richer in 2024",
    "url": "https://www.fool.com/investing/2024/05/06/2-top-stocks-that-will-make-you-richer-in-2024/",
    "time_published": "20240506T081000",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "Here are a couple of great ideas on where to invest your money today.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775823/investors-gettyimages-1295534838.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.361265,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.166048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.157854",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.286193",
        "ticker_sentiment_score": "0.286924",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hedge Fund Legend Druckenmiller Shares His Top Secrets For 30% Returns - Eli Lilly and Co  ( NYSE:LLY ) , Coupang  ( NYSE:CPNG ) ",
    "url": "https://www.benzinga.com/news/24/05/38686502/hedge-fund-legend-druckenmiller-shares-his-top-secrets-for-30-returns",
    "time_published": "20240507T215339",
    "authors": [
      "Natan Ponieman"
    ],
    "summary": "Legendary hedge fund manager Stanley Druckenmiller is known for making the right bets at the right time. He came to fame In the early '90s after a short against the British pound earned George Soros, his boss at the time, over $10 billion overnight.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/Businessman-Markets-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.203615,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "-0.133689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.145807",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "-0.133689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.2035",
        "ticker_sentiment_score": "-0.090771",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "-0.133689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCKRF",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "-0.111378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.104342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.199155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.16571",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38676658/what-about-eli-lillys-drug-for-early-alzheimers-fda-panel-to-discuss-next-month",
    "time_published": "20240507T163835",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co's LLY donanemab for early symptomatic Alzheimer's disease. The open public hearing portion of the meeting will be ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.089696,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.6338",
        "ticker_sentiment_score": "0.003585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs Post Q1 Earnings",
    "url": "https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings",
    "time_published": "20240507T153000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.05748,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.156207",
        "ticker_sentiment_score": "0.043449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.032119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "-0.002079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.156207",
        "ticker_sentiment_score": "0.035777",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mutual Funds Scoop Up Amazon And Broadcom",
    "url": "https://www.investors.com/research/mutual-funds-amazon-stock-amzn-avgo/",
    "time_published": "20240507T120000",
    "authors": [
      "KIMBERLEY KOENIG",
      "Investor's Business Daily"
    ],
    "summary": "Amazon Stock: Mutual Funds Can't Get Enough Of It, Along With Broadcom Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-Amazon-doorstep-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      }
    ],
    "overall_sentiment_score": 0.250445,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.189443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "-0.094096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.238002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "0.232692",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.52706",
        "ticker_sentiment_score": "0.474748",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease - Alphabet  ( NASDAQ:GOOGL ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38711266/google-deepmind-develops-latest-ai-model-to-aid-scientists-in-fighting-disease",
    "time_published": "20240508T191936",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Researchers at Alphabet Inc's GOOG GOOGL Google DeepMind have developed AlphaFold 3, an new artificial intelligence ( AI ) model. AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA and RNA, and small molecules that could function as drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/08/Google-Shutterstock_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.199074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.151297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.423251",
        "ticker_sentiment_score": "0.379492",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.151297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38703781/this-is-what-whales-are-betting-on-eli-lilly-and-co",
    "time_published": "20240508T144608",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 18 unusual trades. Delving into the details, we found 27% of traders were bullish, while 38% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.055419,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.08183",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.782378",
        "ticker_sentiment_score": "0.028099",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "url": "https://www.zacks.com/stock/news/2270578/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick",
    "time_published": "20240508T135010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.353038,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390092",
        "ticker_sentiment_score": "0.254755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy Following Guidance Upgrades",
    "url": "https://www.zacks.com/commentary/2271746/3-stocks-to-buy-following-guidance-upgrades",
    "time_published": "20240509T191900",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/30383.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.361941,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.292248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.397517",
        "ticker_sentiment_score": "0.161504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.306125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Look at Pharma ETFs Post Q1 Earnings - Bristol-Myers Squibb  ( NYSE:BMY ) , First Trust Nasdaq Pharmaceuticals ETF  ( NASDAQ:FTXH ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38676365/a-look-at-pharma-etfs-post-q1-earnings",
    "time_published": "20240509T144107",
    "authors": [
      "Zacks"
    ],
    "summary": "The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so far down 31.2% despite 4.4% revenue growth. The earnings beat ratio of 93.9% and the revenue beat ratio of 75.8% are assuring, though.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/kenny-eliason-8fdhgan5zg0-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.081562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.161982",
        "ticker_sentiment_score": "0.054951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "0.038677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "-0.002404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121856",
        "ticker_sentiment_score": "0.060941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2271115/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240509T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.1496,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.042878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.061272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This 1 Simple ETF Could Turn $100 a Month Into $93,200",
    "url": "https://www.fool.com/investing/2024/05/09/this-1-simple-etf-could-turn-100-a-month-into-9320/",
    "time_published": "20240509T071900",
    "authors": [
      "Anders Bylund"
    ],
    "summary": "Turn small investments into big returns with this surprisingly simple strategy -- and a hands-off ETF investment for the ages.",
    "banner_image": "https://media.ycharts.com/charts/a45af0a2091db2e17ca3b626bbb34aa2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.325681,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.253903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Danaher Sees Relative Strength Rating Climb To 71",
    "url": "https://www.investors.com/ibd-data-stories/danaher-sees-relative-strength-rating-climb-to-71/",
    "time_published": "20240509T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Danaher ( DHR ) had its Relative Strength ( RS ) Rating upgraded from 68 to 71 Thursday - a welcome improvement, but still shy of the 80 or higher score you look for. X IBD's unique rating identifies price performance with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.394743,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.152952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.744196",
        "ticker_sentiment_score": "0.478197",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AstraZeneca ADR Shows Rising Relative Strength; Still Shy Of Key Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/astrazeneca-adr-shows-rising-relative-strength-still-shy-of-key-benchmark/",
    "time_published": "20240509T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "AstraZeneca ADR Shows Rising Relative Strength. Still Shy Of Key Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.389121,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.709186",
        "ticker_sentiment_score": "0.56029",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.234011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nektar's  ( NKTR )  Q1 Earnings and Revenues Surpass Estimates",
    "url": "https://www.zacks.com/stock/news/2272336/nektars-nktr-q1-earnings-and-revenues-surpass-estimates",
    "time_published": "20240510T153300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.081218,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "-0.031499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.303926",
        "ticker_sentiment_score": "0.351756",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.396604",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "-0.094984",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab",
    "url": "https://www.zacks.com/stock/news/2272311/pharma-stock-roundup-pfe-dmd-study-patient-death-fda-panel-meet-for-llys-donanemab",
    "time_published": "20240510T151800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": -0.090108,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "-0.010954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "-0.125009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "-0.070322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.456544",
        "ticker_sentiment_score": "-0.119284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How A Top Fund Beats The Market By Owning Future Leaders",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-fund-beats-the-market-by-owning-future-leaders/",
    "time_published": "20240510T110000",
    "authors": [
      "Investor's Business Daily",
      "ADAM SHELL"
    ],
    "summary": "Julianne McHugh, lead manager of best mutual fund BNY Mellon Large Cap Securities ( DREVX ) , isn't interested in blue-chip stars of yesteryear. When it comes to stock picking, she's more of a futurist than a rear-view-mirror type.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/MFprof051324-959x1024.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999355"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.328806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.126284",
        "ticker_sentiment_score": "0.183787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.188437",
        "ticker_sentiment_score": "0.2235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IR",
        "relevance_score": "0.063341",
        "ticker_sentiment_score": "0.177244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.185016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.063341",
        "ticker_sentiment_score": "0.103831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.31664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks",
    "url": "https://www.zacks.com/stock/news/2271906/zacks-investment-ideas-feature-highlights-eaton-eli-lilly-and-arista-networks",
    "time_published": "20240510T093700",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eaton, Eli Lilly and Arista Networks have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.384695,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.385286",
        "ticker_sentiment_score": "0.263123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "0.122269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.385286",
        "ticker_sentiment_score": "0.278042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 No-Brainer Growth Stock to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/05/11/1-no-brainer-growth-stock-to-buy-and-hold/",
    "time_published": "20240511T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's hard to bet against this high-flying stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775317/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.156289,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.298279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/05/11/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240511T075000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These pharmaceutical companies are top-notch dividend growth stocks for the future.",
    "banner_image": "https://media.ycharts.com/charts/de54d771ee8c900e644a4c59d571e905.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.304021,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.163728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.135875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.440998",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock A Better Pick Over Amgen?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/05/13/is-eli-lilly-stock-a-better-pick-over-amgen/",
    "time_published": "20240513T123029",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Given its better prospects, we believe Eli Lilly stock ( NYSE: LLY ) is a better pick than Amgen stock ( NASDAQ : AMGN ) . Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market. Eli Lilly trades at a higher valuation multiple of 20.4x ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/664190bb712984adff6f12fe/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.30196,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.633079",
        "ticker_sentiment_score": "0.45982",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.633079",
        "ticker_sentiment_score": "0.476129",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.051342",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Pharma Stocks That Just Keep Getting Better and Better",
    "url": "https://www.fool.com/investing/2024/05/14/2-top-pharma-stocks-that-just-keep-getting-better/",
    "time_published": "20240514T135300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Both of these businesses are finding traction in a pair of major markets.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776216/lab-research-scientists-women-in-stem.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.244712,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.154459",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.109912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.131457",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly's Latest Deal a Gamechanger?",
    "url": "https://www.fool.com/investing/2024/05/14/is-eli-lillys-latest-deal-a-gamechanger/",
    "time_published": "20240514T113000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly just took a page out of Novo Nordisk's book.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F776744%2Fgettyimages-1393991949.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.203064,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.620262",
        "ticker_sentiment_score": "0.372595",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.124175",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks That Are Passive Income Machines",
    "url": "https://www.fool.com/investing/2024/05/14/3-magnificent-stocks-that-are-passive-income-machi/",
    "time_published": "20240514T103000",
    "authors": [
      "and David Jagielski",
      "Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "These three companies have track records that should please investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776733/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.29313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.342685",
        "ticker_sentiment_score": "0.330403",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.142799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.416428",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Market Rally Hits Highs, Nvidia Leads 12 Buys; What To Do Now",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp-500-nasdaq-highs-nvidia-leads-new-buys/",
    "time_published": "20240515T205000",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Market Rally Hits Highs, Nvidia Leads 12 Buys. What To Do Now Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.080983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.173126",
        "ticker_sentiment_score": "0.025795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.115927",
        "ticker_sentiment_score": "-0.020505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.25714",
        "ticker_sentiment_score": "-0.013788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.115927",
        "ticker_sentiment_score": "-0.038164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.029078",
        "ticker_sentiment_score": "0.199115",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "-0.068056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "-0.039005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "-0.04497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTAP",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.035372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSTG",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "0.048969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "0.048969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.115927",
        "ticker_sentiment_score": "0.041048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.115927",
        "ticker_sentiment_score": "0.01257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.144621",
        "ticker_sentiment_score": "0.026877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.173126",
        "ticker_sentiment_score": "0.058129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "0.024035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "-0.187043",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should You Hold Viking Therapeutics in Your Portfolio? - Eli Lilly and Co  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/24/05/38851376/should-you-hold-viking-therapeutics-in-your-portfolio",
    "time_published": "20240515T194324",
    "authors": [
      "Zacks"
    ],
    "summary": "Viking Therapeutics VKTX, a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has been in the news, owing to updates from its obesity program. The company, with a market cap of about $8 billion, is developing its lead candidate, VK2735, a dual ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/kristine-wook-kizczaf0jko-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.244896,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.113421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.471099",
        "ticker_sentiment_score": "0.277655",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.078755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212736",
        "ticker_sentiment_score": "0.203603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biogen  ( BIIB )  Partner Begins Filing for Leqembi SC Autoinjector",
    "url": "https://www.zacks.com/stock/news/2274368/biogen-biib-partner-begins-filing-for-leqembi-sc-autoinjector",
    "time_published": "20240515T161200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.19481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.22335",
        "ticker_sentiment_score": "0.005135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "THRD",
        "relevance_score": "0.16849",
        "ticker_sentiment_score": "0.14796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.039932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.521812",
        "ticker_sentiment_score": "0.29949",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.429541",
        "ticker_sentiment_score": "0.230135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38849648/no-wegovy-shortage-in-denmark-amid-high-demand-novo-nordisk-confirms",
    "time_published": "20240515T155908",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does not anticipate a shortage of its weight-loss drug in Denmark.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.026567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.109219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "-0.037058",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Hold Viking Therapeutics  ( VKTX )  in Your Portfolio?",
    "url": "https://www.zacks.com/stock/news/2274279/should-you-hold-viking-therapeutics-vktx-in-your-portfolio",
    "time_published": "20240515T153600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.237893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143629",
        "ticker_sentiment_score": "0.106341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.473582",
        "ticker_sentiment_score": "0.28118",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.143629",
        "ticker_sentiment_score": "0.075299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.194193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38845991/eli-lilly-strikes-deal-to-combat-counterfeit-diabetes-and-weight-loss-drugs-mounjaro-and-zepbound",
    "time_published": "20240515T140337",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.132674,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.686739",
        "ticker_sentiment_score": "0.182227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.294682",
        "ticker_sentiment_score": "0.057591",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Settles With Spa Selling Mounjaro, Zepbound Copies",
    "url": "https://www.zacks.com/stock/news/2274187/eli-lilly-lly-settles-with-spa-selling-mounjaro-zepbound-copies",
    "time_published": "20240515T135300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/4113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.10314,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.016118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.071676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.100401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.198134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now",
    "url": "https://www.fool.com/investing/2024/05/15/these-2-words-explain-why-eli-lilly-stock-is-a-buy/",
    "time_published": "20240515T094400",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its latest medicines for obesity and type 2 diabetes are selling rapidly.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775253/chemist-team-looking-beaker-of-green-chemical.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.212551,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.33446",
        "ticker_sentiment_score": "0.237471",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy Following Positive Earnings Results",
    "url": "https://www.zacks.com/commentary/2275096/3-stocks-to-buy-following-positive-earnings-results",
    "time_published": "20240516T200900",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/650.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.455985,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.417081",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.359167",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.483905",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly: Weekly Insulin Dose On Par With Common Daily Doses - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38874381/eli-lillys-weekly-insulin-dose-on-par-with-commonly-used-daily-doses-phase-3-studies-show",
    "time_published": "20240516T141300",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly and Co LLY released Thursday topline results from two phase 3 trials. The drugmaker evaluated once-weekly insulin efsitora alfa ( efsitora ) in type 2 diabetes patients using insulin for the first time ( insulin na\u00efve ) and those who require multiple daily insulin injections.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/16/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141318,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.316168",
        "ticker_sentiment_score": "0.173389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance",
    "url": "https://www.zacks.com/stock/news/2274825/3-drug-stocks-to-watch-on-raised-2024-earnings-sales-guidance",
    "time_published": "20240516T141300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.258832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.274149",
        "ticker_sentiment_score": "0.235708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.246548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche  ( RHHBY )  Posts Encouraging Phase I Obesity Drug Data",
    "url": "https://www.zacks.com/stock/news/2274860/roche-rhhby-posts-encouraging-phase-i-obesity-drug-data",
    "time_published": "20240516T134400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.17509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.272181",
        "ticker_sentiment_score": "0.159011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.16691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.185723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.220203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.164265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Elevai Labs  ( NASDAQ: ELAB )  Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries - Elevai Labs  ( NASDAQ:ELAB ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/05/38871120/elevai-labs-nasdaq-elab-acquires-rights-to-develop-muscle-loss-prevention-assets-for-anticipated-",
    "time_published": "20240516T123300",
    "authors": [
      "James Blacker"
    ],
    "summary": "Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal Lancet reveals that around 1 billion people are now living with obesity, with the number of obese adults having doubled since 1990 and quadrupled ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/16/Screenshot-2024-05-16-at-5-52-00PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.167884,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ELAB",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.085073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.08398",
        "ticker_sentiment_score": "0.140049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.133806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.08398",
        "ticker_sentiment_score": "0.140049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 No-Brainer Growth Stocks Are Breaking New Ground",
    "url": "https://www.fool.com/investing/2024/05/16/these-2-no-brainer-growth-stocks-are-breaking-new/",
    "time_published": "20240516T111500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The future keeps getting brighter for these companies.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777182/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26523,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.222011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.246391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Research Reports for Microsoft, Eli Lilly & Costco",
    "url": "https://www.zacks.com/research-daily/2275480/top-research-reports-for-microsoft-eli-lilly-costco",
    "time_published": "20240517T192900",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Eli Lilly and Company (LLY) and Costco Wholesale Corporation (COST), as well a micro-cap stock Koss Corporation (KOSS).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fa/1036.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.314644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.223522",
        "ticker_sentiment_score": "0.277081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.16724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.059762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.424399",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly - Altimmune  ( NASDAQ:ALT ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38897093/4-stocks-that-could-break-novo-nordisk-lillys-obesity-duopoly",
    "time_published": "20240517T192425",
    "authors": [
      "Zacks"
    ],
    "summary": "The obesity market has garnered much interest lately, ever since Novo Nordisk NVO received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant - Eli Lilly's LLY Zepbound, which received FDA approval last year in November.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/nick-chong-n__bnvq_w18-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.179517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.212936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.204913",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.09978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.069335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.121379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.020157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.096423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.021146",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells - GameStop  ( NYSE:GME ) ",
    "url": "https://www.benzinga.com/etfs/sector-etfs/24/05/38901285/exclusive-gamestop-amc-buzz-may-prove-to-be-short-lived-ceo-of-company-behind-meme-etf-tells-ben",
    "time_published": "20240517T190443",
    "authors": [
      "Chris Katje"
    ],
    "summary": "The return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week. While there are several ETFs that provide exposure to meme stocks, an ETF that previously focused exclusively on meme stocks closed in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/Meme-Stock-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.279094,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.204591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.204591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.204591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.204591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.241659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.241659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMC",
        "relevance_score": "0.259037",
        "ticker_sentiment_score": "0.14336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.287516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's  ( LLY )  Efsitora Matches Daily Insulins in A1C Control",
    "url": "https://www.zacks.com/stock/news/2275599/eli-lillys-lly-efsitora-matches-daily-insulins-in-a1c-control",
    "time_published": "20240517T155700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.17446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.381255",
        "ticker_sentiment_score": "0.268786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.277748",
        "ticker_sentiment_score": "0.190231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.15197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "-0.028534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates",
    "url": "https://www.zacks.com/stock/news/2275562/pharma-stock-roundup-bayrys-q1-earnings-jnjs-new-buyout-pipeline-updates",
    "time_published": "20240517T153900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.026274,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.279414",
        "ticker_sentiment_score": "-0.008256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.119857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.0639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "-0.079184",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38896380/evaluating-eli-lilly-and-co-against-peers-in-pharmaceuticals-industry",
    "time_published": "20240517T150016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.135675,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.461997",
        "ticker_sentiment_score": "0.1212",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly",
    "url": "https://www.zacks.com/stock/news/2275514/4-stocks-that-could-break-novo-nordisk-lillys-obesity-duopoly",
    "time_published": "20240517T140400",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.211874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.17789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.103479",
        "ticker_sentiment_score": "0.09697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.070244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.205225",
        "ticker_sentiment_score": "0.096103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2275263/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240517T130014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.233149,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.168709",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk",
    "url": "https://www.fool.com/investing/2024/05/17/meet-the-glp-1-drug-that-could-be-the-biggest-conc/",
    "time_published": "20240517T122400",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Could Amgen be the next stock to soar due to a GLP-1 drug?",
    "banner_image": "https://g.foolcdn.com/editorial/images/776990/doctor-meeting-a-salesperson.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.268795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.241651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.514875",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.241651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Apple, Eli Lilly and Crocs",
    "url": "https://www.zacks.com/stock/news/2275146/zacks-investment-ideas-feature-highlights-apple-eli-lilly-and-crocs",
    "time_published": "20240517T093200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Apple, Eli Lilly and Crocs have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7f/511.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.471244,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.329721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.264107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.417001",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?",
    "url": "https://www.fool.com/investing/2024/05/19/is-amgen-a-threat-to-eli-lilly-in-this-market/",
    "time_published": "20240519T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly's biggest growth drivers today are its weight loss drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777578%2Fgettyimages-investor-works-at-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.140873,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.447091",
        "ticker_sentiment_score": "0.211884",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.070167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "-0.009861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "0.110599",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38923808/heres-how-much-100-invested-in-eli-lilly-and-co-5-years-ago-would-be-worth-today",
    "time_published": "20240520T173044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market capitalization of $744.41 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF? - Johnson & Johnson  ( NYSE:JNJ ) , iShares Global Healthcare ETF  ( ARCA:IXJ ) ",
    "url": "https://www.benzinga.com/news/24/05/38915885/should-you-invest-in-the-vanguard-health-care-etf",
    "time_published": "20240520T171816",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Vanguard Health Care ETF VHT, a passively managed exchange traded fund launched on 01/26/2004.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/20/kenny-eliason-8fdhgan5zg0-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.295516,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.14638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.100561",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Just Two Magnificent Seven Stocks Meet This Criteria",
    "url": "https://www.investors.com/news/sp-500-magnificent-seven-earnings-criteria/",
    "time_published": "20240520T120000",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "The Magnificent Seven stocks - S&P 500 giants Amazon.com ( AMZN ) , Apple ( AAPL ) , Google parent Alphabet ( GOOGL ) , Meta Platforms ( META ) , Microsoft ( MSFT ) , Nvidia ( NVDA ) and Tesla ( TSLA ) - have been grouped together since the start of the bull market in January 2023.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-TwoLeaps-sunset-shut.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.315541,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.333188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.352707",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.385655",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.410668",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.008607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.121141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.031399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.264248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.333551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Costco and Koss",
    "url": "https://www.zacks.com/stock/news/2275828/the-zacks-analyst-blog-highlights-microsoft-eli-lilly-costco-and-koss",
    "time_published": "20240520T111200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Microsoft, Eli Lilly, Costco and Koss are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fd/423.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.273721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "0.226258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.137292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.057256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.302208",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KOSS",
        "relevance_score": "0.173749",
        "ticker_sentiment_score": "0.065409",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen",
    "url": "https://www.zacks.com/stock/news/2275810/the-zacks-analyst-blog-highlights-stocks-recently-featured-in-the-blog-include-novo-nordisk-eli-lillys-viking-altimmune-roche-and-amgen",
    "time_published": "20240520T104200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.167697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.154464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.086129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.029675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.053625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.116226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.020964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221385",
        "ticker_sentiment_score": "0.07018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.020964",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2275801/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240520T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.12575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Hits New High But Here Comes Nvidia",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-hits-high-eli-lilly-breaks-out-but-here-comes-nvidia/",
    "time_published": "20240521T205800",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Nasdaq Hits High, Eli Lilly Breaks Out, But Here Comes Nvidia Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-Nvidia-devbox-02-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.05745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.089573",
        "ticker_sentiment_score": "-0.202727",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ARES",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.320027",
        "ticker_sentiment_score": "0.147489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.331329",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOD",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.019195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.051549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NU",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.102542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.178021",
        "ticker_sentiment_score": "0.03631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.043857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.079946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSM",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.090239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDD",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.072112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.012671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "-0.088217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.087971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic - ROUNDHILL ETF TRUST  ( NASDAQ:OZEM ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38951889/exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-o",
    "time_published": "20240521T203305",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "What Happened: The Roundhill GLP-1 & Weight Loss ETF OZEM marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/Munich--Bavaria--Germany---March-31-2023.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.163888,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "-0.024864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.140996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "-0.00176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.059456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.059456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.033675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.140996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestl\u00e9 Launches $5 Pizza For You - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) , Nestle  ( OTC:NSRGY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38949073/weight-loss-drugs-like-wegvoy-and-zepbound-users-nestl-launches-5-pizza-for-you",
    "time_published": "20240521T182559",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Nestl\u00e9 SA NSRGF NSRGY unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. This comes amid fears among investors that food companies could see their sales suffer significantly.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/Nestl.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.207634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.248787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.393474",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.248787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal",
    "url": "https://www.cnbc.com/2024/05/21/eli-lilly-stock-hits-new-highs-after-a-regulatory-win-in-china-this-is-a-big-deal.html",
    "time_published": "20240521T154228",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107361860-1705686940016-gettyimages-1945282910-_s1_4831_x1nimfpp.jpeg?v=1716304466&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.114495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.114495",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day Breaks Out On Its Way To A Record High",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-break-out-record-high-crohns-disease/",
    "time_published": "20240521T153400",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's disease treatment. After a year, more than half of the patients who took Eli Lilly's mirikizumab entered remission.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/SOTD-5-21-2024LLY.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.133419,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.593896",
        "ticker_sentiment_score": "0.306271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today",
    "url": "https://www.fool.com/investing/2024/05/21/if-youd-invested-10000-in-eli-lilly-stock-5-years/",
    "time_published": "20240521T144126",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Have Eli Lilly's successes translated into stock performance?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777819%2Fgettyimages-531714398.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234307,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.019563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.706282",
        "ticker_sentiment_score": "0.365674",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.036161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide Why Is Eli Lilly Stock Trading Higher On Tuesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38941485/eli-lilly-secures-china-nod-for-popular-weight-lossdiabetes-drug-tirzepatide",
    "time_published": "20240521T133601",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Eli Lilly And Company LLY announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval sets the stage for heightened competition with Novo Nordisk A/S NVO in the crucial Asian market.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.205306,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.591019",
        "ticker_sentiment_score": "0.224495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.204782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:DKK",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.111517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:NOK",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.111517",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure",
    "url": "https://www.prnewswire.com/news-releases/more-than-one-half-of-patients-with-crohns-disease-treated-with-lillys-mirikizumab-achieved-clinical-remission-at-one-year-including-patients-with-previous-biologic-failure-302150721.html",
    "time_published": "20240521T120000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.036669,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221897",
        "ticker_sentiment_score": "0.142925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.017294",
        "ticker_sentiment_score": "0.130455",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Hits Record High on Crohn's Disease Study Data",
    "url": "https://www.zacks.com/stock/news/2277543/lilly-lly-hits-record-high-on-crohns-disease-study-data",
    "time_published": "20240522T171600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.278118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.71235",
        "ticker_sentiment_score": "0.466357",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "0.220343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38967989/australia-bans-replica-versions-of-popular-weight-loss-drugs-from-novo-nordisk-eli-lilly-on-safet",
    "time_published": "20240522T154657",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S's NVO Ozempic and Eli Lilly And Co's LLY Mounjaro, citing safety concerns. Recently, the Chinese regulatory authority approved Eli Lilly's diabetes drug, tirzepatide.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/22/Wegovy_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.086967,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "-0.093365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "-0.027034",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Play These New ETFs to Tap Lucrative Weight Loss Drug Market",
    "url": "https://www.zacks.com/stock/news/2277076/play-these-new-etfs-to-tap-lucrative-weight-loss-drug-market",
    "time_published": "20240522T123800",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.007228,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.143843",
        "ticker_sentiment_score": "0.028801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.413425",
        "ticker_sentiment_score": "0.202084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.349575",
        "ticker_sentiment_score": "0.133865",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: Two Titans Flash Buy Signals; Nvidia Up Next",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-target-but-here-comes-nvidia/",
    "time_published": "20240522T105200",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures Fall As Target Tumbles. Here Comes Nvidia Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-Nvidia-devbox-02-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99237"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.057586,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.148752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARES",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.307661",
        "ticker_sentiment_score": "0.121648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.331088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOD",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.035098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.055994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NU",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.100763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.011393",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.226477",
        "ticker_sentiment_score": "0.042461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.112242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSM",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.056765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDD",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.023256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.226477",
        "ticker_sentiment_score": "-0.012266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.142734",
        "ticker_sentiment_score": "-0.086115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.086534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan - Biohaven  ( NYSE:BHVN ) , Structure Therapeutics  ( NASDAQ:GPCR ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38955483/this-biotech-stock-is-poised-for-80-upside-with-breakthrough-in-obesity-drug-market-says-jpmorgan",
    "time_published": "20240522T024137",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "The Structure Therapeutics GPCR stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/weight-loss-ai_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.121821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.244298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.264897",
        "ticker_sentiment_score": "-0.202623",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.501398",
        "ticker_sentiment_score": "-0.028609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.244298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "LLY: Eli Lilly  ( LLY )  vs. Novo Nordisk  ( NVO ) : Which Pharma Stock Is Driving Long-Term 2024 Profits?",
    "url": "https://stocknews.com/news/lly-nvo-eli-lilly-lly-vs-novo-nordisk-nvo-which-pharma-stock/",
    "time_published": "20240523T131712",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "The pharmaceutical industry is thriving due to the increasing incidence of chronic diseases, the rising number of elderly individuals, higher healthcare spending by governmental bodies worldwide, and extensive initiatives aimed at enhancing the affordability and availability of pharma products.",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.278409,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.455797",
        "ticker_sentiment_score": "0.424742",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.314017",
        "ticker_sentiment_score": "0.312523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Blue Chip Stocks That You Can Buy and Hold for Years",
    "url": "https://www.fool.com/investing/2024/05/23/3-blue-chip-stocks-that-you-can-buy-and-hold-for-y/",
    "time_published": "20240523T120500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "You won't be taking on much risk by investing in these stalwarts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777830/a-family-reviewing-financial-results-with-an-advisor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.31243,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.292922",
        "ticker_sentiment_score": "0.311145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.427024",
        "ticker_sentiment_score": "0.373697",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VZIO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.050502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.245835",
        "ticker_sentiment_score": "0.086859",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "8 Massive ETFs With Billions In Assets Are Beating The S&P 500",
    "url": "https://www.investors.com/etfs-and-funds/etfs/sp500-massive-etfs-with-billions-in-assets-are-beating/",
    "time_published": "20240523T120000",
    "authors": [
      "MATT KRANTZ",
      "Investor's Business Daily"
    ],
    "summary": "You don't need to gamble on tiny ETFs with scant assets to beat the S&P 500. Turns out you can do it just fine with massive ones if you know where to look.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/wETF01_gold_022317_adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.37303,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.23394",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.232427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.288973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.113983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.113983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.219323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.179397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Surprise: Eli Lilly Is Racing Toward Yet Another Blockbuster",
    "url": "https://www.fool.com/investing/2024/05/23/surprise-eli-lilly-is-racing-toward-yet-another/",
    "time_published": "20240523T104500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This winner can't stop winning.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777989/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.218495,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.450496",
        "ticker_sentiment_score": "0.3666",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.017459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "-0.011025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rally Narrows But Dow Giants Lead 7 Stocks Near Buy Points",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-narrows-dow-giants-lead-7-stocks-near-buy-points/",
    "time_published": "20240524T211200",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The stock market rally had a mixed week, despite Nvidia ( NVDA ) soaring on booming earnings and guidance. The Nasdaq hit a record high, shrugging off Thursday's ugly downside reversal.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/Stock-Greenarrowsup-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.016983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "-0.014649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.239011",
        "ticker_sentiment_score": "-0.128713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.120885",
        "ticker_sentiment_score": "-0.071339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.073654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSTG",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.073654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.060617",
        "ticker_sentiment_score": "0.171303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.209884",
        "ticker_sentiment_score": "0.149272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "-0.004406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.073654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.149174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.060617",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39012514/eli-lilly-makes-largest-manufacturing-investment-in-its-history-to-boost-production-for-antidiabe",
    "time_published": "20240524T180359",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, Eli Lilly And Company LLY announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/24/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.240274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.223381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.720339",
        "ticker_sentiment_score": "0.35278",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines",
    "url": "https://investingnews.com/lilly-increases-manufacturing-investment-to-9-billion-at-newest-indiana-site-to-boost-api-production-for-tirzepatide-and-pipeline-medicines/",
    "time_published": "20240524T135654",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide ... Investing News Network ...",
    "banner_image": "https://investingnews.com/media-library/image.gif?id=32908904&width=1200&height=600&coordinates=0%2C2%2C0%2C3",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.083186,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.154946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.225321",
        "ticker_sentiment_score": "0.192739",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.127972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Hit A Wall Despite Booming Nvidia: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-hits-wall-despite-nvidia/",
    "time_published": "20240524T135600",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Stock Market Hits A Wall Despite Booming Nvidia: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BullAndMarket-07-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.048906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.098984",
        "ticker_sentiment_score": "0.029132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPG",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "-0.051036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTU",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.029637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.029375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.019846",
        "ticker_sentiment_score": "-0.030649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.019846",
        "ticker_sentiment_score": "0.176327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.098984",
        "ticker_sentiment_score": "0.09459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.021451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDD",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.07713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.020469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.037332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.019846",
        "ticker_sentiment_score": "0.003706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "-0.143801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.001969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "-0.004959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOD",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "-0.129767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "-0.070546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBLK",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.113589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.047708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WSM",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.004071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.043392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.020469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.153264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.071995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXP",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "-0.113268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "-0.032794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/lilly-increases-manufacturing-investment-to-9-billion-at-newest-indiana-site-to-boost-api-production-for-tirzepatide-and-pipeline-medicines-302155135.html",
    "time_published": "20240524T133000",
    "authors": [],
    "summary": "Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999864"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.080778,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.029858",
        "ticker_sentiment_score": "0.151651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.277847",
        "ticker_sentiment_score": "0.215166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.014931",
        "ticker_sentiment_score": "0.12872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More",
    "url": "https://www.zacks.com/stock/news/2278490/pharma-stock-roundup-azns-2030-sales-target-pfes-new-cost-cut-plan-more",
    "time_published": "20240524T131900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.045562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.449723",
        "ticker_sentiment_score": "0.024054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.124637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.057649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.449723",
        "ticker_sentiment_score": "0.07411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: This Basic Materials Stock Is 'Too Dicey,' Shares His Take On Arista Networks - Sigma Lithium  ( NASDAQ:SGML ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/05/39007136/jim-cramer-says-this-basic-materials-stock-is-too-dicey-shares-his-take-on-arista-networ",
    "time_published": "20240524T131150",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Arista Networks, Inc. ANET reported an \"unbelievable\" quarter, and the company's CEO Jayshree Ullal is doing a \"terrific\" job. He added, \"All of these stocks are a little volatile right now, but I think you want to own it and buy it into the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/24/jim-cramer-shutterstock2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.196397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "0.572774",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "0.337062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "0.288251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SGML",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "-0.218279",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "-0.090244",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Flying Stocks That Could Soar Even More",
    "url": "https://www.fool.com/investing/2024/05/25/3-high-flying-stocks-that-could-soar-even-more/",
    "time_published": "20240525T104700",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778486/stock-chart-rocket.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.203016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410505",
        "ticker_sentiment_score": "0.21727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.116918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.062785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212674",
        "ticker_sentiment_score": "0.062603",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/05/39019043/elon-musk-says-ozempic-will-become-very-cheap-after-new-comedy-special-paints-it-as-weight-loss-drug",
    "time_published": "20240525T083055",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk's NVO Ozempic, a popular drug being used for weight loss. What Happened: Musk's comments came after a new South Park special portrayed the drug as a luxury only available to the wealthy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/25/Ozempic-Insulin-Injection-Pen-Or-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.26898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.435266",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.188978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.115393",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What To Do As Rally Narrows But Keeps Rising",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-narrows-stocks-near-buy-points/",
    "time_published": "20240526T144600",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The stock market rally had a mixed week, despite Nvidia ( NVDA ) soaring on booming earnings and guidance. The Nasdaq hit a record high, shrugging off Thursday's ugly downside reversal.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/Stock-Greenarrowsup-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.014538,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.184129",
        "ticker_sentiment_score": "-0.014866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.184129",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.243803",
        "ticker_sentiment_score": "-0.130748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.123367",
        "ticker_sentiment_score": "-0.071998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.092688",
        "ticker_sentiment_score": "-0.074022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSTG",
        "relevance_score": "0.092688",
        "ticker_sentiment_score": "-0.074022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.171431",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.214123",
        "ticker_sentiment_score": "0.151602",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.184129",
        "ticker_sentiment_score": "-0.004471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.092688",
        "ticker_sentiment_score": "-0.074022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "-0.149561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $500? 3 Pharma Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/05/26/got-500-3-pharma-stocks-to-buy-and-hold-forever/",
    "time_published": "20240526T141500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These players might even beat the market when the conditions are right.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778164/investor-thinks-while-looking-out-a-window.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.265035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.164656",
        "ticker_sentiment_score": "0.244994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.239132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.18474",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?",
    "url": "https://www.fool.com/investing/2024/05/26/amgens-catching-up-to-novo-nordisk-and-eli-lilly-s/",
    "time_published": "20240526T105300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The gold rush for obesity medications just got a bit more intense.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778155/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.235454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.181493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.134761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.141448",
        "ticker_sentiment_score": "0.133015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.181493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "10 Best Vanguard Funds to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/05/27/10-best-vanguard-funds-to-buy-right-now/",
    "time_published": "20240527T123000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 10 Vanguard stock ETFs can help you build a top-notch portfolio.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778686%2Fetf.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.391095,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRGP",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.113276",
        "ticker_sentiment_score": "0.092723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.090731",
        "ticker_sentiment_score": "0.122297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.045439",
        "ticker_sentiment_score": "0.217094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.24951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.246548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.300559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.246548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.090731",
        "ticker_sentiment_score": "0.122297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.158611",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APH",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.036053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.180777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.034958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.022729",
        "ticker_sentiment_score": "0.180777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Ramp Up Indiana Site for Mounjaro, Zepbound",
    "url": "https://www.zacks.com/stock/news/2279236/eli-lilly-lly-to-ramp-up-indiana-site-for-mounjaro-zepbound",
    "time_published": "20240527T120200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.176824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.386355",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.072099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.101099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.261237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/05/39026748/chinese-scientists-achieve-worlds-first-diabetes-cure-using-cell-therapy-report",
    "time_published": "20240527T111652",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first. What Happened: The patient, who was at high risk of severe diabetes complications, has been insulin-free for 33 months following the treatment, reported the South China Morning ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/27/Diabetes.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.336302,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.192244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.192244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2279193/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240527T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default49.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.256999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.127481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.089087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.06419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A New Name in Weight Loss Drugs",
    "url": "https://www.fool.com/investing/2024/05/28/a-new-name-in-weight-loss-drugs/",
    "time_published": "20240528T163300",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778379/mfm_20.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.175127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.038268",
        "ticker_sentiment_score": "0.038033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.009571",
        "ticker_sentiment_score": "0.166872",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.038268",
        "ticker_sentiment_score": "0.038033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPOF",
        "relevance_score": "0.009571",
        "ticker_sentiment_score": "0.080371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.009571",
        "ticker_sentiment_score": "0.017847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLNT",
        "relevance_score": "0.057375",
        "ticker_sentiment_score": "0.037081",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2279892/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240528T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.237399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.162466",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/05/28/eli-lilly-stock-could-soar-24-according-to-a-wall/",
    "time_published": "20240528T083900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778632/individual-investor-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.053192,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.541149",
        "ticker_sentiment_score": "0.060841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.059049",
        "ticker_sentiment_score": "0.010027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.059049",
        "ticker_sentiment_score": "0.055072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.044032",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39032738/not-just-a-weight-loss-story-eli-lilly-ceo-thinks-its-possible-to-meet-bofas-60b-revenue-projecti",
    "time_published": "20240528T063857",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "David Ricks, CEO of Eli Lilly and Co LLY, expressed confidence in meeting the lofty revenue expectations set by Bank of America for the company's upcoming drug launches.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/28/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234675,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "0.107363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.630923",
        "ticker_sentiment_score": "0.489293",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "FDA Conditionally Approves Eli Lilly's Thyroid Cancer Drug For Pediatric Patients With Certain Mutations - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39071768/fda-conditionally-approves-eli-lillys-thyroid-cancer-drug-for-pediatric-patients-with-certain-mut",
    "time_published": "20240529T190201",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, the FDA granted accelerated approval to Eli Lilly And Co's LLY selpercatinib ( Retevmo ) for pediatric patients two years of age and older with the following: Advanced or metastatic medullary thyroid cancer ( MTC ) with a RET mutation, who require systemic therapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/Eli-Lilly-Corporate-Center--Indianapolis.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.132497,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.38976",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting' - Apple  ( NASDAQ:AAPL ) , Axcelis Technologies  ( NASDAQ:ACLS ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/05/39062320/jim-cramer-recommends-buying-apple-finds-this-tech-stock-very-interesting",
    "time_published": "20240529T124714",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Apple Inc. AAPL is a \"buy here.\" Apple's iPhone sales in China increased by 52% year-on-year in April, Reuters cited from industry reports. When asked about Palantir Technologies Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/West-Bangal--India---April-20--2022--App.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.242843,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGNA",
        "relevance_score": "0.317869",
        "ticker_sentiment_score": "0.123185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "-0.067926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDD",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.451569",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.317869",
        "ticker_sentiment_score": "0.325594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACLS",
        "relevance_score": "0.317869",
        "ticker_sentiment_score": "0.559078",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.317869",
        "ticker_sentiment_score": "-0.152174",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.554844",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WDAY",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "-0.123917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "-0.072199",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?",
    "url": "https://www.fool.com/investing/2024/05/29/could-eli-lilly-be-the-next-to-join-the-trillion-d/",
    "time_published": "20240529T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Today, Eli Lilly's market value tops $700 billion.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F778758%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999759"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.358063,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.680543",
        "ticker_sentiment_score": "0.4855",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.321931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.054014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.121073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply - Tema Obesity & Cardiometabolic ETF  ( NASDAQ:HRTS ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/05/39057150/weight-loss-drug-forecasts-skyrocket-to-150b-as-novo-nordisk-eli-lilly-ramp-up-supply",
    "time_published": "20240529T093705",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from Novo Nordisk NVO and Eli Lilly and Co ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.191182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.393462",
        "ticker_sentiment_score": "0.402219",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.48028",
        "ticker_sentiment_score": "0.354604",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "New Weight Loss ETF  ( OZEM )  Is Essentially A Play On Eli Lilly And Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) , Roundhill GLP-1 & Weight Loss ETF  ( NASDAQ:OZEM ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39096628/new-weight-loss-etf-is-essentially-a-play-on-eli-lilly-novo-nordisk",
    "time_published": "20240530T193643",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "The recently launched Roundhill GLP-1 & Weight Loss ETF OZEM is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO. These two companies are at the forefront of the burgeoning weight-loss drug market, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/weight-loss-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.354767,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.263396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.358669",
        "ticker_sentiment_score": "0.32511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF? - BlackRock  ( NYSE:BLK ) , iShares U.S. Healthcare ETF  ( ARCA:IYH ) ",
    "url": "https://www.benzinga.com/news/24/05/39083266/should-you-invest-in-the-ishares-u-s-healthcare-etf",
    "time_published": "20240530T170357",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF IYH, a passively managed exchange traded fund launched on 06/12/2000.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/alexander-mils-lcphgxs7pww-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.240467,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.103121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Lilly  ( LLY )  Up 4.5% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2281505/why-is-lilly-lly-up-45-since-last-earnings-report",
    "time_published": "20240530T153109",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.14522,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.434252",
        "ticker_sentiment_score": "0.248318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Incyte  ( INCY )  Up 7.5% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2281515/incyte-incy-up-75-since-last-earnings-report-can-it-continue",
    "time_published": "20240530T153107",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.095103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.125898",
        "ticker_sentiment_score": "0.04632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.507678",
        "ticker_sentiment_score": "0.187793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.212853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39090619/weight-loss-drug-market-to-rocket-to-130b-by-2030-with-eli-lilly-novo-nordisk-in-le",
    "time_published": "20240530T151706",
    "authors": [
      "Anusuya Lahiri"
    ],
    "summary": "Goldman Sachs analysts re-rated Eli Lilly And Co LLY and Novo Nordisk A/S NVO, citing the potential for their weight-loss drugs. The firm expects the global sales of weight-loss drugs to reach $130 billion by 2030, an increase from their prior $100 billion forecast.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.190749,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.08183",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.392537",
        "ticker_sentiment_score": "0.19866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.318422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Costco, Eli Lilly Near New Highs; That Doesn't Scare Mutual Funds",
    "url": "https://www.investors.com/research/costco-stock-cost-mutual-funds-lly-stock/",
    "time_published": "20240530T123000",
    "authors": [
      "KIMBERLEY KOENIG",
      "Investor's Business Daily"
    ],
    "summary": "Costco Stock, Eli Lilly Among Fund Favorites Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/Stock-Costco-05-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.306446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.286864",
        "ticker_sentiment_score": "0.234508",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.352582",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.05933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.09986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.135999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Urban Outfitters, Eli Lilly And 2 Other Stocks Insiders Are Selling - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/05/39084569/urban-outfitters-eli-lilly-and-2-other-stocks-insiders-are-selling",
    "time_published": "20240530T122246",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The Nasdaq 100 closed lower by over 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/30/xrdDAFj0FUZspA2-j5351515556-t23052408.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.133313,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.024712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.326283",
        "ticker_sentiment_score": "0.256547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EA",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "-0.019255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.281746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2281071/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240530T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.21482,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.088144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.069616",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39117961/novo-nordisk-sues-additional-us-clinics-against-fake-semaglutide-products-used-for-weight-loss-di",
    "time_published": "20240531T180828",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug, Wegovy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/31/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.101305,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.068602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "0.167778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Research Reports for Eli Lilly, T-Mobile & BHP",
    "url": "https://www.zacks.com/research-daily/2282096/top-research-reports-for-eli-lilly-t-mobile-bhp",
    "time_published": "20240531T173700",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default362.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.319076,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.230366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Maker Novo Nordisk Stock Is Up More Than 31% In 2024, Trades Near Buy Zone",
    "url": "https://www.investors.com/stock-lists/sector-leaders/novo-nordisk-stock-ozempic/",
    "time_published": "20240531T172000",
    "authors": [
      "RACHEL FOX",
      "Investor's Business Daily"
    ],
    "summary": "Among top medical stocks to watch on the IBD Sector Leaders list, Novo Nordisk ( NVO ) traded close to a buy point Friday as shares bounced from their 21-day exponential moving average the past few days. The Denmark-based drugmaker is a leader in the weight-loss drugs race, alongside Eli Lilly ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.179704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.115979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.228874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.521465",
        "ticker_sentiment_score": "0.145673",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/39113388/performance-comparison-eli-lilly-and-co-and-competitors-in-pharmaceuticals-industry",
    "time_published": "20240531T150014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Eli Lilly and Co LLY alongside its primary ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.180317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.469253",
        "ticker_sentiment_score": "0.269983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nvidia CEO, CrowdStrike, Jobs Report Headline Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/nvidia-ceo-crowdstrike-jobs-report/",
    "time_published": "20240531T142300",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Here is this week's Investing Action Plan, what you need to know for the week ahead. Economic data dominates the week, capped by the May jobs report on Friday. As for earnings, cybersecurity leader CrowdStrike ( CRWD ) headlines a small lineup of earnings reports.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/09/econ01-jobs-090117-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.125102,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.071209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "-0.069689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.126669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.057548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.071161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.12349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.105249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "-0.073547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLLI",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.089852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors",
    "url": "https://www.fool.com/investing/2024/06/01/this-biggest-risk-for-eli-lilly-and-novo-nordisk/",
    "time_published": "20240601T142500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778643/worried-investor-looking-at-their-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.112622,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.074272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.616612",
        "ticker_sentiment_score": "0.15042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.616612",
        "ticker_sentiment_score": "0.15042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO\u00ae Annual Meeting",
    "url": "https://investingnews.com/updated-data-from-the-phase-1-2-study-of-olomorasib-in-kras-g12c-mutant-advanced-solid-tumors-presented-at-the-2024-asco-r-annual-meeting/",
    "time_published": "20240601T122437",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the ... Investing News Network ...",
    "banner_image": "https://investingnews.com/media-library/image.gif?id=32908904&width=1200&height=600&coordinates=0%2C2%2C0%2C3",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.123811,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21643",
        "ticker_sentiment_score": "0.148739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.133021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Giants Lead Five Healthy Stocks Near Buy Points",
    "url": "https://www.investors.com/news/sp-500-giants-stocks-near-buy-points/",
    "time_published": "20240601T120000",
    "authors": [
      "Investor's Business Daily",
      "HARRISON MILLER"
    ],
    "summary": "With many leading stocks in need of some repair, investors may want to seek medical attention. Eli Lilly ( LLY ) , Novo Nordisk ( NVO ) , Vertex Pharmaceuticals ( VRTX ) , Intuitive Surgical ( ISRG ) and Universal Health ( UHS ) are all trading in or near buy zones.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-HealthCloud-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTLT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.132137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.139665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.408769",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.252006",
        "ticker_sentiment_score": "0.092848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.159148",
        "ticker_sentiment_score": "0.132957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.136597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "-0.073241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO\u00ae Annual Meeting",
    "url": "https://www.prnewswire.com/news-releases/updated-data-from-the-phase-12-study-of-olomorasib-in-kras-g12c-mutant-advanced-solid-tumors-presented-at-the-2024-asco-annual-meeting-302160829.html",
    "time_published": "20240601T120000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.128941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.174407",
        "ticker_sentiment_score": "0.135378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.025113",
        "ticker_sentiment_score": "0.135458",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/06/02/prediction-these-could-be-the-best-pharmaceutical/",
    "time_published": "20240602T133000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two drugmakers have a lot more in common than their market-beating potential.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778278/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.270066,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.486729",
        "ticker_sentiment_score": "0.382851",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.486729",
        "ticker_sentiment_score": "0.386445",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says - Structure Therapeutics  ( NASDAQ:GPCR ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39144875/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforgli",
    "time_published": "20240603T191417",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Structure Therapeutics Inc. GPCR revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/GPCR.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.212533,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.162702",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.186443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Unbalanced Iron Condor May Put $285 In Your Pocket",
    "url": "https://www.investors.com/research/options/lly-stock-unbalanced-iron-condor-285-in-your-pocket/",
    "time_published": "20240603T185400",
    "authors": [
      "Investor's Business Daily",
      "GAVIN McMASTER"
    ],
    "summary": "Eli Lilly ( LLY ) rallied to record highs in May thanks to a positive trial for its Crohn's disease treatment. So, today we are looking at an unbalanced iron condor, with a slightly bullish bias, in LLY stock. You can achieve this type of iron condor by trading more put spreads than call spreads.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/stock-Eli-Lilly-02-Shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.055664,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.498188",
        "ticker_sentiment_score": "0.18133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "-0.173257",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.5075",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Beyond Nvidia: 2 Chip Giants, 2 Drugmakers In Spotlight",
    "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/nvidia-stock-amd-tsm-lly-nvo/",
    "time_published": "20240603T181400",
    "authors": [
      "MATTHEW GALGANI",
      "Investor's Business Daily"
    ],
    "summary": "Nvidia Stock Seeks Market-Cap Supremacy As AMD, TSM Etch Buy Points Alngside Two Drugmakers Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/Stock-spotlight-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.153547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.064997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.465196",
        "ticker_sentiment_score": "0.079545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.13364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.168784",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.209892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.302179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "-0.022496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.289967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39143733/eli-lilly-beefs-up-neuro-pipeline-with-addition-of-preclinical-als-dementia-prospect",
    "time_published": "20240603T180545",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. LLY.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/Eli-Lilly-Corporate-Center--Indianapolis.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.189455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASOMF",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.324474",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.537474",
        "ticker_sentiment_score": "0.403012",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Structure Therapeutics Stock Soars On Weight-Loss Drug Results",
    "url": "https://www.investors.com/news/technology/structure-therapeutics-stock-gpcr-weight-loss-drug/",
    "time_published": "20240603T174200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Structure Therapeutics ( GPCR ) stock rocketed to a six-month high Monday after the biotech company delivered \"compelling\" results for its weight-loss drug. The company tested its drug over 12 weeks in patients with obesity but not type 2 diabetes.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/Stock-weightlossmeasure-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.176837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.018128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.119498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.35493",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.35493",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39137913/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240603T140104",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 22 trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.118115,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.807885",
        "ticker_sentiment_score": "0.120088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate",
    "url": "https://www.fool.com/investing/2024/06/03/watch-out-wegovy-here-comes-another-promising-anti/",
    "time_published": "20240603T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The fight for dominance in the weight loss market is just getting started.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778465/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.147539,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.611103",
        "ticker_sentiment_score": "0.345227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.240151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon",
    "url": "https://www.zacks.com/stock/news/2282776/the-zacks-analyst-blog-highlights-eli-lilly-t-mobile-us-bhp-american-international-and-exelon",
    "time_published": "20240603T133300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/536.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.23547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.305437",
        "ticker_sentiment_score": "0.11247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.186259",
        "ticker_sentiment_score": "0.004456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXC",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.003484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHP",
        "relevance_score": "0.186259",
        "ticker_sentiment_score": "0.004456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIG",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.003484",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2282432/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240603T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.124899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.057385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.057385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: AstraZeneca ADR Sees RS Rating Jump To 83",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-astrazeneca-adr-sees-rs-rating-jump-to-83/",
    "time_published": "20240603T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "AstraZeneca ADR ( AZN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Monday, with an upgrade from 80 to 83. X IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.329086,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.717153",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39166413/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-700-today",
    "time_published": "20240604T170016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 5 years by 35.98% on an annualized basis producing an average annual return of 48.73%. Currently, Eli Lilly and Co has a market capitalization of $787.98 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "ETFs to Profit from the Weight Loss Drug Boom",
    "url": "https://www.zacks.com/stock/news/2283455/etfs-to-profit-from-the-weight-loss-drug-boom",
    "time_published": "20240604T154500",
    "authors": [
      "Neena Mishra"
    ],
    "summary": "The market for GLP-1 drugs could soar to $130 billion by ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default239.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.021636,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.256763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.070871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.086773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.256763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Melissa Seymour to join Lilly as executive vice president of Global Quality",
    "url": "https://investingnews.com/melissa-seymour-to-join-lilly-as-executive-vice-president-of-global-quality/",
    "time_published": "20240604T132550",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Eli Lilly and Company ( NYSE: LLY ) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 .",
    "banner_image": "https://investingnews.com/media-library/image.gif?id=32908904&width=1200&height=600&coordinates=0%2C2%2C0%2C3",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.205757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.005842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.138518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.135491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.135491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.23228",
        "ticker_sentiment_score": "0.129198",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.033656",
        "ticker_sentiment_score": "0.135491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.067252",
        "ticker_sentiment_score": "0.113535",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Google And Eli Lilly Have Things In Common Besides Being Mutual Fund Favorites",
    "url": "https://www.investors.com/research/google-googl-stock-netflix-nflx-eli-lilly/",
    "time_published": "20240605T201100",
    "authors": [
      "Investor's Business Daily",
      "KIMBERLEY KOENIG"
    ],
    "summary": "Google Stock, Eli Lilly Have These Things In Common Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/07/Stock-googlecloudserver-02-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211227,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.37643",
        "ticker_sentiment_score": "0.220804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.240965",
        "ticker_sentiment_score": "0.058102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.460452",
        "ticker_sentiment_score": "0.361946",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "-0.126866",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? - Eli Lilly and Co  ( NYSE:LLY ) , Madrigal Pharmaceuticals  ( NASDAQ:MDGL ) , Sagimet Biosciences  ( NASDAQ:SGMT ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39192538/whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-sha",
    "time_published": "20240605T191750",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, the stocks of Madrigal Pharmaceuticals Inc MDGL and Sagimet Biosciences Inc SGMT are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co LLY shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/05/MDGL.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.178341,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.110323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.126301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.215375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.215375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETNB",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.215375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SGMT",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.126301",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39189287/british-agency-supports-eli-lillys-weight-loss-drug-mounjaro-diverging-from-restrictions-on-rival",
    "time_published": "20240605T162148",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Britain's medical costs regulator, the National Institute for Health and Care Excellence ( NICE ) , has recommended Eli Lilly And Co's LLY weight-loss drug Mounjaro for certain patients with obesity. Unlike its stance on Novo Nordisk A/S's NVO rival drug Wegovy, NICE has not imposed a time ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/05/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.250474,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.6244",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.058344",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's why Cramer says Ford stock must be 'bought aggressively' on the dip",
    "url": "https://www.cnbc.com/2024/06/05/why-jim-cramer-says-ford-must-be-bought-aggressively-on-the-dip.html",
    "time_published": "20240605T155533",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107356386-1704840785525-gettyimages-978863380-HPE_NERI.jpeg?v=1717600089&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.028921,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "0.024225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.017816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.012693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.017816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.017816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO - Alphabet  ( NASDAQ:GOOGL ) ",
    "url": "https://www.benzinga.com/news/24/06/39185867/google-parent-alphabet-appoints-eli-lillys-finance-chief-ashkenazi-as-cfo",
    "time_published": "20240605T141149",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co LLY announced that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. Ms. Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/05/google-shuter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.236066,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410059",
        "ticker_sentiment_score": "0.047285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.630923",
        "ticker_sentiment_score": "0.107887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Lilly's Weight-Loss Drug Hammered A Swath Of Biotechs",
    "url": "https://www.investors.com/news/technology/madrigal-stock-eli-lilly-weight-loss-drug-tirzepatide-mash-treatment/",
    "time_published": "20240605T132700",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Madrigal Stock Plummeted After Lilly's Weight-Loss Drug Tackles MASH Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-Lilly-HQ9-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.107533,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.579393",
        "ticker_sentiment_score": "0.049107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "0.054523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "-0.046376",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO",
    "url": "https://www.investors.com/news/technology/google-stock-new-cfo-picked-anat-ashkenazi-eli-lilly/",
    "time_published": "20240605T124300",
    "authors": [
      "Investor's Business Daily",
      "REINHARDT KRAUSE"
    ],
    "summary": "Google parent Alphabet ( GOOGL ) on Wednesday announced that its new chief financial officer will be Anat Ashkenazi, currently executive vice president and CFO at pharmaceutical company Eli Lilly ( LLY ) . Google stock rose on the news.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/01/Stock-googleworkers-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.059388,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "-0.139691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.702434",
        "ticker_sentiment_score": "0.10262",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly announces departure of Anat Ashkenazi, chief financial officer",
    "url": "https://www.prnewswire.com/news-releases/lilly-announces-departure-of-anat-ashkenazi-chief-financial-officer-302163882.html",
    "time_published": "20240605T114500",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "INDIANAPOLIS, June 5, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.143234,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.383995",
        "ticker_sentiment_score": "0.08894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.005889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.139471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme's ENHANZE Product Gets New Patent Grant in EU - AbbVie  ( NYSE:ABBV ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",
    "url": "https://www.benzinga.com/news/24/06/39208619/halozymes-enhanze-product-gets-new-patent-grant-in-eu",
    "time_published": "20240606T193629",
    "authors": [
      "Zacks"
    ],
    "summary": "Halozyme Therapeutics HALO announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/joshua-mayo-objbg2lzjmg-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.177356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANVS",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.090561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHGCF",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.088707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.083964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.350833",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia Stock, These Other Companies Make Waves As IBD Sector Leaders",
    "url": "https://www.investors.com/stock-lists/sector-leaders/nvidia-nvda-stock-novo-nordisk-wingstop-sector-leaders/",
    "time_published": "20240606T184700",
    "authors": [
      "Investor's Business Daily",
      "RUSS BRITT"
    ],
    "summary": "Only a small handful of companies currently comprise the list of IBD Sector Leaders, but while the list of standouts is short, their recent performance has been huge. Among the players: Novo Nordisk ( NVO ) , Wingstop ( WING ) and the market's current superstar, Nvidia stock.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/Stock-Nvidia-cornice-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.256335,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.188508",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.523202",
        "ticker_sentiment_score": "0.390687",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.523202",
        "ticker_sentiment_score": "0.291463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.446742",
        "ticker_sentiment_score": "0.282832",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39210889/eli-lillys-alzheimers-drug-donanemab-faces-fdas-adcomm-vote-next-week-on-data-risk-profile",
    "time_published": "20240606T160742",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, June 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the data from Eli Lilly And Co's LLY Phase 3 Study AACI ( TRAILBLAZER-ALZ 2 ) support a favorable benefit-risk assessment for the use of donanemab for Alzheimer's ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/dementia-Photo-by-Gerd-Altmann-via-Pixab.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.291495,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.197075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39210072/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20240606T153052",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly and Co LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.099576,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.106816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Veteran Anat Ashkenazi to Join Alphabet as CFO",
    "url": "https://www.zacks.com/stock/news/2284718/eli-lilly-lly-veteran-anat-ashkenazi-to-join-alphabet-as-cfo",
    "time_published": "20240606T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) CFO Anat Ashkenazi joins Google's parent company Alphabet as CFO and senior vice president, effective from ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.148998,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACRV",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.157738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.650245",
        "ticker_sentiment_score": "0.18603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.244723",
        "ticker_sentiment_score": "0.194661",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.19016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics Stock a Buy on the Dip?",
    "url": "https://www.fool.com/investing/2024/06/06/is-viking-therapeutics-stock-a-buy-on-the-dip/",
    "time_published": "20240606T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "Short-term thinking is creating an intriguing opportunity for investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779740%2Fu-turn.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.156248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.038587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.142676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "-0.074294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.038587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/06/39197516/chinese-generic-ozempic-wegovy-versions-could-put-novo-nordisk-at-the-risk-of-stiff-competition-in-k",
    "time_published": "20240606T010728",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Novo Nordisk A/S NVO is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/05/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.236504,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.27358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.586747",
        "ticker_sentiment_score": "0.205047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:DKK",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.054997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:NOK",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.054997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39230898/over-10-000-lawsuits-in-novo-nordisks-ozempic-case-assigned-to-new-judge",
    "time_published": "20240607T155807",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, Wegovy, and Mounjaro. The Judicial Panel on Multidistrict Litigation appointed Marston to manage over 10,000 personal injury lawsuits. U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.14255,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "-0.334362",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MARZF",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.380978",
        "ticker_sentiment_score": "-0.018818",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/06/07/up-400-in-three-years-eli-lilly-stock-just-keeps-giving/",
    "time_published": "20240607T150023",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 400% from levels of $170 in early 2021 to around $840 now. This reflects a meaningful outperformance compared to some of its peers, with Pfizer stock ( NYSE: PFE ) seeing a 15% decline and Johnson & Johnson stock ( NYSE: JNJ ) seeing no ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662b6a87b3af139422324bac/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.213202,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.849174",
        "ticker_sentiment_score": "0.358132",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.174885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.098765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.200134",
        "ticker_sentiment_score": "0.123411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39228957/etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potent",
    "time_published": "20240607T144212",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds ( ETFs ) ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/Weightloss-i-yunmai-5jctAMjz21A-unsplash.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.124196,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.236698",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.081317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.126225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.385286",
        "ticker_sentiment_score": "0.214537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval",
    "url": "https://www.zacks.com/stock/news/2285380/pharma-stock-roundup-llys-cfo-departs-abbv-azn-drugs-get-chmp-approval",
    "time_published": "20240607T142000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106674,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.093901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.097289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.424317",
        "ticker_sentiment_score": "0.186385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.001979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.008356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "-0.109142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39228433/ozempic-wegovy-create-domino-effect-as-new-products-emerge-across-industries-to-capture-new-consu",
    "time_published": "20240607T141714",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk NVO is leading to new product developments across various sectors. What Happened: Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.14414,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.156518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.046598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.123872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.131719",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?",
    "url": "https://www.fool.com/investing/2024/06/07/is-this-trend-a-threat-to-eli-lillys-weight-loss-d/",
    "time_published": "20240607T094500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "The weight loss drug market is growing rapidly.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779850%2Fgettyimages-1213513544.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212041,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.469744",
        "ticker_sentiment_score": "0.343258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.107857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.107857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.246001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.102039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?",
    "url": "https://www.fool.com/investing/2024/06/08/the-company-behind-mounjaro-and-zepbound-is-sponso/",
    "time_published": "20240608T140500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "One of the most lucrative sports sponsorship opportunities is jersey patches, and one leading pharmaceutical company may have just struck gold.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779066%2Fgettyimages-1256247098.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.114625,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.22577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "-0.094134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.174147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:SOC",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "-0.107888",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks",
    "url": "https://www.prnewswire.com/news-releases/lillys-tirzepatide-was-superior-to-placebo-for-mash-resolution-and-more-than-half-of-patients-achieved-improvement-in-fibrosis-at-52-weeks-302167649.html",
    "time_published": "20240608T130300",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.110852,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.142214",
        "ticker_sentiment_score": "0.078182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011914",
        "ticker_sentiment_score": "0.126366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.011914",
        "ticker_sentiment_score": "0.078149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug",
    "url": "https://www.zacks.com/stock/news/2286266/apple-joins-ai-race-lilly-thumbs-up-on-alzheimers-drug",
    "time_published": "20240610T212200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/2552.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.146626,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.15796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.711352",
        "ticker_sentiment_score": "0.252281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.121833",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39258323/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240610T200140",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.12297,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.803061",
        "ticker_sentiment_score": "0.151469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Rises, Again, As FDA Panel Mulls Alzheimer's Drug",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-fda-advisory-committee-alzheimers-treatment/",
    "time_published": "20240610T142700",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Eli Lilly Stock Edges Higher As FDA Panel Mulls Alzheimer's Treatment Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.093172,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.286915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "-0.178613",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.120744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.326499",
        "ticker_sentiment_score": "0.23572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "-0.178613",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Biogen  ( BIIB )  & Eisai's Leqembi sBLA Gets FDA Acceptance",
    "url": "https://www.zacks.com/stock/news/2286055/biogen-biib-eisais-leqembi-sbla-gets-fda-acceptance",
    "time_published": "20240610T135400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.106485,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "-0.09641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "-0.012265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.369685",
        "ticker_sentiment_score": "0.121423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.577527",
        "ticker_sentiment_score": "0.187908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Happening With Eli Lilly Shares On Monday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39250499/whats-happening-with-eli-lilly-shares-on-monday",
    "time_published": "20240610T131854",
    "authors": [
      "Shivani Kumaresan"
    ],
    "summary": "Eli Lilly and Co LLY shared detailed results from the SYNERGY-NASH phase 2 study on Saturday. This trial involved 190 patients, both with and without type 2 diabetes, evaluating tirzepatide in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis ( MASH ) and stage 2 or 3 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/10/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.169121,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.381463",
        "ticker_sentiment_score": "0.136392",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2285839/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240610T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.2505,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.185909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39277429/eli-lillys-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-",
    "time_published": "20240611T181910",
    "authors": [
      "Nabaparna Bhattacharya"
    ],
    "summary": "BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000. An advisory committee to the U.S. Food and Drug Administration ( FDA ) delivered a favorable verdict on the company's Alzheimer's treatment, donanemab, declaring its ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.240359,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.488007",
        "ticker_sentiment_score": "0.009441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.132907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.212255",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Best ETF Areas of Last Week",
    "url": "https://www.zacks.com/stock/news/2286872/best-etf-areas-of-last-week",
    "time_published": "20240611T170000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Wall Street was upbeat last week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.234623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.052382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.186999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.186999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.309578",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.164282",
        "ticker_sentiment_score": "0.254417",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.052382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.270373",
        "ticker_sentiment_score": "0.074919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Drags Alzheimer's Stocks Lower Despite FDA Win",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-alzheimers-treatment-donanemab-leqembi/",
    "time_published": "20240611T162000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) stock reversed premarket gains at the open Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab. Despite the stock move, analysts largely expect donanemab to gain FDA approval. The agency isn't bound by the panel's recommendation, ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.158646,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.435177",
        "ticker_sentiment_score": "0.134427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.1503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.250902",
        "ticker_sentiment_score": "0.096823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.435177",
        "ticker_sentiment_score": "0.21139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's an undervalued stock that can benefit from new Alzheimer's drugs",
    "url": "https://www.cnbc.com/2024/06/11/ge-healthcare-is-undervalued-can-benefit-from-eli-lillys-alzheimers-drug.html",
    "time_published": "20240611T154152",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107096722-1659359582418-Screen_Shot_2022-08-01_at_91243_AM.png?v=1694796809&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.075291,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.047153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOV",
        "relevance_score": "0.351807",
        "ticker_sentiment_score": "0.079088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.047153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.047153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.033161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Fall On Inflation Jitters; Apple Hits Buy Point As Analyst Sees AI 'Supercycle' While Roaring Kitty Affirms This",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-apple-stock-gamestop/",
    "time_published": "20240611T143600",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Stocks Fall On Inflation Jitters. Apple Hits Buy Point As Analyst Sees AI 'Supercycle' While Roaring Kitty Affirms This Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/Stock-apple-seoulretail-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.052919,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.328227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.332658",
        "ticker_sentiment_score": "0.046257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CASY",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.155505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.074447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.2035",
        "ticker_sentiment_score": "-0.269683",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Structure Therapeutics  ( GPCR )  Rallying on Obesity Drug Data",
    "url": "https://www.zacks.com/stock/news/2286691/structure-therapeutics-gpcr-rallying-on-obesity-drug-data",
    "time_published": "20240611T135900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.204047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.180748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.425925",
        "ticker_sentiment_score": "0.171171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.064997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.103646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.33006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Alzheimer's Drug Donanemab Gets FDA Panel Nod",
    "url": "https://www.zacks.com/stock/news/2286552/eli-lilly-lly-alzheimers-drug-donanemab-gets-fda-panel-nod",
    "time_published": "20240611T132900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8e/391.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.114666,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.329866",
        "ticker_sentiment_score": "0.140113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.144853",
        "ticker_sentiment_score": "0.0657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.284972",
        "ticker_sentiment_score": "0.185742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top 4 Health Care Stocks That May Keep You Up At Night This Month - Applied Therapeutics  ( NASDAQ:APLT ) ",
    "url": "https://www.benzinga.com/news/24/06/39269583/top-4-health-care-stocks-that-may-keep-you-up-at-night-this-month",
    "time_published": "20240611T124436",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/health-care-workers-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.348732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.299505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APLT",
        "relevance_score": "0.390396",
        "ticker_sentiment_score": "0.379996",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.375932",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "INSM",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.319436",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39267782/why-is-eli-lilly-stock-trading-higher-premarket-tuesday",
    "time_published": "20240611T115112",
    "authors": [
      "Shivani Kumaresan"
    ],
    "summary": "Eli Lilly And Co's LLY shares are trading higher after an advisory committee to the U.S. Food and Drug Administration ( FDA ) delivered a favorable verdict on the company's Alzheimer's treatment, donanemab, declaring its benefits to surpass the associated risks.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.130351,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.442082",
        "ticker_sentiment_score": "0.2587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "-0.094833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "-0.094833",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How To Bag Massive 9.1% Dividends As AI 'Bubble' Pops",
    "url": "https://www.forbes.com/sites/michaelfoster/2024/06/11/how-to-bag-massive-91-dividends-as-ai-bubble-pops/",
    "time_published": "20240611T114500",
    "authors": [
      "Michael Foster"
    ],
    "summary": "You probably remember the first time you heard about ChatGPT. The AI tool's lifelike responses seemed like magic-so much so that people were debating whether generative AI tools like it were actually conscious. Such a debate was honestly a bit silly, and it didn't last long.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6661fd1b6cf45409177bc5ed/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.288136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "-0.04065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "-0.034098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "0.107247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "-0.034098",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/06/11/eli-lilly-all-time-high-buy-pharma-stock/",
    "time_published": "20240611T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The world's biggest healthcare company might become even larger.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780172/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.287937,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.683932",
        "ticker_sentiment_score": "0.49332",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.050001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.050001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?",
    "url": "https://www.fool.com/investing/2024/06/11/structure-therapeutics-stock-could-rocket-87-highe/",
    "time_published": "20240611T085700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780117/individual-investor-looking-at-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.203523,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.051197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.346894",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "-0.009934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.224673",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks For Your June 2024 Watchlist",
    "url": "https://stockmarket.com/featured/2-biotech-stocks-for-your-june-2024-watchlist-2024-06-10",
    "time_published": "20240611T005227",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The biotech sector includes companies that develop drugs and diagnostic technologies based on biology. These firms often focus on developing innovative treatments for various medical conditions. Investments in this sector are driven by the potential for significant breakthroughs that can lead to ...",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/12/LLY-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.210229,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "0.225504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.346642",
        "ticker_sentiment_score": "0.102762",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab",
    "url": "https://www.zacks.com/stock/news/2287324/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab",
    "time_published": "20240612T142200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.147923,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.039243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.189231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.064671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.254862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "0.303139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.050549",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's $50 Billion View From The Weight-Loss Arena",
    "url": "https://www.investors.com/research/the-new-america/eli-lilly-stock-weight-loss-drug-expectations/",
    "time_published": "20240612T120000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Runs Up 48% Amid Lofty Expectations For Weight-Loss Drug Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/wNAsales061724.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.137497,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.092378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "-0.05814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.029003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.49669",
        "ticker_sentiment_score": "0.167766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.230533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.032226",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge",
    "url": "https://www.fool.com/investing/2024/06/12/a-life-expansion-revolution-is-coming-3-stocks-tha/",
    "time_published": "20240612T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The integration of AI and healthcare is well underway.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780297%2Fbiotech.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.325863,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.034246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAI",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.226022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.400754",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.204477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly the Best Pharmaceutical Stock for You?",
    "url": "https://www.fool.com/investing/2024/06/12/is-eli-lilly-the-best-pharmaceutical-stock-for-you/",
    "time_published": "20240612T092500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly is serving a market that may reach $100 billion.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780158%2Fgettyimages-1226994628.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.241736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.245286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.709986",
        "ticker_sentiment_score": "0.373581",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.064572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation' - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39284116/jim-cramer-sees-eli-lilly-as-more-than-a-one-trick-pony-after-fda-advisors-back-its-alzheimers-d",
    "time_published": "20240612T035210",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer has expressed his confidence in Eli Lilly and Co LLY, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors. What Happened: Cramer, the host of CNBC's \"Mad Money,\" has been a long-time supporter of Eli Lilly.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/jim-cramer-chart-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.290042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.475251",
        "ticker_sentiment_score": "0.309995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.153995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.153995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Hot Growth Stocks: Buy on the Highs or Wait for a Pullback?",
    "url": "https://www.zacks.com/stock/news/2288059/5-hot-growth-stocks-buy-on-the-highs-or-wait-for-a-pullback",
    "time_published": "20240613T173800",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "These 5 stocks are red hot and hitting new all-time highs. Have you missed the trade?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default230.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.307488,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.503018",
        "ticker_sentiment_score": "0.107627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.503018",
        "ticker_sentiment_score": "0.12433",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "0.342584",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.503018",
        "ticker_sentiment_score": "0.393188",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.349329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This portfolio chip stock is the second-best AI play behind Nvidia",
    "url": "https://www.cnbc.com/2024/06/13/this-portfolio-chip-stock-is-the-second-best-ai-play-behind-nvidia-.html",
    "time_published": "20240613T152829",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107391096-1711047611808-gettyimages-2102403796-img_7514_nrpukd9a.jpeg?v=1711048000&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.067586,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.353059",
        "ticker_sentiment_score": "0.071201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.042372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.042372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.029842",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Expands AstraZeneca's  ( AZN )  Farxiga Label in Pediatric T2D",
    "url": "https://www.zacks.com/stock/news/2287930/fda-expands-astrazenecas-azn-farxiga-label-in-pediatric-t2d",
    "time_published": "20240613T141100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.250174,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.209607",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.066702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.43816",
        "ticker_sentiment_score": "0.195587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.321393",
        "ticker_sentiment_score": "0.139035",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly  ( LLY )  is a Top Momentum Stock for the Long-Term",
    "url": "https://www.zacks.com/stock/news/2287885/why-eli-lilly-lly-is-a-top-momentum-stock-for-the-long-term",
    "time_published": "20240613T135012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default126.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.324167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.605937",
        "ticker_sentiment_score": "0.330348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage' - JPMorgan Chase  ( NYSE:JPM ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39312262/jpmorgans-500m-venture-capital-fund-bets-big-on-weight-loss-drugs-theyre-all-the-rage",
    "time_published": "20240613T132651",
    "authors": [
      "Nabaparna Bhattacharya"
    ],
    "summary": "JPMorgan Chase & Co.'s JPM asset management division has reportedly secured over $500 million for a biotech venture capital fund focusing on weight-loss drugs, targeting the booming sector of the healthcare industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/13/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.177934,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune",
    "url": "https://www.zacks.com/stock/news/2287623/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune",
    "time_published": "20240613T100900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.152173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.029956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.145093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.041398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.23699",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.431554",
        "ticker_sentiment_score": "0.255128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.057891",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 57%, Is AbCellera Biologics a Buy on the Dip?",
    "url": "https://www.fool.com/investing/2024/06/13/down-57-is-abcellera-biologics-a-buy-on-the-dip/",
    "time_published": "20240613T094000",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Wall Street analysts say this drug developer can more than double your money.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780372/investor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.086499,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABCL",
        "relevance_score": "0.16099",
        "ticker_sentiment_score": "0.079496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.122046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Berkshire Hathaway, Eli Lilly & PepsiCo",
    "url": "https://www.zacks.com/research-daily/2288461/top-stock-reports-for-berkshire-hathaway-eli-lilly-pepsico",
    "time_published": "20240614T205000",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Eli Lilly and Company (LLY) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Hovnanian Enterprises, Inc. (HOV) and IDT Corporation (IDT).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/72/1912.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      }
    ],
    "overall_sentiment_score": 0.269345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.157827",
        "ticker_sentiment_score": "0.12357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.300089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39333999/pharma-stock-roundup-fda-panel-endorses-llys-donanemab-pfes-dmd-therapy-study-fails",
    "time_published": "20240614T173910",
    "authors": [
      "Zacks"
    ],
    "summary": "This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's LLY Alzheimer's disease drug, donanemab. Pfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for ambulatory boys with Duchenne muscular dystrophy failed to meet the primary ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/14/national-cancer-institute-nfvdkihxylu-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.123922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.01642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.050948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.120834",
        "ticker_sentiment_score": "0.155669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.120834",
        "ticker_sentiment_score": "0.017575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.307362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab  ( Revised ) ",
    "url": "https://www.zacks.com/stock/news/2288637/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab-revised",
    "time_published": "20240614T152100",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14108,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.050434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.185819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.06373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.250374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.298879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.038672",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune  ( Revised ) ",
    "url": "https://www.zacks.com/stock/news/2288638/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune-revised",
    "time_published": "20240614T151000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default58.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.147698,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.132855",
        "ticker_sentiment_score": "0.034244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.142834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.040747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.233404",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.422897",
        "ticker_sentiment_score": "0.251811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.035045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39334728/analyzing-eli-lilly-and-co-in-comparison-to-competitors-in-pharmaceuticals-industry",
    "time_published": "20240614T150014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Eli Lilly and Co LLY in relation to its major competitors in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.202473,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.556946",
        "ticker_sentiment_score": "0.296173",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",
    "url": "https://www.zacks.com/stock/news/2288361/pharma-stock-roundup-fda-panel-endorses-llys-donanemab-pfes-dmd-therapy-study-fails",
    "time_published": "20240614T130500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.116569,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.03351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.056638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.168232",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.118257",
        "ticker_sentiment_score": "0.032249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.306918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug",
    "url": "https://www.fool.com/investing/2024/06/14/wegovys-precarious-position-3-drugs-most-likely-to/",
    "time_published": "20240614T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Novo Nordisk's competition in the obesity drug market is heating up.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780375/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.17509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.263643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.159962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.377958",
        "ticker_sentiment_score": "0.175532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: CAVA, Abercrombie & Fitch, Eli Lilly, CrowdStrike and Deckers Outdoor",
    "url": "https://www.zacks.com/stock/news/2288189/zacks-market-edge-highlights-cava-abercrombie-fitch-eli-lilly-crowdstrike-and-deckers-outdoor",
    "time_published": "20240614T084600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "CAVA, Abercrombie & Fitch, Eli Lilly, CrowdStrike and Deckers Outdoor have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/68/1006.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.304816,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.093962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.108349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.295941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.408949",
        "ticker_sentiment_score": "0.347091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.279813",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/06/15/mounjaro-is-targeting-another-multibillion-dollar/",
    "time_published": "20240615T180500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company has too many weapons at its disposal.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780296/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.234679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.360005",
        "ticker_sentiment_score": "0.311241",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.079698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.079698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.079698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.079698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster",
    "url": "https://www.fool.com/investing/2024/06/15/eli-lilly-scores-another-major-win-and-lines-up-it/",
    "time_published": "20240615T111500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drugmaker continues to make headlines for all the right reasons.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780428/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.253204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.370602",
        "ticker_sentiment_score": "0.197338",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Growth Stocks You Can Buy Right Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/06/15/3-growth-stocks-you-can-buy-right-now-without-any/",
    "time_published": "20240615T105000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Want peace of mind about your investments? Consider these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780514/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.230394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.308407",
        "ticker_sentiment_score": "0.342258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.127925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.003901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.241327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.",
    "url": "https://www.fool.com/investing/2024/06/16/thinking-of-buying-madrigal-pharmaceuticals-stock/",
    "time_published": "20240616T160500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780409/researchers-work-in-the-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.234355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.244354",
        "ticker_sentiment_score": "0.072335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.054597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.121597",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Walmart Reach a Trillion-Dollar Market Cap by 2030?",
    "url": "https://www.fool.com/investing/2024/06/16/will-walmart-reach-trillion-dollar-market-cap-2030/",
    "time_published": "20240616T102000",
    "authors": [
      "James Brumley"
    ],
    "summary": "This seemingly unlikely non-tech name quietly deserves to be on the list of contenders that could achieve the feat in the foreseeable future.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780557%2F061324-walmart-revenue-eps-past-projected.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.184808,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.001348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.001348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZIO",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.048908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.116161",
        "ticker_sentiment_score": "0.00463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.090793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.045656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.158021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.373751",
        "ticker_sentiment_score": "0.242741",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies - Eli Lilly and Co  ( NYSE:LLY ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/06/39366548/biorestorative-therapies-enters-preclinical-assessment-of-its-patented-stem-cell-technology-prior",
    "time_published": "20240617T203011",
    "authors": [
      "Anthony Termini"
    ],
    "summary": "Clinical-stage biotech innovator BioRestorative Therapies BRTX recently announced that it is entering a new program of preclinical metabolic testing for its patented stem cell biology technology, ThermoStem\u00ae.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/17/Screenshot-2024-06-18-at-1-15-14AM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.16771,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.036721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRTX",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.180693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.127276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.036721",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead's New Revelation For Its Weight-Loss Contender",
    "url": "https://www.investors.com/news/technology/gilead-stock-weight-loss-drugs-mash-treatment/",
    "time_published": "20240617T181200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Gilead Stock Dips On This Revelation For Its Weight-Loss Drugs Rival Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Gilead-07-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.057316,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AVTE",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.036648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.068247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.260183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.068247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.068247",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs",
    "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/novo-nordisk-nvo-eli-lilly-lly-stock/",
    "time_published": "20240617T170100",
    "authors": [
      "Investor's Business Daily",
      "MATTHEW GALGANI"
    ],
    "summary": "Novo Nordisk, Eli Lilly In Demand For Weight-Loss Drugs As Shares Face Elevated Risks Separator Investor's ... Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/Stock-bullsred-generatedai-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.202637,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.590482",
        "ticker_sentiment_score": "0.216164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "-0.005607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.697425",
        "ticker_sentiment_score": "0.278366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? - Nurix Therapeutics  ( NASDAQ:NRIX ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39360973/whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday",
    "time_published": "20240617T154708",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Sunday, Nurix Therapeutics Inc NRIX announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton's tyrosine kinase ( BTK ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/17/cancer.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.072859,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.056933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.056933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.056933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "-0.037643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39358134/spotlight-on-eli-lilly-and-co-analyzing-the-surge-in-options-activity",
    "time_published": "20240617T134705",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Eli Lilly and Co LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.118913,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.746491",
        "ticker_sentiment_score": "0.264415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Berkshire Hathaway, Eli Lilly, PepsiCo, Hovnanian and IDT",
    "url": "https://www.zacks.com/stock/news/2289110/the-zacks-analyst-blog-highlights-berkshire-hathaway-eli-lilly-pepsico-hovnanian-and-idt",
    "time_published": "20240617T123100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Berkshire Hathaway, Eli Lilly, PepsiCo, Hovnanian and IDT are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.235619,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.287441",
        "ticker_sentiment_score": "0.132888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOVNP",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.03778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.114466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.042536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2288894/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240617T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.050009",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( LLY )  - Analyzing Eli Lilly and Co's Short Interest - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/06/39390250/lly-analyzing-eli-lilly-and-cos-short-interest",
    "time_published": "20240618T204517",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co's LLY short percent of float has risen 14.06% since its last report. The company recently reported that it has 6.16 million shares sold short, which is 0.73% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.283215,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.301788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39380817/heres-how-much-1000-invested-in-eli-lilly-and-co-10-years-ago-would-be-worth-today",
    "time_published": "20240618T140023",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 10 years by 19.61% on an annualized basis producing an average annual return of 30.51%. Currently, Eli Lilly and Co has a market capitalization of $843.36 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Best Biotech Stock to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/06/18/the-best-biotech-stock-to-invest-1000-in-right-now/",
    "time_published": "20240618T115000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This stock may not be a slam dunk, but it's looking very promising.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780622/doctors-at-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.227574,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.147216",
        "ticker_sentiment_score": "0.23147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.0559",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2289552/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240618T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.032048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.043607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.064137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?",
    "url": "https://www.zacks.com/stock/news/2290613/can-eli-lilly-etfs-surge-on-approval-of-alzheimers-drug",
    "time_published": "20240619T170000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.146612,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.405215",
        "ticker_sentiment_score": "0.198809",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.060737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.16849",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Registers a Bigger Fall Than the Market: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2291076/eli-lilly-lly-registers-a-bigger-fall-than-the-market-important-facts-to-note",
    "time_published": "20240620T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default159.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.164536,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.52949",
        "ticker_sentiment_score": "0.195861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Has a New Drug That Could Push the Stock Higher",
    "url": "https://www.fool.com/investing/2024/06/20/eli-lilly-has-a-new-drug-that-could-push-the-stock/",
    "time_published": "20240620T182500",
    "authors": [
      "Leo Miller"
    ],
    "summary": "The Alzheimer's treatment market is large and expected to grow.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781205/gettyimages-1296945064.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.178134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.1789",
        "ticker_sentiment_score": "0.03087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.179362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "-0.114418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.158017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount - Evotec  ( NASDAQ:EVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39419032/german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount",
    "time_published": "20240620T174642",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "German drug developer Evotec SE EVO is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/20/Audit-Business-Businessman.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.062272,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "-0.105814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.148154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.316168",
        "ticker_sentiment_score": "0.100163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVO",
        "relevance_score": "0.722509",
        "ticker_sentiment_score": "0.073527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly  ( LLY )  is Probably the Best Drug Stock Now",
    "url": "https://www.zacks.com/stock/news/2290782/heres-why-eli-lilly-lly-is-probably-the-best-drug-stock-now",
    "time_published": "20240620T130100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.233627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.240335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.153717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.273532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.059562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.068567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Growth Prospects Just Got a Huge Upgrade",
    "url": "https://www.fool.com/investing/2024/06/20/eli-lillys-growth-prospects-just-got-huge-upgrade/",
    "time_published": "20240620T123000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The company's promising Alzheimer's drug could soon obtain approval from regulators.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780718/person-reviewing-a-sample-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.300179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.445848",
        "ticker_sentiment_score": "0.333639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39408786/eli-lilly-expands-fight-against-counterfeit-obesity-drug-zepbound-with-new-legal-actions",
    "time_published": "20240620T114410",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Eli Lilly & Co. LLY has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/20/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.045943,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.11213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.613743",
        "ticker_sentiment_score": "0.065014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.150778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "All Public Company News from PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/all-public-company-news/",
    "time_published": "20240621T214040",
    "authors": [],
    "summary": "All Public Company PR ...",
    "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/common/JournalistsBloggers.jpg",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.185027,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENPH",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.107088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAND",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.356288",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RNA",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.152404",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GL",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAFE",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UA",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.24477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PTCT",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.146314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXTI",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.094042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KORE",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "-0.086679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRSN",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.0195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.146676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.098389",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.159415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EC",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.107088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39432381/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T193114",
    "authors": [
      "Zacks"
    ],
    "summary": "Chicago, IL - June 21, 2024 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/jason-briscoe-amlfrl8lgls-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.23596,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.208813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.133763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.486415",
        "ticker_sentiment_score": "0.240245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.069699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.159305",
        "ticker_sentiment_score": "0.067239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen",
    "time_published": "20240621T154222",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Gilead Sciences, Inc. GILD witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/Doctors-And-Nurses-Walking-In-Hospital-H.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.219317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.089516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.206652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today",
    "url": "https://www.zacks.com/stock/news/2291308/heres-how-much-a-1000-investment-in-eli-lilly-made-10-years-ago-would-be-worth-today",
    "time_published": "20240621T123003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.151557,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.618121",
        "ticker_sentiment_score": "0.240224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.025867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.041948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.047013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.047013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss - Novo Nordisk  ( OTC:NONOF ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39431082/move-aside-ozempic-wegovy-denmarks-new-drug-just-showed-positive-results-for-weightloss",
    "time_published": "20240621T121228",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Danish biotech company Zealand Pharma A/S ZLDPF has announced encouraging topline results from a Phase 1b multiple ascending dose ( MAD ) trial of its weight management drug, petrelintide.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/weight-loss-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.247654,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.170189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.406197",
        "ticker_sentiment_score": "0.275069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZLDPF",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "-0.043205",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2291339/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T115900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.235581,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.208275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.120071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.478768",
        "ticker_sentiment_score": "0.243569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.069463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.062196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nestle Carefully Targets Weight-Loss Drug Users with New Food Line - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) , Nestle  ( OTC:NSRGY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39429336/nestle-carefully-targets-weight-loss-drug-users-with-new-food-line",
    "time_published": "20240621T101815",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Last month, Nestl\u00e9 SA NSRGF NSRGY unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. The European food giant said the company will not mention the weight loss drugs on the packaging.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.10018,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.175521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.227987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.012621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "-0.019511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAG",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.012621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "-0.025833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.079633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead",
    "url": "https://www.fool.com/investing/2024/06/21/forget-eli-lilly-buy-magnificent-biotech-stock/",
    "time_published": "20240621T095100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly is a good pick...but this one is better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780926/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.310445,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.583672",
        "ticker_sentiment_score": "0.52003",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "0.298239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Shares Monday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/06/39466189/whats-going-on-with-eli-lilly-shares-monday",
    "time_published": "20240624T201806",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Eli Lilly and Co LLY shares are moving higher Monday following the release of positive Phase 3 trial results for its weight loss drug, tirzepatide, marketed as Zepbound.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/24/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.227822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.693563",
        "ticker_sentiment_score": "0.410357",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why ResMed Shares Are Trading Lower Monday - ResMed  ( NYSE:RMD ) ",
    "url": "https://www.benzinga.com/news/24/06/39464160/why-resmed-shares-are-trading-lower-monday",
    "time_published": "20240624T183317",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "ResMed, Inc. RMD stock is trading lower Monday after Eli Lilly and Company LLY released data from a clinical trial in regards to the treatment of sleep apnea. The Details: Lilly released data on Friday from its SURMOUNT-OSA phase 3 clinical trial which tested tirzepatide as a treatment for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/24/Medical-Examination-And-Healthcare-Busin_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.075397,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "-0.018932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.744196",
        "ticker_sentiment_score": "0.058419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely' - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39463758/will-novo-nordisk-building-fires-serve-as-a-catalyst-for-eli-lilly-redditors-see-a-stock-split-fo",
    "time_published": "20240624T180851",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly And Co LLY might see a significant boost due to supply issues at competitor Novo Nordisk A/S NVO, according to Reddit user serkankster. It was noted that Eli Lilly's weight loss drug Zepbound resolved previous supply issues, especially in major cities.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/24/NovoNordisk-Elililly-shutterstock.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.065736,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.815635",
        "ticker_sentiment_score": "-0.032951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.153136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.250813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly's Weight-Loss Drug Takes Down ResMed, Inspire - Again",
    "url": "https://www.investors.com/news/technology/resmed-stock-inspire-medical-systems-stock-obstructive-sleep-apnea-eli-lilly-weight-loss/",
    "time_published": "20240624T132300",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "ResMed Stock Collapses After Eli Lilly's Weight-Loss Drug Reduces Sleep Apnea Events Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/Stock-weightloss-generic-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.213802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INSP",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.038547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.038547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.522333",
        "ticker_sentiment_score": "0.160612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2292048/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20240624T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default314.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.248303,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.49407",
        "ticker_sentiment_score": "0.177968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock On Monday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39454632/eli-lillys-zepbound-for-weight-loss-shows-disease-resolution-in-obese-sleep-apnea-patients-lays-f",
    "time_published": "20240624T122943",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Eli Lilly And Co LLY released detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide injection ( 10 mg or 15 mg ) for moderate-to-severe obstructive sleep apnea ( OSA ) in adults with obesity, with and without positive airway pressure ( PAP ) therapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/24/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.016657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.033584",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Future of Weight-Loss Drugs for Investors",
    "url": "https://www.kiplinger.com/investing/healthcare-stocks/the-future-of-weight-loss-drugs-for-investors",
    "time_published": "20240624T111555",
    "authors": [
      "Adam Shell"
    ],
    "summary": "Investing in shrinking waistlines might not have the wow factor of other market obsessions. But a new class of weight-loss drugs that help people shed pounds without dieting or doing cardio looks like a game-changer.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.215295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "0.187721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.175147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JHG",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "0.102883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.174713",
        "ticker_sentiment_score": "0.190248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.008654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.142129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "-0.024444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.199704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "-0.099345",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39487352/novo-nordisks-older-generation-weight-loss-drug-saxenda-associated-with-decreased-bone-mass-densi",
    "time_published": "20240625T181226",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S's NVO Saxenda ( liraglutide ) , an earlier-generation weight loss drug, reveals significant declines in bone density among patients in the hips, spine, and forearm.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/25/Ozempic-maker-Novo-Nordisk_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.0264,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "-0.032335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "-0.047015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock On Tuesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39485742/whats-going-on-with-eli-lilly-stock-on-tuesday",
    "time_published": "20240625T165029",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Eli Lilly and Co LLY announced a collaboration with Microsoft Corp MSFT-backed OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/25/Eli-Lilly-Corporate-Center--Indianapolis.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.039285,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.512596",
        "ticker_sentiment_score": "0.043716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.080317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.401447",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  to Invest $4.1B in Clayton Facility Expansion",
    "url": "https://www.zacks.com/stock/news/2293002/novo-nordisk-nvo-to-invest-41b-in-clayton-facility-expansion",
    "time_published": "20240625T142200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.237193,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.133593",
        "ticker_sentiment_score": "0.125019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.177475",
        "ticker_sentiment_score": "-0.025494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.177475",
        "ticker_sentiment_score": "-0.025508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.498987",
        "ticker_sentiment_score": "0.297308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria",
    "url": "https://www.prnewswire.com/news-releases/lilly-collaborates-with-openai-to-discover-novel-medicines-to-treat-drug-resistant-bacteria-302180973.html",
    "time_published": "20240625T140000",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.151043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "0.325596",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39480553/this-is-what-whales-are-betting-on-eli-lilly-and-co",
    "time_published": "20240625T134807",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.094923,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.806275",
        "ticker_sentiment_score": "0.120723",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly  ( LLY )  a Buy on Tirzepatide Success in Sleep Apnea?",
    "url": "https://www.zacks.com/stock/news/2292780/is-eli-lilly-lly-a-buy-on-tirzepatide-success-in-sleep-apnea",
    "time_published": "20240625T130500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.319276,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.503831",
        "ticker_sentiment_score": "0.38817",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.276936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.240279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Company News for Jun 25, 2024",
    "url": "https://www.zacks.com/stock/news/2292592/company-news-for-jun-25-2024",
    "time_published": "20240625T080900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: RXO, UPS, LLY, ALNY, META, AAPL.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.257411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.695921",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.203599",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RXO",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.491021",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.348194",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.491021",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.348194",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Drops Despite Market Gains: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2293935/eli-lilly-lly-stock-drops-despite-market-gains-important-facts-to-note",
    "time_published": "20240626T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $901.26, indicating a -0.37% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.239594,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.280565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Active Fund Managers Bet These 6 Stocks Will Trade Near All-Time Highs - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39508567/active-fund-managers-bet-these-6-stocks-will-trade-near-all-time-highs",
    "time_published": "20240626T170630",
    "authors": [
      "Hayden Buckfire"
    ],
    "summary": "Active fund managers are making large bets on six already high-performing stocks. The Data: A post on X relayed data from Bank of America research.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/26/Big-Five-Companies--Big-Tech-Company-Log_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.265044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.318016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.160441",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.160441",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.238575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "-0.181099",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.318016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "url": "https://www.zacks.com/stock/news/2293477/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
    "time_published": "20240626T125005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.382262,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.222419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNC",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "0.340067",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day",
    "url": "https://www.zacks.com/stock/news/2293447/la-z-boy-and-winnebago-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
    "time_published": "20240626T123200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - June 26, 2024 - Zacks Equity Research shares La-Z-Boy ( LZB Quick QuoteLZB - ) as the Bull of the Day and Winnebago Industries ( WGO Quick QuoteWGO - ) as the Bear of the Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a3/1381.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.208412,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRBZF",
        "relevance_score": "0.019634",
        "ticker_sentiment_score": "0.42442",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MPX",
        "relevance_score": "0.019634",
        "ticker_sentiment_score": "-0.090554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LZB",
        "relevance_score": "0.213389",
        "ticker_sentiment_score": "0.173672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078418",
        "ticker_sentiment_score": "0.158756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.250982",
        "ticker_sentiment_score": "0.219819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "THO",
        "relevance_score": "0.039257",
        "ticker_sentiment_score": "0.151903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WGO",
        "relevance_score": "0.058855",
        "ticker_sentiment_score": "-0.009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.078418",
        "ticker_sentiment_score": "0.135047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Stock: Archer Aviation or Viking Therapeutics?",
    "url": "https://www.fool.com/investing/2024/06/26/better-growth-stock-archer-aviation-or-viking-ther/",
    "time_published": "20240626T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "Which one of these potential disruptors is the better buy?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781668%2Fparabola.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.192916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.069075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.298023",
        "ticker_sentiment_score": "0.185726",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.298023",
        "ticker_sentiment_score": "0.055661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.069075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.347584",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked",
    "url": "https://www.fool.com/investing/2024/06/26/2-reasons-why-eli-lillys-stock-likely-hasnt-peaked/",
    "time_published": "20240626T083500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The stock may seem expensive right now, but that may not be the case in a few years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781335/a-team-of-scientists-reviewing-results-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.14553,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.500995",
        "ticker_sentiment_score": "0.305068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "-0.029808",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39530614/novo-nordisk-to-restrict-initial-wegovy-sales-in-china-amid-high-demand",
    "time_published": "20240627T161334",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply. China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.054627,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.264381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVZPF",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.101766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.4499",
        "ticker_sentiment_score": "-0.006014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why - Eli Lilly and Co  ( NYSE:LLY ) , Nestle  ( OTC:NSRGY ) ",
    "url": "https://www.benzinga.com/news/24/06/39517176/ben-jerrys-co-founders-not-worried-about-ozempics-impact-on-ice-cream-business-heres-why",
    "time_published": "20240627T053840",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent company Unilever plc's UL ice cream division.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/Close-Up-Ice-Cream-Scoops-Collection-On-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.233194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "-0.1811",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.118012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.118012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.029818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "0.111454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "HIMS Stock Tumbles: Here's Why It's a Buy Right Now",
    "url": "https://www.zacks.com/commentary/2295212/hims-stock-tumbles-heres-why-its-a-buy-right-now",
    "time_published": "20240628T190000",
    "authors": [
      "Ethan Feller"
    ],
    "summary": "Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.280719,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.199584",
        "ticker_sentiment_score": "0.351047",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.688096",
        "ticker_sentiment_score": "0.469967",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.199584",
        "ticker_sentiment_score": "0.351047",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Insights Into Eli Lilly and Co's Performance Versus Peers In Pharmaceuticals Sector - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39551314/insights-into-eli-lilly-and-cos-performance-versus-peers-in-pharmaceuticals-sector",
    "time_published": "20240628T150013",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Eli Lilly and Co LLY in relation to its major competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.191717,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.477986",
        "ticker_sentiment_score": "0.296171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2294734/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240628T102004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.269207,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.240627",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.048612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.048612",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Split Watch: Is Eli Lilly Next?",
    "url": "https://www.fool.com/investing/2024/06/28/stock-split-watch-is-eli-lilly-next/",
    "time_published": "20240628T083500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly's revenue has climbed, thanks to high demand for its weight loss drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781919%2Fscientists-work-in-lab-smiling.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.216238,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.531147",
        "ticker_sentiment_score": "0.28032",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.08857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.08857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "-0.035946",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is Massive News for Eli Lilly Investors",
    "url": "https://www.fool.com/investing/2024/06/29/this-is-massive-news-for-eli-lilly-investors/",
    "time_published": "20240629T110000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781684%2Fgettyimages-1185122199.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.376812,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.648024",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.157285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.157285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.",
    "url": "https://www.fool.com/investing/2024/06/29/eli-lilly-is-teaming-up-with-openai-here-are-3-thi/",
    "time_published": "20240629T101500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781806%2Fgettyimages-1441663123.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.27641,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.687678",
        "ticker_sentiment_score": "0.506307",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Healthcare Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/30/2-top-healthcare-stocks-to-buy-in-june/",
    "time_published": "20240630T115200",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Healthcare businesses tend to hold up through various economic cycles.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781624/dna-sequencing-genome-science-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.211862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.281692",
        "ticker_sentiment_score": "0.209486",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.236281",
        "ticker_sentiment_score": "0.039551",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant - Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39577874/sanofi-nears-decision-on-1-6b-upgrade-for-frankfurt-insulin-plant",
    "time_published": "20240701T151328",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ( $1.4 billion - $1.6 billion ) to enhancing its insulin production site in Frankfurt, Germany. The site in Frankfurt's Hoechst district is known for producing the company's insulin brand, Lantus.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/01/Sanofi.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.362382,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.223568",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.149597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.149597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.330334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Top-Performing S&P 500 Stocks of 1H Set to Shine Further",
    "url": "https://www.zacks.com/stock/news/2295833/5-top-performing-sp-500-stocks-of-1h-set-to-shine-further",
    "time_published": "20240701T135000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The S&P 500 wraps up the first half with gains of 14%, representing one of the strongest performances since the late-1990s dot-com bubble.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e4/61050.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      }
    ],
    "overall_sentiment_score": 0.27945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.148867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "0.138543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.382193",
        "ticker_sentiment_score": "0.352544",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.231663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.160245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.224368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.248833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Soars To 52-Week High: Can The Momentum Continue? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39575214/eli-lilly-soars-to-52-week-high-can-the-momentum-continue",
    "time_published": "20240701T132704",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Company LLY has hit a new 52-week high, climbing to $915.54 during Friday trading. The stock is up a remarkable 97.38% over the past year and 55.32% year-to-date, fueled by groundbreaking collaborations and bullish technical indicators.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/01/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.399912,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.397209",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.085016",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/07/01/passive-income-top-dividend-stocks-to-buy/",
    "time_published": "20240701T113700",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "These stalwart companies could help you safely grow your wealth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781995%2Flmt-f-35-lockheed-martin.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.325126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.154822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.268801",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.204321",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-fda-approval-alzheimers-treatment-kisunla/",
    "time_published": "20240702T181600",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock In Red After Snagging FDA Approval For Alzheimer's Treatment Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.102883,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.663719",
        "ticker_sentiment_score": "-0.022609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "-0.185109",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.159186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?",
    "url": "https://www.fool.com/investing/2024/07/02/customers-for-life/",
    "time_published": "20240702T174748",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We also talk about weight loss drugs and sleep apnea, and other stock market news.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782157/mfm_24.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.148721,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SHOP",
        "relevance_score": "0.072498",
        "ticker_sentiment_score": "0.094323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGT",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.083051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.049118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.031105",
        "ticker_sentiment_score": "0.053374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.010371",
        "ticker_sentiment_score": "0.026485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.027274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.010371",
        "ticker_sentiment_score": "0.102792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.02074",
        "ticker_sentiment_score": "0.092794",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.113695",
        "ticker_sentiment_score": "0.048062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly's Kisunla\u2122  ( donanemab-azbt )  Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease",
    "url": "https://www.prnewswire.com/news-releases/lillys-kisunla-donanemab-azbt-approved-by-the-fda-for-the-treatment-of-early-symptomatic-alzheimers-disease-302188299.html",
    "time_published": "20240702T173500",
    "authors": [
      "Eli Lilly and Company"
    ],
    "summary": "Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39%",
    "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.060111,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.372188",
        "ticker_sentiment_score": "0.311547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015472",
        "ticker_sentiment_score": "0.128124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39600377/joe-biden-suggests-novo-nordisk-eli-lilly-to-lower-prices-for-its-popular-obesity-drugs",
    "time_published": "20240702T153823",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription drugs in the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/02/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.128269,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "-0.079301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.027749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking  ( VKTX )  Skyrockets 197% YTD: Is the Stock Worth a Buy?",
    "url": "https://www.zacks.com/stock/news/2296305/viking-vktx-skyrockets-197-ytd-is-the-stock-worth-a-buy",
    "time_published": "20240702T150600",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268191,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.004931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.100941",
        "ticker_sentiment_score": "0.057445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.150906",
        "ticker_sentiment_score": "0.433308",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.15931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.100941",
        "ticker_sentiment_score": "-0.135925",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Jones Dips As Powell Says This On Rate Cuts; Tesla Deliveries Crush Views  ( Live Coverage ) ",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-jerome-powell-fed-tesla-deliveries-amazon-nvidia/",
    "time_published": "20240702T144700",
    "authors": [
      "MICHAEL LARKIN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Dips As Powell Says This On Rate Cuts. Tesla Deliveries Crush Views ( Live Coverage ) Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-05-gov.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.182187,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TSLA",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.091045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.348369",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.257077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.125025",
        "ticker_sentiment_score": "0.04207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.02691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.348369",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALKT",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.213606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.115657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.111365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.070014",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo, Lilly Dive After Biden Slams Their 'Unconscionably High' Prices",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-eli-lilly-stock-weight-loss-drugs-prices/",
    "time_published": "20240702T140600",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Novo Nordisk Stock Dives After Biden Slams Drugmaker For 'Unconscionably High' Prices Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.102098,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.433523",
        "ticker_sentiment_score": "-0.428776",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.55533",
        "ticker_sentiment_score": "-0.134913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst - Eli Lilly and Co  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a",
    "time_published": "20240703T161319",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, the FDA approved Eli Lilly and Co's LLY Kisunla ( donanemab ) once-monthly injection for IV infusion ) for adults with early symptomatic Alzheimer's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/03/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.170139,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.146277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.173179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.231367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.329992",
        "ticker_sentiment_score": "0.419654",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top 3 Health Care Stocks That May Crash This Quarter - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39617741/top-3-health-care-stocks-that-may-crash-this-quarter",
    "time_published": "20240703T134108",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/03/GE-Healthcare-Amersham-radiopharmaceutic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.28721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.360942",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LBPH",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.382351",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HROW",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.088319",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Gets FDA Nod for Alzheimer's Drug Donanemab",
    "url": "https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimers-drug-donanemab",
    "time_published": "20240703T123400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.06643,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.047636",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.251132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 4 Vanguard ETFs Soared Over 20% in the First Half of 2024. Here's Which One Is Most Likely to Fly Even Higher.",
    "url": "https://www.fool.com/investing/2024/07/03/these-4-vanguard-etfs-soared-over-20-in-the-first/",
    "time_published": "20240703T094900",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These Vanguard ETFs have a lot in common.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782342/etf-chart-going-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999326"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.272141,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.200081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.200081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.200081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.200081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.200081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39612822/eli-lilly-shares-gain-after-drug-maker-gets-fdas-nod-for-early-alzheimers-treatment",
    "time_published": "20240703T082041",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a significant development in the battle against Alzheimer's disease, the U.S. Food and Drug Administration ( FDA ) has approved Eli Lilly and Company's LLY Alzheimer's treatment, \"Kisunla.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/03/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.122878,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.487279",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "TSLA, PARA, ANVS, LLY, AMZN: Top 5 Trending Stocks Today - Annovis Bio  ( NYSE:ANVS ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/07/39611561/tesla-paramount-global-annovis-bio-eli-lilly-amazon-why-these-5-stocks-are-on-investors-radars-t",
    "time_published": "20240703T033825",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory, increasing by 0.6% to finish at 5,509.01. Additionally, the Nasdaq gained 0.8%, closing at 18,028.76.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/02/Stocks-Photo-by-Phongphan-on-Shutterstoc.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211608,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "-0.143512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.122805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.02957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.113914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39637162/heres-how-much-100-invested-in-eli-lilly-and-co-15-years-ago-would-be-worth-today",
    "time_published": "20240704T180032",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 24.56%. Currently, Eli Lilly and Co has a market capitalization of $807.66 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss",
    "url": "https://www.zacks.com/stock/news/2296877/nvo-lly-slip-after-study-links-obesity-drug-use-to-vision-loss",
    "time_published": "20240704T121900",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.080587,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.461468",
        "ticker_sentiment_score": "0.259244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "0.09481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.141808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.267413",
        "ticker_sentiment_score": "0.17688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "-0.025525",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation",
    "url": "https://www.fool.com/investing/2024/07/04/mounjaro-and-zepbound-are-great-but-this-is-the-re/",
    "time_published": "20240704T113000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782110/businessperson-giving-a-presentation.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.198146,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.560379",
        "ticker_sentiment_score": "0.313712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly: 3 Biotech Stocks to Buy Instead",
    "url": "https://www.fool.com/investing/2024/07/04/forget-eli-lilly-3-biotech-stocks-to-buy-instead/",
    "time_published": "20240704T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Eli Lilly is a good stock to buy, but these should be even better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782405/scientists-in-a-lab-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.331406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "0.507325",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.140216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.049168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.424724",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Weight-Loss Drug Linked to Blindness in New Study",
    "url": "https://decrypt.co/238410/ozempic-weight-loss-drug-linked-blindness-new-study",
    "time_published": "20240704T011934",
    "authors": [
      "Jose Antonio Lanz"
    ],
    "summary": "Drugmaker Novo Nordisk says its product is safe, while company stock took a hit.",
    "banner_image": "https://cdn.decrypt.co/resize/1024/height/512/wp-content/uploads/2024/07/Ozempic_shutterstock_2392173591-gID_7.jpg",
    "source": "Decrypt.co",
    "category_within_source": "n/a",
    "source_domain": "decrypt.co",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.11263,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "-0.066266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "-0.118747",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Shares Friday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39651098/whats-going-on-with-eli-lilly-shares-friday",
    "time_published": "20240705T184749",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Eli Lilly and Co. LLY shares are experiencing increased activity Friday afternoon. Here's what you need to know. What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lilly with a price target of $1023.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/05/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.09426,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "-0.008057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "-0.05564",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39650276/glp-1-treatments-such-as-wegvoy-mounjaro-cut-obesity-related-cancer-risks-study-finds",
    "time_published": "20240705T172847",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and other diabetes medications.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/05/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.06295,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.30298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD",
    "url": "https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-llys-kisunla-snys-dupixent-gets-eu-nod-for-copd",
    "time_published": "20240705T141600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.167399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.036637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.173582",
        "ticker_sentiment_score": "0.085146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.120564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORINY",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.06065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "-0.105939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.028349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.188766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In LLY Options - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39646966/smart-money-is-betting-big-in-lly-options",
    "time_published": "20240705T134737",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on Eli Lilly and Co LLY, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.038473,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.824317",
        "ticker_sentiment_score": "0.077629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "-0.096041",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Best Mutual Fund Hits Home Runs In Addition To Nvidia",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-fund-hits-home-runs-in-addition-to-nvidia/",
    "time_published": "20240705T110000",
    "authors": [
      "Investor's Business Daily",
      "ADAM SHELL"
    ],
    "summary": "Delaware Ivy Global Growth Fund ( IVINX ) isn't about making big bets on a single country. It's not about going all-in on a single megatrend like AI, either. Nor is the best mutual loading up on a single stock like AI darling and stock-market juggernaut Nvidia ( NVDA ) .",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/Stock-MutualFundswork-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.319736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.177896",
        "ticker_sentiment_score": "0.199691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EADSF",
        "relevance_score": "0.025624",
        "ticker_sentiment_score": "0.254385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.227479",
        "ticker_sentiment_score": "0.222556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "0.167153",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.025624",
        "ticker_sentiment_score": "0.031314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CASY",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.115696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "0.158969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.054592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.268634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio",
    "url": "https://www.fool.com/investing/2024/07/05/missed-out-on-eli-lilly-this-much-smaller-biotech/",
    "time_published": "20240705T102200",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Could Zealand Pharma be a better option for growth-oriented investors?",
    "banner_image": "https://g.foolcdn.com/editorial/images/782123/investor-at-home-looking-at-multiple-charts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.116207,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.13516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:DKK",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "-0.063338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:NOK",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "-0.063338",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gold Falls Over 1%; HilleVax Shares Plunge - Morphic Holding  ( NASDAQ:MORF ) ",
    "url": "https://www.benzinga.com/news/24/07/39673593/gold-falls-over-1-hillevax-shares-plunge",
    "time_published": "20240708T183108",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.12% to 39,329.47 while the NASDAQ rose 0.27% to 18,401.75. The S&P 500 also rose, gaining, 0.09% to 5,572.23. Information technology shares jumped by 0.6% on Monday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/08/Gold-goldbar-goldnugget-shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.074811,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.2256",
        "ticker_sentiment_score": "0.361817",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SVMH",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.286359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.440559",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.009192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVA",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.066195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLVX",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.077705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2298006/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240708T165056",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.21509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.159245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly  ( LLY )  is a Strong Momentum Stock",
    "url": "https://www.zacks.com/stock/news/2297922/heres-why-eli-lilly-lly-is-a-strong-momentum-stock",
    "time_published": "20240708T164330",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default288.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.394079,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.312423",
        "ticker_sentiment_score": "0.218932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now",
    "url": "https://www.zacks.com/stock/news/2297887/if-you-invested-1000-in-eli-lilly-a-decade-ago-this-is-how-much-itd-be-worth-now",
    "time_published": "20240708T163324",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default43.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.19057,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.614932",
        "ticker_sentiment_score": "0.295879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.025855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.210731",
        "ticker_sentiment_score": "0.041732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKUS",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.047009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.047009",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market News From Amazon, Nike, McCormick, and More",
    "url": "https://www.fool.com/investing/2024/07/08/stock-market-news-from-amazon-nike-mccormick-and-m/",
    "time_published": "20240708T155600",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We also talk with author Nicola Twilley about her new book, \"Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves.\" ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/782215/mfm_28.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.067362,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ITRI",
        "relevance_score": "0.025679",
        "ticker_sentiment_score": "0.161437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.03851",
        "ticker_sentiment_score": "0.022395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEN",
        "relevance_score": "0.01926",
        "ticker_sentiment_score": "0.099594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.01926",
        "ticker_sentiment_score": "0.045321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.059934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.032095",
        "ticker_sentiment_score": "0.048614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.057736",
        "ticker_sentiment_score": "-0.020019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.012841",
        "ticker_sentiment_score": "-0.055571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.012841",
        "ticker_sentiment_score": "0.0764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYND",
        "relevance_score": "0.006421",
        "ticker_sentiment_score": "-0.036342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.006421",
        "ticker_sentiment_score": "-0.089129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.006421",
        "ticker_sentiment_score": "0.057281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.03851",
        "ticker_sentiment_score": "0.035219",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF  ( RSPH ) ?",
    "url": "https://www.zacks.com/stock/news/2297704/should-you-invest-in-the-invesco-sp-500-equal-weight-health-care-etf-rsph",
    "time_published": "20240708T143035",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.275297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.063868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.197951",
        "ticker_sentiment_score": "0.17444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.063868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.132733",
        "ticker_sentiment_score": "0.063868",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc.  ( Nasdaq - MORF ) , Desktop Metal, Inc.  ( NYSE - DM ) , Alimera Sciences, Inc.  ( Nasdaq - ALIM ) , Avangrid, Inc.  ( NYSE - AGR ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39667973/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-morphic-holdi",
    "time_published": "20240708T141229",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., July 08, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.237877,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALIM",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.216215",
        "ticker_sentiment_score": "0.064783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.20535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DM",
        "relevance_score": "0.216215",
        "ticker_sentiment_score": "0.165663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.230799",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AGR",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.159262",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBDSF",
        "relevance_score": "0.216215",
        "ticker_sentiment_score": "0.136838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NNDM",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.220987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.216215",
        "ticker_sentiment_score": "0.178361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B Why Is Morphic Holding  ( MORF )  Stock Jumping Today? - Morphic Holding  ( NASDAQ:MORF ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39665674/eli-lillys-first-biotech-deal-of-2024-buys-chronic-disease-player-morphic-for-3-2b",
    "time_published": "20240708T125513",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for chronic diseases, including autoimmune, cardiovascular, and ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/08/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.142959,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "0.464791",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.930964",
        "ticker_sentiment_score": "0.223828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "-0.107298",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in July",
    "url": "https://www.fool.com/investing/2024/07/08/3-no-brainer-stocks-to-buy-in-july/",
    "time_published": "20240708T120000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "Investors shouldn't have to think too hard about these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782643/scientists-in-a-lab-monitor-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.340429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.355812",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.140868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.120086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-acquire-morphic-to-improve-outcomes-for-patients-with-inflammatory-bowel-disease-302190489.html",
    "time_published": "20240708T104500",
    "authors": [],
    "summary": "Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.262255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.02105",
        "ticker_sentiment_score": "0.108886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.02105",
        "ticker_sentiment_score": "0.13199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.58661",
        "ticker_sentiment_score": "0.359877",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.042085",
        "ticker_sentiment_score": "0.136706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.555831",
        "ticker_sentiment_score": "0.402242",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.02105",
        "ticker_sentiment_score": "-0.126565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.02105",
        "ticker_sentiment_score": "0.150917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche",
    "url": "https://www.zacks.com/stock/news/2297514/the-zacks-analyst-blog-highlights-eli-lilly-sanofi-merck-astrazenecas-and-roche",
    "time_published": "20240708T092900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.171743,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.075088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.120218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORINY",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.065434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "-0.105074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.028172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.163687",
        "ticker_sentiment_score": "0.161687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2298774/eli-lilly-lly-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240709T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $932.50, indicating a +1.58% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.226093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.587278",
        "ticker_sentiment_score": "0.326366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39696780/eli-lillys-3-2b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attent",
    "time_published": "20240709T185912",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/09/Eli-Lilly_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.295586,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.549581",
        "ticker_sentiment_score": "0.317278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "0.286072",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.009201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Lilly  ( LLY )  is Poised to Beat Earnings Estimates Again",
    "url": "https://www.zacks.com/stock/news/2298695/why-lilly-lly-is-poised-to-beat-earnings-estimates-again",
    "time_published": "20240709T161013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.317079,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.411848",
        "ticker_sentiment_score": "0.434163",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Study Shows Lilly's  ( LLY )  Obesity Drug More Effective Than NVO's",
    "url": "https://www.zacks.com/stock/news/2298718/study-shows-lillys-lly-obesity-drug-more-effective-than-nvos",
    "time_published": "20240709T160500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.133551,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.213002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.092408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.141773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.174039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.109265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39692752/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240709T154645",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 56 unusual trades. Delving into the details, we found 41% of traders were bullish, while 35% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.055588,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.677342",
        "ticker_sentiment_score": "0.094204",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Buy Morphic for $3.2B, Boost IBD Presence",
    "url": "https://www.zacks.com/stock/news/2298543/eli-lilly-lly-to-buy-morphic-for-32b-boost-ibd-presence",
    "time_published": "20240709T141700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.193747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.36255",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.068382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.165658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ROIV",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.05304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.025065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.05304",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for July 9, 2024",
    "url": "https://www.zacks.com/stock/news/2298393/company-news-for-july-9-2024",
    "time_published": "20240709T132700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article Are:MORF, LLY, IDYA, ETSY, INTC.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.325898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.248402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IDYA",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.376102",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.248402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.183839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.765938",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2298251/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240709T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.184208,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.043286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.061839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?",
    "url": "https://www.fool.com/investing/2024/07/09/is-eli-lilly-stock-a-no-brainer-buy-after-its-fda/",
    "time_published": "20240709T101500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "No matter how you look at it, the FDA approval of Kisunla is big for Eli Lilly.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782797/scientists-smiling-and-shaking-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297209,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.737286",
        "ticker_sentiment_score": "0.526207",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.037011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.104861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.104861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.104861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.037011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?",
    "url": "https://www.fool.com/investing/2024/07/09/can-eli-lilly-surpass-1000-this-year/",
    "time_published": "20240709T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "This pharma company is posting double-digit revenue growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F782698%2Fgettyimages-1292931102.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.301168,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.680677",
        "ticker_sentiment_score": "0.506886",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.11247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.062656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.11247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.00799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone - PepsiCo  ( NASDAQ:PEP ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39680466/s-p-500-closes-at-record-high-ahead-of-inflation-data-fear-greed-index-remains-in-neutral-zone",
    "time_published": "20240709T072730",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the \"Neutral\" zone on Monday. U.S. stocks closed mixed on Monday, with the S&P 500 closing at a record high during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/09/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": -0.155479,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "MORF",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.285234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGH",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.192885",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "KRUS",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.192885",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HELE",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.192885",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.285234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.297533",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/07/39680165/eli-lillys-mounjaro-outpaces-novo-nordisks-ozempic-in-weight-loss-effectiveness-study-shows",
    "time_published": "20240709T070507",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Eli Lilly and Co. LLY has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's NVO Ozempic.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/09/NovoNordisk-Elililly-shutterstock.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": -0.064481,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "-0.053163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "-0.002558",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39713169/only-25-patients-stick-with-novo-nordisks-wegovy-or-ozempic-after-2-years-a-study-shows-company-c",
    "time_published": "20240710T155245",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S's NVO weight-loss drugs, Wegovy and Ozempic, continue their treatment after two years. The data provided to Reuters highlights a significant decline in long-term adherence to these ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/10/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.007234,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.082178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "-0.134826",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39738803/eli-lilly-novo-nordisk-shares-dip-as-pfizer-ramps-up-diabetes-drug-competition",
    "time_published": "20240711T201016",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Shares of Eli Lilly and Co LLY and Novo Nordisk A/S NVO finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector. What Happened: Pfizer has selected its preferred once-daily modified release formulation for danuglipron, a GLP-1 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/Medical-Technology-Concept-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.158492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.695767",
        "ticker_sentiment_score": "0.336953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.695767",
        "ticker_sentiment_score": "0.204012",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.096544",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bernie Sanders Targets High Prices of Ozempic and Wegovy In US - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39736330/bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us",
    "time_published": "20240711T174717",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Senator Bernie Sanders expressed confidence that Novo Nordisk A/S NVO can be persuaded to reduce the U.S. prices of its popular weight-loss drugs, Ozempic and Wegovy, by publicly highlighting the disparity between domestic and international pricing.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/Bernie-Sanders-Ozempic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.072516,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.100102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "0.170469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.100102",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Invest in Beam Therapeutics  ( BEAM )  Now",
    "url": "https://www.zacks.com/stock/news/2300260/heres-why-you-should-invest-in-beam-therapeutics-beam-now",
    "time_published": "20240711T165600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.151426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.848651",
        "ticker_sentiment_score": "0.242103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.323783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADPT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.006671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RAPT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.006676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "0.06845",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  Soars 38% YTD: How Should You Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2300219/novo-nordisk-nvo-soars-38-ytd-how-should-you-play-the-stock",
    "time_published": "20240711T160900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.402052,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.165469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "0.076649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037329",
        "ticker_sentiment_score": "0.137251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.600455",
        "ticker_sentiment_score": "0.579738",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo  ( NVO )  Gets CRL From FDA for Weekly Basal Insulin Icodec",
    "url": "https://www.zacks.com/stock/news/2300248/novo-nvo-gets-crl-from-fda-for-weekly-basal-insulin-icodec",
    "time_published": "20240711T153000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.134459,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.040786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORT",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.18454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.069608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.055928",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer Vs. Eli Lilly Stock - Which Is A Better Pick?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/07/11/pfizer-vs-eli-lilly-stock--which-is-a-better-pick/",
    "time_published": "20240711T133050",
    "authors": [
      "Trefis Team"
    ],
    "summary": "We believe that Eli Lilly stock ( NYSE: LLY ) is currently a better pick than its industry peer - Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662b6a87b3af139422324bac/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.204968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.793468",
        "ticker_sentiment_score": "0.350362",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.336296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "url": "https://www.zacks.com/stock/news/2299780/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
    "time_published": "20240711T125009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.340985,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.366772",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.25838",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath - Eli Lilly and Co  ( NYSE:LLY ) , Axsome Therapeutics  ( NASDAQ:AXSM ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/07/39726993/a-redux-of-the-lyrica-cymbalta-fibromyalgia-war-of-the-2010s-may-look-more-like-david-vs-goliath",
    "time_published": "20240711T120018",
    "authors": [
      "James Blacker"
    ],
    "summary": "The following post was written and/or published as a collaboration between Benzinga's in-house sponsored content team and Tonix Pharmaceuticals Holding Corp. The sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/Screenshot-2024-07-10-at-9-08-28PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.079298,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.008517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032871",
        "ticker_sentiment_score": "0.102629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.163243",
        "ticker_sentiment_score": "0.104851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.008517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.103349",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares",
    "url": "https://www.fool.com/investing/2024/07/11/better-growth-play-eli-lilly-vs-vanguard-growth-in/",
    "time_published": "20240711T093000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Both equities have been incredible growth plays of late.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783016%2Fgrowth-chart.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.332818,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.268542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.209677",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.209677",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club - Elon Musk's Tesla, Eli Lilly Top Contenders - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/07/39722838/jim-cramer-identifies-eight-companies-eyeing-trillion-dollar-club-elon-musks-tesla-eli-lilly-top",
    "time_published": "20240711T070011",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, joining tech giants Microsoft Corp. MSFT, Apple Inc. AAPL, and Nvidia Corp. NVDA, among others. What Happened: Cramer, on his show \"Mad Money\" on Wednesday, named Eli Lilly and Co. LLY and Tesla ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/jim-cramer-chart-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.27756,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.038619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.038619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.165354",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.032018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.14103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.185537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.038619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.465093",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.40734",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic Maker Novo Nordisk Stock Stuck In Buy Zone; Is It A Buy Now?",
    "url": "https://www.investors.com/stock-lists/sector-leaders/novo-nordisk-stock-ozempic-2/",
    "time_published": "20240712T173700",
    "authors": [
      "Investor's Business Daily",
      "RACHEL FOX"
    ],
    "summary": "Ozempic Maker Novo Nordisk Stock Stuck In Buy Zone. Is It A Buy Now? Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.081311,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.004304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "-0.11946",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-",
    "time_published": "20240712T162642",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Pfizer Inc PFE announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 ( GLP-1 ) receptor agonist.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/Pfizer-shutterstock2_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.15411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "-0.105941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "-0.14635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.397586",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Pops After Weight-Loss Drug Cuts Dementia Risk",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-semaglutide-weight-loss-drug-dementia-risk/",
    "time_published": "20240712T155800",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.036018,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.110705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.58463",
        "ticker_sentiment_score": "0.062453",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE )  Moves Forward With Once-Daily Obesity Pill Study",
    "url": "https://www.zacks.com/stock/news/2300888/pfizer-pfe-moves-forward-with-once-daily-obesity-pill-study",
    "time_published": "20240712T142800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.155349,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.084185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.062873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.104214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.084185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.60415",
        "ticker_sentiment_score": "0.234469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Small Caps Soar After Tame CPI: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-shifts-small-caps-cpi-jpmorgan-tesla/",
    "time_published": "20240712T141400",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Stock Market Shifts Toward Small Caps After Tame CPI. JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/STock-NYSEstockExchange-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": -0.041305,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.125076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.059364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.059364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.250755",
        "ticker_sentiment_score": "0.036195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.028462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.197496",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.144926",
        "ticker_sentiment_score": "0.104804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.018231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.180595",
        "ticker_sentiment_score": "0.094905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LNTH",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "-0.038295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.032184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.13101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39750186/using-ozempic-zepbound-or-other-weight-loss-drugs-inform-doctors-before-anesthesia-or-surgery-eur",
    "time_published": "20240712T141148",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, the European Medicines Agency ( EMA ) warned patients using weight-loss drugs, such as Novo Nordisk A/S's NVO Wegovy, to inform their doctors before general anesthesia or deep sedation surgery. This recommendation stems from potential respiratory complications linked to these ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.041134,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.032439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.098728",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development",
    "url": "https://www.zacks.com/stock/news/2300869/pharma-stock-roundup-lly-to-buy-morphic-pfe-advances-obesity-drug-development",
    "time_published": "20240712T141000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.07527,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.3527",
        "ticker_sentiment_score": "0.020044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.3527",
        "ticker_sentiment_score": "0.005038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.092839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.191042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "url": "https://www.zacks.com/stock/news/2300584/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
    "time_published": "20240712T125010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999937"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.390546,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.266671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELV",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.415002",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Tesla And Nvidia Investors Dangerously Delude Themselves Of Reality",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-tesla-and-nvidia-investors-delude-themselves/",
    "time_published": "20240712T120000",
    "authors": [
      "MATT KRANTZ",
      "Investor's Business Daily"
    ],
    "summary": "Stock prices anticipate the future. But such wishful thinking is reaching extreme levels in some S&P 500 stocks. More than 80% of the prices of three S&P 500 stocks, Tesla ( TSLA ) , Eli Lilly ( LLY ) and Nvidia ( NVDA ) , are based on expected earnings in the future, says Nicholas Colas of ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-upsetinvestor-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.184304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.07581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.07581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.442082",
        "ticker_sentiment_score": "0.142981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy Eli Lilly Stock After Another Major Win?",
    "url": "https://www.fool.com/investing/2024/07/12/should-you-buy-eli-lilly-stock-after-another-major/",
    "time_published": "20240712T101300",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It was a buy even before this development.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782806/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.27627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.454511",
        "ticker_sentiment_score": "0.456989",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/07/39745003/novo-nordisks-miracle-weight-loss-drug-ozempic-linked-to-48-lower-risk-of-dementia-study-finds",
    "time_published": "20240712T091951",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Novo Nordisk A/S. NVO has found that its \"miracle\" weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/dementia-Photo-by-Gerd-Altmann-via-Pixab.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.148082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.108643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.348592",
        "ticker_sentiment_score": "0.276857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.",
    "url": "https://www.fool.com/investing/2024/07/13/eli-lillys-alzheimers-drug-obtains-fda-approval-he/",
    "time_published": "20240713T103100",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The news likely didn't come as a big surprise to investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782716/an-fda-approved-stamp-next-to-pills.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.197224,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.280896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.093754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Did Eli Lilly Just Get a Leg Up on Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/07/13/did-eli-lilly-just-say-checkmate-to-novo-nordisk/",
    "time_published": "20240713T093000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F782926%2Fgettyimages-1644169924.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.263571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.805852",
        "ticker_sentiment_score": "0.417777",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.318211",
        "ticker_sentiment_score": "0.256065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PMNT",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "-0.017987",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Flying Growth Stocks You Can Buy Right Now Before They Surge Even Higher",
    "url": "https://www.fool.com/investing/2024/07/14/2-high-flying-growth-stocks-you-can-buy-right-now/",
    "time_published": "20240714T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Shares are up for very good reasons.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783033/happy-person-at-laptop-success-winning-fists-up-victory-yes.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.248265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "0.179376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.291512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.156127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "-0.022572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly a Good Dividend Stock to Buy Now?",
    "url": "https://www.fool.com/investing/2024/07/14/is-eli-lilly-a-good-dividend-stock-to-buy-now/",
    "time_published": "20240714T103100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "A leading anti-obesity treatment plus a new Alzheimer's drug could drive profits through the roof.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783133/ozempic-injector-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.143158,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.448513",
        "ticker_sentiment_score": "0.172494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.140903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock",
    "url": "https://www.fool.com/investing/2024/07/14/bad-news-for-novo-nordisk-good-news-for-eli-lilly/",
    "time_published": "20240714T092000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "A new study raises important implications regarding the competitive balance between these two companies.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783065/investor-considers-papers-at-a-cafe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.11803,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.094932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "0.142457",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth",
    "url": "https://www.zacks.com/research-daily/2301382/q2-earnings-season-scorecard-and-analyst-reports-for-microsoft-eli-lilly-unitedhealth",
    "time_published": "20240715T190500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Microsoft (MSFT), Eli Lilly (LLY) and UnitedHealth (UNH), as well as a micro-cap stock Tile Shop Holdings (TTSH).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default258.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.137166,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "-0.109369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.129727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.090989",
        "ticker_sentiment_score": "0.202741",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "-0.109369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.308464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39778341/this-analyst-sees-potential-downside-in-eli-lilly-adjusts-model-for-acquired-ipr-d-",
    "time_published": "20240715T171312",
    "authors": [
      "Shivani Kumaresan"
    ],
    "summary": "Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885. The company is slated to report its second-quarter FY24 earnings on August 8.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/15/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.174618,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.577527",
        "ticker_sentiment_score": "0.064894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.088996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.088996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  GLP-1 Drug Regarded Safe for Brain by Oxford",
    "url": "https://www.zacks.com/stock/news/2301936/novo-nordisk-nvo-glp-1-drug-regarded-safe-for-brain-by-oxford",
    "time_published": "20240715T154200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.229763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.031842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.263373",
        "ticker_sentiment_score": "0.083922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.580434",
        "ticker_sentiment_score": "0.28747",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.194749",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Americans Are Flying; Airline Stocks Are Not",
    "url": "https://www.fool.com/investing/2024/07/15/americans-are-flying-airline-stocks-are-not/",
    "time_published": "20240715T153251",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783010/mfm_08-copy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.158069,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENPH",
        "relevance_score": "0.008765",
        "ticker_sentiment_score": "-0.005749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.061293",
        "ticker_sentiment_score": "0.080175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SVNDF",
        "relevance_score": "0.008765",
        "ticker_sentiment_score": "0.216074",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.008765",
        "ticker_sentiment_score": "0.146251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.096178",
        "ticker_sentiment_score": "0.089974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.008765",
        "ticker_sentiment_score": "0.096247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERII",
        "relevance_score": "0.008765",
        "ticker_sentiment_score": "-0.005749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39772711/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240715T134718",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.014413,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.700759",
        "ticker_sentiment_score": "0.034519",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Growth Stocks to Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/07/15/2-unstoppable-growth-stocks-to-buy-and-hold/",
    "time_published": "20240715T114500",
    "authors": [
      "Joe Tenebruso"
    ],
    "summary": "These elite companies can help you build lasting wealth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783221/robotics-gettyimages-1278639909.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.379179,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.336855",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.406745",
        "ticker_sentiment_score": "0.404865",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.178207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OPTGF",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.070188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split",
    "url": "https://www.fool.com/investing/2024/07/15/stock-split-watch-2-stocks-that-could-split/",
    "time_published": "20240715T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Revenue is climbing at these two drug companies -- and the trend should continue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783050%2Fgettyimages-investor-uses-tablet-and-phone.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      }
    ],
    "overall_sentiment_score": 0.266356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.056158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.310283",
        "ticker_sentiment_score": "0.203449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.37177",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Slides as Market Rises: Facts to Know Before You Trade",
    "url": "https://www.zacks.com/stock/news/2302958/eli-lilly-lly-stock-slides-as-market-rises-facts-to-know-before-you-trade",
    "time_published": "20240716T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $941.60, signifying a -0.93% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default31.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.235658,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.543535",
        "ticker_sentiment_score": "0.335446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Senate To Review Novo Nordisk's Levemir Insulin Discontinuation - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39801282/senate-to-review-novo-nordisks-levemir-insulin-discontinuation",
    "time_published": "20240716T174939",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Democratic U.S. Senate aides will meet with executives from Novo Nordisk A/S NVO on Tuesday to discuss the ramifications of the company's decision to cease selling its long-acting insulin Levemir in the U.S. by the end of 2024.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.054546,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.655281",
        "ticker_sentiment_score": "0.27038",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39796638/eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240716T143121",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly and Co LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.050599,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.754753",
        "ticker_sentiment_score": "0.145352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "-0.096246",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Large Drug Stocks to Watch as Innovation, M&A Pick Up",
    "url": "https://www.zacks.com/commentary/2302224/4-large-drug-stocks-to-watch-as-innovation-ma-pick-up",
    "time_published": "20240716T125300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99737"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.223572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.197592",
        "ticker_sentiment_score": "0.143355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.022181",
        "ticker_sentiment_score": "0.068758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.022181",
        "ticker_sentiment_score": "0.068758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.132489",
        "ticker_sentiment_score": "0.147328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.132489",
        "ticker_sentiment_score": "0.069107",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Eli Lilly, UnitedHealth and Tile Shop",
    "url": "https://www.zacks.com/stock/news/2302211/the-zacks-analyst-blog-eli-lilly-unitedhealth-and-tile-shop",
    "time_published": "20240716T104900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, UnitedHealth and Tile Shop are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fd/423.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.171992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.146925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.11345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.183352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped",
    "url": "https://www.fool.com/investing/2024/07/17/roche-group-stock-pops-eli-lilly-novo-nordisk-drop/",
    "time_published": "20240717T172154",
    "authors": [
      "Rich Smith"
    ],
    "summary": "Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783680/1-red-arrow-going-down-crosses-1-green-arrow-going-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.116688,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.648995",
        "ticker_sentiment_score": "0.22517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.648995",
        "ticker_sentiment_score": "0.22517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Accepts Lexicon's  ( LXRX )  NDA for Type I Diabetes Drug",
    "url": "https://www.zacks.com/stock/news/2303768/fda-accepts-lexicons-lxrx-nda-for-type-i-diabetes-drug",
    "time_published": "20240717T151500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069916,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.04652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.04652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LXRX",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.038325",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer And Roche Advance On Their Weight Loss Drug Journeys - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/news/24/07/39817877/pfizer-and-roche-advance-on-their-weight-loss-drug-journeys",
    "time_published": "20240717T144852",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc PFE moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during ...",
    "banner_image": "https://cdn.benzinga.com/files/top-view-green-weights-meter.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.122173,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390613",
        "ticker_sentiment_score": "0.201296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.158",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.693171",
        "ticker_sentiment_score": "0.065215",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? - Viking Therapeutics  ( NASDAQ:VKTX ) , Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) , Structure Therapeutics  ( NASDAQ:GPCR ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin",
    "time_published": "20240717T144740",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY, Novo Nordisk A/S NVO, Viking Therapeutics Inc VKTX, and Structure Therapeutics Inc GPCR stocks are trading lower on Wednesday. What happened? Earlier on Wednesday, Roche Holdings AG RHHBY announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.035589,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.088809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.516656",
        "ticker_sentiment_score": "0.215418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.073388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.088809",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer",
    "url": "https://www.zacks.com/stock/news/2303338/zacks-industry-outlook-eli-lilly-novo-nordisk-merck-and-pfizer",
    "time_published": "20240717T133600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221315,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.208824",
        "ticker_sentiment_score": "0.141258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.009986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.021124",
        "ticker_sentiment_score": "0.086404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.147044",
        "ticker_sentiment_score": "0.145458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.147044",
        "ticker_sentiment_score": "0.066643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' - Air Products & Chemicals  ( NYSE:APD ) , BJ's Wholesale Club  ( NYSE:BJ ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/07/39814553/jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there",
    "time_published": "20240717T125511",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Fortinet, Inc. FTNT is not his favorite. He added that we own Palo Alto Networks, Inc. PANW for the charitable trust. On July 11, Barclays analyst Saket Kalia maintained Fortinet with an Equal-Weight and lowered the price target from $75 to $70.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/17/Jim-Cramer-Photo-by-s-bukley-on-Shutters.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.267749,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SRPT",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.261891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "-0.106368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BJ",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.300068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LIN",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.043569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.045455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.300068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "-0.070204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APD",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.043569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "-0.061447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.402181",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.187308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.402181",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.333557",
        "ticker_sentiment_score": "0.082826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.012017",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche  ( RHHBY )  Reports Positive Phase I Data on Obesity Drug",
    "url": "https://www.zacks.com/stock/news/2303452/roche-rhhby-reports-positive-phase-i-data-on-obesity-drug",
    "time_published": "20240717T125200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.19265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.272933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.272933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks That You Can Buy and Hold for Years",
    "url": "https://www.fool.com/investing/2024/07/17/3-unstoppable-stocks-that-you-can-buy-and-hold-for/",
    "time_published": "20240717T121500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These blue chip stocks are leaders within their respective industries.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783385/a-couple-shaking-hands-with-an-advisor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.266252,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.370733",
        "ticker_sentiment_score": "0.292632",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.19589",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TKO",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.066838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.151875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.143631",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly, Novo Nordisk Fall On Rival's Weight-Loss Drug",
    "url": "https://www.investors.com/news/technology/eli-lilly-novo-nordisk-fall-roche-weight-loss-drug/",
    "time_published": "20240717T121000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) fell early Wednesday as Roche released positive early-stage data for its oral weight-loss drug. Roche's Genentech unit said its GLP-1 treatment CT-996 led to 6% weight loss within four weeks of a Phase 1 trial.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": -0.09579,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.23967",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.668568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.668568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.23967",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Alphabet Retreats To Near 50-Day Line. Is Google Stock A Buy Or Sell?",
    "url": "https://www.investors.com/news/technology/google-stock-buy-now-alphabet/",
    "time_published": "20240717T115500",
    "authors": [
      "Investor's Business Daily",
      "REINHARDT KRAUSE"
    ],
    "summary": "Cash Rich, Debt Light Alphabet Eyes Big Deals. Is Google Stock A Buy? Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/08/stock-Google-4-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.14412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.011519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.840693",
        "ticker_sentiment_score": "0.170607",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.030273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.030273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.018029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.059049",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.059049",
        "ticker_sentiment_score": "-0.038078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.049474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.059049",
        "ticker_sentiment_score": "-0.029053",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the SPDR S&P Pharmaceuticals ETF  ( XPH ) ?",
    "url": "https://www.zacks.com/stock/news/2303092/should-you-invest-in-the-spdr-sp-pharmaceuticals-etf-xph",
    "time_published": "20240717T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128831,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.062949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.031001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.062949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.123844",
        "ticker_sentiment_score": "0.062949",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39846742/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-s",
    "time_published": "20240718T185135",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70. RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/jnj-johnson-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.389788,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.102643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.190417",
        "ticker_sentiment_score": "0.182895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.52974",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? - Alcoa  ( NYSE:AA ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/07/39845998/vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-los",
    "time_published": "20240718T180528",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "It's another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index ( VIX ) , often referred to as the market's fear gauge, spiked over 10%, reaching levels last seen in late April.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Bull-and-bear-stock-market-index.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.061521,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.079457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.06853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.018315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.059696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.241445",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.06853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VIRT",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.040451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.446115",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly And Company Shares Thursday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39844030/whats-going-on-with-eli-lilly-and-company-shares-thursday",
    "time_published": "20240718T163256",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Eli Lilly and Company LLY stock is moving lower on Thursday on possible continued weakness after recent weight loss data from Roche. What To Know: On Wednesday, Roche announced positive Phase I data from its clinical trial in regards to CT-996, a once-daily oral pharmaceutical being developed for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": 0.190729,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.585052",
        "ticker_sentiment_score": "0.2066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva's Migraine Treatment Found Effective For Children As Young As 6 - Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6",
    "time_published": "20240718T160636",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Teva Pharmaceutical Industries Ltd TEVA announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy ( fremanezumab ) for the prevention of episodic migraine in children and adolescent patients aged 6-17.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Child-headache-migraine.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.215142,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.138785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.031183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The 5 Most Important Stocks to Watch During Q2 Earnings Season",
    "url": "https://www.zacks.com/stock/news/2304630/the-5-most-important-stocks-to-watch-during-q2-earnings-season",
    "time_published": "20240718T150300",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "All eyes will be on these 5 companies over the next few weeks. Will another beat add fuel to this already red-hot stock market?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9973"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.289877,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.076277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.541943",
        "ticker_sentiment_score": "0.355901",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.410105",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.162942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.403913",
        "ticker_sentiment_score": "0.465427",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data",
    "url": "https://www.zacks.com/stock/news/2304649/novo-nordisk-lilly-slide-on-roches-obesity-drug-study-data",
    "time_published": "20240718T142000",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.266741,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.317254",
        "ticker_sentiment_score": "0.246389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.181477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.181477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.050225",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.06515",
        "ticker_sentiment_score": "0.158294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.148104",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Eli Lilly Do a Stock Split in 2024?",
    "url": "https://www.fool.com/investing/2024/07/18/will-eli-lilly-do-a-stock-split-in-2024/",
    "time_published": "20240718T092300",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly hasn't done a stock split in decades.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783383/investor-pointing-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.897321"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.187722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMG",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "-0.031047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.360716",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "-0.031047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications - Eli Lilly and Co  ( NYSE:LLY ) , Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39864734/craze-for-ozempic-and-zepbound-for-weight-loss-leave-diabetic-patients-without-critical-glp-1-med",
    "time_published": "20240719T173211",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The skyrocketing demand for GLP-1 medications for weight loss is causing significant supply issues, often leaving type 2 diabetic patients without access to these critical drugs. GLP-1 receptor agonists are blockbuster drugs due to their dual role in managing type 2 diabetes and aiding in weight ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/ozempic-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.007251,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "-0.112491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.110976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "-0.112491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Viking  ( VKTX )  Stock be in Your Portfolio Pre-Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2305388/should-viking-vktx-stock-be-in-your-portfolio-pre-q2-earnings",
    "time_published": "20240719T135100",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.193825,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.086568",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.023257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.180056",
        "ticker_sentiment_score": "0.09935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.105402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.023257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.022187",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data",
    "url": "https://www.zacks.com/stock/news/2305154/pharma-stock-roundup-jnj-nvs-q2-earnings-rhhbys-positive-obesity-pill-data",
    "time_published": "20240719T132600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.143768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "-0.110727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.349153",
        "ticker_sentiment_score": "0.06668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2305089/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240719T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default341.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.224032,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.119797",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Stock Trades Higher On Friday - Here's Why - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39857064/eli-lillys-famed-weight-loss-drug-zepbound-scores-chinese-approval",
    "time_published": "20240719T112559",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, China's National Medical Products Administration ( NMPA ) approved Eli Lilly And Co LLY Tirzepatide for long-term weight management.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.053344,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.532941",
        "ticker_sentiment_score": "-0.106057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "-0.178711",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics a Millionaire-Maker?",
    "url": "https://www.fool.com/investing/2024/07/19/is-viking-therapeutics-a-millionaire-maker/",
    "time_published": "20240719T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This biotech stock fits the profile of a potentially big winner to a T.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783729/getty-happy-person-with-cash-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.108383,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.05056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.035",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Saving Just $10 Per Day for 30 Years Can Create a $1 Million Portfolio",
    "url": "https://www.fool.com/investing/2024/07/19/heres-how-saving-just-10-per-day-for-30-years-can/",
    "time_published": "20240719T094500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "If you can save money, finding a good investment to put that cash into won't be hard.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783399/rich-person-on-a-boat.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99992"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.34011,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.197425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia Recently Completed a 10-for-1 Stock Split: Here Are the 3 Likeliest Candidates to Become Wall Street's Next Stock-Split Stocks",
    "url": "https://www.fool.com/investing/2024/07/19/nvidia-recently-completed-a-10-for-1-stock-split/",
    "time_published": "20240719T090600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Roughly a dozen amazing companies have announced a stock split in 2024. Three high-flying stocks look like logical candidates to join this exclusive club.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783403%2Fstock-split-us-dollar-coin-certificate-forward-reverse-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.933642"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.175196,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "-0.010483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.095726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.243194",
        "ticker_sentiment_score": "0.145767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.030878",
        "ticker_sentiment_score": "-0.190605",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FICO",
        "relevance_score": "0.183662",
        "ticker_sentiment_score": "0.158498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.06171",
        "ticker_sentiment_score": "-0.054181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.030878",
        "ticker_sentiment_score": "0.038202",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?",
    "url": "https://www.fool.com/investing/2024/07/21/billionaires-are-buying-these-2-beaten-down-stocks/",
    "time_published": "20240721T093700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.",
    "banner_image": "https://media.ycharts.com/charts/4ee025a853ba95e999d7e1d530de2244.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.160502,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.012659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABCL",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FATE",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.19758",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.098994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Advances But Underperforms Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2306385/eli-lilly-lly-advances-but-underperforms-market-key-facts",
    "time_published": "20240722T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default308.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.198998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.264188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39891746/bidens-exit-from-presidential-race-yet-another-curveball-for-equity-investors-analysts",
    "time_published": "20240722T185441",
    "authors": [
      "Michael Juliano"
    ],
    "summary": "President Joe Biden's decision on Sunday to drop his bid for a second term in the White House was \"yet another curveball for equity investors,\" according to RBC Capital Markets analyst Lori Calvasina.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/Fueling-Up.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.107802,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "-0.311435",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.22263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.262705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.394509",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "-0.484568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.204802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst - AnaptysBio  ( NASDAQ:ANAB ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal",
    "time_published": "20240722T185308",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/ANAB.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.193296,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "-0.005196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.178387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.230952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment",
    "url": "https://www.zacks.com/stock/news/2306321/etfs-in-focus-as-competition-heats-up-in-weight-loss-drug-segment",
    "time_published": "20240722T180900",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972476"
      }
    ],
    "overall_sentiment_score": -0.016894,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.359881",
        "ticker_sentiment_score": "0.176651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.118513",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39890609/oral-weight-loss-drugs-vs-injections-pills-are-promising-yet-challenging-frontier",
    "time_published": "20240722T174206",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG RHHBY, Eli Lilly And Co LLY, Novo Nordisk A/S NVO, and Pfizer Inc PFE strive to create alternatives to injectable drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/22/ozempic-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.201875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.184778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.056547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.184778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.",
    "url": "https://www.fool.com/investing/2024/07/22/missed-out-on-eli-lilly-these-2-healthcare-stocks/",
    "time_published": "20240722T132000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783974/two-scientists-smile-at-lab-bench-while-holding-sample.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.215761,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.173645",
        "ticker_sentiment_score": "0.167818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.130689",
        "ticker_sentiment_score": "0.034481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.173645",
        "ticker_sentiment_score": "0.160377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.076304",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2305775/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240722T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.234733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.12575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.064229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39907670/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20240723T134658",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 15 unusual trades. Delving into the details, we found 26% of traders were bullish, while 33% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721742415_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.014474,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.785534",
        "ticker_sentiment_score": "-0.043984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.082393",
        "ticker_sentiment_score": "-0.118494",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Time for Healthcare ETFs?",
    "url": "https://www.zacks.com/stock/news/2306667/time-for-healthcare-etfs",
    "time_published": "20240723T125100",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default151.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.279458,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.068617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.068617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?",
    "url": "https://www.fool.com/investing/2024/07/23/look-out-eli-lilly-and-novo-nordisk-roches-obesity/",
    "time_published": "20240723T094800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784123/scales-feet-tape-measure.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.166524,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.464844",
        "ticker_sentiment_score": "0.309865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.464844",
        "ticker_sentiment_score": "0.309865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2308035/what-lies-in-store-for-healthcare-etfs-in-q2-earnings",
    "time_published": "20240724T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.169447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.052088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.016864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.082674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.142692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.007802",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39927535/novo-nordisks-stock-dips-in-pre-market-despite-winning-uks-approval-of-weight-loss-drug-whats-goi",
    "time_published": "20240724T105733",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In Wednesday's pre-market trading, shares of Novo Nordisk A/S NVO are witnessing a fall after the U.K.'s Medicines and Healthcare products Regulatory Agency ( MHRA ) approved a new indication for Novo Nordisk's semaglutide, Wegovy, to reduce the risk of heart complications or strokes in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/24/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.124379,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.198221",
        "ticker_sentiment_score": "-0.103092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.469744",
        "ticker_sentiment_score": "0.186494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.198221",
        "ticker_sentiment_score": "-0.103092",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years",
    "url": "https://www.fool.com/investing/2024/07/24/3-dividend-growth-stocks-that-have-doubled-their-p/",
    "time_published": "20240724T103900",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Their yields may seem low, but these stocks have been growing their dividend payments at a fast pace.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784051/a-couple-reviewing-a-statement.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.348953,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.2589",
        "ticker_sentiment_score": "0.265939",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "0.449581",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "0.314766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is SPDR S&P Pharmaceuticals ETF  ( XPH )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2307474/is-spdr-sp-pharmaceuticals-etf-xph-a-strong-etf-right-now",
    "time_published": "20240724T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default74.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999953"
      }
    ],
    "overall_sentiment_score": 0.206646,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.055623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.108828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.055623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.055623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today",
    "url": "https://www.fool.com/investing/2024/07/24/if-youd-invested-10000-in-eli-lilly-stock-5-years/",
    "time_published": "20240724T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Could today's momentum continue?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784151%2Fdoctors-white-coat-healthcare.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.340406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.06635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.742397",
        "ticker_sentiment_score": "0.539549",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.06635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Weight Loss Drug Developer Stocks Tumbled on Thursday",
    "url": "https://www.fool.com/investing/2024/07/25/why-weight-loss-drug-developer-stocks-tumbled-on-t/",
    "time_published": "20240725T230606",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784705/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.149914,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.642187",
        "ticker_sentiment_score": "0.240735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.116876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.333862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Shares Decline Amid Competitive Pressure - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39970646/novo-nordisk-shares-decline-amid-competitive-pressure",
    "time_published": "20240725T202521",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Novo Nordisk A/S Common Stock NVO experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. VKTX. What To Know: Viking Therapeutics announced the company has advanced its obesity candidate VK2735 into late-stage trials.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.112337,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.221664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.55533",
        "ticker_sentiment_score": "0.226754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.873652",
        "ticker_sentiment_score": "0.062815",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly and Company Shares Are Moving Lower On Thursday - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/39965143/why-eli-lilly-and-company-shares-are-moving-lower-on-thursday",
    "time_published": "20240725T164915",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Eli Lilly and Company LLY stock is trading lower on Thursday after Viking Therapeutics, Inc. VKTX announced the advancement of its novel treatment for obesity, VK2735. The Details: Viking is advancing the injectable form of VK2735 to Phase 3 after receiving written feedback from an FDA Type C ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/25/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.185151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "0.152841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.009975",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39960766/heres-how-much-you-would-have-made-owning-eli-lilly-and-co-stock-in-the-last-15-years",
    "time_published": "20240725T143022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly and Co LLY has outperformed the market over the past 15 years by 11.36% on an annualized basis producing an average annual return of 23.33%. Currently, Eli Lilly and Co has a market capitalization of $730.31 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721917819_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.229957,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.949596",
        "ticker_sentiment_score": "0.358087",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected - AbbVie  ( NYSE:ABBV ) , Axsome Therapeutics  ( NASDAQ:AXSM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39956575/global-fibromyalgia-treatment-market-projected-to-reach-3-86-billion-by-2031-as-positive-growth-tr",
    "time_published": "20240725T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., July 25, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this ...",
    "banner_image": "https://ml.globenewswire.com/media/f326183f-8829-42af-8851-525b1d7503ed/small/finacialnews-logo-final-01-2-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.993856"
      }
    ],
    "overall_sentiment_score": 0.103598,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "-0.016712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.030218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.071552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.077694",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the First Trust Health Care AlphaDEX ETF  ( FXH ) ?",
    "url": "https://www.zacks.com/stock/news/2308497/should-you-invest-in-the-first-trust-health-care-alphadex-etf-fxh",
    "time_published": "20240725T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.284192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.063349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRA",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.063349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.063349",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE )  Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline",
    "url": "https://www.zacks.com/stock/news/2308514/pfizer-pfe-gains-73-in-2024-on-its-weigh-loss-drug-pipeline",
    "time_published": "20240725T094900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/2257.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.06152,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "0.139623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.700945",
        "ticker_sentiment_score": "0.124358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH - Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/news/24/07/39950408/elon-musk-agrees-with-former-executive-who-thinks-everyone-has-strong-opinions-on-tesla-unlike-in-th",
    "time_published": "20240725T074508",
    "authors": [
      "Anan Ashraf"
    ],
    "summary": "Investors have a strong opinion on Tesla Inc. TSLA unlike other companies such as LVMH Mo\u00ebt Hennessy Louis Vuitton SE LVMHF or Eli Lilly and Co LLY, former Tesla Investor Relations head Martin Viecha said on Wednesday and company CEO Elon Musk agrees.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/25/Tesla-logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.145423,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.020033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.269455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly's Stock in a Bubble?",
    "url": "https://www.zacks.com/stock/news/2310243/is-eli-lillys-stock-in-a-bubble",
    "time_published": "20240726T161100",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.042982,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.620083",
        "ticker_sentiment_score": "-0.010796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "-0.138701",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39986767/analyzing-eli-lilly-and-co-in-comparison-to-competitors-in-pharmaceuticals-industry",
    "time_published": "20240726T150013",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722006010_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.203115,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.517168",
        "ticker_sentiment_score": "0.294437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Biogen Stock Trading Lower On Friday? - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39985709/biogeneisais-alzheimers-drug-leqembi-gets-no-go-from-european-drug-regulators-advisory-panel-cite",
    "time_published": "20240726T142100",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) adopted a negative opinion on the approval of Eisai Co., Ltd ESALY ESALF and Biogen Inc.'s BIIB lecanemab.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/26/medical-bottles-syringe-seen-biogen-logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.09137,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.378166",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.709611",
        "ticker_sentiment_score": "-0.10792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "-0.034724",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in Novo Nordisk  ( NVO )  Ahead of Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2310035/should-you-invest-in-novo-nordisk-nvo-ahead-of-q2-earnings",
    "time_published": "20240726T125500",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/57943.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999858"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.306721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.230537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.247561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.427425",
        "ticker_sentiment_score": "0.438799",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Is What Eli Lilly Stock Will Do Next",
    "url": "https://www.fool.com/investing/2024/07/26/prediction-this-is-what-eli-lilly-stock-will-do/",
    "time_published": "20240726T114500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784274%2Fgettyimages-1978065812.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.232982,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.61135",
        "ticker_sentiment_score": "0.416174",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.08747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.08747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.08747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "-0.06371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.08747",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/07/27/novo-nordisks-next-gen-diabetes-candidate-could-ch/",
    "time_published": "20240727T150500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company should maintain its lead in this growing area.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783838/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.283158,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.061003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.518708",
        "ticker_sentiment_score": "0.280929",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 2 Growth Stocks Are Set to Soar This Summer and Beyond",
    "url": "https://www.fool.com/investing/2024/07/27/these-2-growth-stocks-are-set-to-soar-this-summer/",
    "time_published": "20240727T121500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "It's a great time to invest in wonderful stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784334/woman-finance-calculator-laptop-notebook.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.217682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.155497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.391645",
        "ticker_sentiment_score": "0.162087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bull Market Buys: 2 Growth Stocks to Own for the Long Run",
    "url": "https://www.fool.com/investing/2024/07/27/bull-market-buys-2-growth-stocks-to-own-for-the/",
    "time_published": "20240727T111500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies are no strangers to beating the market.",
    "banner_image": "https://media.ycharts.com/charts/796d5ec30bcaa8ef406477cc309666b0.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.26283,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.445352",
        "ticker_sentiment_score": "0.36374",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.077383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.116889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Calling All Morphic Holding, Inc.  ( MORF )  Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses - Morphic Holding  ( NASDAQ:MORF ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g40001866/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-gewirtz-grossman-llc-to-claim-you",
    "time_published": "20240728T200000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, July 28, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ( \"Morphic\" ) MORF and Eli Lilly and Company ( \"Eli Lilly\" ) LLY. Investors who purchased Morphic and continue to hold to the present ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.118023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.103711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.820009",
        "ticker_sentiment_score": "0.302412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Home Depot Stock Turned $1,000 Into $17.5 Million, and One of Its Founders Just Revealed His Investing Secrets to Achieve Generational Wealth",
    "url": "https://www.fool.com/investing/2024/07/28/home-depot-stock-turned-1000-into-175-million-and/",
    "time_published": "20240728T130600",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Home Depot founder Ken Langone recently shared his investment wisdom on the American Optimist podcast.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784466%2Fgetty-focus-on-the-long-term-planning-patience-diligence-goals-retirement-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.299257,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.381463",
        "ticker_sentiment_score": "0.314662",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.244354",
        "ticker_sentiment_score": "0.187884",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/07/28/is-eli-lilly-stock-a-buy/",
    "time_published": "20240728T085500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "The stock is up 250% in three years on growth in GLP-1 medications.",
    "banner_image": "https://media.ycharts.com/charts/17d004bce79956a5f807eb1e794b6e1e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      }
    ],
    "overall_sentiment_score": 0.256102,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.458799",
        "ticker_sentiment_score": "0.399481",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2311334/eli-lilly-lly-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240729T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $807.79, indicating a +0.39% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default48.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.133092,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.214088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/40014415/unpacking-the-latest-options-trading-trends-in-eli-lilly-and-co",
    "time_published": "20240729T144635",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 51 trades. If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722264392_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.107088,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.84827",
        "ticker_sentiment_score": "0.147589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.103989",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.103989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/07/29/what-will-be-the-best-weight-loss-drug-stock-2030/",
    "time_published": "20240729T132000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's reason to believe that one of these two players will eventually win.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783278/a-young-scientist-recording-her-findings-on-a-tablet.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.17958,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.268786",
        "ticker_sentiment_score": "0.13338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.268786",
        "ticker_sentiment_score": "0.126106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?",
    "url": "https://www.fool.com/investing/2024/07/29/weight-loss-drug-stocks-just-took-a-hit-should-you/",
    "time_published": "20240729T113000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Roche's latest breakthrough could be a game changer, but it's still too early to say.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784432/chart-reflected-on-investor-glasses.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.198686,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.147852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.121016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "-0.049863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.11568",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.147852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: LLY and NVO",
    "url": "https://www.zacks.com/stock/news/2310465/zacks-market-edge-highlights-lly-and-nvo",
    "time_published": "20240729T092400",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "LLY and NVO have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.099538,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.511256",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "-0.122068",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.",
    "url": "https://www.fool.com/investing/2024/07/29/this-biotech-stock-is-crushing-nvidia/",
    "time_published": "20240729T082000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Should you get in on this stock now?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784762%2Fgettyimages-1172040755.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.251835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.090895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.391923",
        "ticker_sentiment_score": "0.424944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.058322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.090895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.090895",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Today? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/07/40053808/whats-going-on-with-eli-lilly-today",
    "time_published": "20240730T212805",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Eli Lilly & Co LLY shares are trading lower Tuesday. Here's what you need to know. What To Know: The company is set to report its second-quarter earnings on Aug. 8. The upcoming earnings report is expected to show EPS of $2.70 and revenue of $9.949 billion.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/30151759/LLY-2.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.597525",
        "ticker_sentiment_score": "0.294687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.185933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Incyte's  ( INCY )  Q2 Earnings Lag Estimates, Revenues Top",
    "url": "https://www.zacks.com/stock/news/2312126/incytes-incy-q2-earnings-lag-estimates-revenues-top",
    "time_published": "20240730T140700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.173799,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.17813",
        "ticker_sentiment_score": "0.051223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.273188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.213905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.217773",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/40038875/this-is-what-whales-are-betting-on-eli-lilly-and-co",
    "time_published": "20240730T134550",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 20 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722347147_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106915,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.837089",
        "ticker_sentiment_score": "0.094002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "-0.095472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "-0.095472",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Q2 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2311559/merck-mrk-q2-earnings-and-revenues-top-estimates",
    "time_published": "20240730T114007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default198.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.159566,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Weight Loss Pharma Stock to Buy, and 1 to Consider",
    "url": "https://www.fool.com/investing/2024/07/30/1-weight-loss-pharma-stock-to-buy-1-to-consider/",
    "time_published": "20240730T110700",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's more than one type of worthy opportunity in this space.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783281/investor-ponders-phone-and-laptop-stock-charts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.190778,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.264897",
        "ticker_sentiment_score": "0.235217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.214494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2311499/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20240730T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.210296,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.088211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.070304",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?",
    "url": "https://www.fool.com/investing/2024/07/30/dexcom-stock-plunged-eli-lilly-novo-nordisk/",
    "time_published": "20240730T094800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785036/diabetes-cgm-man-in-wheelchair.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.009701,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.056535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.091966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.019978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.056535",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF? - Johnson & Johnson  ( NYSE:JNJ ) , iShares Global Healthcare ETF  ( ARCA:IXJ ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/07/40064785/should-you-invest-in-the-health-care-select-sector-spdr-etf",
    "time_published": "20240731T184825",
    "authors": [
      "Zacks"
    ],
    "summary": "Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Health Care Select Sector SPDR ETF XLV, a passively managed exchange traded fund launched on 12/16/1998.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/31/clay-banks-cezmop5ftv4-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.323143,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.147857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.089138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.097968",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2312779/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
    "time_published": "20240731T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.246161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.133767",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2312590/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20240731T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.296331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.127413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.089064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.063863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is First Trust Health Care AlphaDEX ETF  ( FXH )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2312597/is-first-trust-health-care-alphadex-etf-fxh-a-strong-etf-right-now",
    "time_published": "20240731T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default212.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999953"
      }
    ],
    "overall_sentiment_score": 0.384467,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.060201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRA",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.060201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.060201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Trounced the Market on Thursday",
    "url": "https://www.fool.com/investing/2024/08/01/why-eli-lilly-stock-trounced-the-market-on-thursda/",
    "time_published": "20240801T223501",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "What's good for Zepbound is good for the company, it seems.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785636/stethescope-atop-us-currency-and-coins.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.172079,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410059",
        "ticker_sentiment_score": "0.257372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.036372",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "url": "https://www.zacks.com/stock/news/2314332/eli-lilly-lly-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
    "time_published": "20240801T140114",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.157097,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.3007",
        "ticker_sentiment_score": "0.059967",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher On Thursday? - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40102279/eli-lillys-popular-weight-lossdiabetes-drug-tirzepatide-cuts-heart-failure-risk-by-38-pivotal-pha",
    "time_published": "20240801T134508",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Eli Lilly and Company LLY released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection ( 5 mg, 10 mg, or 15 mg ) in adults with heart failure with preserved ejection fraction ( HFpEF ) and obesity.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/01/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.088808,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.406197",
        "ticker_sentiment_score": "0.115459",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer Just Confirmed It's a Dividend Investor's Dream Stock",
    "url": "https://www.fool.com/investing/2024/08/01/pfizer-confirmed-dividend-investors-dream-stock/",
    "time_published": "20240801T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785266/pfizer_logo_on_glass_pfe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.318666,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.211792",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.118024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.211792",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.684845",
        "ticker_sentiment_score": "0.49371",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening",
    "url": "https://www.fool.com/investing/2024/08/01/pfizer-to-buy-a-glp-1-drugmaker-heres-why-you-shou/",
    "time_published": "20240801T082000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term.",
    "banner_image": "https://media.ycharts.com/charts/e0ce946b8ad486197d7378c66adb3cdb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.214437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.105828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.132976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.105828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.327564",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Calling All Morphic Holding, Inc.  ( MORF )  Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses - Morphic Holding  ( NASDAQ:MORF ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40140938/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-gewirtz-grossman-llc-to-claim-you",
    "time_published": "20240802T200000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ( \"Morphic\" ) MORF and Eli Lilly and Company ( \"Eli Lilly\" ) LLY. Investors who purchased Morphic and continue to hold to the present ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.118023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.103711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.820009",
        "ticker_sentiment_score": "0.302412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40136397/using-weight-loss-medications-such-as-wegovy-zepbound-psychologist-warns-of-linked-eating-disorde",
    "time_published": "20240802T163122",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Over the past six months, psychologist Tom Hildebrandt has seen a surge in patients with eating disorders who are using popular weight loss drugs like Novo Nordisk A/S' NVO Wegovy ( semaglutide ) or Eli Lilly And Co's LLY Zepbound ( Tirzepatide ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/02/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.215946,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.016291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.181137",
        "ticker_sentiment_score": "0.016291",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities - ResMed  ( NYSE:RMD ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40133504/resmed-earnings-reflect-increased-demand-for-sleep-devices-performance-indicates-po",
    "time_published": "20240802T144626",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion. The growth was driven by increased demand for sleep devices and masks portfolio and strong growth across Software as a ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/02/ResMed---logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.310554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "-0.040729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly and Company Shares Friday - Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40133292/whats-going-on-with-eli-lilly-and-company-shares-friday",
    "time_published": "20240802T143942",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Eli Lilly and Company LLY stock is trading lower on Friday. The company is anticipated to release earnings on Aug. 8 for the 2024 fiscal year second quarter. Also, Eli Lilly announced promising results from its SUMMIT phase 3 clinical trial earlier this week.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/02/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.01981,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "-0.064028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Aug 2, 2024",
    "url": "https://www.zacks.com/stock/news/2315020/company-news-for-aug-2-2024",
    "time_published": "20240802T124800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article Are: LLY,MGM,SO and TRP ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2c/68763.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.012483,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.181803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MGM",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.321868",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TRP",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.481028",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.106642",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Could Be Amgen's Next Massive Growth Opportunity",
    "url": "https://www.fool.com/investing/2024/08/02/prediction-this-could-be-amgen-stocks-next-massive/",
    "time_published": "20240802T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The innovative biotech is looking for its next blockbuster.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784305/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.332323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.258659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.57877",
        "ticker_sentiment_score": "0.415944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.258659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.",
    "url": "https://www.fool.com/investing/2024/08/02/are-eli-lilly-and-novo-nordisk-too-expensive-for/",
    "time_published": "20240802T113000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784833%2Fgettyimages-1498947160.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.202733,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.278662",
        "ticker_sentiment_score": "0.192437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.187949",
        "ticker_sentiment_score": "0.010785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.111063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.157073",
        "ticker_sentiment_score": "0.115409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.218535",
        "ticker_sentiment_score": "0.150786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug",
    "url": "https://www.fool.com/investing/2024/08/03/eli-lilly-vs-novo-nordisk-a-recent-study-suggests/",
    "time_published": "20240803T102000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784782/weight-loss-pills-with-measuring-tape.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.225302,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.542261",
        "ticker_sentiment_score": "0.258336",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.396798",
        "ticker_sentiment_score": "0.189059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is This Decision by Pfizer Bad News for Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/08/03/is-this-decision-by-pfizer-bad-news-for-eli-lilly/",
    "time_published": "20240803T081000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly's revenue gains have helped its stock to roar higher.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785370%2Fgettyimages-1292931102.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.150152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.752508",
        "ticker_sentiment_score": "0.229261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.070374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.228716",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here are 4 things we're watching closely in the stock market this week",
    "url": "https://www.cnbc.com/2024/08/04/here-are-4-things-were-watching-closely-in-the-stock-market-this-week.html",
    "time_published": "20240804T135944",
    "authors": [],
    "summary": "Expect earnings reports, and CEO commentaries, to drive the market action.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.007224,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APP",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROAD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.082582",
        "ticker_sentiment_score": "0.004136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLW",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.090183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPW",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPST",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARRY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZI",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERJ",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RKLB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCRX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APPS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEDG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSCR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GXO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNUT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRON",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VFC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PZZA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.054424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLSK",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MNKD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASPN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNMF",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.004759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.054424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LUMN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOUN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKLA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.082582",
        "ticker_sentiment_score": "0.090235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUK",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLNT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRPT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LCID",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGNI",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GCT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Simple ETFs Could Turn $500 a Month Into $1 Million.",
    "url": "https://www.fool.com/investing/2024/08/04/these-2-simple-etfs-could-turn-500-a-month-into-1/",
    "time_published": "20240804T111600",
    "authors": [
      "Jake Lerch"
    ],
    "summary": "Learn how $500 a month can grow into a sizable nest egg.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784861%2Fjar-full-of-dollar-bills-money-savings.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99986"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.281974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.054997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.054997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.231087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "-0.006001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?",
    "url": "https://www.fool.com/investing/2024/08/04/eli-lilly-a-buy-now/",
    "time_published": "20240804T092600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785688/investor-charts-closeup-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.063433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.470606",
        "ticker_sentiment_score": "0.175086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "-0.081967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "0.029852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40165692/eli-lillys-zepbound-challenges-novo-nordisks-wegovy-amid-supply-issues",
    "time_published": "20240805T155928",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Company's LLY weight-loss drug, Zepbound ( tirzepatide ) , is gaining traction in the U.S., rivaling Novo Nordisk A/S's NVO Wegovy ( semaglutide ) . Due to ongoing supply issues, some doctors are prioritizing availability when prescribing these medications.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/05/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235061,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.278118",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.32511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2316241/will-these-5-medical-stocks-surpass-q2-earnings-forecasts",
    "time_published": "20240805T153600",
    "authors": [
      "Kanishka Das"
    ],
    "summary": "Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.203258,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.038677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.278618",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.210884",
        "ticker_sentiment_score": "0.050423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "-0.009196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.126514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40163393/after-ozempic-and-botox-hollywood-is-going-gaga-over-this-new-anti-aging-supplement",
    "time_published": "20240805T144309",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "NAD+ boosters are the new anti-aging trend in Hollywood, taking over from Ozempic and Botox in high-end wellness regimens.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/05/Woman-Beats-Bryan-Johnson-In-Anti-Aging-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.325577,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.191491",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.191491",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Decoding Eli Lilly's Options Activity: What's the Big Picture? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40161870/decoding-eli-lillys-options-activity-whats-the-big-picture",
    "time_published": "20240805T141625",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 14 unusual trades. Delving into the details, we found 42% of traders were bullish, while 42% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722867381_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.072335,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.786972",
        "ticker_sentiment_score": "-0.040297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "-0.115148",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy, Sell or Hold Lilly  ( LLY )  Ahead of Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2316000/should-you-buy-sell-or-hold-lilly-lly-ahead-of-q2-earnings",
    "time_published": "20240805T133600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995869"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.280482,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.50235",
        "ticker_sentiment_score": "0.47047",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.19729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.107661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "url": "https://www.zacks.com/stock/news/2315866/lilly-lly-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures",
    "time_published": "20240805T131611",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default307.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.097131,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.338119",
        "ticker_sentiment_score": "0.173347",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy Eli Lilly Before Aug. 8?",
    "url": "https://www.fool.com/investing/2024/08/05/should-you-buy-eli-lilly-before-aug-8/",
    "time_published": "20240805T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "There's reason to be optimistic about what's to come.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785523%2Fgettyimages-1134003590.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999816"
      }
    ],
    "overall_sentiment_score": 0.206088,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.533481",
        "ticker_sentiment_score": "0.21543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.01301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.098019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.01301",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  & Novo Nordisk  ( NVO )  Earnings: A Closer Look",
    "url": "https://www.zacks.com/stock/news/2317485/eli-lilly-lly-novo-nordisk-nvo-earnings-a-closer-look",
    "time_published": "20240806T222900",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.265974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.427184",
        "ticker_sentiment_score": "0.03446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.264897",
        "ticker_sentiment_score": "-0.071514",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Mounjaro & Zepbound Drive Eli Lilly  ( LLY )  Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2317100/can-mounjaro-zepbound-drive-eli-lilly-lly-q2-earnings",
    "time_published": "20240806T140900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.157621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489057",
        "ticker_sentiment_score": "0.221341",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.059774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.231544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years",
    "url": "https://www.fool.com/investing/2024/08/06/prediction-this-will-be-the-best-pharmaceutical/",
    "time_published": "20240806T135300",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly is one of the most innovative pharmaceutical companies right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785581%2Fgettyimages-1978065812-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.321907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.606834",
        "ticker_sentiment_score": "0.512614",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.051659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.051659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.142897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "National Fuel Gas and Landstar System Industries have been highlighted as Zacks Bull and Bear of the Day",
    "url": "https://www.zacks.com/stock/news/2316944/national-fuel-gas-and-landstar-system-industries-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
    "time_published": "20240806T133600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - August 6, 2024 - Zacks Equity Research shares National Fuel Gas Company's ( NFG Quick QuoteNFG - ) as the Bull of the Day and Landstar System ( LSTR Quick QuoteLSTR - ) asthe Bear of the Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/1083.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.133989,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BYDDF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.053624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSTR",
        "relevance_score": "0.040645",
        "ticker_sentiment_score": "-0.091433",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.013553",
        "ticker_sentiment_score": "0.181425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.118681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.118681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.067689",
        "ticker_sentiment_score": "0.123519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.074006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYDDY",
        "relevance_score": "0.040645",
        "ticker_sentiment_score": "0.009758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "-0.06195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFG",
        "relevance_score": "0.121513",
        "ticker_sentiment_score": "0.201272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Value Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/08/06/prediction-these-could-be-the-best-performing-valu/",
    "time_published": "20240806T093400",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These tried-and-true businesses can deliver returns to investors for many years to come.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785275/stocks-investing-financial-empowerment.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.22956,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.245693",
        "ticker_sentiment_score": "0.213345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.108312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.312599",
        "ticker_sentiment_score": "0.178864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly: Bearish Signals Loom Over Zepbound Manufacturer Ahead Of Q2 Earnings - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/health-care/24/08/40231406/eli-lilly-bearish-signals-loom-over-weight-loss-stock-ahead-of-q2-earnings",
    "time_published": "20240807T192824",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours. The stock is up 69% over the past year, and has gained 30% YTD.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/07140547/Screenshot-2024-08-07-at-11.32.23-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.028788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.839046",
        "ticker_sentiment_score": "-0.056971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly And Company Shares Wednesday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/08/40227163/whats-going-on-with-eli-lilly-and-company-shares-wednesday",
    "time_published": "20240807T162244",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Eli Lilly And Company LLY stock is trading lower on Wednesday. The company is anticipated to release 2024 fiscal year earnings on Thursday before the market opens. What To Know: Analyst estimates EPS of $2.70 and sales of $9.94 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/Eli-Lilly_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.191657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.776097",
        "ticker_sentiment_score": "0.10329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.167069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Down Despite Q2 Earnings & Sales Beat",
    "url": "https://www.zacks.com/stock/news/2318113/amgen-amgn-stock-down-despite-q2-earnings-sales-beat",
    "time_published": "20240807T135500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.127984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.057284",
        "ticker_sentiment_score": "0.051998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.482178",
        "ticker_sentiment_score": "0.207457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.266893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.057284",
        "ticker_sentiment_score": "0.051998",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40221288/how-to-earn-500-a-month-from-eli-lilly-stock-ahead-of-q2-earnings",
    "time_published": "20240807T132625",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8. Analysts expect the Indianapolis-based company to report quarterly earnings at $2.60 per share, up from $2.11 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.779048"
      }
    ],
    "overall_sentiment_score": 0.190871,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.689652",
        "ticker_sentiment_score": "0.382264",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?",
    "url": "https://www.fool.com/investing/2024/08/07/is-it-too-late-to-buy-novo-nordisk-stock-after-its/",
    "time_published": "20240807T104000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785577%2Fgettyimages-1665778558.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.302093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "-0.011009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.06532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.677751",
        "ticker_sentiment_score": "0.605931",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Three Stocks: Palantir, Eli Lilly, and Lumen Technologies",
    "url": "https://moneymorning.com/2024/08/08/three-stocks-palantir-eli-lilly-and-lumen-technologies/",
    "time_published": "20240808T210108",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "Palantir As if they needed it, Palantir ( PLTR ) announced this morning that the company has expanded their relationship with another AI leading company. The company announced an expansion of the existing partnership with Microsoft to bring some of the most sophisticated and secure cloud, AI, and ...",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/08/pexels-markusspiske-225769-1200x800.jpg",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.22198,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.240259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.144306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUMN",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.009224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "-0.077618",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q2 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/08/08/eli-lilly-lly-q2-2024-earnings-call-transcript/",
    "time_published": "20240808T210021",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "LLY earnings call for the period ending June 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.23493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.012432",
        "ticker_sentiment_score": "-0.003482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.097557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.008288",
        "ticker_sentiment_score": "-0.016345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "-0.034382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.130419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.072099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.067848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.004144",
        "ticker_sentiment_score": "0.02958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly: The Next $1 Trillion Market Cap Stock?",
    "url": "https://www.zacks.com/commentary/2319475/eli-lilly-the-next-1-trillion-market-cap-stock",
    "time_published": "20240808T172900",
    "authors": [
      "Ethan Feller"
    ],
    "summary": "Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999862"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.369497,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.655534",
        "ticker_sentiment_score": "0.524655",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.320121",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.294682",
        "ticker_sentiment_score": "0.266737",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jumps Over 500 Points; Eli Lilly Posts Upbeat Earnings - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40259926/dow-jumps-over-500-points-eli-lilly-posts-upbeat-earnings",
    "time_published": "20240808T160632",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 500 points on Thursday. The Dow traded up 1.40% to 39,307.07 while the NASDAQ rose 2.14% to 16,543.06. The S&P 500 also rose, gaining, 1.79% to 5,292.43. Information technology shares climbed by 1.6% on Thursday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/Bull-Wall-Street_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.193686,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GVP",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.400653",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.249531",
        "ticker_sentiment_score": "0.211904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VSAT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.47663",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMBL",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.053464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDLX",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.185537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OM",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.115137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Sealed Air  ( NYSE:SEE ) ",
    "url": "https://www.benzinga.com/news/24/08/40257600/parker-hannifin-posts-upbeat-earnings-joins-under-armour-zillow-group-yeti-holdings-eli-lilly-and-ot",
    "time_published": "20240808T150943",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were higher, with the Dow Jones index gaining over 1% on Thursday. Shares of Parker-Hannifin Corporation PH rose sharply during Thursday's session following better-than-expected fourth-quarter financial results and upbeat FY25 guidance.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/movers-image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999917"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.544135,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXGN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.463147",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVMI",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.344467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FWRD",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.337765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YETI",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.411825",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ICUI",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.368459",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UA",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.337765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BOOT",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.324314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LESL",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.344467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SEE",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.337765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COMM",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.324314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DCGO",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.344467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.318916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.488185",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VSAT",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.480749",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.368276",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.324314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLNE",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.337765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.3547",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q2 Earnings Top, Mounjaro, Zepbound Drive View",
    "url": "https://www.zacks.com/stock/news/2319330/eli-lilly-lly-q2-earnings-top-mounjaro-zepbound-drive-view",
    "time_published": "20240808T145300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.251722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.441059",
        "ticker_sentiment_score": "0.393029",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.093047",
        "ticker_sentiment_score": "0.036684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.093047",
        "ticker_sentiment_score": "0.084616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.045296",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Continuing Claims Hit Highest Since Nov 2021",
    "url": "https://www.zacks.com/stock/news/2319303/continuing-claims-hit-highest-since-nov-2021",
    "time_published": "20240808T142900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Continuing Claims Hit Highest Since Nov ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/47493.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.088904,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "QSR",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.105725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.028427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YETI",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.044866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.049385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DBX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jobless Claims Decline, Pre-Markets in the Green",
    "url": "https://www.zacks.com/stock/news/2319299/jobless-claims-decline-pre-markets-in-the-green",
    "time_published": "20240808T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/be/54779.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.083911,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "QSR",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.115211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.0312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YETI",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.048347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.047423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DBX",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Surging On Thursday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40251130/mounjaro-maker-eli-lillys-bumper-q2-earnings-exceeds-estimates-hikes-outlook-again-on-strong-diab",
    "time_published": "20240808T122557",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Eli Lilly And Co LLY reported second-quarter revenue of $11.3 billion, up 36% year over year, easily surpassing the consensus of $9.95 billion. The increase was driven by a 27% increase in volume and a 10% increase due to higher realized prices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.298711,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.465012",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Surpasses Q2 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2318864/eli-lilly-lly-surpasses-q2-earnings-and-revenue-estimates",
    "time_published": "20240808T115505",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.168723,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.207252",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRPH",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bears Betting Against Nvidia And Eli Lilly For 'Easy Money,' Says Jim Cramer: 'Those Are The Two Keys To This Market And Don't You Know It' - Apple  ( NASDAQ:AAPL ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/08/40245839/bears-betting-against-nvidia-and-eli-lilly-for-easy-money-says-jim-cramer-those-are-the-two-keys-to",
    "time_published": "20240808T101153",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Jim Cramer has issued a warning about the bearish pressure on Nvidia Corp. NVDA and Eli Lilly and Co LLY, stating that these two companies are crucial to the market's performance. What Happened: Cramer, the host of CNBC's \"Mad Money,\" took to social media platform X to highlight the increased ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/Jim-Cramer-Photo-by-s-bukley-on-Shutters_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.012142,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "-0.163922",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.028925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.110877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "-0.154703",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "US Stocks Decline As SMCI's Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In 'Extreme Fear' Zone - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40243140/us-stocks-decline-as-smcis-margin-miss-brings-nvidia-and-other-ai-stocks-under-pressure-investor-se",
    "time_published": "20240808T065822",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the \"Extreme Fear\" zone on Wednesday. U.S. stocks settled lower on Wednesday, after recording gains earlier during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.249959,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.101234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.073248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.101234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.401235",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "USFD",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly, US Foods And 3 Stocks To Watch Heading Into Thursday - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40242779/eli-lilly-us-foods-and-3-stocks-to-watch-heading-into-thursday",
    "time_published": "20240808T062632",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading mixed this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Eli Lilly and Company LLY to report quarterly earnings at $2.70 per share on revenue of $9.95 billion before the opening bell, according to ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.29015,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.219107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.119226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLBD",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.72821",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "USFD",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.469951",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "OM",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.232068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly Stock Dropped 12% Last Month",
    "url": "https://www.fool.com/investing/2024/08/08/heres-why-eli-lilly-stock-dropped-12-last-month/",
    "time_published": "20240808T050443",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "News from a competitor gave investors an unwelcome dose of reality.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786437%2Fgettyimages-1488338820-1201x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.183467,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.171369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.073495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.069927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nektar's Q2 Earnings Lag Estimates, Revenues Top - Eli Lilly  ( NYSE:LLY ) , Nektar Therapeutics  ( NASDAQ:NKTR ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40290042/nektars-q2-earnings-lag-estimates-revenues-top",
    "time_published": "20240809T200533",
    "authors": [
      "Zacks"
    ],
    "summary": "Nektar Therapeutics NKTR incurred a loss per share of 25 cents in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 21 cents.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/fa/73847.jpg?v=1471947569",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.052551,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.219477",
        "ticker_sentiment_score": "-0.037607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.289748",
        "ticker_sentiment_score": "0.081575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.289748",
        "ticker_sentiment_score": "0.15608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.357636",
        "ticker_sentiment_score": "-0.100917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40294656/eli-lillys-q2-sales-surge-36-analysts-cautious-on-future-supply-market-dynamics-opt",
    "time_published": "20240809T200304",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion. Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/09/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.275944,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.469457",
        "ticker_sentiment_score": "0.150556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.259304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.186303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.189391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday - Expedia Group  ( NASDAQ:EXPE ) ",
    "url": "https://www.benzinga.com/news/24/08/40290461/expedia-posts-upbeat-earnings-joins-akamai-technologies-trade-desk-dxc-technology-and-other-big-stoc",
    "time_published": "20240809T165133",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Expedia Group, Inc. EXPE rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/09/Expedia-Group---logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.50876,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RNA",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.4101",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.26616",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "G",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.199731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AKAM",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.282998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.267559",
        "ticker_sentiment_score": "0.307071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.327316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PAY",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.289004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RKLB",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.194839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CARG",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.374825",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DXC",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.282998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IAG",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.425272",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.374825",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.282998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOCN",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.289004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EVH",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.282998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.295005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOCS",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.36181",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BLND",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.448466",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nektar's  ( NKTR )  Q2 Earnings Lag Estimates, Revenues Top",
    "url": "https://www.zacks.com/stock/news/2320141/nektars-nktr-q2-earnings-lag-estimates-revenues-top",
    "time_published": "20240809T145800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.021455,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "-0.034536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.059413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "0.149238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "-0.09159",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40284878/eli-lilly-unusual-options-activity",
    "time_published": "20240809T134608",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723211165_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.085641,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.740902",
        "ticker_sentiment_score": "0.074197",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates",
    "url": "https://www.zacks.com/stock/news/2319903/pharma-stock-roundup-lly-nvo-bayry-q2-earnings-mrks-new-deal-other-updates",
    "time_published": "20240809T132800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.200917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.248924",
        "ticker_sentiment_score": "0.253651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.108141",
        "ticker_sentiment_score": "0.078756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.108141",
        "ticker_sentiment_score": "0.078756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.013196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.179254",
        "ticker_sentiment_score": "0.101282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.0132",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Aug 9, 2024",
    "url": "https://www.zacks.com/stock/news/2319896/company-news-for-aug-9-2024",
    "time_published": "20240809T131800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies in The News Are: CYBR, PH, ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.138482,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.428516",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "-0.088461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.145581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.300751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year",
    "url": "https://www.fool.com/investing/2024/08/09/prediction-this-weight-loss-stock-will-be-acquired/",
    "time_published": "20240809T124600",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785878%2Fmergers-and-acquisitions-graphic-calculator-4.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.159085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.377776",
        "ticker_sentiment_score": "0.260461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.415927",
        "ticker_sentiment_score": "0.186736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.298437",
        "ticker_sentiment_score": "0.239376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day",
    "url": "https://www.zacks.com/stock/news/2319763/twilio-and-floor-decor-holdings-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
    "time_published": "20240809T103400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - August 9, 2024 - Zacks Equity Research shares Twilio ( TWLO Quick QuoteTWLO - ) as the Bull of the Day and Floor & D\u00e9cor Holdings, Inc. ( FND ) asthe Bear of the Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3b/3776.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.779048"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.242242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.355906",
        "ticker_sentiment_score": "0.362347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.023035",
        "ticker_sentiment_score": "0.165083",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FND",
        "relevance_score": "0.069028",
        "ticker_sentiment_score": "-0.034377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.205032",
        "ticker_sentiment_score": "0.181487",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.160175",
        "ticker_sentiment_score": "0.152533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in August",
    "url": "https://www.fool.com/investing/2024/08/09/2-healthcare-stocks-buy-hand-over-fist-in-august/",
    "time_published": "20240809T100200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These longtime winners still have a lot to offer.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786004/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.267759,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.19601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.498827",
        "ticker_sentiment_score": "0.28759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.362254",
        "ticker_sentiment_score": "0.316795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "S&P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40277332/s-p-500-records-best-session-since-january-2023-investor-sentiment-improves-but-greed-index-remains",
    "time_published": "20240809T081653",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the \"Extreme Fear\" zone on Thursday. U.S. stocks settled higher on Thursday, with the S&P 500 index, as tracked by the SPDR S&P 500 ETF Trust SPY, notching its best daily ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/09/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.017134,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.531389",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "-0.220355",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SATS",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "USFD",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.531389",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXL",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMCX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.",
    "url": "https://www.fool.com/investing/2024/08/11/a-blood-test-could-detect-early-alzheimers-that-co/",
    "time_published": "20240811T130500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785842/doctor-talking-to-a-patient-while-making-notes.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.269987,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410697",
        "ticker_sentiment_score": "0.375109",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.084446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.050153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.410697",
        "ticker_sentiment_score": "0.256645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Investors Buy Eli Lilly's  ( LLY )  Stock After Strong Q2 Results?",
    "url": "https://www.zacks.com/commentary/2320976/should-investors-buy-eli-lillys-lly-stock-after-strong-q2-results",
    "time_published": "20240812T220200",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.229144,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.602879",
        "ticker_sentiment_score": "0.41072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.088057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.088057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40320417/weight-loss-drugs-like-ozempic-zepbound-may-reduce-cancer-risks-studies-suggest",
    "time_published": "20240812T173730",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "GLP-1 agonists, drugs like Novo Nordisk A/S's NVO Ozempic, Wegovy, and Eli Lilly And Co's LLY Zepbound, have revolutionized the treatment of obesity and diabetes. Now, researchers are investigating their potential to address a range of other conditions, including addiction, sleep apnea, and even ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/12/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.036812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.210947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.210947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 ETFs to Make the Most of Eli Lilly's Strength",
    "url": "https://www.zacks.com/stock/news/2320811/5-etfs-to-make-the-most-of-eli-lillys-strength",
    "time_published": "20240812T155000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99998"
      }
    ],
    "overall_sentiment_score": 0.119227,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.132166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLGDD",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.127447",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/08/40313853/eli-lilly-to-rally-around-15-here-are-10-top-analyst-forecasts-for-monday",
    "time_published": "20240812T134600",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Truist Securities cut the price target for Hyatt Hotels Corporation H from $168 to $164.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12093008/image-79-1024x554.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.176924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PCT",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "0.073627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HI",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.115019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.175847",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "0.319299",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TGI",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.233176",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "H",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.208123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.300394",
        "ticker_sentiment_score": "0.402578",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.131483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CARG",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "0.198867",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.0985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.216939",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLSK",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "-0.178118",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "International Markets and Lilly  ( LLY ) : A Deep Dive for Investors",
    "url": "https://www.zacks.com/stock/news/2320553/international-markets-and-lilly-lly-a-deep-dive-for-investors",
    "time_published": "20240812T131534",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default248.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.192111,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move",
    "url": "https://www.fool.com/investing/2024/08/12/prediction-buying-biotech-and-pharma-stocks-during/",
    "time_published": "20240812T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There isn't much to suggest these businesses are actually vulnerable.",
    "banner_image": "https://media.ycharts.com/charts/c77dbb5bd22548eae3acf96a5feddc01.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.007295,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.020662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.055994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.095124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.095124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.020662",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Robinhood Markets  ( NASDAQ:HOOD ) ",
    "url": "https://www.benzinga.com/news/24/08/40312954/this-robinhood-analyst-turns-bullish-here-are-top-5-upgrades-for-monday",
    "time_published": "20240812T131146",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler analyst Patrick Moley upgraded Robinhood Markets, Inc.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12091046/image-78-1024x571.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.356243,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.399204",
        "ticker_sentiment_score": "0.522161",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PAR",
        "relevance_score": "0.399204",
        "ticker_sentiment_score": "0.439214",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.244368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.069929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.399204",
        "ticker_sentiment_score": "0.152809",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTWO",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.35225",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40347917/heres-how-much-you-would-have-made-owning-eli-lilly-stock-in-the-last-10-years",
    "time_published": "20240813T180034",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 10 years by 20.19% on an annualized basis producing an average annual return of 30.74%. Currently, Eli Lilly has a market capitalization of $816.78 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723572031_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View - AbbVie  ( NYSE:ABBV ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40344193/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view",
    "time_published": "20240813T172417",
    "authors": [
      "Zacks"
    ],
    "summary": "The second-quarter earnings season has come to an end for large drug and biotech companies, with Eli Lilly LLY reporting its results last week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/cf/74103.jpg?v=720680589",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.257179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.422599",
        "ticker_sentiment_score": "0.362428",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.296969",
        "ticker_sentiment_score": "0.213455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.185484",
        "ticker_sentiment_score": "0.134731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.04677",
        "ticker_sentiment_score": "0.216503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs",
    "url": "https://www.fool.com/investing/2024/08/13/the-next-big-biotech-stock-boom-will-be-longevity/",
    "time_published": "20240813T171400",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Investing based on the segment's long-term prospects is likely to be very lucrative.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785973/doctors-with-investors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.23205,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.193001",
        "ticker_sentiment_score": "0.177125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.116536",
        "ticker_sentiment_score": "0.150298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Upgraded to Buy: Here's Why",
    "url": "https://www.zacks.com/stock/news/2321510/lilly-lly-upgraded-to-buy-heres-why",
    "time_published": "20240813T160011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.32033,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.380439",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's How to Play Novo Nordisk  ( NVO )  After Q2 Earnings Miss",
    "url": "https://www.zacks.com/stock/news/2321469/heres-how-to-play-novo-nordisk-nvo-after-q2-earnings-miss",
    "time_published": "20240813T153100",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.309532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.147366",
        "ticker_sentiment_score": "0.228021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.596796",
        "ticker_sentiment_score": "0.456144",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View",
    "url": "https://www.zacks.com/stock/news/2321388/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view",
    "time_published": "20240813T142700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.252511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.423718",
        "ticker_sentiment_score": "0.357685",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.2978",
        "ticker_sentiment_score": "0.213738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.131924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.20352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Analysts See Lilly  ( LLY )  as a Buy: Should You Invest?",
    "url": "https://www.zacks.com/stock/news/2321243/wall-street-analysts-see-lilly-lly-as-a-buy-should-you-invest",
    "time_published": "20240813T133011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/LLY_08132024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.32274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.357783",
        "ticker_sentiment_score": "0.197498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2321168/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20240813T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.217696,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.488469",
        "ticker_sentiment_score": "0.147379",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock",
    "url": "https://www.fool.com/investing/2024/08/13/this-1-piece-good-news-for-eli-lilly-is-bad-news-f/",
    "time_published": "20240813T110500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "A company's investments can easily ruin the plans of its competitors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786530/investors-considers-papers-on-a-table-while-holding-a-tablet.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.165112,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.116569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.099683",
        "ticker_sentiment_score": "0.159049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.137851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run",
    "url": "https://www.fool.com/investing/2024/08/13/why-eli-lilly-stocks-big-jump-last-week-could-be-j/",
    "time_published": "20240813T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Many more quarters like Lilly's stellar second quarter could be on the way.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786875/woman-smiling-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.268674,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.581269",
        "ticker_sentiment_score": "0.330063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma ETFs in Focus Post Solid Q2 Earnings - Bristol-Myers Squibb  ( NYSE:BMY ) , First Trust Nasdaq Pharmaceuticals ETF  ( NASDAQ:FTXH ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40374036/pharma-etfs-in-focus-post-solid-q2-earnings",
    "time_published": "20240814T200034",
    "authors": [
      "Zacks"
    ],
    "summary": "The second-quarter results of the healthcare sector have been impressive, with earnings of 78.8% of the sector participants that have reported so far up 17.1% on 7.6% revenue growth. The earnings beat ratio of 85.7% and the revenue beat ratio of 75.5% are also assuring.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/14/ani-kolleshi-7jjnj-qa9fy-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.196113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.082696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.074673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.078615",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40376247/dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates",
    "time_published": "20240814T183514",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY has issued a series of cease-and-desist letters to U.S. healthcare providers, including telehealth companies, wellness centers, and medical spas, demanding they halt the promotion of compounded versions of the company's weight-loss drugs, Mounjaro and Zepbound that contain ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/14/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.041161,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.620083",
        "ticker_sentiment_score": "-0.087145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.03927",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma ETFs in Focus Post Solid Q2 Earnings",
    "url": "https://www.zacks.com/stock/news/2322190/pharma-etfs-in-focus-post-solid-q2-earnings",
    "time_published": "20240814T154900",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.173992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.166583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.071772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.081138",
        "ticker_sentiment_score": "0.066897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121445",
        "ticker_sentiment_score": "0.073403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Philips  ( PHG )  Extends Isala Partnership, Boosts Customer Base",
    "url": "https://www.zacks.com/stock/news/2322111/philips-phg-extends-isala-partnership-boosts-customer-base",
    "time_published": "20240814T145900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Philips (PHG) extends its partnership Isala hospital to optimize the latter's healthcare processes, expanding its customer base.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.438099,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.165409",
        "ticker_sentiment_score": "0.168834",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.152684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.165409",
        "ticker_sentiment_score": "0.168834",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.272181",
        "ticker_sentiment_score": "0.426059",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/08/40369350/eli-lilly-smashed-estimates-thanks-to-unbelievable-demand-for-its-diabetes-and-weight-loss-blockbust",
    "time_published": "20240814T142617",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Thursday, Eli Lilly and Company LLY reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound.",
    "banner_image": "https://cdn.benzinga.com/files/fitness-training-concept-with-clipboard.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.160983,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.545493",
        "ticker_sentiment_score": "0.328078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.322233",
        "ticker_sentiment_score": "0.027024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.322233",
        "ticker_sentiment_score": "0.134024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly  ( LLY )  a Buy Post Stellar Q2 Earnings & Raised View?",
    "url": "https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view",
    "time_published": "20240814T133400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.368089,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.575926",
        "ticker_sentiment_score": "0.550738",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.105947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.111082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.096786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.187769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen",
    "url": "https://www.zacks.com/stock/news/2322034/the-zacks-analyst-blog-highlights-eli-lilly-pfizer-abbvie-and-biogen",
    "time_published": "20240814T124900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.252246,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.426105",
        "ticker_sentiment_score": "0.33308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.306144",
        "ticker_sentiment_score": "0.197729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.199767",
        "ticker_sentiment_score": "0.11812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.067221",
        "ticker_sentiment_score": "0.10124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/08/14/up-10-in-1-day-is-it-too-late-to-buy-eli-lilly-sto/",
    "time_published": "20240814T103500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "How much upside could this juggernaut stock possibly have left?",
    "banner_image": "https://g.foolcdn.com/editorial/images/786708/two-investors-look-at-figures.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.127343,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.335367",
        "ticker_sentiment_score": "0.256055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What Makes Eli Lilly  ( LLY )  a Strong Momentum Stock: Buy Now?",
    "url": "https://www.zacks.com/stock/news/2322724/what-makes-eli-lilly-lly-a-strong-momentum-stock-buy-now",
    "time_published": "20240815T160007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default151.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.332142,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.575055",
        "ticker_sentiment_score": "0.459043",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Biden Targets $6B Savings Via Medicare Drug Price Negotiations - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40397706/biden-administration-targets-6b-savings-through-medicare-drug-price-negotiations",
    "time_published": "20240815T143821",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Biden administration announced that Medicare's newly negotiated prescription drug prices are expected to save the U.S. government $6 billion in the first year alone. The lower prices, a result of the Inflation Reduction Act, aim to address the high costs of medications for the Medicare ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/15/What-Happened_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.002434,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.136081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.136081",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity For August 15 - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40396876/eli-lilly-unusual-options-activity-for-august-15",
    "time_published": "20240815T141727",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on Eli Lilly LLY, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723731444_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.050417,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.764792",
        "ticker_sentiment_score": "0.059792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.114125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market  ( Hint: It's Not Pfizer ) ",
    "url": "https://www.fool.com/investing/2024/08/15/prediction-this-company-will-disrupt-eli-lilly-and/",
    "time_published": "20240815T134800",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "There are a number of pharmaceutical companies looking to make waves in the weight loss market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786818%2Fgettyimages-2025836701.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.148023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.314151",
        "ticker_sentiment_score": "0.166087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.073097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.022789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.314151",
        "ticker_sentiment_score": "0.166087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.02832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy",
    "time_published": "20240816T175937",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Older Americans are having little success getting prescriptions for Novo Nordisk A/S's NVO weight-loss drug Wegovy, covered by Medicare, despite the federal healthcare program's decision to pay for patients with obesity at risk of heart disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/16/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.199808,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.306157",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "0.24075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market - Roche Holding  ( OTC:RHHBY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market",
    "time_published": "20240816T175616",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Roche Holding AG RHHBY reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co LLY to acquire the drug, now known as orforglipron, for just $50 million.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/16/Roche.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.052747,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.018894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.464633",
        "ticker_sentiment_score": "0.051514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "-0.179456",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Why Lilly  ( LLY )  Might be Well Poised for a Surge",
    "url": "https://www.zacks.com/stock/news/2323318/why-lilly-lly-might-be-well-poised-for-a-surge",
    "time_published": "20240816T162008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.432377,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.67841",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal",
    "url": "https://www.zacks.com/stock/news/2323142/pharma-stock-roundup-azn-gets-approvals-for-imfinzi-expanded-use-mrk-inks-new-deal",
    "time_published": "20240816T143500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.05775,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "-0.069855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.2138",
        "ticker_sentiment_score": "0.060893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.068314",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Companies Reporting Remarkable Results: WMT, LLY, CAH",
    "url": "https://www.zacks.com/commentary/2322741/3-companies-reporting-remarkable-results-wmt-lly-cah",
    "time_published": "20240816T141500",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "All three companies posted robust results and upped their outlooks, a bullish pairing. Is it time to buy?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0a/1429.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      }
    ],
    "overall_sentiment_score": 0.352543,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.366832",
        "ticker_sentiment_score": "0.323142",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.317527",
        "ticker_sentiment_score": "0.38479",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.317527",
        "ticker_sentiment_score": "0.447012",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater",
    "url": "https://www.fool.com/investing/2024/08/16/prediction-up-74-so-far-this-year-this-weight-loss/",
    "time_published": "20240816T074700",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "A small telemedicine company just entered the weight loss race.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786826%2Fgettyimages-1088326366.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.093417,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.263467",
        "ticker_sentiment_score": "0.21408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.013802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.089295",
        "ticker_sentiment_score": "-0.122219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.133593",
        "ticker_sentiment_score": "0.054609",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Madrigal Pharmaceuticals Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/08/17/is-madrigal-pharmaceuticals-stock-a-buy/",
    "time_published": "20240817T141500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech could be worth a lot more in 10 years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786018/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.208553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.047999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.274012",
        "ticker_sentiment_score": "0.306045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.047999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fantastic Growth Stocks to Buy in August",
    "url": "https://www.fool.com/investing/2024/08/17/3-fantastic-growth-stocks-to-buy-in-august/",
    "time_published": "20240817T113000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks should keep up their winning ways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787352/woman-smiling-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.361236,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.374",
        "ticker_sentiment_score": "0.277379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.179105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FMBRY",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.236572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.374",
        "ticker_sentiment_score": "0.43317",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters",
    "url": "https://www.fool.com/investing/2024/08/17/eli-lillys-top-glp-1-drugs-now-account-for-nearly/",
    "time_published": "20240817T112100",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786778/a-person-trying-to-lose-weight-and-who-is-measuring-their-waist.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.214936,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.452295",
        "ticker_sentiment_score": "0.333552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived",
    "url": "https://www.fool.com/investing/2024/08/18/forget-mounjaro-eli-lillys-next-big-blockbuster-ha/",
    "time_published": "20240818T181000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly has a lot going for it.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F787061%2Fscreenshot-2024-08-13-131428.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.238917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "0.044655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.676093",
        "ticker_sentiment_score": "0.416606",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.315397",
        "ticker_sentiment_score": "0.25529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock",
    "url": "https://www.fool.com/investing/2024/08/18/prediction-this-hypergrowth-company-could-be-the-n/",
    "time_published": "20240818T160500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's no stopping this incredible pharmaceutical stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786915/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99737"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.288539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420705",
        "ticker_sentiment_score": "0.401701",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.123595",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.132682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "0.143737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years",
    "url": "https://www.fool.com/investing/2024/08/18/novo-nordisk-and-eli-lilly-could-have-a-big-rival/",
    "time_published": "20240818T101200",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Should Novo Nordisk and Eli Lilly investors be worried about Roche?",
    "banner_image": "https://g.foolcdn.com/editorial/images/786781/person-standing-on-a-scale.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.088918,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "0.170376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "0.170376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Three Biotech Stocks to Buy for the \"Golden Age of Medicine\"",
    "url": "https://www.benzinga.com/personal-finance/24/08/40446326/three-biotech-stocks-to-buy-for-the-golden-age-of-medicine",
    "time_published": "20240819T174930",
    "authors": [
      "Nic Chahine"
    ],
    "summary": "A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed \"a Golden Age of Medicine\" is here. And in the 12 months since, a flurry of new drug and medical discoveries has proven them to be right.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19133532/IDNA.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.208491,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.187654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.102342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.150608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RYTM",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.060263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.270014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.447091",
        "ticker_sentiment_score": "0.197109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.094611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.150608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.163211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "0.295768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Walmart Wins Bargain Games",
    "url": "https://www.fool.com/investing/2024/08/19/walmart-wins-bargain-games/",
    "time_published": "20240819T165100",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "The world's largest retailer is crushing the market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787527/mfm_15.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999921"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.176233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WSM",
        "relevance_score": "0.023229",
        "ticker_sentiment_score": "0.073137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.023229",
        "ticker_sentiment_score": "0.043756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.007744",
        "ticker_sentiment_score": "0.038249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.023229",
        "ticker_sentiment_score": "0.004514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.023229",
        "ticker_sentiment_score": "0.039413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.007744",
        "ticker_sentiment_score": "-0.002453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.015487",
        "ticker_sentiment_score": "0.085152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.11575",
        "ticker_sentiment_score": "0.097565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40440501/telehealth-firm-hims-hers-health-rides-high-on-demand-for-copycat-weight-loss-drugs-amid-supply-s",
    "time_published": "20240819T132402",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Hims & Hers Health Inc HIMS, a telehealth company known for offering compounded alternatives to popular GLP-1 weight-loss treatments, has seen its shares soar over 120% since August 2023. The surge surpasses gains by industry giants Eli Lilly And Co LLY and Novo Nordisk A/S NVO, which have ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/19/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.11705,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.043649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.244339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.043649",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE ) , BioNTech COVID-Flu Combo Shot Study Falters",
    "url": "https://www.zacks.com/stock/news/2323673/pfizer-pfe-biontech-covid-flu-combo-shot-study-falters",
    "time_published": "20240819T132300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.118219,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.077191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.286019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.536866",
        "ticker_sentiment_score": "0.259627",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.164113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2323505/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20240819T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303954,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Walmart, Cardinal Health and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2323468/zacks-investment-ideas-feature-highlights-walmart-cardinal-health-and-eli-lilly",
    "time_published": "20240819T093200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Walmart, Cardinal Health and Eli Lilly have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2c/546.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      }
    ],
    "overall_sentiment_score": 0.371589,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.316168",
        "ticker_sentiment_score": "0.210345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.270485",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.357146",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond",
    "url": "https://www.fool.com/investing/2024/08/19/prediction-these-2-unstoppable-pharma-stocks-will/",
    "time_published": "20240819T091100",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Impediments to growth are melting away while new opportunities begin to rise.",
    "banner_image": "https://media.ycharts.com/charts/79abf809571885a9aab471411906d726.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.269828,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.095444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.095444",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Topped the Market on Tuesday",
    "url": "https://www.fool.com/investing/2024/08/20/why-eli-lilly-topped-the-market-on-tuesday/",
    "time_published": "20240820T204642",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company had very encouraging news to report about its hottest product.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787958/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.271151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.551173",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.424251",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.20972",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Massive Weight Loss Market: Viking  ( VKTX )  is Best-in-Breed",
    "url": "https://www.zacks.com/commentary/2324438/massive-weight-loss-market-viking-vktx-is-best-in-breed",
    "time_published": "20240820T145400",
    "authors": [
      "Andrew Rocco"
    ],
    "summary": "Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.151298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.581269",
        "ticker_sentiment_score": "0.380969",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "-0.010047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "-0.012004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.09923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.191675",
        "ticker_sentiment_score": "0.115678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHAK",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "-0.012004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "-0.069872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday - Fabrinet  ( NYSE:FN ) ",
    "url": "https://www.benzinga.com/news/24/08/40464197/fabrinet-posts-strong-earnings-joins-amer-sports-hawaiian-holdings-and-other-big-stocks-moving-highe",
    "time_published": "20240820T140732",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday. Shares of Fabrinet FN rose sharply in today's session as the company reported better-than-expected fourth-quarter financial results and issued strong guidance on Monday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/20/Movers.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.299857,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPRY",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "-0.162052",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NNE",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "0.235892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FN",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.44479",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LITE",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NMM",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.49881",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AS",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.286795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLRN",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.447596",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ZKH",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "0.05255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "-0.07739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HA",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.10029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTBT",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.281235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RDFN",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.354088",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TEM",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.374609",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.176663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Should You Play Pfizer  ( PFE )  After COVID-Flu Shot Setback?",
    "url": "https://www.zacks.com/stock/news/2324368/how-should-you-play-pfizer-pfe-after-covid-flu-shot-setback",
    "time_published": "20240820T134500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.132382,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.068871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.068871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.513269",
        "ticker_sentiment_score": "0.130273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "-0.053381",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Eli Lilly Stock Trading Higher On Tuesday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-",
    "time_published": "20240820T121700",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Eli Lilly And Company LLY released topline results from the SURMOUNT-1 three-year study ( 176-week treatment period ) evaluating tirzepatide once weekly for long-term weight management and delay in progression to diabetes in adults with pre-diabetes and obesity or overweight.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/20/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.007123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "-0.174552",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2324114/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20240820T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.032025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.043051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.069241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40489364/wegovy-now-available-through-sesames-249-monthly-compounded-program-despite-supply-shortages",
    "time_published": "20240821T154423",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Healthcare platform Sesame announced a new weight loss program offering compounded versions of Novo Nordisk A/S's NVO blockbuster drug Wegovy for $249 per month.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/21/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.143683,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.239305",
        "ticker_sentiment_score": "-0.040284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.239305",
        "ticker_sentiment_score": "-0.184797",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.457566",
        "ticker_sentiment_score": "0.045917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Up 3% on Obesity Drug Cutting Diabetes Risk",
    "url": "https://www.zacks.com/stock/news/2325158/lilly-lly-up-3-on-obesity-drug-cutting-diabetes-risk",
    "time_published": "20240821T143700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.257592,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.259835",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.08953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.139591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.09473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.129983",
        "ticker_sentiment_score": "0.274143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40484188/novo-nordisk-vs-eli-lilly-beyond-the-weight-loss-drug-battle",
    "time_published": "20240821T125104",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/21/weight-loss-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.308909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.475461",
        "ticker_sentiment_score": "0.266192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.532941",
        "ticker_sentiment_score": "0.395325",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Company News for Aug 21, 2024",
    "url": "https://www.zacks.com/stock/news/2324719/company-news-for-aug-21-2024",
    "time_published": "20240821T091500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: LLY, BA, AS, MDT.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.084125,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.010179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AS",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.071662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.404103",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "-0.095961",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?",
    "url": "https://www.fool.com/investing/2024/08/21/eli-lilly-stock-could-soar-to-1150-according-to-a/",
    "time_published": "20240821T083600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787727/individual-investor-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.216542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.160005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.448513",
        "ticker_sentiment_score": "0.20258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2324711/zacks-investment-ideas-feature-highlights-viking-therapeutics-mcdonalds-starbucks-novo-nordisk-and-eli-lilly",
    "time_published": "20240821T082700",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/355.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.158652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.207176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.339949",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "-0.029981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.208248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "-0.06203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With LLY - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40508405/check-out-what-whales-are-doing-with-lly",
    "time_published": "20240822T140212",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724335328_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.107207,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.681225",
        "ticker_sentiment_score": "0.097571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "-0.111749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better",
    "url": "https://www.fool.com/investing/2024/08/22/eli-lillys-growth-rate-is-fantastic-but-this-numbe/",
    "time_published": "20240822T104500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly's valuation may seem high right now, but with fast earnings growth, today's price could look like a deal in a few years.",
    "banner_image": "https://media.ycharts.com/charts/abd4cf519c87894c31a1975033c322d3.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999813"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.491152,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.270523",
        "ticker_sentiment_score": "0.525304",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club",
    "url": "https://www.fool.com/investing/2024/08/22/this-undervalued-stock-could-join-the-race-with-el/",
    "time_published": "20240822T101700",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "This leading pharmaceutical stock is flying under the radar right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F787705%2Fpills-dollar-sign-money-pharmaceuticals-1201x643-518128e.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.178374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "-0.050838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.401915",
        "ticker_sentiment_score": "0.207704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking Rises 25% in a Month: Should You Buy or Wait? - Eli Lilly  ( NYSE:LLY ) , Madrigal Pharmaceuticals  ( NASDAQ:MDGL ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40531837/viking-rises-25-in-a-month-should-you-buy-or-wait",
    "time_published": "20240823T201127",
    "authors": [
      "Zacks"
    ],
    "summary": "Shares of Viking Therapeutics VKTX have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis ( NASH ) candidates, which management plans to advance to late-stage development by early 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/0f/75223.jpg?v=505765586",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.264343,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.264761",
        "ticker_sentiment_score": "0.138729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "0.064997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.195812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.214325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.059286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "0.142697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "0.064997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking  ( VKTX )  Rises 25% in a Month: Should You Buy or Wait?",
    "url": "https://www.zacks.com/stock/news/2326555/viking-vktx-rises-25-in-a-month-should-you-buy-or-wait",
    "time_published": "20240823T150400",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.244138,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.277208",
        "ticker_sentiment_score": "0.139879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.065374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.120834",
        "ticker_sentiment_score": "0.189234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.212514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.05449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.143253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.065374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exploring The Competitive Space: Eli Lilly Versus Industry Peers In Pharmaceuticals - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40530061/exploring-the-competitive-space-eli-lilly-versus-industry-peers-in-pharmaceuticals",
    "time_published": "20240823T150026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724425223_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.183742,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.576977",
        "ticker_sentiment_score": "0.246843",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Falls 10% in 3 Months: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2326367/merck-mrk-falls-10-in-3-months-should-you-buy-the-dip",
    "time_published": "20240823T142300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.102832,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.110056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.011422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.011422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.019733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.017938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "0.105277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More",
    "url": "https://www.zacks.com/stock/news/2326355/pharma-stock-roundup-fda-nod-to-pfe-mrna-new-covid-jabs-more",
    "time_published": "20240823T141500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.102717,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.071271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.16463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "-0.105939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.004386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.096589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.085203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.031017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.147163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bayer  ( BAYRY )  Starts Mid-Stage Study on Chronic Kidney Disease Drug",
    "url": "https://www.zacks.com/stock/news/2326377/bayer-bayry-starts-mid-stage-study-on-chronic-kidney-disease-drug",
    "time_published": "20240823T134200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.131332,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.068153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.195287",
        "ticker_sentiment_score": "0.136622",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk",
    "url": "https://www.fool.com/investing/2024/08/23/these-were-top-selling-glp-1-drugs-last-quarter/",
    "time_published": "20240823T120000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Ozempic remains on top in the GLP-1 drug market -- but for how long?",
    "banner_image": "https://g.foolcdn.com/editorial/images/787582/a-physician-using-a-scale-to-measure-a-persons-weight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.306983,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.437082",
        "ticker_sentiment_score": "0.368942",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.320557",
        "ticker_sentiment_score": "0.310181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Like Eli Lilly, Then You'll Love This Little-Known Specialty Manufacturing Stock",
    "url": "https://www.fool.com/investing/2024/08/24/if-you-like-eli-lilly-then-youll-love-this-little/",
    "time_published": "20240824T222900",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Jacobs Solutions stands to be a beneficiary of the red-hot weight loss movement fueling the pharmaceutical market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F787903%2Fgettyimages-1481351241.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.34128,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.255106",
        "ticker_sentiment_score": "0.289243",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "J",
        "relevance_score": "0.351273",
        "ticker_sentiment_score": "0.325217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024",
    "url": "https://www.fool.com/investing/2024/08/24/prediction-best-performing-sp-500-stocks-2024/",
    "time_published": "20240824T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The S&P 500's top three at year-end could look a little different than they do now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787977/stock-chart-rocket.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.252363,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277748",
        "ticker_sentiment_score": "0.199222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.430454",
        "ticker_sentiment_score": "0.328207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.136217",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy",
    "url": "https://www.fool.com/investing/2024/08/25/mounjaro-scores-yet-another-win-why-eli-lilly-is-s/",
    "time_published": "20240825T111000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drugmaker looks unstoppable.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788185/person-sitting-at-a-desk-looking-at-two-monitors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.214069,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.392362",
        "ticker_sentiment_score": "0.381238",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r",
    "time_published": "20240826T175943",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Several state and local governments have filed lawsuits against drug companies and pharmacy benefit managers ( PBMs ) , accusing them of inflating insulin prices. While these entities claim they're fighting for patients, they've quietly benefitted from the very system they now condemn.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/Ozempic-Insulin-Injection-Pen-Or-Insulin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.014724,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.136491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.157647",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.157647",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Buy 4 Top-Ranked Stocks to Play Likely Earnings Beat",
    "url": "https://www.zacks.com/stock/news/2327252/buy-4-top-ranked-stocks-to-play-likely-earnings-beat",
    "time_published": "20240826T153100",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Top-ranked stocks Norwegian Cruise Line (NCLH), Eli Lilly (LLY), The Progressive (PGR) and Fortinet (FTNT) are likely to beat on earnings in their upcoming releases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.327783,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201356",
        "ticker_sentiment_score": "0.224851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PGR",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.127666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.114426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NCLH",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.128987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.184296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why You Should Consider Buying Akebia  ( AKBA )  Stock",
    "url": "https://www.zacks.com/stock/news/2327123/heres-why-you-should-consider-buying-akebia-akba-stock",
    "time_published": "20240826T144500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.331008,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.309864",
        "ticker_sentiment_score": "0.200871",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.202785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARCT",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.352514",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AKBA",
        "relevance_score": "0.309864",
        "ticker_sentiment_score": "0.25777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Gets EU Approval for Bladder Cancer Drug Balversa",
    "url": "https://www.zacks.com/stock/news/2326921/jj-jnj-gets-eu-approval-for-bladder-cancer-drug-balversa",
    "time_published": "20240826T132900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.480536",
        "ticker_sentiment_score": "0.293993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.125863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.05002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2326848/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240826T130019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.253055,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.196245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40551066/eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safet",
    "time_published": "20240826T124522",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The U.K.'s National Health Service ( NHS ) is expected to block the use of another Alzheimer's treatment, Eli Lilly And Co's LLY donanemab, following the recent rejection of Biogen Inc's BIIB Leqembi ( lecanemab ) by the National Institute for Health and Care Excellence ( NICE ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.121357,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.134288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.130502",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?",
    "url": "https://www.fool.com/investing/2024/08/26/viking-therapeutics-stock-could-rocket-76-higher-a/",
    "time_published": "20240826T085700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The new drugs this company is developing could be worth a lot more than the present market value of its stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788443/investor-calculator-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.173304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.090285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.074612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.294237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.141556",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Viking Therapeutics Stock Got Thrashed on Tuesday",
    "url": "https://www.fool.com/investing/2024/08/27/why-viking-therapeutics-stock-got-thrashed-on-tues/",
    "time_published": "20240827T224223",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A monster rival is making aggressive moves in one particular segment.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788774/medical-professional-with-hand-on-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031716,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.102999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Hims & Hers Stock Crashed on Tuesday",
    "url": "https://www.fool.com/investing/2024/08/27/why-hims-hers-stock-crashed-on-tuesday/",
    "time_published": "20240827T204518",
    "authors": [
      "Travis Hoium"
    ],
    "summary": "Could a competitor lowering prices eat into Hims & Hers market share?",
    "banner_image": "https://g.foolcdn.com/editorial/images/788749/pills-dollar-sign-money-pharmaceuticals.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.045591,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "-0.331712",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/m-a/24/08/40586451/regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna",
    "time_published": "20240827T192226",
    "authors": [
      "Anthony Noto"
    ],
    "summary": "Some 3 million Americans, and approximately 24 million people worldwide, are likely looking forward to a pivotal date next month in which U.S. regulators are expected to decide on whether to approve a new - more innovative - schizophrenia drug. What Happened: The U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/Medication.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151577,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.212701",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "-0.030727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.239266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche Obtains Approval For its Rare Blood Disorder Drug in the EU",
    "url": "https://www.zacks.com/stock/news/2327876/roche-obtains-approval-for-its-rare-blood-disorder-drug-in-the-eu",
    "time_published": "20240827T160400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14221,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.075435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.069706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.153502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Hims & Hers Health Stock Is Falling - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/news/24/08/40579770/why-hims-hers-health-stock-is-falling",
    "time_published": "20240827T145444",
    "authors": [
      "Henry Khederian"
    ],
    "summary": "Eli Lilly and Co LLY today announced an expansion in the availability of its obesity treatment, Zepbound ( tirzepatide ) , which is now offered in 2.5 mg and 5 mg single-dose vials at a discounted price.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/doctor-2568481.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      }
    ],
    "overall_sentiment_score": 0.27169,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.040823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.058622",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.",
    "url": "https://www.fool.com/investing/2024/08/27/eli-lillys-stock-keeps-looking-better-and-better/",
    "time_published": "20240827T140000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its rock-star therapy looks like it could be marketed as a preventative treatment.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788195/investor-smiles-while-reading-report.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.079362,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.268589",
        "ticker_sentiment_score": "0.082579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?",
    "url": "https://www.zacks.com/stock/news/2327685/merck-stock-worth-watching-on-pah-drug-winrevairs-approval-in-europe",
    "time_published": "20240827T135700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.2493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.123309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.253473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.201934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Releases Cheaper Zepbound Vials Priced Up To 50% Lower To Boost Access, Supply For Its Popular Weight Loss Drug - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40573775/eli-lilly-releases-cheaper-zepbound-vials-priced-upto-50-lower-to-boost-access-supply-for-its-pop",
    "time_published": "20240827T121252",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly and Co LLY on Tuesday released vials containing low doses of its weight-loss drug Zepbound. Zepbound ( tirzepatide ) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.131574,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.446742",
        "ticker_sentiment_score": "0.232288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?",
    "url": "https://www.fool.com/investing/2024/08/27/ozempic-could-have-a-terrible-side-effect-is-novo/",
    "time_published": "20240827T100000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Shareholders don't have too much to fear -- yet.",
    "banner_image": "https://media.ycharts.com/charts/0c2c21867d55139740d12968fe45e6bb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": -0.022002,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.02008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.263475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace",
    "url": "https://www.zacks.com/stock/news/2327368/the-zacks-analyst-blog-eli-lilly-chevron-abbott-and-bridger-aerospace",
    "time_published": "20240827T063000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/73/488.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.292416,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.131484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAER",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "-0.028124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.200844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.273767",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40614334/heres-how-much-1000-invested-in-eli-lilly-10-years-ago-would-be-worth-today",
    "time_published": "20240828T213031",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 10 years by 20.24% on an annualized basis producing an average annual return of 31.02%. Currently, Eli Lilly has a market capitalization of $850.90 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724880628_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound",
    "url": "https://www.zacks.com/stock/news/2328500/eli-lilly-launches-discounted-versions-of-obesity-drug-zepbound",
    "time_published": "20240828T171800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.141525,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.172408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.080551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.195449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "-0.009469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.056869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2328498/jjs-stock-up-128-in-3-months-time-to-buy-sell-or-hold",
    "time_published": "20240828T171200",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.177094,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.118988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.20715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs",
    "url": "https://www.zacks.com/stock/news/2328497/pfizer-follows-lillys-example-unveils-dtc-service-for-selling-drugs",
    "time_published": "20240828T160800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/1434.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.227232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.192095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.20254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.457274",
        "ticker_sentiment_score": "0.365075",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.268653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday",
    "url": "https://www.zacks.com/stock/news/2328479/why-viking-therapeutics-stock-price-moved-down-6-on-tuesday",
    "time_published": "20240828T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.129667,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.174991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.149056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.14513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.021097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.061511",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender - Broadcom  ( NASDAQ:AVGO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/top-stories/24/08/40604676/warren-buffetts-berkshire-hathaway-breaks-1-trillion-poll-points-to-big-pharma-not-tech-as-next-cont",
    "time_published": "20240828T151156",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Conglomerate Berkshire Hathaway Inc BRK BRK became the 10th public company to surpass the $1 trillion market capitalization milestone on Wednesday, further reshaping the dynamic leaderboard of the most valuable company in the world.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/28/Warren-Buffett-ai5.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.208698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "-0.038424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "0.137443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "0.051376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "0.05034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.405029",
        "ticker_sentiment_score": "0.30703",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "0.163289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "0.131702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "0.046999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/markets/equities/24/08/40594187/eli-lilly-is-the-nvidia-of-weight-loss-and-glp-1-space-says-roundhill-investments-ceo-emphasizes",
    "time_published": "20240828T082126",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co LLY to NVIDIA Corp NVDA in the weight loss and GLP-1 space. What Happened: Mazza highlighted that weight loss drugs were not on anyone's radar until recently, similar to how AI and Nvidia emerged.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/28/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.16001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "-0.11798",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "-0.123395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.10864",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Incyte  ( INCY )  Up 0.9% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2329078/incyte-incy-up-09-since-last-earnings-report-can-it-continue",
    "time_published": "20240829T153104",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.152622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.11324",
        "ticker_sentiment_score": "0.044171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.462824",
        "ticker_sentiment_score": "0.26688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MPSYF",
        "relevance_score": "0.03786",
        "ticker_sentiment_score": "0.217789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Decoding Eli Lilly's Options Activity: What's the Big Picture? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40628427/decoding-eli-lillys-options-activity-whats-the-big-picture",
    "time_published": "20240829T151612",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724944569_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.09533,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "-0.015565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "-0.129137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study",
    "url": "https://www.zacks.com/stock/news/2328995/novartis-cholesterol-drug-meets-primary-goals-in-late-stage-study",
    "time_published": "20240829T135000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220198,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.223925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.054846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.11636",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Is Considered a Good Investment by Brokers: Is That True?",
    "url": "https://www.zacks.com/stock/news/2328857/lilly-lly-is-considered-a-good-investment-by-brokers-is-that-true",
    "time_published": "20240829T133013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/LLY_08292024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.321709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.361501",
        "ticker_sentiment_score": "0.198986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bayer, NextRNA to Develop Therapeutics Targeting Oncology",
    "url": "https://www.zacks.com/stock/news/2328976/bayer-nextrna-to-develop-therapeutics-targeting-oncology",
    "time_published": "20240829T131800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.098803,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.055036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.117011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.091024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2328811/gsk-stock-gains-185-year-to-date-time-to-buy-sell-or-hold",
    "time_published": "20240829T131400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.185887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.076731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.076731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.07083",
        "ticker_sentiment_score": "0.037147",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?",
    "url": "https://www.fool.com/investing/2024/08/29/is-eli-lilly-stock-a-buy-after-the-companys-brilli/",
    "time_published": "20240829T094400",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788699/scales-feet-tape-measure.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.207894,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.513494",
        "ticker_sentiment_score": "0.34665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.160068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2328646/the-zacks-analyst-blog-highlights-johnson-johnson-kenvue-and-eli-lilly",
    "time_published": "20240829T091500",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      }
    ],
    "overall_sentiment_score": 0.181374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.083444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.121124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "-0.015087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day",
    "url": "https://www.zacks.com/stock/news/2328641/bioventus-and-pool-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
    "time_published": "20240829T090000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - August 29, 2024 - Zacks Equity Research shares Bioventus ( BVS Quick QuoteBVS - ) as the Bull of the Day and Pool Corp ( POOL Quick QuotePOOL - ) as the Bear of the Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986413"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094916,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.328035",
        "ticker_sentiment_score": "0.083175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.103666",
        "ticker_sentiment_score": "0.053862",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.025985",
        "ticker_sentiment_score": "0.182976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.076544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.103666",
        "ticker_sentiment_score": "0.041587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40658828/judges-early-ruling-may-shape-outcome-in-ozempic-wegovy-lawsuits",
    "time_published": "20240830T173820",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. District Judge Karen Marston of Philadelphia recently issued a pivotal ruling in a closely watched multidistrict litigation ( MDL ) involving diabetes and weight-loss drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/30/10-Celebrities-Open-Up-About-Their-Ozemp.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.058031,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "-0.12254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARZF",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.087805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "-0.1692",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Bayer Initiates Late-Stage Study on Investigational NSCLC Drug",
    "url": "https://www.zacks.com/stock/news/2329942/bayer-initiates-late-stage-study-on-investigational-nsclc-drug",
    "time_published": "20240830T173100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.154111,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.063188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.114811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.16317",
        "ticker_sentiment_score": "0.120344",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs",
    "url": "https://www.zacks.com/stock/news/2329707/pharma-stock-roundup-lly-offers-cheap-zepbound-eu-okays-some-drugs",
    "time_published": "20240830T153500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.144825,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.089869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.122645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.082915",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40652763/novo-nordisk-touts-encouraging-wegovy-data-to-lower-risk-of-severe-complications-in-heart-failure",
    "time_published": "20240830T135413",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, The Lancet published a new pooled, participant-level analysis of patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction ( HFpEF ) from Novo Nordisk A/S' NVO SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/30/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.086086,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "-0.195143",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "0.066598",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind",
    "url": "https://www.fool.com/investing/2024/08/30/think-eli-lilly-stock-has-peaked-these-10-words/",
    "time_published": "20240830T114500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788415/a-doctor-looking-at-a-tablet-with-another-person.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.20556,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.417501",
        "ticker_sentiment_score": "0.319566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock",
    "url": "https://www.fool.com/investing/2024/08/30/this-new-finding-about-ozempic-and-wegovy-could-hu/",
    "time_published": "20240830T101500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The addressable market for the treatments could potentially contract significantly.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788380/three-doctors-and-three-nurses-discuss-a-readout-at-a-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.131148,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "-0.020805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.030668",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Hims & Hers Health Stock Was Falling This Week",
    "url": "https://www.fool.com/investing/2024/08/29/why-hims-hers-health-stock-was-falling-this-week/",
    "time_published": "20240830T015217",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "A new threat from Eli Lilly pushed the stock lower.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F789123%2Fnutrition-tracking-food-diet-lose-weight-wellness.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.031878,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "-0.33353",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "-0.070837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in September",
    "url": "https://www.fool.com/investing/2024/08/31/3-no-brainer-stocks-to-buy-in-september/",
    "time_published": "20240831T113000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "There's at least one key common denominator here: tremendous growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789084/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      }
    ],
    "overall_sentiment_score": 0.20788,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277658",
        "ticker_sentiment_score": "0.142045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.160901",
        "ticker_sentiment_score": "0.062054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.315325",
        "ticker_sentiment_score": "0.205306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now",
    "url": "https://www.fool.com/investing/2024/08/31/these-3-factors-could-make-eli-lilly-stock-better-/",
    "time_published": "20240831T111000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This competitive showdown just saw one of the players hit a couple of bumps.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787336/team-of-doctors-and-businessmen-communicating.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.270454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.559145",
        "ticker_sentiment_score": "0.365161",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.40638",
        "ticker_sentiment_score": "0.208706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Growth Stocks to Buy Right Now for Less Than $1,000",
    "url": "https://www.fool.com/investing/2024/08/31/2-unstoppable-growth-stocks-to-buy-right-now-for-l/",
    "time_published": "20240831T094000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Business is booming for these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788784/getty-woman-reading-book.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.198195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHWY",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.096781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.420847",
        "ticker_sentiment_score": "0.310609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.100983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Growth Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/09/01/2-no-brainer-growth-stocks-to-buy-with-1000-right/",
    "time_published": "20240901T112000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These disruptive stocks could reap generous rewards for long-term investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788787/businesswoman-remote-work-from-cafe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.191305,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "0.213881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UPST",
        "relevance_score": "0.272354",
        "ticker_sentiment_score": "0.170575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study",
    "url": "https://www.zacks.com/stock/news/2330383/bayer-presents-encouraging-data-from-late-stage-cardiovascular-study",
    "time_published": "20240902T131800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.062582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.118118",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others",
    "url": "https://www.zacks.com/stock/news/2330244/snys-ms-drug-meets-goal-in-one-phase-iii-study-misses-in-two-others",
    "time_published": "20240902T123500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.170405,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.439243",
        "ticker_sentiment_score": "0.264145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.26042",
        "ticker_sentiment_score": "0.104852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.322233",
        "ticker_sentiment_score": "0.023465",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal",
    "time_published": "20240902T074318",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Eli Lilly LLY is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. What Happened: The pharmaceutical giant is seeking to end a regulatory designation that has permitted cheaper, off-brand versions to thrive.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/02/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189607,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.675413",
        "ticker_sentiment_score": "0.324231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.062049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.142144",
        "ticker_sentiment_score": "-0.0303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Medical Stocks to Hedge Against the September Effect",
    "url": "https://www.zacks.com/stock/news/2331059/top-medical-stocks-to-hedge-against-the-september-effect",
    "time_published": "20240903T222700",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "Often sought out for defensive protection amid heightened market volatility, medical stocks may be of interest to investors in September which has historically been the most challenging month for stocks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.288742,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "0.280578",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.217363",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.265141",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs",
    "time_published": "20240903T191209",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Over the weekend, the U.S. government announced first-ever negotiated prices for prescription drugs for ten drugs covered under Medicare Part D that will go into effect beginning January 1, 2026. The negotiated prices are expected to save an estimated $6 billion in net covered prescription drug ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/03/over-the-counter-pills.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.07688,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.074765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.187219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Big Winners from the Q2 Earnings Season: LLY, LMT, META",
    "url": "https://www.zacks.com/commentary/2329973/3-big-winners-from-the-q2-earnings-season-lly-lmt-meta",
    "time_published": "20240903T141500",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. And during the period, these three companies stole the spotlight.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0a/4202.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.330865,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.393241",
        "ticker_sentiment_score": "0.19938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.282883",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.4111",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Viking Surges 342% in the Past Year: How Should You Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2330874/viking-surges-342-in-the-past-year-how-should-you-play-the-stock",
    "time_published": "20240903T134400",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.196322,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261584",
        "ticker_sentiment_score": "0.080206",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.088635",
        "ticker_sentiment_score": "0.12724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.016801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.19931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.173744",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.132611",
        "ticker_sentiment_score": "-0.043697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly is a Great Momentum Stock: Should You Buy? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40715046/eli-lilly-is-a-great-momentum-stock-should-you-buy",
    "time_published": "20240904T193746",
    "authors": [
      "Zacks"
    ],
    "summary": "Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be \"buying high, but hoping to sell even higher.\" With this methodology, taking advantage of trends in a stock's price is key.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/04/national-cancer-institute-v7ibb19eubq-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.299948,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.5239",
        "ticker_sentiment_score": "0.376913",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  is a Great Momentum Stock: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2331633/eli-lilly-lly-is-a-great-momentum-stock-should-you-buy",
    "time_published": "20240904T160010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.298772,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.596651",
        "ticker_sentiment_score": "0.396278",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NVS or LLY: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2331584/nvs-or-lly-which-is-the-better-value-stock-right-now",
    "time_published": "20240904T154014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default161.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.473927,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.632565",
        "ticker_sentiment_score": "0.566109",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race - Eli Lilly  ( NYSE:LLY ) , Renaissance IPO ETF  ( ARCA:IPO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40712264/bioage-labs-files-for-100m-ipo-becomes-the-new-entrant-in-obesity-drugs-race",
    "time_published": "20240904T151309",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/04/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.170937,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.132431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.132431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.132431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma",
    "url": "https://www.zacks.com/stock/news/2331488/mercks-keytruda-padcev-combo-gets-eu-nod-for-urothelial-carcinoma",
    "time_published": "20240904T145100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.193779,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "0.152668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "0.148935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2331470/abbvie-stock-up-almost-20-in-3-months-buy-sell-or-hold",
    "time_published": "20240904T143500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.302096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.083802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.083802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.720733",
        "ticker_sentiment_score": "0.462319",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/signals/24/09/40707373/trade-pulse-power-inflow-alert-eli-lilly-stock-rises-over-7-points",
    "time_published": "20240904T130216",
    "authors": [
      "Finit"
    ],
    "summary": "Power Inflow occurred at 10:31 am at 958.10. The stock rose to 965.94 at 11:37 am. Yesterday, Eli Lilly LLY witnessed a Power Inflow, marking a significant event for investors who incorporate order flow analytics into their investment strategies.",
    "banner_image": "https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/03205659/Screen-Shot-2024-09-03-at-4.50.48-PM.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.350936,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.379435",
        "ticker_sentiment_score": "0.44048",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Meta Platforms, Lockheed Martin and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2331160/zacks-investment-ideas-feature-highlights-meta-platforms-lockheed-martin-and-eli-lilly",
    "time_published": "20240904T111200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Meta Platforms, Lockheed Martin and Eli Lilly are part of the Zacks Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.343892,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.34648",
        "ticker_sentiment_score": "0.227444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.291644",
        "ticker_sentiment_score": "0.307592",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.291644",
        "ticker_sentiment_score": "0.446723",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is SPDR MSCI USA StrategicFactors ETF  ( QUS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2331112/is-spdr-msci-usa-strategicfactors-etf-qus-a-strong-etf-right-now",
    "time_published": "20240904T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default360.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.17511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.056476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.056476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.056476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.035956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation",
    "time_published": "20240905T164747",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In the rapidly expanding weight-loss drug market, telehealth provider Hims & Hers Health, Inc. HIMS has found a niche by offering affordable alternatives to popular anti-obesity medications like Eli Lilly And Co's LLY Zepbound and Novo Nordisk A/S' NVO Wegovy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/Eli-Lilly-and-Company-Zepbound-Vials.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.094591,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.098123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.199136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.080203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2332203/amgen-stock-rises-almost-20-in-6-months-buy-sell-or-hold",
    "time_published": "20240905T151400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.22158,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.258132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.271355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.692648",
        "ticker_sentiment_score": "0.351172",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-",
    "time_published": "20240905T134718",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Eli Lilly and Co LLY released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa ( efsitora ) in adults with type 2 diabetes.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.124662,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Walgreens Boots Alliance Fell Another 22% in August",
    "url": "https://www.fool.com/investing/2024/09/05/why-walgreens-boots-alliance-fell-another-22-in-au/",
    "time_published": "20240905T103000",
    "authors": [
      "Billy Duberstein"
    ],
    "summary": "The retail pharmacy giant faces ever-mounting headwinds.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789730/people-in-masks-at-pharmacy-retired-man-getting-medication.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.002423,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.253866",
        "ticker_sentiment_score": "-0.137913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.100019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "-0.101927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.253866",
        "ticker_sentiment_score": "-0.07353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.141831",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals",
    "url": "https://www.zacks.com/stock/news/2333037/eli-lillys-weekly-insulin-shot-meets-two-late-stage-study-goals",
    "time_published": "20240906T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.086984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.553082",
        "ticker_sentiment_score": "0.12132",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight-Loss Drug Maker Eli Lilly And Co. Stock Hits Resistence - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/health-care/24/09/40751984/stock-of-the-day-heres-why-weight-loss-drug-maker-eli-lilly-has-reversed",
    "time_published": "20240906T152539",
    "authors": [
      "Mark Putrino"
    ],
    "summary": "When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower. As you can see on the chart, this is what just happened with shares of Eli Lilly and Co LLY. This is why our team of ...",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06112206/EjLilly-1024x552.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": -0.004923,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.432291",
        "ticker_sentiment_score": "-0.176566",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40751200/comparative-study-eli-lilly-and-industry-competitors-in-pharmaceuticals-industry",
    "time_published": "20240906T150014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Eli Lilly LLY in relation to its major competitors in the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725634811_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.212171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.470482",
        "ticker_sentiment_score": "0.253095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More",
    "url": "https://www.zacks.com/stock/news/2332784/pharma-stock-roundup-eu-nod-for-expanded-use-of-mrks-keytruda-more",
    "time_published": "20240906T134500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.042782,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.248851",
        "ticker_sentiment_score": "0.060121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.100941",
        "ticker_sentiment_score": "-0.136604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.248851",
        "ticker_sentiment_score": "-0.030474",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2332634/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240906T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.234827,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.185476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem",
    "url": "https://www.fool.com/investing/2024/09/06/this-big-move-by-eli-lilly-may-solve-the-weight-lo/",
    "time_published": "20240906T083500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "The weight loss drug market may soon be worth $100 billion.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F789780%2Fgettyimages-1357572936.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.144215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.021141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.78982",
        "ticker_sentiment_score": "0.246007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.007062",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?",
    "url": "https://www.fool.com/investing/2024/09/07/billionaires-are-buying-viking-therapeutics-stock/",
    "time_published": "20240907T082600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789440/wall-street-analyst-with-laptop-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.105038,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.013127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.447528",
        "ticker_sentiment_score": "0.050981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.141448",
        "ticker_sentiment_score": "0.021073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.",
    "url": "https://www.fool.com/investing/2024/09/08/this-unstoppable-stock-has-gained-100203-over-the/",
    "time_published": "20240908T104500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F789691%2Fpills-dollar-sign-money-pharmaceuticals.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.164882,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.565644",
        "ticker_sentiment_score": "0.298102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.02263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.150791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.116536",
        "ticker_sentiment_score": "0.09017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.150791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly",
    "url": "https://www.fool.com/investing/2024/09/08/beyond-mounjaro-and-zepbound-eli-lilly/",
    "time_published": "20240908T094200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This drugmaker should have a basketful of growth drivers over the next decade.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789779/ozempic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.254915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.089167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.568953",
        "ticker_sentiment_score": "0.359281",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.073137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX",
    "url": "https://www.zacks.com/commentary/2333689/why-you-should-buy-the-200-day-dip-in-arm-mstr-vktx",
    "time_published": "20240909T221400",
    "authors": [
      "Andrew Rocco"
    ],
    "summary": "The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/74523.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.095594,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.391158",
        "ticker_sentiment_score": "0.298865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.173871",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BITF",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.174398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.080005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.080005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.078309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.258811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.040989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In LLY Options - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40774793/smart-money-is-betting-big-in-lly-options",
    "time_published": "20240909T141556",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 21 unusual trades. Delving into the details, we found 28% of traders were bullish, while 52% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725891352_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124761,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.689185",
        "ticker_sentiment_score": "-0.086801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "-0.19092",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40803167/heres-how-much-you-would-have-made-owning-eli-lilly-stock-in-the-last-20-years",
    "time_published": "20240910T200020",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 20 years by 5.71% on an annualized basis producing an average annual return of 13.92%. Currently, Eli Lilly has a market capitalization of $810.81 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725998417_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug - Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40799808/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug",
    "time_published": "20240910T195711",
    "authors": [
      "Zacks"
    ],
    "summary": "Shares of Terns Pharmaceuticals TERN, a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose ( SAD and MAD ) obesity study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/a9/77177.jpg?v=1148197964",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.148734,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.188828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.730167",
        "ticker_sentiment_score": "-0.00791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.175884",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.045349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.142324",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug",
    "url": "https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug",
    "time_published": "20240910T152900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.124879,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.182041",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.749166",
        "ticker_sentiment_score": "0.01996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.17599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.044995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.133934",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Best Momentum Stocks to Buy for September 10th",
    "url": "https://www.zacks.com/commentary/2333720/best-momentum-stocks-to-buy-for-september-10th",
    "time_published": "20240910T141500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY, MCO, and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 10, 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/88/1725956222.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.243083,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.209505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCH",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study",
    "url": "https://www.zacks.com/stock/news/2334056/mrk-stock-dips-after-smmts-cancer-drug-outshines-keytruda-in-study",
    "time_published": "20240910T141100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.201235,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "0.112887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKESF",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "-0.059068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "-0.032497",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg",
    "url": "https://www.zacks.com/stock/news/2334045/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg",
    "time_published": "20240910T130500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.233134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.055715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.204345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "New Strong Buy Stocks for September 10th",
    "url": "https://www.zacks.com/commentary/2333188/new-strong-buy-stocks-for-september-10th",
    "time_published": "20240910T120500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CLCO, BCH, ZUO, LLY and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 10, 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.085237,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.567144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLCO",
        "relevance_score": "0.567144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZUO",
        "relevance_score": "0.567144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCH",
        "relevance_score": "0.567144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYTS",
        "relevance_score": "0.567144",
        "ticker_sentiment_score": "0.166337",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Growth ETF Will Beat the Market Over the Next 5 Years",
    "url": "https://www.fool.com/investing/2024/09/10/prediction-this-growth-etf-will-beat-the-market-ov/",
    "time_published": "20240910T103400",
    "authors": [
      "Jennifer Saibil"
    ],
    "summary": "Is past performance a guarantee of future results?",
    "banner_image": "https://media.ycharts.com/charts/349acbebdaefb6127e339a7b14045ae8.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.20426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.15393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/markets/equities/24/09/40785056/zepbound-and-mounjaro-maker-eli-illy-has-a-new-cfo-as-it-navigates-regulatory-challenges-what-yo",
    "time_published": "20240910T030059",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Eli Lilly and Co. LLY has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately. What Happened: Montarce, who joined Lilly in 2001, has held numerous finance leadership positions.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/09/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.100428,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.663374",
        "ticker_sentiment_score": "-0.067173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "0.03504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "-0.019354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Roche Holdings Stock Withered on Wednesday",
    "url": "https://www.fool.com/investing/2024/09/11/why-roche-holdings-stock-withered-on-wednesday/",
    "time_published": "20240911T224958",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company had a dispiriting update to offer about an investigational drug.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790483/medical-professional-with-hand-on-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.083403,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.053219",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40813963/ozempic-maker-novo-nordisk-touts-encouraging-data-from-new-obesity-pill-showing-double-weight-los",
    "time_published": "20240911T131352",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S NVO shared an abstract with data from the company's next-generation weight loss candidate, amycretin. Earlier today, Novo Nordisk announced that its weight-loss drug liraglutide is safe and effective for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/10-Celebrities-Open-Up-About-Their-Ozemp.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.026396,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.169081",
        "ticker_sentiment_score": "-0.077905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.406526",
        "ticker_sentiment_score": "0.269235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More  ( Hint: I'm Not Talking About Zepbound ) ",
    "url": "https://www.fool.com/investing/2024/09/11/forget-mounjaro-1-reason-investors-should-love-eli/",
    "time_published": "20240911T122000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "There's a little appreciated reason to own Eli Lilly stock, and it has nothing to do with its medicines.",
    "banner_image": "https://media.ycharts.com/charts/b127b5dbadb0c6347b5fba892cc7d617.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.400592,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.872444",
        "ticker_sentiment_score": "0.66635",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.075874",
        "ticker_sentiment_score": "0.109252",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Hims & Hers Health the Next Teladoc?",
    "url": "https://www.fool.com/investing/2024/09/11/is-hims-hers-health-the-next-teladoc/",
    "time_published": "20240911T115000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790093%2Fgettyimages-1438278348.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.187867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.101963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.295043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.172179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.08817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.089934",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These 2 Companies Will Split Their Stocks by 2027",
    "url": "https://www.fool.com/investing/2024/09/11/prediction-these-2-companies-will-split-their-stoc/",
    "time_published": "20240911T104500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789565/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.779048"
      }
    ],
    "overall_sentiment_score": 0.226974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221616",
        "ticker_sentiment_score": "0.304028",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.480355",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.053862",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2334367/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20240911T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default319.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.197602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.043079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval - Eli Lilly  ( NYSE:LLY ) , Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/markets/equities/24/09/40809053/novo-nordisk-reports-positive-results-of-weight-loss-drug-liraglutide-for-children-as-young-as-6",
    "time_published": "20240911T081930",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Novo Nordisk NVO has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children aged 6 to 12 using the injectable pens over a year compared to a placebo group.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/Novo-Nordisk-NVO.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.048663,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.061347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.090768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.370418",
        "ticker_sentiment_score": "0.057947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Investors Plowed Into Viking Therapeutics Stock Today",
    "url": "https://www.fool.com/investing/2024/09/12/why-investors-plowed-into-viking-therapeutics-stoc/",
    "time_published": "20240912T231200",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company is looking especially good after some bad news coming from a rival.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790612/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.274676,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.379557",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.406003",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.379557",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Looking At Eli Lilly's Recent Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40842030/looking-at-eli-lillys-recent-unusual-options-activity",
    "time_published": "20240912T193246",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726169563_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.083826,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.714462",
        "ticker_sentiment_score": "0.219543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "-0.291166",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise",
    "url": "https://www.zacks.com/stock/news/2335487/nvo-oral-obesity-pill-tops-wegovy-lly-vktx-gpcr-stocks-rise",
    "time_published": "20240912T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.124806,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.381255",
        "ticker_sentiment_score": "0.261197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.277748",
        "ticker_sentiment_score": "0.166603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.198926",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.157035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.127107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy",
    "url": "https://www.zacks.com/stock/news/2335433/novo-nordisk-stock-rises-as-oral-obesity-pill-outshines-wegovy",
    "time_published": "20240912T155500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.167426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.236326",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.154122",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.284861",
        "ticker_sentiment_score": "0.224178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.488777",
        "ticker_sentiment_score": "0.409219",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2335423/fda-grants-label-expansion-to-jjs-tremfya-in-ulcerative-colitis",
    "time_published": "20240912T153900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.280659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.277154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.191675",
        "ticker_sentiment_score": "0.31084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.384992",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks",
    "url": "https://www.zacks.com/stock/news/2335385/boost-your-portfolios-health-with-these-4-large-cap-drug-stocks",
    "time_published": "20240912T144700",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.277297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.32231",
        "ticker_sentiment_score": "0.250449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03014",
        "ticker_sentiment_score": "0.150026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.237551",
        "ticker_sentiment_score": "0.14317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.03014",
        "ticker_sentiment_score": "0.150026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MPSYF",
        "relevance_score": "0.03014",
        "ticker_sentiment_score": "0.159753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/09/40834619/eli-lilly-pumps-800m-into-irish-operations-to-meet-skyrocketing-demand-for-mounjaro-zepbound",
    "time_published": "20240912T140557",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly & Co. LLY has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/12/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.221333,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.143667",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40834477/unpacking-the-latest-options-trading-trends-in-eli-lilly",
    "time_published": "20240912T140316",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 22 unusual trades. Delving into the details, we found 31% of traders were bullish, while 40% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726149751_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.050675,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "-0.155862",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "-0.192823",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug",
    "url": "https://www.zacks.com/stock/news/2335182/roche-stock-down-on-concerns-of-side-effects-from-its-obesity-drug",
    "time_published": "20240912T123300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.076985,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.242665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.314449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day",
    "url": "https://www.zacks.com/stock/news/2334977/eli-lilly-and-hertz-global-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
    "time_published": "20240912T090000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chicago, IL - September 12, 2024 - Zacks Equity Research shares Eli Lilly ( LLY Quick QuoteLLY - ) as the Bull of the Day and Hertz Global ( HTZ Quick QuoteHTZ - ) as the Bear of the Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.232478,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHOP",
        "relevance_score": "0.383905",
        "ticker_sentiment_score": "0.31595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.044427",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRTO",
        "relevance_score": "0.022222",
        "ticker_sentiment_score": "0.07464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADYYF",
        "relevance_score": "0.022222",
        "ticker_sentiment_score": "0.07464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.303443",
        "ticker_sentiment_score": "0.387461",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.022222",
        "ticker_sentiment_score": "0.07464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANH",
        "relevance_score": "0.022222",
        "ticker_sentiment_score": "0.07464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.088717",
        "ticker_sentiment_score": "0.092987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.154596",
        "ticker_sentiment_score": "-0.165615",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Bull of the Day: Eli Lilly  ( LLY ) ",
    "url": "https://www.zacks.com/commentary/2334886/bull-of-the-day-eli-lilly-lly",
    "time_published": "20240912T083000",
    "authors": [
      "Ethan Feller"
    ],
    "summary": "Eli Lilly stock boasts both defensive and growth characteristics ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default121.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.430288,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.67044",
        "ticker_sentiment_score": "0.636499",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Biotech Stocks to Buy With $200 Right Now",
    "url": "https://www.fool.com/investing/2024/09/12/3-no-brainer-biotech-stocks-to-buy-with-200-now/",
    "time_published": "20240912T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "An investment in these players today could score a big win down the road.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790260%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.249603,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.097013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "-0.109128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.097013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.224006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.097013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq",
    "url": "https://www.zacks.com/stock/news/2336072/roche-gets-fda-approval-for-subcutaneous-formulation-of-tecentriq",
    "time_published": "20240913T165400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.223635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.087397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "6 Incredible Reasons to Invest in Eli Lilly",
    "url": "https://www.fool.com/investing/2024/09/13/6-incredible-reasons-to-invest-in-eli-lilly/",
    "time_published": "20240913T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drug giant's winning ways look set to continue for a while.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789393/person-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.206963,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.222557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/14/3-stocks-to-buy-and-hold-forever/",
    "time_published": "20240914T113000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks are built for the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.302576,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420783",
        "ticker_sentiment_score": "0.432652",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.218423",
        "ticker_sentiment_score": "0.259411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.074855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss",
    "time_published": "20240916T173643",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, the FDA approved Eli Lilly And Co's LLY Ebglyss ( lebrikizumab-lbkz ) , a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds ( 40 kg ) with moderate-to-severe atopic dermatitis ( eczema ) that is not well controlled despite treatment ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/16/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.179124,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "-0.008359",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Eli Lilly's Recent Short Interest - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/40909431/looking-into-eli-lillys-recent-short-interest",
    "time_published": "20240917T204514",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly's LLY short percent of float has risen 14.71% since its last report. The company recently reported that it has 6.27 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726605911_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.28994,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Gets FDA Approval for Eczema Drug Ebglyss - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/news/earnings/24/09/40892929/lilly-gets-fda-approval-for-eczema-drug-ebglyss",
    "time_published": "20240917T190804",
    "authors": [
      "Zacks"
    ],
    "summary": "Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss ( lebrikizumab ) for treating moderate-to-severe atopic dermatitis, also called eczema.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/93/77794.jpg?v=624696101",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.288484,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.572379",
        "ticker_sentiment_score": "0.320131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.281584",
        "ticker_sentiment_score": "0.389905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.260547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?",
    "url": "https://www.zacks.com/stock/news/2337416/eli-lilly-stock-up-21-in-6-months-time-to-add-to-your-portfolio",
    "time_published": "20240917T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.356399,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "0.506143",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.070263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.07391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.123885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.202159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%",
    "url": "https://www.zacks.com/stock/news/2337393/novartis-kisqali-lowers-risk-of-breast-cancer-recurrence-by-28",
    "time_published": "20240917T160900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193596,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.051577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.066536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40901160/unpacking-the-latest-options-trading-trends-in-eli-lilly",
    "time_published": "20240917T141612",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 30 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726582568_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.050562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.106118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.239862",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.185522",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club",
    "url": "https://www.fool.com/investing/2024/09/17/prediction-this-will-be-the-first-healthcare-stock/",
    "time_published": "20240917T141500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790770%2Fgettyimages-1426368585.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.219432,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.11629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.11629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.11629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.015998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.386626",
        "ticker_sentiment_score": "0.279105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.015998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.115944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.015998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.115944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Most-Watched Stock Eli Lilly and Company  ( LLY )  Worth Betting on Now?",
    "url": "https://www.zacks.com/stock/news/2337011/is-most-watched-stock-eli-lilly-and-company-lly-worth-betting-on-now",
    "time_published": "20240917T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.266109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.213201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Gets FDA Approval for Eczema Drug Ebglyss",
    "url": "https://www.zacks.com/stock/news/2336877/lilly-gets-fda-approval-for-eczema-drug-ebglyss",
    "time_published": "20240917T081600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.254912,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.597724",
        "ticker_sentiment_score": "0.308009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.296582",
        "ticker_sentiment_score": "0.370588",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.248998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why ResMed Stock Tumbled by 5% Today",
    "url": "https://www.fool.com/investing/2024/09/18/why-resmed-stock-tumbled-by-5-today/",
    "time_published": "20240918T214935",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A looming threat from a very powerful rival could significantly dampen a key business for the company.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791199/medical-professional-with-hand-on-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.017473,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.127064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.63188",
        "ticker_sentiment_score": "0.029924",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise",
    "url": "https://www.zacks.com/stock/news/2338136/study-merck-and-daiichis-lung-cancer-treatment-shows-promise",
    "time_published": "20240918T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.069057,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.154125",
        "ticker_sentiment_score": "0.119943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.302553",
        "ticker_sentiment_score": "-0.08822",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.302553",
        "ticker_sentiment_score": "-0.08822",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.154125",
        "ticker_sentiment_score": "-0.062107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.154125",
        "ticker_sentiment_score": "0.120371",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novartis Wins FDA Approval of Kisqali for Early Breast Cancer - Eli Lilly  ( NYSE:LLY ) , Novartis  ( NYSE:NVS ) ",
    "url": "https://www.benzinga.com/news/earnings/24/09/40921029/novartis-wins-fda-approval-of-kisqali-for-early-breast-cancer",
    "time_published": "20240918T175230",
    "authors": [
      "Zacks"
    ],
    "summary": "Novartis NVS announced that the FDA has approved breast cancer drug Kisqali ( ribociclib ) for a broader population.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/e0/78240.jpg?v=1246149801",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.111568,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.119936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novartis Wins FDA Approval of Kisqali for Early Breast Cancer",
    "url": "https://www.zacks.com/stock/news/2337925/novartis-wins-fda-approval-of-kisqali-for-early-breast-cancer",
    "time_published": "20240918T131200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.075279,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.114094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.078549",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Tandem Diabetes Care Stock Thrashed the Market Today",
    "url": "https://www.fool.com/investing/2024/09/19/why-tandem-diabetes-care-stock-thrashed-the-market/",
    "time_published": "20240919T224908",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "At a stroke, it's got a product authorized for a specific use in 27 countries.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791311/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.314869,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.33055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.369433",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2338765/sanofi-stock-up-almost-23-in-3-months-buy-sell-or-hold",
    "time_published": "20240919T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/2080.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.294848,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.083396",
        "ticker_sentiment_score": "0.084644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.083396",
        "ticker_sentiment_score": "0.157409",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.083396",
        "ticker_sentiment_score": "0.084644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.680149",
        "ticker_sentiment_score": "0.354913",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?",
    "url": "https://www.zacks.com/stock/news/2338405/pfizer-stock-rises-73-in-3-months-should-you-invest-now",
    "time_published": "20240919T130500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.178634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.070983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.070983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.744396",
        "ticker_sentiment_score": "0.254925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025",
    "url": "https://www.fool.com/investing/2024/09/19/1-unstoppable-stock-that-could-join-the-1-trillion/",
    "time_published": "20240919T095000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.",
    "banner_image": "https://media.ycharts.com/charts/9263ab18bbec182246ec3f505c14b538.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.614086",
        "ticker_sentiment_score": "0.348868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.052574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Will be Eli Lilly's Next Big Move.",
    "url": "https://www.fool.com/investing/2024/09/19/prediction-this-will-be-eli-lillys-next-big-move/",
    "time_published": "20240919T081000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly could take a step that's positive for the stock and investors over the long term.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790977%2Fgettyimages-1253877215.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.27454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.561775",
        "ticker_sentiment_score": "0.425824",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.0284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.039076",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today",
    "url": "https://www.fool.com/investing/2024/09/20/why-novo-nordisk-stock-fell-while-eli-lilly-and-vi/",
    "time_published": "20240920T221445",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791468/medical-professional-holding-dollar-sign-paperweight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.154788,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.185227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.089296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "-0.011623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices - CVS Health  ( NYSE:CVS ) , Cigna  ( NYSE:CI ) , UnitedHealth Group  ( NYSE:UNH ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl",
    "time_published": "20240920T192652",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, the Federal Trade Commission ( FTC ) filed a formal complaint against three major pharmacy benefit managers ( PBMs ) -CVS Health Inc's CVS Caremark, Cigna Corp's CI Express Scripts, and UnitedHealth Group Inc's UNH Optum-for allegedly engaging in unfair and anti-competitive practices ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/20/Insulin-towfiqu-barbhuiya-unsplash.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.038726,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "-0.04132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "-0.04132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?",
    "url": "https://www.zacks.com/stock/news/2339393/nvo-stock-loses-around-29b-in-3-months-buy-the-dip-or-steer-clear",
    "time_published": "20240920T150300",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.260764,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.150357",
        "ticker_sentiment_score": "0.11855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.112471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.112471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.579577",
        "ticker_sentiment_score": "0.42745",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU",
    "url": "https://www.zacks.com/stock/news/2339290/nvo-gets-positive-chmp-opinion-for-wegovys-label-update-in-eu",
    "time_published": "20240920T150100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.223109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.285949",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.06957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.43494",
        "ticker_sentiment_score": "0.441017",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40957505/eli-lilly-fights-183m-medicaid-fraud-judgment-cites-reasonable-interpretation-of-medicaid-rules",
    "time_published": "20240920T131156",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co LLY has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid. The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/20/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.16509,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.640873",
        "ticker_sentiment_score": "-0.296838",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.276995",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.395464",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Roche Antiviral Drug Reduces Transmission in Late-stage Study",
    "url": "https://www.zacks.com/stock/news/2339163/roche-antiviral-drug-reduces-transmission-in-late-stage-study",
    "time_published": "20240920T124200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.050825,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.208166",
        "ticker_sentiment_score": "0.068439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.208166",
        "ticker_sentiment_score": "0.068439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Is What Eli Lilly Stock Will Do Next  ( Hint: It's Not a Stock Split ) ",
    "url": "https://www.fool.com/investing/2024/09/21/prediction-what-eli-lilly-stock-will-do-next/",
    "time_published": "20240921T135300",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "History shows that Eli Lilly tends to do something special with its stock toward the end of the year.",
    "banner_image": "https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.199341,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.852088",
        "ticker_sentiment_score": "0.373313",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.112378",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom",
    "url": "https://www.fool.com/investing/2024/09/22/investing-in-this-healthcare-stock-could-be-like/",
    "time_published": "20240922T121500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791156%2Fgettyimages-1302801668.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.256151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.615992",
        "ticker_sentiment_score": "0.396044",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.274166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time",
    "url": "https://www.zacks.com/stock/news/2340100/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time",
    "time_published": "20240923T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031987,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.098272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.098272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.538639",
        "ticker_sentiment_score": "-0.055105",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study",
    "url": "https://www.zacks.com/stock/news/2340066/nvo-stock-down-on-unsatisfactory-data-from-mid-stage-obesity-study",
    "time_published": "20240923T151900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.128342,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "0.241962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "0.086494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRBP",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.055207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.569063",
        "ticker_sentiment_score": "0.396414",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Spotlight on Eli Lilly: Analyzing the Surge in Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40981747/spotlight-on-eli-lilly-analyzing-the-surge-in-options-activity",
    "time_published": "20240923T134602",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 12 unusual trades. Delving into the details, we found 41% of traders were bullish, while 50% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727099159_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "-0.215429",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "-0.070692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "-0.070692",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU",
    "url": "https://www.zacks.com/stock/news/2339693/tndm-stock-likely-to-benefit-from-the-tslim-x2-lyumjev-offering-in-eu",
    "time_published": "20240923T123500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.254549,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TNDM",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.266416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.062079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.149955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PAHC",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.062079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.12696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.079319",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.045981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/41012589/1000-invested-in-eli-lilly-20-years-ago-would-be-worth-this-much-today",
    "time_published": "20240924T183013",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 20 years by 6.08% on an annualized basis producing an average annual return of 14.48%. Currently, Eli Lilly has a market capitalization of $827.14 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727202610_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "VTYX Stock Rises on Strategic Equity Investment Deal With SNY - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41009066/vtyx-stock-rises-on-strategic-equity-investment-deal-with-sny",
    "time_published": "20240924T180609",
    "authors": [
      "Zacks"
    ],
    "summary": "Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx's Series A non-voting convertible preferred stock for $3.8243 per share.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/36/78953.jpg?v=1922698421",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      }
    ],
    "overall_sentiment_score": 0.174697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.095841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTYX",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.373834",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.095841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.258166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time - Bayer  ( OTC:BAYRY ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40991131/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time",
    "time_published": "20240924T155553",
    "authors": [
      "Zacks"
    ],
    "summary": "Johnson & Johnson JNJ, via its subsidiary called Red River Talc, for the third time, filed for voluntary bankruptcy to resolve thousands of lawsuits related to its talc products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/52/78741.jpg?v=633076405",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.071284,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.141684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.116441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.518333",
        "ticker_sentiment_score": "-0.053958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VTYX Stock Rises on Strategic Equity Investment Deal With SNY",
    "url": "https://www.zacks.com/stock/news/2340664/vtyx-stock-rises-on-strategic-equity-investment-deal-with-sny",
    "time_published": "20240924T142400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/4119.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      }
    ],
    "overall_sentiment_score": 0.148818,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.256314",
        "ticker_sentiment_score": "0.090264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTYX",
        "relevance_score": "0.256314",
        "ticker_sentiment_score": "0.346839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.256314",
        "ticker_sentiment_score": "0.090264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.317254",
        "ticker_sentiment_score": "0.293467",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Blue Chip Stocks To Watch In Late September 2024",
    "url": "https://stockmarket.com/featured/2-blue-chip-stocks-to-watch-in-late-september-2024-2024-09-24",
    "time_published": "20240924T135449",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The stock market is a platform where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. Blue chip stocks represent shares of large, well-established companies with a history of stable ...",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/12/LLY-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.271091,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.227265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.375738",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?",
    "url": "https://www.zacks.com/stock/news/2340436/jj-seeks-3rd-talc-related-bankruptcy-time-to-sell-the-stock",
    "time_published": "20240924T131100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.097438,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.097721",
        "ticker_sentiment_score": "0.109881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.065238",
        "ticker_sentiment_score": "0.213554",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.097721",
        "ticker_sentiment_score": "-0.142317",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke",
    "time_published": "20240924T125032",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co's LLY Kisunla ( donanemab ) for adults with early symptomatic Alzheimer's disease ( AD ) , which includes people with mild cognitive impairment ( MCI ) as well as people with the mild dementia stage of AD, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/24/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.083482,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313484",
        "ticker_sentiment_score": "0.141562",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41036415/eli-lilly-stock-soars-in-2024-on-weight-loss-drug-success-now-the-company-wants-medical-records-o",
    "time_published": "20240925T220135",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Eli Lilly And Co LLY is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe. What Happened: A recent report says Eli Lilly is seeking medical records of people who took ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Eli-Lilly_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.007335,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.912924",
        "ticker_sentiment_score": "-0.173542",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic",
    "time_published": "20240925T195925",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes ( T2D ) and opioid use disorder ( OUD ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Ozempic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.01945,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.119309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.087455",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear",
    "time_published": "20240925T185437",
    "authors": [
      "Maureen Meehan"
    ],
    "summary": "A new study has found that people with a history of opioid abuse who took Novo Nordisk's NVO Ozempic weight loss drug were significantly less likely to overdose, adding to growing evidence suggesting that the drug, primarily used for diabetes and weight loss, could help manage drug addiction.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Ozempic-copy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.024084,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "-0.109479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.036994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/41032570/eli-lilly-unusual-options-activity",
    "time_published": "20240925T183132",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727289089_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095605,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.061994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "-0.049726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "-0.049726",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol",
    "time_published": "20240925T173000",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna ( inebilizumab ) . HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis ( eczema ) in 726 patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Amgen-stock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.260004,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.270171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.242617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.523202",
        "ticker_sentiment_score": "-0.042106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.270171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan",
    "url": "https://www.zacks.com/stock/news/2341519/eli-lilly-secures-approval-for-alzheimers-drug-kisunla-in-japan",
    "time_published": "20240925T154500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.056537,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.572601",
        "ticker_sentiment_score": "0.178968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.308504",
        "ticker_sentiment_score": "0.05686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.191609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.207091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.044083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41024832/eli-lilly-touts-results-of-eu-approved-dermatitis-treatment-shows-sustained-disease-control-for-u",
    "time_published": "20240925T131612",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co MRK revealed new long-term results on Wednesday, showing promise for treatment in patients with moderate-to-severe atopic dermatitis. What Happened: The company's data for the ADjoin long-term extension study of Ebglyss ( EHB-glihs ) will be presented at the European Academy of ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.202857,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.154518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why This Stock Could Be the Nvidia of Healthcare",
    "url": "https://www.fool.com/investing/2024/09/25/why-this-stock-could-be-the-nvidia-of-healthcare/",
    "time_published": "20240925T113000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "The opportunities for artificial intelligence (AI) to have an impact in the healthcare space are enormous.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791495%2Fgettyimages-1496103634.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.235754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.42944",
        "ticker_sentiment_score": "0.457571",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.058956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEXAF",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.174807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2342235/eli-lilly-lly-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240926T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.172015,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.259654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health",
    "url": "https://www.zacks.com/stock/news/2341944/buy-these-5-big-drug-stocks-to-boost-your-portfolios-health",
    "time_published": "20240926T134000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.98396"
      }
    ],
    "overall_sentiment_score": 0.279823,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.199271",
        "ticker_sentiment_score": "0.266416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.281584",
        "ticker_sentiment_score": "0.273174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.028764",
        "ticker_sentiment_score": "0.225484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.10702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.137164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Analysts Think Lilly  ( LLY )  Is a Good Investment: Is It?",
    "url": "https://www.zacks.com/stock/news/2341861/wall-street-analysts-think-lilly-lly-is-a-good-investment-is-it",
    "time_published": "20240926T133012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/LLY_09262024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.308698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.359262",
        "ticker_sentiment_score": "0.232405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2341689/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240926T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default18.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.250919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.125682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should SPDR MSCI USA StrategicFactors ETF  ( QUS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2341685/should-spdr-msci-usa-strategicfactors-etf-qus-be-on-your-investing-radar",
    "time_published": "20240926T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.148051,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.063022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.063022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.063022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.048004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.",
    "url": "https://www.fool.com/investing/2024/09/26/novo-nordisk-million-gambit-gamechange-stock/",
    "time_published": "20240926T094000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The healthcare company's pivot into a new set of technologies will have many implications for the stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791600/investors-holding-printouts-talk-to-each-other-at-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.21222,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "-0.068116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.158113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.223618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRRO",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.132125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks to Buy and Hold for 5 Years",
    "url": "https://www.zacks.com/stock/news/2342944/stocks-to-buy-and-hold-for-5-years",
    "time_published": "20240927T195200",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      }
    ],
    "overall_sentiment_score": 0.183571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.294682",
        "ticker_sentiment_score": "0.081759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.124202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.323818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.317308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.42944",
        "ticker_sentiment_score": "0.029153",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More",
    "url": "https://www.zacks.com/stock/news/2342934/pharma-stock-roundup-jnjs-3rd-talc-related-bankruptcy-filing-more",
    "time_published": "20240927T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": -0.014763,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.105295",
        "ticker_sentiment_score": "-0.059719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.097752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.097752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.0374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.254136",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.242544",
        "ticker_sentiment_score": "-0.088631",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bayer Submits Application for Label Expansion of Prostate Cancer Drug",
    "url": "https://www.zacks.com/stock/news/2342761/bayer-submits-application-for-label-expansion-of-prostate-cancer-drug",
    "time_published": "20240927T141900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.043887,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.054909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.202887",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.054909",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason",
    "url": "https://www.fool.com/investing/2024/09/27/prediction-lilly-will-dominate-weight-loss-market/",
    "time_published": "20240927T075000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly is focusing on research and manufacturing.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792059%2Fgettyimages-researcher-works-in-lab_computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.166971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.760593",
        "ticker_sentiment_score": "0.251004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.050011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.011016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.075706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.050011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years",
    "url": "https://www.fool.com/investing/2024/09/28/success-in-new-battleground-could-make-eli-lilly/",
    "time_published": "20240928T140000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These two players are set on finding the next big therapeutic modality.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791605/group-of-scientists-with-microscopes-lab-testing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.277518,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.336852",
        "ticker_sentiment_score": "0.301353",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.214557",
        "ticker_sentiment_score": "0.104989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Unstoppable Growth Stock Heading to $2 Trillion by 2030",
    "url": "https://www.fool.com/investing/2024/09/28/1-unstoppable-growth-stock-heading-to-2-trillion-b/",
    "time_published": "20240928T094500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's hard to bet against this company right now.",
    "banner_image": "https://media.ycharts.com/charts/c1ffc679f00f27f088ba9db617ffc8ab.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.266974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.229485",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "-0.050198",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/28/got-1000-2-superior-growth-stocks-to-buy-and-hold/",
    "time_published": "20240928T091500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Eli Lilly and Lululemon operate in very different industries, but both are on promising trajectories.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791867/shocked-woman-looking-at-mobile-phone-screen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998682"
      }
    ],
    "overall_sentiment_score": 0.21249,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.051986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.271059",
        "ticker_sentiment_score": "0.251986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "-0.026527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is the Best Pharma Stock to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/09/29/this-is-the-best-pharma-stock-to-invest-1000-in/",
    "time_published": "20240929T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Eli Lilly could keep growing for years without changing its strategy.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791713/standing-pair-of-investors-consider-tablet-and-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.187663,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.509589",
        "ticker_sentiment_score": "0.3078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/signals/24/09/41107464/tradepulse-power-inflow-alert-eli-lilly-and-company-climbs-15-points",
    "time_published": "20240930T232834",
    "authors": [
      "Finit"
    ],
    "summary": "STOCK RISES THOUGHT THE DAY AND HITS HIGH AT 3:55 PM EDT ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.",
    "banner_image": "https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/30203158/Screen-Shot-2024-09-30-at-4.28.14-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.293278,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.230033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sanofi, Regeneron's Dupixent Gets FDA Approval For COPD - Eli Lilly  ( NYSE:LLY ) , Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41103940/sanofi-regenerons-dupixent-gets-fda-approval-for-copd",
    "time_published": "20240930T203720",
    "authors": [
      "Zacks"
    ],
    "summary": "Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication - chronic obstructive pulmonary disease ( COPD ) - in the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/e4/79621.jpg?v=1565371588",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.260147,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261818",
        "ticker_sentiment_score": "0.154928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.261818",
        "ticker_sentiment_score": "0.154928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.496201",
        "ticker_sentiment_score": "0.428699",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD",
    "url": "https://www.zacks.com/stock/news/2343644/sanofi-regenerons-dupixent-gets-fda-approval-for-copd",
    "time_published": "20240930T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.241884,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.14211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.14211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.513353",
        "ticker_sentiment_score": "0.42038",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate - Aquestive Therapeutics  ( NASDAQ:AQST ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41101457/optimism-around-aquestive-as-it-moves-forward-with-severe-allergy-baldness-candidat",
    "time_published": "20240930T182549",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Aquestive Therapeutics, Inc. AQST hosted a virtual investor day highlighting the company's Anaphylm ( epinephrine ) Sublingual Film and AQST-108 ( epinephrine ) Topical Gel. Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/30/Genetic-Research-And-Biotech-Science-Con_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.115617,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.010465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.010465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.008883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AQST",
        "relevance_score": "0.735253",
        "ticker_sentiment_score": "0.204658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential - Roche Holding  ( OTC:RHHBY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41097630/roche-fast-tracks-obesity-drug-development-eyes-over-3b-sales-potential",
    "time_published": "20240930T153910",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG RHHBY outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, renal, and metabolism diseases.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/30/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.068411,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.16003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.16003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Trending Stock Eli Lilly and Company  ( LLY )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2343214/is-trending-stock-eli-lilly-and-company-lly-a-buy-now",
    "time_published": "20240930T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default154.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.248649,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.182563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Invesco Large Cap Growth ETF  ( PWB )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2343100/should-invesco-large-cap-growth-etf-pwb-be-on-your-investing-radar",
    "time_published": "20240930T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default149.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.309298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADBE",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.06112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.06112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.06112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.263785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy AbbVie Stock After Recent Parkinson's Study Success?",
    "url": "https://www.zacks.com/stock/news/2344351/should-you-buy-abbvie-stock-after-recent-parkinsons-study-success",
    "time_published": "20241001T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.298836,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.082318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.082318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.671398",
        "ticker_sentiment_score": "0.432166",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Options: A Look at What the Big Money is Thinking - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41121247/eli-lillys-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20241001T150140",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727794897_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.074406,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.578355",
        "ticker_sentiment_score": "-0.134594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "-0.070999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors",
    "url": "https://www.zacks.com/stock/news/2344150/roche-ramps-up-breast-cancer-pipeline-with-regors-cdk-inhibitors",
    "time_published": "20241001T140400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.07535,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.260827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.260827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41118751/eli-lilly-eyes-new-trials-for-weight-loss-drugs-in-non-obese-patients",
    "time_published": "20241001T133619",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Pharmaceutical giant Eli Lilly and Co LLY is reportedly exploring broader applications for its popular weight-loss drugs, Mounjaro and Zepbound.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/01/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.095851,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.208435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41116758/eli-lilly-aims-to-expand-weight-loss-drug-trials-to-those-at-risk-not-just-overweight",
    "time_published": "20241001T125101",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight. What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity drugs, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/01/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.041114,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.576289",
        "ticker_sentiment_score": "0.139203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/10/41114297/the-rush-for-non-addictive-painkillers-to-counter-the-opioid-crisis-puts-two-companies-closer-to-",
    "time_published": "20241001T113000",
    "authors": [
      "Mangeet Kaur Bouns"
    ],
    "summary": "This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/01/Screenshot-2024-09-30-at-9-13-36PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.201281,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.107931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.121159",
        "ticker_sentiment_score": "-0.019561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "-0.101306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana",
    "time_published": "20241002T181155",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/02/TNDM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.223992,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.10428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock",
    "url": "https://www.zacks.com/stock/news/2344870/heres-why-you-should-consider-buying-jazz-pharmaceuticals-stock",
    "time_published": "20241002T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.187809,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "0.04661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "-0.002792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.094578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "-0.002789",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41143302/eli-lilly-commits-4-5b-to-new-facility-banking-on-mounjaro-zepbounds-weight-loss-success-despite-",
    "time_published": "20241002T143712",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co LLY is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility. The goal? To bolster its drug pipeline and develop faster, more efficient ways to bring treatments to market.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.23398,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.628473",
        "ticker_sentiment_score": "0.386513",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-",
    "time_published": "20241002T130645",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co. LLY announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/02/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.333852,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.68039",
        "ticker_sentiment_score": "0.448187",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.324918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation",
    "time_published": "20241002T110258",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. Pharmaceutical giant Eli Lilly And Co LLY is riding high on the popularity of weight loss drugs and is on the brink of becoming the world's first trillion-dollar pharmaceutical company. According to data from Benzinga Pro, the company's market cap stood at $796.4 billion, and its enterprise ...",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.154286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.665097",
        "ticker_sentiment_score": "0.037579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.130666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2344495/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20241002T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.08818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.070004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2344496/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20241002T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default259.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.276668,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.127463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.089081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.064107",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000% - CVS Health  ( NYSE:CVS ) , Cigna  ( NYSE:CI ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/government/24/10/41172976/texas-attorney-general-sues-insulin-manufacturers-and-pharmacy-benefit-managers-over-price-fixing-co",
    "time_published": "20241003T192706",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Texas Attorney General Ken Paxton has filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers ( PBMs ) , alleging a conspiracy to inflate insulin prices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/Insulin-towfiqu-barbhuiya-unsplash.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.029332,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.17429",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "-0.234729",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant",
    "url": "https://www.zacks.com/stock/news/2345654/eli-lilly-to-invest-45b-for-new-manufacturing-research-plant",
    "time_published": "20241003T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.290343,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.652756",
        "ticker_sentiment_score": "0.48243",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "-0.00299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.140218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "-0.001492",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are Medical Stocks Lagging Eli Lilly  ( LLY )  This Year?",
    "url": "https://www.zacks.com/stock/news/2345380/are-medical-stocks-lagging-eli-lilly-lly-this-year",
    "time_published": "20241003T134012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.283441,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLFS",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.320537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.729556",
        "ticker_sentiment_score": "0.457071",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Hims & Hers Health Stock Is Tumbling Thursday: Here's Why - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/news/24/10/41164688/hims-hers-health-stock-is-tumbling-thursday-heres-why",
    "time_published": "20241003T133126",
    "authors": [
      "Adam Eckert"
    ],
    "summary": "Hims & Hers Health Inc HIMS shares are trading lower Thursday in possible sympathy with Eli Lilly And Co's LLY, after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs shortage list.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/10-Celebrities-Open-Up-About-Their-Ozemp.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.026678,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "-0.143353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.473208",
        "ticker_sentiment_score": "0.181696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "-0.145883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This IPO Biotech Stock Could Be the Next Eli Lilly",
    "url": "https://www.fool.com/investing/2024/10/03/this-ipo-biotech-stock-could-be-the-next-eli-lilly/",
    "time_published": "20241003T130500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "BioAge has its eyes on a handful of truly gargantuan markets.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792435/3-investors-gather-around-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.188187,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.168426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIOA",
        "relevance_score": "0.095327",
        "ticker_sentiment_score": "0.103925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.110574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Rises But Trails Market: What Investors Should Know",
    "url": "https://www.zacks.com/stock/news/2346351/eli-lilly-lly-rises-but-trails-market-what-investors-should-know",
    "time_published": "20241004T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244562,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.548363",
        "ticker_sentiment_score": "0.360438",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More",
    "url": "https://www.zacks.com/stock/news/2346320/pharma-stock-roundup-fda-approves-snys-dupixent-for-copd-more",
    "time_published": "20241004T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.091334,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.182684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.031172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.095327",
        "ticker_sentiment_score": "0.071683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "-0.123788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "0.099977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages - Hims & Hers Health  ( NYSE:HIMS ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41190700/hims-hers-health-asserts-demand-for-its-compounded-weight-loss-offering-to-continue",
    "time_published": "20241004T182139",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, The FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 ( GLP-1 ) medication, has been resolved. Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/04/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.123986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.127387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.409503",
        "ticker_sentiment_score": "-0.049865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "-0.190632",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41186834/evaluating-eli-lilly-against-peers-in-pharmaceuticals-industry",
    "time_published": "20241004T150014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Eli Lilly LLY in relation to its major competitors in the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728054011_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.216608,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.465599",
        "ticker_sentiment_score": "0.324733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41186057/englands-nhs-proposes-phased-rollout-of-eli-lillys-mounjaro-considers-digital-services-to-boost-a",
    "time_published": "20241004T141941",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes. Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co LLY, has shown remarkable results in clinical trials.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/04/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.27692,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.251673",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.154459",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs",
    "url": "https://www.zacks.com/stock/news/2345929/abbvie-cuts-2024-earnings-guidance-to-include-acquisition-costs",
    "time_published": "20241004T131100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999326"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.229059,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.13576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.072391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.584103",
        "ticker_sentiment_score": "0.385825",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades",
    "url": "https://www.fool.com/investing/2024/10/05/want-1-million-in-retirement-3-stocks-to-buy-now-a/",
    "time_published": "20241005T084500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Investors can find market-trouncing blue chip stocks in the healthcare industry.",
    "banner_image": "https://media.ycharts.com/charts/101205710d2eec3e01faedec405c08eb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.35083,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.19113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.275246",
        "ticker_sentiment_score": "0.267149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.164612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2347080/should-jnj-stock-be-in-your-portfolio-ahead-of-q3-earnings",
    "time_published": "20241007T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.194534,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073434",
        "ticker_sentiment_score": "0.158442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073434",
        "ticker_sentiment_score": "0.194941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.16237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Momentum Trades Too Good Pass Up - Intel  ( NASDAQ:INTC ) , Dell Technologies  ( NYSE:DELL ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/10/41206980/3-momentum-trades-too-good-pass-up",
    "time_published": "20241007T171054",
    "authors": [
      "MarketBeat"
    ],
    "summary": "Momentum investing is based on the idea that stocks that have risen recently will tend to keep rising and that stocks that have fallen tend to keep falling. In 1993, researchers Narasimhan Jegadeesh and Sheridan Titman at UCLA brought the idea forward. Momentum investing has held up over the past ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/07/its-me-pravin-0uvsmgdeukm-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.219564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.3038",
        "ticker_sentiment_score": "0.135723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.103554",
        "ticker_sentiment_score": "0.135472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.103554",
        "ticker_sentiment_score": "0.084805",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Large Drug Stocks to Watch From a Thriving Industry",
    "url": "https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industry",
    "time_published": "20241007T135800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.99986"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.236353,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.121547",
        "ticker_sentiment_score": "0.237206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.020335",
        "ticker_sentiment_score": "0.055942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.201188",
        "ticker_sentiment_score": "0.195477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.020335",
        "ticker_sentiment_score": "0.268563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.081207",
        "ticker_sentiment_score": "0.012409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.141607",
        "ticker_sentiment_score": "0.119724",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company",
    "time_published": "20241007T135744",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc REGN, has voiced concerns that the popular GLP-1s class of weight-loss drugs may lead to unintended health risks, particularly rapid muscle loss.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/07/REGN.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.045783,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "-0.080395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.015503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "-0.194565",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now",
    "url": "https://www.fool.com/investing/2024/10/07/2-next-gen-weight-loss-stocks-worth-buying/",
    "time_published": "20241007T120000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "One of these businesses is a risky play, but the other is very likely to succeed.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793007/scientist-gestures-to-diagram-on-whiteboard.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.227144,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.215702",
        "ticker_sentiment_score": "0.139251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOA",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.153321",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "0.097323",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity - Has US Reached A Turning Point? - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41199948/economist-justin-wolfers-points-to-obesity-rate-decline-as-ozempic-and-wegovy-spur-historic-shif",
    "time_published": "20241007T024605",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "The United States may have reached a turning point in its decades-long battle against obesity. Recent data suggests that 2020 could mark the year when obesity rates in America not only peaked but began to decline, echoing the historic moment in 1963 when cigarette sales in the U.S. hit their apex ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/06/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.033949,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "-0.134788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "-0.030346",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Was Such a Healthy Stock Today",
    "url": "https://www.fool.com/investing/2024/10/08/why-eli-lilly-was-such-a-healthy-stock-today/",
    "time_published": "20241008T221603",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793481/patient-being-weighed-by-a-medical-professional.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.256301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.386875",
        "ticker_sentiment_score": "0.373214",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pfizer Receives $1 Billion From Starboard Value, Stock Rises",
    "url": "https://www.zacks.com/stock/news/2347809/pfizer-receives-1-billion-from-starboard-value-stock-rises",
    "time_published": "20241008T181700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.233338,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.287875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.079908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.287875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.752955",
        "ticker_sentiment_score": "0.428529",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41232660/fda-sparks-controversy-with-sudden-removal-of-eli-lillys-weight-loss-drug-from-shortage-list",
    "time_published": "20241008T151646",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Last week, the FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 ( GLP-1 ) medication, has been resolved. The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.024547,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.110567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.098931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( LLY )  - Analyzing Eli Lilly's Short Interest - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41228527/lly-analyzing-eli-lillys-short-interest",
    "time_published": "20241008T131518",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly's LLY short percent of float has risen 5.13% since its last report. The company recently reported that it has 6.58 million shares sold short, which is 0.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.61 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728393315_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.28994,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/10/08/with-its-glp-1-drugs-no-longer-in-a-shortage-is-no/",
    "time_published": "20241008T101500",
    "authors": [
      "Geoffrey Seiler"
    ],
    "summary": "Growth for its GLP-1 weight loss drugs continues to be robust.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792974%2Fgettyimages-2025836701.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.197849,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.266246",
        "ticker_sentiment_score": "0.124842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.049405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.05567",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer",
    "url": "https://www.zacks.com/stock/news/2347200/zacks-industry-outlook-eli-lilly-astrazeneca-pfizer-sanofi-and-bayer",
    "time_published": "20241008T080300",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.99986"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.240928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.019443",
        "ticker_sentiment_score": "-0.038667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.211358",
        "ticker_sentiment_score": "0.196511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.019443",
        "ticker_sentiment_score": "0.126689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.019443",
        "ticker_sentiment_score": "0.255771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135456",
        "ticker_sentiment_score": "0.212526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.096984",
        "ticker_sentiment_score": "0.011819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.154578",
        "ticker_sentiment_score": "0.113853",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billion-Dollar News for Eli Lilly Stock Investors",
    "url": "https://www.fool.com/investing/2024/10/07/billion-dollar-news-for-eli-lilly-stock-investors/",
    "time_published": "20241008T001000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793148%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.187586,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.109937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.594341",
        "ticker_sentiment_score": "0.304819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.00331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit - CVS Health  ( NYSE:CVS ) , UnitedHealth Group  ( NYSE:UNH ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit",
    "time_published": "20241009T173917",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In September, the Federal Trade Commission ( FTC ) filed a formal complaint against three major pharmacy benefit managers ( PBMs ) -CVS Health Inc's CVS Caremark, Cigna Corp's CI Express Scripts, and UnitedHealth Group Inc's UNH Optum-for allegedly engaging in unfair and anti-competitive ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/09/Medicine.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.041383,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "-0.204373",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.503018",
        "ticker_sentiment_score": "-0.057885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "-0.240315",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "NVS or LLY: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2348444/nvs-or-lly-which-is-the-better-value-stock-right-now",
    "time_published": "20241009T154013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.48896,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.632565",
        "ticker_sentiment_score": "0.575962",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "What's Going With WeightWatchers Stock On Wednesday? - WW International  ( NASDAQ:WW ) ",
    "url": "https://www.benzinga.com/news/24/10/41250079/whats-going-with-weightwatchers-stock-on-wednesday",
    "time_published": "20241009T130912",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "WeightWatchers ( WW International ) WW stock is trading higher on Wednesday, with a session volume strong at 31.45 million, compared to an average volume of 3.25 million as per data from Benzinga Pro.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/09/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.079133,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "-0.209369",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WW",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "0.207166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.460395",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Growth ETF  ( PWB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2347946/is-invesco-large-cap-growth-etf-pwb-a-strong-etf-right-now",
    "time_published": "20241009T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.334234,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADBE",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.056456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.056456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.056456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.294446",
        "ticker_sentiment_score": "0.399151",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly  ( LLY )  Fell More Than Broader Market",
    "url": "https://www.zacks.com/stock/news/2349031/heres-why-eli-lilly-lly-fell-more-than-broader-market",
    "time_published": "20241010T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default213.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.141033,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.469457",
        "ticker_sentiment_score": "0.18429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Don't Sleep on Skye Bioscience-This Weight Loss Drug Could Soar - Skye Bioscience  ( NASDAQ:SKYE ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41271761/dont-sleep-on-skye-bioscience-this-weight-loss-drug-could-soar",
    "time_published": "20241010T181828",
    "authors": [
      "MarketBeat"
    ],
    "summary": "Skye Bioscience SKYE is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 ( GLP-1 ) agonist drugs sold by Eli Lilly LLY and Novo Nordisk has prompted Wall Street analysts to place high ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/10/pina-messina-iidirmityik-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.038893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.065126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.060757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKYE",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "0.02337",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears - Catalent  ( NYSE:CTLT ) , Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41277809/ftc-faces-pressure-to-block-novo-nordisk-catalent-merger-over-antitrust-fears",
    "time_published": "20241010T171225",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "United States Senator Elizabeth Warren wrote a letter to the Federal Trade Commission's chair, Lina Khan, urging to investigate Novo Nordisk A/S NVO proposed $16.5 billion acquisition of contract development and manufacturing organization Catalent Inc CTLT thoroughly, amid growing concerns about ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/10/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.113107,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.132977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.050147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.045963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.656549",
        "ticker_sentiment_score": "0.104972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41275991/eli-lilly-issues-cease-and-desist-letters-to-compounders-over-weight-loss-drug-copies-as-shortage",
    "time_published": "20241010T154859",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co. LLY is ramping up its legal campaign against the compounding companies temporarily allowed to make and sell copycat versions of its blockbuster drugs for weight loss until a U.S. shortage.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/10/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.079359,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.125254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.068921",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease",
    "url": "https://www.zacks.com/stock/news/2348881/rvtys-latest-launch-to-enable-apoe-genotyping-of-alzheimers-disease",
    "time_published": "20241010T140000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.159322,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.0954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.009276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.111598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.159444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RVTY",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.189334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 No-Brainer Dividend Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/10/10/2-no-brainer-dividend-growth-stocks-to-buy-right-n/",
    "time_published": "20241010T104500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793564%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.509785,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.352223",
        "ticker_sentiment_score": "0.691403",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.405963",
        "ticker_sentiment_score": "0.629441",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2348655/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20241010T102002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.182104,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.117587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p",
    "time_published": "20241011T181110",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO and Eli Lilly And Co LLY have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.277047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.24847",
        "ticker_sentiment_score": "0.364435",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.307731",
        "ticker_sentiment_score": "0.439554",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.045317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.107055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top 3 Stocks with Explosive Call Option Activity: What to Watch - Hims & Hers Health  ( NYSE:HIMS ) , SPDR Gold Trust  ( ARCA:GLD ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41290214/top-3-stocks-with-explosive-call-option-activity-what-to-watch",
    "time_published": "20241011T172939",
    "authors": [
      "MarketBeat"
    ],
    "summary": "When considering a long position in a stock, investors usually consider buying shares in a company to express their views. However, they need to realize that there is a much more aggressive way to gain long exposure to a stock.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/m-zzoa5g8hspi-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227439,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "-0.16509",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MSCI",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.084559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.058786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.201894",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.20799",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.20799",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.047891",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Beating the S&P 500 in 2024  ( Excluding NVIDIA ) ",
    "url": "https://www.zacks.com/stock/news/2349475/stocks-beating-the-sp-500-in-2024-excluding-nvidia",
    "time_published": "20241011T170000",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "Some say it is \"easy\" to beat the S&P 500 this year. Tracey picked 5 random hot stocks to test the theory.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/02/36829.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.262694,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.105696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.447528",
        "ticker_sentiment_score": "0.275589",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.317089",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.226582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.396798",
        "ticker_sentiment_score": "0.328203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.344074",
        "ticker_sentiment_score": "0.265685",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.396798",
        "ticker_sentiment_score": "0.059158",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41294060/criminal-networks-cash-in-on-demand-for-weight-loss-drugs-authorities-say",
    "time_published": "20241011T153631",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The shortage of drugs like Novo Nordisk A/S' NVO Ozempic, Wegovy, and Eli Lilly And Co's LLY Mounjaro and Zepbound have fueled an illicit market of counterfeit and diverted weight loss drugs, revealing an international issue that poses significant health risks.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/Ozempic.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.151899,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.423843",
        "ticker_sentiment_score": "-0.289712",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.358669",
        "ticker_sentiment_score": "-0.27197",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "url": "https://www.fool.com/investing/2024/10/11/warning-this-skyrocketing-stock-has-a-hidden-risk/",
    "time_published": "20241011T080500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly stock has jumped 200% over the past two years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793516%2Fgettyimages-1199696916.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.029351,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.614932",
        "ticker_sentiment_score": "-0.021992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "-0.267876",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.210731",
        "ticker_sentiment_score": "-0.147122",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Growth Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/13/3-no-brainer-growth-stocks-to-buy-in-october/",
    "time_published": "20241013T111500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks look like slam-dunk picks for growth investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793761/dog-with-owners-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.163964,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.15936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.212407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.303644",
        "ticker_sentiment_score": "0.119385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/13/got-500-magnificent-growth-stocks-to-buy-and-hold/",
    "time_published": "20241013T091600",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These industry leaders still look like top-notch buys.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793590/shocked-woman-looking-at-mobile-phone-screen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.310693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMG",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.063665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.304248",
        "ticker_sentiment_score": "0.259475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.060316",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41318886/eli-lillys-alzheimers-drug-raises-hopes-but-faces-regulatory-hurdles-in-europe",
    "time_published": "20241014T175152",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly And Co LLY announced plans to boost its presence in the U.K., following a collaboration with the U.K. government that was revealed at the International Investment Summit. The global pharmaceutical giant is set to invest in a new Gateway Lab in the U.K., building on the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Indianapolis---Circa-November-2021-Eli-L.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.14584,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.215579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "-0.134955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "-0.181939",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Hims & Hers Health Stock Is Popping Monday: What's Behind The Move? - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/news/24/10/41317548/hims-hers-health-stock-is-popping-monday-whats-behind-the-move",
    "time_published": "20241014T163549",
    "authors": [
      "Adam Eckert"
    ],
    "summary": "Hims & Hers Health Inc HIMS shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own versions of blockbuster weight loss drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/10-Celebrities-Open-Up-About-Their-Ozemp.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.019497,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "-0.058249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.60415",
        "ticker_sentiment_score": "0.206134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "-0.106333",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41314649/more-patients-on-eli-lillys-mirikizumab-achieved-histologic-response-at-one-year-compared-to-john",
    "time_published": "20241014T144905",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly And Co LLY announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control ( Johnson & Johnson's JNJ Stelara ( ustekinumab ) ) in adults with moderately to severely active Crohn's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.084845,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.520773",
        "ticker_sentiment_score": "0.013186",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/10/14/which-pharma-stock-is-better-buy-pfizer-eli-lilly/",
    "time_published": "20241014T140000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These two stocks will appeal to very different types of investors at the moment.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793712/investor-holds-glasses-while-considering-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.14991,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.222437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.378795",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41313216/fda-to-reassess-ban-on-cheaper-compounded-versions-of-eli-lilly-weight-loss-drugs",
    "time_published": "20241014T134347",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The U.S. Food and Drug Administration ( FDA ) is reassessing a decision to ban compounding pharmacies to supply cheaper versions of Eli Lilly And Co's LLY blockbuster weight loss and diabetes drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/FDAheadquarters-copy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.113469,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.640349",
        "ticker_sentiment_score": "-0.080774",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2349720/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
    "time_published": "20241014T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default116.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.235287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.120082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Value Trader Highlights: Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy",
    "url": "https://www.zacks.com/stock/news/2349624/zacks-value-trader-highlights-costco-wholesale-cava-eli-lilly-toll-brothers-and-constellation-energy",
    "time_published": "20241014T103000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy are part of the Zacks Value Trader article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.308209,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.087344",
        "ticker_sentiment_score": "0.096856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.339162",
        "ticker_sentiment_score": "0.227613",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.216087",
        "ticker_sentiment_score": "0.257973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.257895",
        "ticker_sentiment_score": "0.181813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.298957",
        "ticker_sentiment_score": "0.267664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAVA",
        "relevance_score": "0.257895",
        "ticker_sentiment_score": "0.212846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.298957",
        "ticker_sentiment_score": "0.047638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List",
    "url": "https://www.zacks.com/stock/news/2350986/fda-to-reconsider-removal-of-lillys-obesity-drug-from-shortage-list",
    "time_published": "20241015T173900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.028985,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.180574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.005456",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance",
    "url": "https://www.zacks.com/stock/news/2350818/jj-beats-on-q3-earnings-raises-sales-view-but-cuts-eps-guidance",
    "time_published": "20241015T152600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.100143,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.058117",
        "ticker_sentiment_score": "0.06697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.079239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "0.042513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.08708",
        "ticker_sentiment_score": "-0.020869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41335525/eli-lilly-unusual-options-activity",
    "time_published": "20241015T141621",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729001778_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.088155,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "-0.007437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival - Halliburton  ( NYSE:HAL ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca",
    "time_published": "20241015T122207",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Uranium Energy Corp. UEC is going higher. \"UEC's the real deal\u2026We need more uranium. I think it's a great situation,\" he added. On Sept. 23, Uranium Energy disclosed a deal to fully acquire Rio Tinto Plc's RIO Wyoming assets for a purchase ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/15/Jim-Cramer-questo-titolo--un-affare-da-n_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.149487,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIO",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.135308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.478939",
        "ticker_sentiment_score": "0.120095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "-0.069383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.369685",
        "ticker_sentiment_score": "-0.073595",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win",
    "url": "https://www.zacks.com/stock/news/2351761/inside-the-booming-obesity-drug-market-weight-loss-etfs-to-win",
    "time_published": "20241016T174700",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/60715.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.012062,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.260004",
        "ticker_sentiment_score": "0.06956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.042766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.02597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.107639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.034954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.076525",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon",
    "url": "https://www.fool.com/investing/2024/10/16/3-reasons-eli-lilly-stock-isnt-going-to-run-out-of/",
    "time_published": "20241016T140700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793882/a-doctor-using-a-scale-to-measure-a-persons-weight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      }
    ],
    "overall_sentiment_score": 0.344054,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "0.56166",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU",
    "url": "https://www.zacks.com/stock/news/2351586/bayer-seeks-approval-for-elinzanetant-for-vasomotor-symptoms-in-eu",
    "time_published": "20241016T135000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.154276,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.066185",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024",
    "url": "https://www.fool.com/investing/2024/10/16/this-artificial-intelligence-move-is-1-new-reason/",
    "time_published": "20241016T113000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Lilly is staying ahead of the technology curve instead of falling behind.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793848/woman-stock-broker-investor-tracking-stocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.246506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.492659",
        "ticker_sentiment_score": "0.400955",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?",
    "url": "https://www.fool.com/investing/2024/10/16/eli-lilly-vs-novo-nordisk-which-weight-loss-stock/",
    "time_published": "20241016T101500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793948%2Fgettyimages-2025836701-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.338516,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.55207",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.491488",
        "ticker_sentiment_score": "0.528343",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should Eli Lilly Investors Worry About This Unexpected FDA Move?",
    "url": "https://www.fool.com/investing/2024/10/16/should-lilly-investors-worry-about-fda-decision/",
    "time_published": "20241016T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Lilly has invested billions of dollars to ramp up production capacity.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794106%2Fgettyimages-1276837766.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.060196,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.786972",
        "ticker_sentiment_score": "0.163731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Loses Around $14B This Week: How to Play LLY Stock",
    "url": "https://www.zacks.com/stock/news/2352659/lilly-loses-around-14b-this-week-how-to-play-lly-stock",
    "time_published": "20241017T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.230998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.536294",
        "ticker_sentiment_score": "0.365905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.064274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.068196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.170774",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.196415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41384970/1000-invested-in-eli-lilly-15-years-ago-would-be-worth-this-much-today",
    "time_published": "20241017T153116",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 15 years by 12.7% on an annualized basis producing an average annual return of 24.6%. Currently, Eli Lilly has a market capitalization of $827.94 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729179073_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 High-Flying Growth Stocks With Massive Upside Potential",
    "url": "https://www.fool.com/investing/2024/10/17/2-high-flying-growth-stocks-with-massive-upside/",
    "time_published": "20241017T135300",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These innovative drugmakers have potential catalysts ahead.",
    "banner_image": "https://media.ycharts.com/charts/c2e291f11a385bb7b4af3232ce32d262.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.334681,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.360005",
        "ticker_sentiment_score": "0.504517",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.261678",
        "ticker_sentiment_score": "0.163607",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This is Huge News For Eli Lilly Investors",
    "url": "https://www.fool.com/investing/2024/10/17/this-is-huge-news-for-eli-lilly-investors/",
    "time_published": "20241017T125500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly is investing billions into new research and manufacturing capabilities.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794006%2Fgettyimages-1292069762.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.249124,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.482402",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR",
    "url": "https://www.zacks.com/stock/news/2352101/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-pph-hrts-and-thnr",
    "time_published": "20241017T120500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938238"
      }
    ],
    "overall_sentiment_score": 0.024061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.041605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "-0.043301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "-0.026796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "-0.106742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.03472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.04007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Is Soaring-And How It Plans To Stay On Top - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41399187/why-eli-lilly-stock-is-soaring-and-how-it-plans-to-stay-on-top",
    "time_published": "20241018T190300",
    "authors": [
      "MarketBeat"
    ],
    "summary": "In a year and a half, Eli Lilly LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson JNJ back in May of 2023 and hasn't looked back since.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/18/yiorgos-ntrahas-mcauhlgirvs-unsplash_3.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.25492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.339578",
        "ticker_sentiment_score": "0.160727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.041577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.130543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.141852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Eli Lilly's Latest Options Trends - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41405774/behind-the-scenes-of-eli-lillys-latest-options-trends",
    "time_published": "20241018T160105",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729267261_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.107191,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.613172",
        "ticker_sentiment_score": "0.025066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41404245/investigating-eli-lillys-standing-in-pharmaceuticals-industry-compared-to-competitors",
    "time_published": "20241018T150014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly LLY against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729263611_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.214386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.332091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2353004/jjs-q3-earnings-sales-top-time-to-buy-sell-or-hold-the-stock",
    "time_published": "20241018T132000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.157938,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.157074",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.065076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.065076",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?",
    "url": "https://www.zacks.com/stock/news/2353104/viking-stock-rises-29-in-three-months-time-to-buy-hold-or-sell",
    "time_published": "20241018T124900",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.257267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148045",
        "ticker_sentiment_score": "0.247192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "0.062071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.256025",
        "ticker_sentiment_score": "0.205446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037213",
        "ticker_sentiment_score": "0.167775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.074345",
        "ticker_sentiment_score": "0.118532",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now",
    "url": "https://www.fool.com/investing/2024/10/19/1-reason-to-buy-eli-lilly-stock-hand-over-fist-rig/",
    "time_published": "20241019T221000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly just secured a huge win, and it's not related to the weight loss industry.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794499%2Fgettyimages-1289220585-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.271746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.555911",
        "ticker_sentiment_score": "0.657889",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million",
    "url": "https://www.fool.com/investing/2024/10/19/investing-10000-into-each-of-these-3-stocks-10-yea/",
    "time_published": "20241019T090000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These hot growth stocks may not be running out of steam just yet.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793893/an-excited-investor-looking-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.272346,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.316667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.147407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.085144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.052003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.159672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41436151/eli-lilly-sues-some-vendors-for-unauthorized-sale-of-fake-weight-loss-drug",
    "time_published": "20241021T181710",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Eli Lilly And Co LLY has reportedly sued some medical spas and online vendors for allegedly selling unauthorized versions of tirzepatide, the active ingredient in its weight-loss medication, Zepbound. Earlier this month, the FDA said the Eli Lilly tirzepatide injection shortage was resolved.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/21/Eli-Lilly-and-Company-Zepbound-Vials.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.078864,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.529185",
        "ticker_sentiment_score": "-0.251316",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Novartis Gets CHMP Recommendation for Kisqali in Broader Population",
    "url": "https://www.zacks.com/stock/news/2354296/novartis-gets-chmp-recommendation-for-kisqali-in-broader-population",
    "time_published": "20241021T175100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default16.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128755,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.111775",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?",
    "url": "https://www.zacks.com/stock/news/2354260/nvo-stock-falls-5-in-a-month-should-investors-buy-now-or-wait",
    "time_published": "20241021T155900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.237029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.155985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.111458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.111458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.385554",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Are Medical Stocks Lagging BioLife Solutions  ( BLFS )  This Year?",
    "url": "https://www.zacks.com/stock/news/2353946/are-medical-stocks-lagging-biolife-solutions-blfs-this-year",
    "time_published": "20241021T134011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.194207,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLFS",
        "relevance_score": "0.800175",
        "ticker_sentiment_score": "0.344891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.391923",
        "ticker_sentiment_score": "0.269165",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2354047/viking-therapeutics-stock-buy-or-sell-before-q3-earnings",
    "time_published": "20241021T130300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.200706,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.151301",
        "ticker_sentiment_score": "0.129665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.046595",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "0.035952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.141986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.046595",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.044386",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2353598/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20241021T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.156769,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.043671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2353607/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20241021T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281477,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.049883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Pfizer's Attractive Valuation Enough to Invest in the Stock?",
    "url": "https://www.zacks.com/stock/news/2355264/is-pfizers-attractive-valuation-enough-to-invest-in-the-stock",
    "time_published": "20241022T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.140727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.645091",
        "ticker_sentiment_score": "0.172398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains? - Viking Therapeutics  ( NASDAQ:VKTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41460609/viking-therapeutics-stock-up-240-ytd-can-q3-earnings-weight-loss-drug-drive-further-gains",
    "time_published": "20241022T161437",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22095602/Screenshot-2024-10-22-at-7.25.44-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.225739,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.210259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "0.155574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.210259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "0.050651",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Decoding Eli Lilly's Options Activity: What's the Big Picture? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41490483/decoding-eli-lillys-options-activity-whats-the-big-picture",
    "time_published": "20241023T141559",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 23 trades. If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729692956_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.154354,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.643211",
        "ticker_sentiment_score": "0.058696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "url": "https://www.zacks.com/stock/news/2355853/eli-lilly-lly-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
    "time_published": "20241023T140206",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default242.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.16149,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.300088",
        "ticker_sentiment_score": "0.06582",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2355778/should-you-buy-sell-or-hold-pfizer-stock-before-q3-earnings",
    "time_published": "20241023T134600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/1434.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.153848,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.055855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.245807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024",
    "url": "https://www.zacks.com/stock/news/2355969/vabysmo-hemlibra-drive-roches-sales-in-q3-first-9-months-of-2024",
    "time_published": "20241023T131100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default192.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.096572,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.075754",
        "ticker_sentiment_score": "0.181289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.075754",
        "ticker_sentiment_score": "0.181289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock",
    "url": "https://www.fool.com/investing/2024/10/23/this-setback-for-johnson-johnson-is-1-more-green-l/",
    "time_published": "20241023T083000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Fewer contenders means fewer constraints on expanding market share.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794812/three-investors-gather-around-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.101339,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.515749",
        "ticker_sentiment_score": "0.16788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.052065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.035921",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases",
    "url": "https://www.zacks.com/stock/news/2357119/ctlt-stock-falls-as-potential-hindrance-to-nvo-buyout-deal-increases",
    "time_published": "20241024T151000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/2666.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.048287,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "-0.049602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "-0.049602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.624898",
        "ticker_sentiment_score": "0.090511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.59616",
        "ticker_sentiment_score": "0.113388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.124378",
        "ticker_sentiment_score": "-0.015696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "-0.049602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "0.112252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.083107",
        "ticker_sentiment_score": "-0.063365",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analysts Estimate Merck  ( MRK )  to Report a Decline in Earnings: What to Look Out for",
    "url": "https://www.zacks.com/stock/news/2356894/analysts-estimate-merck-mrk-to-report-a-decline-in-earnings-what-to-look-out-for",
    "time_published": "20241024T140118",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.121561,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.174903",
        "ticker_sentiment_score": "0.021177",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2356609/is-lilly-stock-a-portfolio-must-have-ahead-of-its-q3-earnings",
    "time_published": "20241024T125000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.289427,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.477401",
        "ticker_sentiment_score": "0.424762",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.175858",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: 'Wait For A Pullback' - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac",
    "time_published": "20241024T124411",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said no to Nextracker Inc. NXT. \"Nextracker's a mistake that I made,\" he added. On Oct. 17, JP Morgan analyst Mark Strouse maintained NEXTracker with an Overweight and lowered the price target from $62 to $58. When asked about Viper Energy, Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/24/Jim-Cramer-questo-titolo--un-affare-da-n.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.044153,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410059",
        "ticker_sentiment_score": "-0.144897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.52759",
        "ticker_sentiment_score": "0.162746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VNOM",
        "relevance_score": "0.52759",
        "ticker_sentiment_score": "0.095571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.264687",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.410059",
        "ticker_sentiment_score": "-0.431228",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "-0.371919",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity' - Hims & Hers Health  ( NYSE:HIMS ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41506422/ozempic-and-wegovy-maker-novo-nordisk-asks-fda-to-halt-production-of-compounded-fat-loss-drugs-due-t",
    "time_published": "20241024T002316",
    "authors": [
      "Shivdeep Dhaliwal"
    ],
    "summary": "Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration ( FDA ) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/23/Ozempic-maker-Novo-Nordisk_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.014745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.146345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.176502",
        "ticker_sentiment_score": "0.170328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.422897",
        "ticker_sentiment_score": "-0.099105",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tesla To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday - Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/news/24/10/41554083/tesla-to-rally-over-21-here-are-10-top-analyst-forecasts-for-friday",
    "time_published": "20241025T185008",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised Eli Lilly and Company LLY price target from $1,060 to $1,250.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/25/What-Happened_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.128345,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WHR",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.003566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.076031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.104497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WCN",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.141151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.002042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COUR",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "-0.282536",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "KDP",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.120881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.016068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LC",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.101663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.229872",
        "ticker_sentiment_score": "0.101663",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41553086/eli-lillys-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously-treated-w",
    "time_published": "20241025T175734",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Eli Lilly and Company LLY revealed new results from the Phase 3b ADapt study of Ebglyss ( lebrikizumab ) , which will be presented at the Fall Clinical Dermatology Conference.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/25/Eli-Lilly-LLY.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.151982,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.28664",
        "ticker_sentiment_score": "-0.088634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.115199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.115199",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?",
    "url": "https://www.zacks.com/stock/news/2358024/merck-to-report-q3-earnings-to-buy-or-not-to-buy-mrk-stock",
    "time_published": "20241025T164200",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9973"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.199513,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.090565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.090565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.145759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.086736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales",
    "url": "https://www.zacks.com/stock/news/2358010/sanofi-q3-earnings-beat-dupixent-new-drugs-vaccines-drive-sales",
    "time_published": "20241025T162000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/2080.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.178092,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.082393",
        "ticker_sentiment_score": "0.089801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.092993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.31449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://www.zacks.com/stock/news/2357943/nvs-vs-lly-which-stock-is-the-better-value-option",
    "time_published": "20241025T154011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis ( NVS Quick QuoteNVS - ) and Eli Lilly ( LLY Quick QuoteLLY - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default187.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.475792,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.534672",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2357907/what-lies-in-store-for-healthcare-etfs-in-q3-earnings",
    "time_published": "20241025T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Big stocks are likely to dominate the returns of the healthcare ETF going into Q3 earnings announcements.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/2723.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      }
    ],
    "overall_sentiment_score": 0.15352,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.108324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.008537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.02845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.160577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.010135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2357873/should-abbvie-stock-be-in-your-portfolio-pre-q3-earnings",
    "time_published": "20241025T131600",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.273432,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.12123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.12123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.449106",
        "ticker_sentiment_score": "0.348312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "url": "https://www.zacks.com/stock/news/2357647/lilly-lly-q3-earnings-on-the-horizon-analysts-insights-on-key-performance-measures",
    "time_published": "20241025T131523",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Beyond analysts' top -and-bottom-line estimates for Lilly (LLY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default341.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.131458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.204378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2357578/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
    "time_published": "20241025T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default104.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.23968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.168564",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Gary Black Fights Off Criticism, Says Worst Performer In Future Fund Was Tesla - Here Are His Holdings That Did Better - Advanced Micro Devices  ( NASDAQ:AMD ) , Salesforce  ( NYSE:CRM ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41536727/gary-black-fights-off-criticism-says-worst-peformer-in-future-fund-was-tesla-here-are-his-holdin",
    "time_published": "20241025T035659",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Gary Black, Managing Partner of The Future Fund LLC, shared insights on social media platform X regarding his investment performance since January 2022. What Happened: Black claimed that Tesla Inc TSLA had been his largest negative contributor during this period, noting a decline of 34% compared ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/25/Tesla-Inc-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.260176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.223499",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.288075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.684305",
        "ticker_sentiment_score": "0.129711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.111761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.111761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.111761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.111761",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Soaring Growth Stocks That Are Still Worth Buying",
    "url": "https://www.fool.com/investing/2024/10/26/2-soaring-growth-stocks-that-are-still-worth-buyin/",
    "time_published": "20241026T133000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two companies -- leaders in their industries -- look unstoppable.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794914/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.314462,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.273399",
        "ticker_sentiment_score": "0.331179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.37552",
        "ticker_sentiment_score": "0.281703",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.",
    "url": "https://www.fool.com/investing/2024/10/27/druckenmiller-closed-out-his-position-in-eli-lilly/",
    "time_published": "20241027T110200",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter.",
    "banner_image": "https://media.ycharts.com/charts/216055bf4413d389a6216977ec32392d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.119995,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.773794",
        "ticker_sentiment_score": "0.243216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.038118",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2358964/will-non-covid-drugs-again-boost-pfizers-top-line-in-q3-earnings",
    "time_published": "20241028T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.109037,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.112728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.346365",
        "ticker_sentiment_score": "0.012517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "-0.135945",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2358849/will-these-5-big-drug-stocks-surpass-q3-earnings-forecasts",
    "time_published": "20241028T160600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.036211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.035956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.034366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.117668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Mirikizumab Shows Long-Term Sustained Efficacy, Safety For Ulcerative Colitis And Crohn's Disease - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41580394/eli-lillys-mirikizumab-shows-long-term-sustained-efficacy-safety-for-ulcerative-colitis-and-crohn",
    "time_published": "20241028T160551",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly And Co LLY announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases ( IBD ) . The studies showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis and Crohn's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/28/Indianapolis---Circa-November-2021-Eli-L.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.094305,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.445179",
        "ticker_sentiment_score": "-0.112044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41579226/1000-invested-in-this-stock-20-years-ago-would-be-worth-16-000-today",
    "time_published": "20241028T153026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.72%. Currently, Eli Lilly has a market capitalization of $804.44 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730129422_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split",
    "url": "https://www.fool.com/investing/2024/10/28/stock-split-watch-2-healthcare-stocks-that-look-re/",
    "time_published": "20241028T082000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "One of these players has split its stock in the past. The other one hasn't.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795314%2Fgettyimages-936284004.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.088232,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "-0.016053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.046987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "-0.014062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.107993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.186747",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?",
    "url": "https://www.zacks.com/stock/news/2359935/can-mounjaro-zepbound-help-eli-lilly-top-earnings-estimates-again",
    "time_published": "20241029T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.282793,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.539872",
        "ticker_sentiment_score": "0.47637",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.054858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.178969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.169598",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-",
    "time_published": "20241029T183417",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Eli Lilly And Co LLY released results from the TRAILBLAZER-ALZ 6 Phase 3b study to investigate different dosing regimens of donanemab and their effect on amyloid-related imaging abnormalities with edema/effusion ( ARIA-E ) in adults with early symptomatic Alzheimer's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/29/Indianapolis---Circa-November-2021-Eli-L.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.042309,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41604706/eli-lilly-q3-earnings-on-deck-stock-split-rumors-heat-up-with-weight-loss-gains",
    "time_published": "20241029T160440",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m. ET.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29101844/Screenshot-2024-10-29-at-7.48.09-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.169055,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.756417",
        "ticker_sentiment_score": "0.179796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.04806",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales",
    "url": "https://www.zacks.com/stock/news/2359805/incy-q3-earnings-miss-estimates-revenues-beat-on-higher-product-sales",
    "time_published": "20241029T144700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.150609,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.051155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGNX",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.089372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.534816",
        "ticker_sentiment_score": "0.112251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FATE",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.035971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPSYF",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.105046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at Eli Lilly's Options Market Dynamics - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41601231/a-closer-look-at-eli-lillys-options-market-dynamics",
    "time_published": "20241029T141538",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 43 unusual trades. Delving into the details, we found 44% of traders were bullish, while 32% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730211335_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.128407,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.801457",
        "ticker_sentiment_score": "0.092721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.038259",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever",
    "url": "https://www.fool.com/investing/2024/10/29/1-huge-new-reason-to-buy-eli-lilly-or-novo-nordisk/",
    "time_published": "20241029T110500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "One key disease-prevention market is drawing closer to being within reach.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795338/two-investors-look-at-figures.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.221383,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.286082",
        "ticker_sentiment_score": "0.228524",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "0.099279",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock",
    "url": "https://www.fool.com/investing/2024/10/29/eli-lillys-latest-setback-could-portend-an-unexpec/",
    "time_published": "20241029T103000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The odds of its new drug getting established in the U.K. are now much lower.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795356/frustrated-investor-at-computers.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.131836,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.406901",
        "ticker_sentiment_score": "0.184395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neuralink's Promise For Alzheimer's Has A Crucial Time Window - Elon Musk Explains Why - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41592351/neuralinks-promise-for-alzheimers-has-a-crucial-time-window-elon-musk-explains-why",
    "time_published": "20241029T071740",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "Tesla and SpaceX CEO Elon Musk has hinted at the possibility of his brain-machine interface company, Neuralink, developing an implant for early-stage Alzheimer's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/29/Musks-Views.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.150456,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Three Stocks: Super Micro Computer, Dell, and Eli Lilly",
    "url": "https://moneymorning.com/2024/10/30/three-stocks-super-micro-computer-dell-and-eli-lilly/",
    "time_published": "20241030T214703",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "Super Micro Computer Shares of Super Micro Computer ( SMCI ) traded more than 30% lower on Wednesday after the company disclosed that its accounting firm had resigned. Ernst & Young resigned while in the process of conducting an audit for the server company's recent fiscal year.",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/10/SMCI-4.png",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.149792,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.335306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.059266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.398939",
        "ticker_sentiment_score": "0.108866",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Novartis  ( NYSE:NVS ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni",
    "time_published": "20241030T191203",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% ( +10% on constant currency ) , beating the consensus of $12.76 billion. Guidance: Novartis also raised its 2024 full-year guidance again this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Stein--Switzerland---February-18--2020-N.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222077,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "-0.123398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.114885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YMAB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.152993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Applied DNA Sciences  ( NASDAQ:APDN ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41634156/crude-oil-gains-over-2-eli-lilly-cuts-2024-forecast",
    "time_published": "20241030T190040",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday. The Dow traded up 0.07% to 42,262.68 while the NASDAQ fell 0.05% to 18,703.09. The S&P 500 also fell, dropping, 0.03% to 5,831.09. Communication services shares rose by 1.8% on Wednesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Oil-Price-Photo-by-William-Potter-on-Shu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.122853,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "OMCL",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.398264",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "THAR",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.155505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.413524",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TCS",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.187031",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APDN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.093811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.269033",
        "ticker_sentiment_score": "0.079777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SVMH",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.017716",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/30/eli-lilly-lly-q3-2024-earnings-call-transcript/",
    "time_published": "20241030T183013",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "LLY earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.212933,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.050969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "-0.023953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.082617",
        "ticker_sentiment_score": "0.109318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPTGF",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "-0.004748",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41632224/wall-street-mixed-semiconductors-tumble-as-amd-disappoints-alphabet-rallies-smci-plummets-",
    "time_published": "20241030T173506",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. The U.S. economy grew at an annualized rate of 2.8% in the third quarter, according to advance estimates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/semiconductor.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.193292,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.29601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "-0.327517",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.383541",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.13792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.083351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.222777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks",
    "url": "https://www.zacks.com/stock/news/2360915/lillys-q3-earnings-miss-mounjaro-zepbound-disappoint-stock-tanks",
    "time_published": "20241030T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999858"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.157435,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.427518",
        "ticker_sentiment_score": "0.294163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.103628",
        "ticker_sentiment_score": "0.120224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.168832",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Stock Is Sinking Today",
    "url": "https://www.fool.com/investing/2024/10/30/why-eli-lilly-stock-is-sinking-today/",
    "time_published": "20241030T153421",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The big pharmaceutical company provided a disappointing Q3 update.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795836/young-man-worried-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.798255",
        "ticker_sentiment_score": "0.264954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ADP Higher Than Expected",
    "url": "https://www.zacks.com/stock/news/2360837/adp-higher-than-expected",
    "time_published": "20241030T145400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Jobs Week continues this morning, further articulating one half of the Fed's mandate in determining future interest rate cuts. Pre-market futures haven't changed much in the minutes following the release, which are mixed right now: the Dow -63 points at this hour, the S&P 500 +3 and the Nasdaq ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/47493.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.156619,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.149323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.269181",
        "ticker_sentiment_score": "0.125948",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Goldilocks ADP Jobs Numbers, Q3 GDP and Earnings",
    "url": "https://www.zacks.com/stock/news/2360828/goldilocks-adp-jobs-numbers-q3-gdp-and-earnings",
    "time_published": "20241030T143200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "ADP private-sector payrolls for October came in at +253K, far ahead of the 113K expected.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/82952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.14485,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.154125",
        "ticker_sentiment_score": "0.135614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.254042",
        "ticker_sentiment_score": "0.116366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41623322/o-i-glass-posts-downbeat-results-joins-amd-qorvo-and-other-big-stocks-moving-lower-in-wednesdays-pre",
    "time_published": "20241030T122955",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Wednesday. Shares of O-I Glass, Inc. OI fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/movers-image_17.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      }
    ],
    "overall_sentiment_score": -0.068978,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ANAB",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.351922",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.350224",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "CRTO",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.373345",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.091677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.236758",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "OI",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "-0.047726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.127703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "THRY",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.053982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.022195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Lags Q3 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2360281/eli-lilly-lly-lags-q3-earnings-and-revenue-estimates",
    "time_published": "20241030T115507",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of -22.37% and 4.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default12.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.162049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.402403",
        "ticker_sentiment_score": "0.19103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua",
    "time_published": "20241030T115138",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly and Co LLY stock plummeted after the company released worse-than-expected third-quarter earnings and lowered 2024 guidance. The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over year, but it missed the consensus of $12.10 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/mounjaro-medication-for-weight-loss.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.046023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "0.160233",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "-0.12051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/24/10/41618702/zepbound-mounjaro-maker-eli-lilly-climbs-in-wednesday-pre-market-as-impressive-51-ytd-gain-sparks-st",
    "time_published": "20241030T090129",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs as the company gears up to announce its third-quarter earnings. Wall Street analysts are forecasting earnings per share of $1.45 and revenues of $12.1 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.29224,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.605937",
        "ticker_sentiment_score": "0.29332",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years",
    "url": "https://www.fool.com/investing/2024/10/30/a-once-in-a-decade-investment-opportunity-1-pharma/",
    "time_published": "20241030T084500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795387%2Fgettyimages-1665778558-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.354043,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.709611",
        "ticker_sentiment_score": "0.572829",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.250015",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/30/is-eli-lilly-stock-a-buy/",
    "time_published": "20241030T084000",
    "authors": [
      "Geoffrey Seiler"
    ],
    "summary": "Eli Lilly has been a huge winner with its GLP-1 drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795512%2Fgettyimages-2025836701.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.195417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.199821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.023997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.123399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.102766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Oct 31, 2024",
    "url": "https://www.zacks.com/stock/news/2361626/company-news-for-oct-31-2024",
    "time_published": "20241031T132400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.060103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.134317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITW",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.368768",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CLH",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.150109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "-0.503704",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus",
    "url": "https://www.zacks.com/stock/news/2361422/amgen-q3-earnings-beat-sales-in-line-obesity-candidate-in-focus",
    "time_published": "20241031T114300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.118796,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.055046",
        "ticker_sentiment_score": "0.024004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.419298",
        "ticker_sentiment_score": "0.180918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.137044",
        "ticker_sentiment_score": "0.261416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055046",
        "ticker_sentiment_score": "0.024004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41647762/nasdaq-tumbles-over-100-points-ahead-of-big-tech-earnings-fear-greed-index-remains-in-greed-zone",
    "time_published": "20241031T102208",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index remained in the \"Greed\" zone on Wednesday. U.S. stocks settled lower on Wednesday, with the Nasdaq Composite falling more than 100 points during the session. Eli Lilly and Co LLY posted worse-than-expected third-quarter earnings and lowered 2024 guidance.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/31/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.048709,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.298374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.298374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "-0.447519",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.298374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are Eli Lilly's Lowered Expectations a Reason to Sell?",
    "url": "https://www.fool.com/investing/2024/10/31/are-eli-lillys-lowered-expectations-a-reason-to-se/",
    "time_published": "20241031T092100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795813/individual-investor-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.026459,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.624423",
        "ticker_sentiment_score": "-0.025449",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus",
    "url": "https://www.zacks.com/stock/news/2362882/pharma-stock-roundup-mrk-pfe-abbv-nvs-llys-q3-earnings-in-focus",
    "time_published": "20241101T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.057517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.021907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.300292",
        "ticker_sentiment_score": "0.123993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034185",
        "ticker_sentiment_score": "-0.176359",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.102303",
        "ticker_sentiment_score": "0.03196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus",
    "url": "https://www.zacks.com/stock/news/2362882/pharma-stock-roundup-mrk-pfe-abbv-nvs-llys-q3-earnings-in-focus",
    "time_published": "20241101T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.057517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.021907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.300292",
        "ticker_sentiment_score": "0.123993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034185",
        "ticker_sentiment_score": "-0.176359",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.102303",
        "ticker_sentiment_score": "0.03196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial",
    "time_published": "20241101T131200",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Novo Nordisk A/S NVO released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis ( MASH ) and moderate to advanced liver fibrosis ( stage 2 or 3 ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/01/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.183111,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.155104",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.121183",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/11/01/why-eli-lilly-no-brainer-stock-buy-on-the-dip/",
    "time_published": "20241101T094400",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796056/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.148299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.640873",
        "ticker_sentiment_score": "0.255484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could This Near Trillion-Dollar Stock Be a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/11/03/could-this-near-trillion-dollar-stock-be-a-million/",
    "time_published": "20241103T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Size means little in light of this company's prospects.",
    "banner_image": "https://media.ycharts.com/charts/83bc02340ed665ce2175a7934fc932ba.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.265388,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.415318",
        "ticker_sentiment_score": "0.307814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.027986",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?",
    "url": "https://www.zacks.com/stock/news/2363742/buy-sell-or-hold-pfizer-stock-after-q3-earnings-beat-guidance-boost",
    "time_published": "20241104T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.11984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.56803",
        "ticker_sentiment_score": "0.164389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.018702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Nektar Therapeutics  ( NASDAQ:NKTR ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41723740/eczema-drug-developer-nektar-gains-analyst-confidence-with-400-upside-potential",
    "time_published": "20241104T184441",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's ( REZPEG ) differentiated mechanism of action. The analyst writes that Alopecia areata ( AA ) is an inflammatory skin disorder where patients require lifelong use of JAK ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/04/NKTR.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.240384,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "-0.137643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.56296",
        "ticker_sentiment_score": "0.194709",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Hims & Hers Health Stock Monday? - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/news/earnings/24/11/41718402/whats-going-on-with-hims-hers-health-stock-monday",
    "time_published": "20241104T160453",
    "authors": [
      "Adam Eckert"
    ],
    "summary": "Hims & Hers Health HIMS shares are moving higher Monday ahead of earnings after the bell. Here's what you need to know before the report. What To Know: Hims & Hers Health will report third-quarter financial results after the market close on Monday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/04/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.270693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.018223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.738815",
        "ticker_sentiment_score": "0.251103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unlocking Lilly  ( LLY )  International Revenues: Trends, Surprises, and Prospects",
    "url": "https://www.zacks.com/stock/news/2363300/unlocking-lilly-lly-international-revenues-trends-surprises-and-prospects",
    "time_published": "20241104T141536",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.188045,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.075001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2363193/novo-nordisk-before-q3-earnings-how-should-investors-play-the-stock",
    "time_published": "20241104T140600",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.296334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.177889",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.247493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.574476",
        "ticker_sentiment_score": "0.476382",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25% - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th",
    "time_published": "20241104T075426",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "Novo Nordisk A/S NVO is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/04/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.237832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.23863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.362065",
        "ticker_sentiment_score": "0.213608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBS",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.072776",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Investors Buy Weakness in These High-Growth Stocks?",
    "url": "https://www.zacks.com/commentary/2363928/should-investors-buy-weakness-in-these-high-growth-stocks",
    "time_published": "20241105T151500",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Several popular stocks have seen negative post-earnings reactions, raising some questions. But should investors just block out the noise?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/14/83359.jpg?v=670022896",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.214431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.394125",
        "ticker_sentiment_score": "0.159207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.49292",
        "ticker_sentiment_score": "0.206653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/41747126/assessing-eli-lillys-performance-against-competitors-in-pharmaceuticals-industry",
    "time_published": "20241105T150025",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly LLY against its key competitors in the Pharmaceuticals ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730818822_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.156966,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574235",
        "ticker_sentiment_score": "0.310983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks and ETFs in Focus as Americans Head to Polls",
    "url": "https://www.zacks.com/stock/news/2364296/stocks-and-etfs-in-focus-as-americans-head-to-polls",
    "time_published": "20241105T143000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Let's discuss the sectors and ETFs that are the potential gainers or losers as Americans head to the polls, which indicate a tight race between Harris and Trump.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e1/31054.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.407422,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GCEI",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.377758",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.030667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BE",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.377758",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.108222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.286198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.286198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.396722",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.206115",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.030667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.030667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.377758",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.138366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.138366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.138366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.108222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.286198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.030667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.315145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.314257",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2364196/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241105T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.226426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.53074",
        "ticker_sentiment_score": "0.135411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?",
    "url": "https://www.fool.com/investing/2024/11/06/eli-lilly-posts-a-huge-earnings-miss-should-invest/",
    "time_published": "20241106T233300",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796255/a-couple-using-a-laptop-and-reviewing-documents.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999939"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.613588",
        "ticker_sentiment_score": "-0.040019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings",
    "url": "https://www.zacks.com/stock/news/2365523/buy-sell-or-hold-astrazeneca-stock-key-tips-ahead-of-q3-earnings",
    "time_published": "20241106T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.209961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.094163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.566543",
        "ticker_sentiment_score": "0.363414",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.094163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.093531",
        "ticker_sentiment_score": "0.097093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View",
    "url": "https://www.zacks.com/stock/news/2365440/nvo-misses-q3-earnings-revenue-estimates-updates-2024-view",
    "time_published": "20241106T164900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225745,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.14069",
        "ticker_sentiment_score": "0.077634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.175348",
        "ticker_sentiment_score": "0.006139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.342329",
        "ticker_sentiment_score": "0.28082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41811226/compounded-versions-of-weight-loss-and-diabetes-drugs-led-to-death-and-hospitalization-novo-nordi",
    "time_published": "20241107T151308",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Earlier, Novo Nordisk A/S NVO petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved versions of its drugs Wegovy and Ozempic. Amid shortages and rising demand for branded drugs, compounded semaglutide has gained popularity due to its affordability.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/07/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.041436,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.164468",
        "ticker_sentiment_score": "-0.14122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.532556",
        "ticker_sentiment_score": "-0.047623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41810596/market-whales-and-their-recent-bets-on-lly-options",
    "time_published": "20241107T150127",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 13 unusual trades. Delving into the details, we found 53% of traders were bullish, while 15% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730991683_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.130718,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.797517",
        "ticker_sentiment_score": "0.07654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.039748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.039748",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Novo Nordisk  ( NYSE:NVO ) , Merck & Co  ( NYSE:MRK ) , Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordis",
    "time_published": "20241108T193505",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/08/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.263867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "-0.288291",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.292055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.112666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "-0.186951",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.211306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.318081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.230164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.116145",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus",
    "url": "https://www.zacks.com/stock/news/2367660/nektar-q3-loss-narrower-than-expected-pipeline-development-in-focus",
    "time_published": "20241108T170200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.056593,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.210731",
        "ticker_sentiment_score": "0.102585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.158868",
        "ticker_sentiment_score": "-0.029659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTR",
        "relevance_score": "0.452384",
        "ticker_sentiment_score": "-0.100364",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Like Certainty. Trump's Win Gave Them Some.",
    "url": "https://www.fool.com/investing/2024/11/08/investors-like-certainty-trumps-win-gave-them-some/",
    "time_published": "20241108T161200",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We're also talking about Super Micro, Nvidia, and weight loss.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797019/mfm_06.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.123213,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.058789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.152628",
        "ticker_sentiment_score": "0.08558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.030707",
        "ticker_sentiment_score": "0.0422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061368",
        "ticker_sentiment_score": "0.039156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "-0.078472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.066853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.025734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.066853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.054949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.051155",
        "ticker_sentiment_score": "0.064759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.060282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.051155",
        "ticker_sentiment_score": "0.024997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.194847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.",
    "url": "https://www.fool.com/investing/2024/11/08/eli-lilly-hit-milestone-disappoint-buy-stock/",
    "time_published": "20241108T095500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The market's perception of the pharmaceutical company has undeniably shifted.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796474/woman-stock-broker-investor-tracking-stocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.202768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.378777",
        "ticker_sentiment_score": "0.169338",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock",
    "url": "https://www.fool.com/investing/2024/11/10/1-stubborn-cloud-and-2-silver-linings-for-eli-lill/",
    "time_published": "20241110T170500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Conditions are getting a bit more challenging for the drugmaker.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796968/concerned-investor-with-two-people-in-background.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.091035,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.265089",
        "ticker_sentiment_score": "0.016199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "-0.065044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?",
    "url": "https://www.fool.com/investing/2024/11/10/does-this-new-issue-threaten-eli-lilly-and-novo-no/",
    "time_published": "20241110T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The good times aren't over, but the peak of the party might be passing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796960/healthcare-lab-treatment-research-scientist.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.04371,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.034624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.275246",
        "ticker_sentiment_score": "-0.027981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics a Buy on the Dip?",
    "url": "https://www.fool.com/investing/2024/11/10/is-viking-therapeutics-a-buy-on-the-dip/",
    "time_published": "20241110T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Viking stock has slipped more than 20% from its peak.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797203%2Fgettyimages-scientist_computer_others-in-background.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.168386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.318211",
        "ticker_sentiment_score": "0.037036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "0.060387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "-0.014001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.113144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.267413",
        "ticker_sentiment_score": "0.042372",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2368432/eli-lilly-falls-more-than-10-in-a-month-buy-sell-or-hold-the-stock",
    "time_published": "20241111T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.206754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.411434",
        "ticker_sentiment_score": "0.210962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.194138",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066322",
        "ticker_sentiment_score": "0.202645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.099339",
        "ticker_sentiment_score": "0.04262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.066322",
        "ticker_sentiment_score": "0.264081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NVS or LLY: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2368337/nvs-or-lly-which-is-the-better-value-stock-right-now",
    "time_published": "20241111T164015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.479976,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.577219",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
    "url": "https://www.zacks.com/stock/news/2367863/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
    "time_published": "20241111T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for PPH ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default80.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.191039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.043079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.061552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tesla Remains Core For Gary Black Despite Price Cuts, Earnings Drop - Nvidia, Google, Eli Lilly Among Top Performers In Tech Bull's Portfolio - The Future Fund Active ETF  ( ARCA:FFND ) , Salesforce  ( NYSE:CRM ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41870590/tesla-remains-core-for-gary-black-despite-price-cuts-earnings-drop-nvidia-google-el",
    "time_published": "20241111T020546",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Tesla Inc. TSLA remains a significant holding for The Future Fund despite position reductions, according to Managing Partner Gary Black, who cited concerns over the impact of price cuts of its electric vehicles on earnings.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/10/The-Tesla-Trade.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.122021,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.123671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.123671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.123671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.123671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.642555",
        "ticker_sentiment_score": "0.139308",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/signals/24/11/41924463/tradepulse-power-inflow-alert-eli-lilly-company-moves-up-over-13-points-after-signal",
    "time_published": "20241112T224149",
    "authors": [
      "Finit"
    ],
    "summary": "RISES OVER 1.6% AT IT'S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL Eli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.",
    "banner_image": "https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/12211646/Screen-Shot-2024-11-12-at-4.13.02-PM.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.280829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.284045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock",
    "time_published": "20241112T174839",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy ( a schizophrenia drug ) and milvexian ( anticoagulant ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/02-LVL-Exterior-Sign-101520-media.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.086575,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.04032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.333455",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.142037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-imp",
    "time_published": "20241113T185920",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031369,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.133579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.172874",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.152959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.133579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Hims & Hers Health Stock On Wednesday? - Hims & Hers Health  ( NYSE:HIMS ) ",
    "url": "https://www.benzinga.com/general/health-care/24/11/41950541/whats-going-on-with-hims-hers-health-stock-on-wednesday",
    "time_published": "20241113T184512",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Health and wellness platform Hims & Hers Health, Inc. HIMS, which has gained traction for its obesity-related portfolio, has highlighted the ongoing difficulties Americans face in accessing branded GLP-1 medications.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.082203,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.173371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.186292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.272698",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity For November 13 - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41942125/eli-lilly-unusual-options-activity-for-november-13",
    "time_published": "20241113T150044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731510041_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.130497,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.74725",
        "ticker_sentiment_score": "0.16363",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.035312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.035312",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Did Viking Therapeutics Just Say \"Checkmate\" To Eli Lilly?",
    "url": "https://www.fool.com/investing/2024/11/13/did-viking-therapeutics-just-say-checkmate-to-eli/",
    "time_published": "20241113T144500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795713%2Fgettyimages-1978065812-3.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.133031,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "0.212601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.167709",
        "ticker_sentiment_score": "-0.041884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "-0.017092",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards",
    "time_published": "20241113T142458",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Ahead of World Diabetes Day, Doctors Without Borders/M\u00e9decins Sans Fronti\u00e8res ( MSF ) called for all insulin manufacturers to provide injection pen devices at $1 per pen.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/Insulin-towfiqu-barbhuiya-unsplash.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.185834,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "-0.004181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.445179",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "-0.004181",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts",
    "url": "https://www.fool.com/investing/2024/11/13/2-sp-500-dividend-stocks-that-could-soar-more-than/",
    "time_published": "20241113T095700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796326/investor-individual-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.195804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.430251",
        "ticker_sentiment_score": "0.230957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.295273",
        "ticker_sentiment_score": "0.272766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.092999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.141818",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop - Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/health-care/24/11/41928127/jim-cramer-says-eli-lillys-pathetic-stock-performance-could-get-a-breather-if-amgen-has-hidde",
    "time_published": "20241113T031233",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Amgen Inc.'s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could benefit rival Eli Lilly And Co LLY.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.029061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.518022",
        "ticker_sentiment_score": "-0.056193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.587962",
        "ticker_sentiment_score": "-0.102365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.032978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for",
    "time_published": "20241114T192549",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study ( 176-week treatment period ) , the longest completed study to date of tirzepatide.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.016687,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.432291",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?",
    "url": "https://www.fool.com/investing/2024/11/14/low-cost-vanguard-etfs-lag-election-sell/",
    "time_published": "20241114T131200",
    "authors": [
      "Daniel Foelber"
    ],
    "summary": "Stocks in these \"safe\" sectors are selling off as investors gravitate toward growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797222%2Fgettyimages-1207323692-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.23936,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.05106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.175137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "-0.015509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.102116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "-0.015509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.018684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "-0.149518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.175137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "-0.018684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.05106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Growth Stocks to Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/11/14/2-top-growth-stocks-to-buy-on-the-dip/",
    "time_published": "20241114T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Their recent issues are nothing to fret over for investors focused on the long game.",
    "banner_image": "https://media.ycharts.com/charts/9b261ac48a49702049da2034307c6867.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141488,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.145106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.096091",
        "ticker_sentiment_score": "-0.039599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.048133",
        "ticker_sentiment_score": "0.030759",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years",
    "url": "https://www.fool.com/investing/2024/11/14/3-ultra-safe-dividend-stocks-that-have-been-paying/",
    "time_published": "20241114T111900",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These are income stocks you can buy and hold forever.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797238/a-couple-looking-at-a-statement.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.286386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.287248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.243864",
        "ticker_sentiment_score": "0.150183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.196658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2371100/abbvie-stock-falls-11-in-a-month-should-you-buy-the-dip",
    "time_published": "20241115T150800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.234354,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.082567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.082567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.674346",
        "ticker_sentiment_score": "0.376455",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
    "url": "https://www.zacks.com/stock/news/2370937/biogen-partner-eisai-gets-positive-chmp-nod-for-leqembi-in-europe",
    "time_published": "20241115T140400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.209998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.322225",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRTA",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.052037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.3796",
        "ticker_sentiment_score": "0.217336",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.212834",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/42002487/mounjaro-maker-eli-lilly-files-lawsuit-against-us-agency-over-drug-rebate-program",
    "time_published": "20241115T100258",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "Eli Lilly And Co. LLY has filed a lawsuit against the Health Resources and Services Administration ( HRSA ) . The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/15/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.03881,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.548633",
        "ticker_sentiment_score": "-0.084695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "-0.041519",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?",
    "url": "https://www.fool.com/investing/2024/11/15/should-you-forget-eli-lilly-and-buy-this-biotech/",
    "time_published": "20241115T090500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times. It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797672%2Fgettyimages-woman-points-at-computer-with-a-pen-to-show-something-to-a-colleague.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.230808,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.406197",
        "ticker_sentiment_score": "0.308495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.211398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.112663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.005001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.",
    "url": "https://www.fool.com/investing/2024/11/16/prediction-acquisitions-will-skyrocket-under-the-t/",
    "time_published": "20241116T103000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Mergers and acquisitions could make a comeback with Trump headed back to Washington.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797732%2Fmergers-and-acquisitions-chess-board.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.095957,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.001082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.011671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.030999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now",
    "url": "https://www.fool.com/investing/2024/11/17/if-you-bought-1-share-of-eli-lilly-in-1984-heres-h/",
    "time_published": "20241117T133200",
    "authors": [
      "Bram Berkowitz"
    ],
    "summary": "The drugmaker Ely Lilly ( NYSE: LLY ) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well this year, rising roughly 36% ( as of Nov. 14 ) , ahead of the broader market.Given that Eli Lilly ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797730/person-computer-5.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.23437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.727604",
        "ticker_sentiment_score": "0.363859",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now",
    "url": "https://www.fool.com/investing/2024/11/17/prediction-3-stocks-thatll-be-worth-more-than-walm/",
    "time_published": "20241117T114200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks have realistic paths to grow larger than Tesla.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797838/stock-chart-in-eyeglasses.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.216014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.018996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.030246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.208274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.370169",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.739039",
        "ticker_sentiment_score": "0.272697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.029021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity",
    "url": "https://markets.businessinsider.com/news/stocks/lilly-tirzepatide-reduces-heart-failure-risk-improves-symptoms-in-hfpef-patients-with-obesity-1034027157",
    "time_published": "20241117T023013",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - Eli Lilly and Co. ( LLY ) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction ( HFpEF ) and obesity.",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.0274,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.239305",
        "ticker_sentiment_score": "-0.098224",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2371433/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241118T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.219424,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.521151",
        "ticker_sentiment_score": "0.133954",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Growth Stocks You Can Buy Right Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/11/18/3-growth-stocks-you-can-buy-right-now-without-any/",
    "time_published": "20241118T110300",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Many investors have a type of acrophobia ( the fear of heights ) . It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the market is skyrocketing.Three Fool.com contributors think they've identified stocks that can ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797880/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.22085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.148906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.129861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.326884",
        "ticker_sentiment_score": "0.248437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.007799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley",
    "url": "https://www.zacks.com/research-daily/2371997/top-research-reports-for-eli-lilly-pepsico-morgan-stanley",
    "time_published": "20241119T211800",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.265784,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.327328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.293044",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "0.113347",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study",
    "url": "https://www.zacks.com/stock/news/2372410/lly-oral-cholesterol-drug-lowers-lipoprotein-levels-in-phase-ii-study",
    "time_published": "20241119T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly's muvalaplin significantly reduces elevated Lp(a) levels compared to placebo in a phase II study ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.063744,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "0.031832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.273807",
        "ticker_sentiment_score": "-0.071486",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86% - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/11/42070751/eli-lillys-investigational-drug-cuts-sticky-cholesterol-levels-by-almost-86",
    "time_published": "20241119T180820",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly And Co LLY announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein ( a ) [Lp ( a ) ], a genetically inherited risk factor for heart disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/19/Indianapolis---Circa-November-2021-Eli-L.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.072788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.114967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/11/42068776/jim-cramer-coinbase-is-a-winner-suggests-buying-this-hated-big-pharma-stock",
    "time_published": "20241119T170158",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Eli Lilly LLY is a buy. \"This stock is as hated now as it was loved not that long ago,\" he added. Eli Lilly on Monday said Muvalaplin met secondary endpoints for all three tested doses. Coinbase Global, Inc. COIN is a \"winner,\" Cramer said.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/19/Jim-Cramer-questo-titolo--un-affare-da-n.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.197862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.147378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "-0.171441",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CCJ",
        "relevance_score": "0.462953",
        "ticker_sentiment_score": "0.196158",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.112181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.446312",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IESC",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.393861",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "-0.023941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMTC",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.277278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42066851/eli-lilly-unusual-options-activity",
    "time_published": "20241119T154617",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732031174_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.766998",
        "ticker_sentiment_score": "0.222465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.018233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.018233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Megacap Growth ETF to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/11/19/the-smartest-mega-cap-growth-etf-to-buy-with-500/",
    "time_published": "20241119T094500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Growth stocks have soared this year as investors bet on an improving economic environment and technology players involved in the high-potential area of artificial intelligence ( AI ) . This has helped the overall market advance, bringing the S&P 500 to a 23% increase over the past 10 and a half ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798093%2Fgetty-happy-colleagues.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.448951,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.099951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.099951",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Loses Around $24B in a Month: How to Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2373021/jj-loses-around-24b-in-a-month-how-to-play-the-stock",
    "time_published": "20241120T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.125711,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.158888",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "-0.08027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease",
    "time_published": "20241120T195601",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Verge Genomics announced that Eli Lilly And Co LLY has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis ( ALS ) as part of the companies' collaboration, which was initiated in July 2021.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/20/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.176618,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.619618",
        "ticker_sentiment_score": "0.284994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial - Eli Lilly  ( NYSE:LLY ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/11/42086534/biorestorative-ends-q3-in-strong-financial-position-reports-positive-data-for-its-phase-2-brtx-10",
    "time_published": "20241120T130344",
    "authors": [
      "Meg Flippin"
    ],
    "summary": "BioRestorative Therapies, Inc. BRTX, a regenerative medicine company focused on stem cell-based therapies and products, is advancing toward profitability, narrowing its loss in the third quarter and releasing favorable data for its BRTX-100 treatment for chronic back pain.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/20/Screenshot-2024-11-20-at-6-30-30PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.134257,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "0.07073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRTX",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.031657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "0.07073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.0864",
        "ticker_sentiment_score": "0.07073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Time to Sell Eli Lilly and Pfizer Stocks?",
    "url": "https://www.fool.com/investing/2024/11/20/is-it-time-to-sell-eli-lilly-and-pfizer-stocks/",
    "time_published": "20241120T104800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly ( NYSE: LLY ) and Pfizer ( NYSE: PFE ) .When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.",
    "banner_image": "https://g.foolcdn.com/editorial/images/798328/scientist-with-head-down.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.009716,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.035446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.61919",
        "ticker_sentiment_score": "0.171801",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.032013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley",
    "url": "https://www.zacks.com/stock/news/2372497/the-zacks-analyst-blog-highlights-eli-lilly-pepsico-and-morgan-stanley",
    "time_published": "20241120T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, PepsiCo and Morgan Stanley are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.256141,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.281153",
        "ticker_sentiment_score": "0.227817",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.281153",
        "ticker_sentiment_score": "0.200053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/11/42119511/eli-lilly-stock-tumbles-as-rfk-jr-targets-weight-loss-drugs-buying-opportunity",
    "time_published": "20241121T174749",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.031875,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "-0.285155",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.124465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.124465",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ralph Alvarez Boosts Confidence With $231K Purchase Of Eli Lilly Stock - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114605/ralph-alvarez-boosts-confidence-with-231k-purchase-of-eli-lilly-stock",
    "time_published": "20241121T150337",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "A notable insider purchase on November 20, was reported by Ralph Alvarez, Board Member at Eli Lilly LLY, based on the most recent SEC filing. What Happened: In a significant move reported in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.299227,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.395903",
        "ticker_sentiment_score": "0.287605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Director Trades $233K In Company Stock - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114589/eli-lilly-director-trades-233k-in-company-stock",
    "time_published": "20241121T150316",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "A notable insider purchase on November 20, was reported by J. Erik Fyrwald pursuant to authorization on file, Director at Eli Lilly LLY, based on the most recent SEC filing. What Happened: A Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.250098,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.262133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Massive Insider Trade At Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114577/massive-insider-trade-at-eli-lilly",
    "time_published": "20241121T150306",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Mary Lynne Hedley, Board Member at Eli Lilly LLY, reported an insider buy on November 20, according to a new SEC filing. What Happened: Hedley's recent purchase of 315 shares of Eli Lilly, disclosed in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.304481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.063916",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Board Member Trades $229K In Company Stock - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114572/eli-lilly-board-member-trades-229k-in-company-stock",
    "time_published": "20241121T150301",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Disclosed in the latest SEC filing, a significant insider purchase on November 20, involves Kimberly H Johnson, Board Member at Eli Lilly LLY. What Happened: Johnson's recent purchase of 315 shares of Eli Lilly, disclosed in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.301286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.351392",
        "ticker_sentiment_score": "0.29741",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Insider Confidence On Display: Juan R Luciano Acquires $234K In Eli Lilly Stock - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114570/insider-confidence-on-display-juan-r-luciano-acquires-234k-in-eli-lilly-stock",
    "time_published": "20241121T150256",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In a recent SEC filing, it was revealed that Juan R Luciano, Board Member at Eli Lilly LLY, made a noteworthy insider purchase on November 20,. What Happened: Luciano demonstrated confidence in Eli Lilly by purchasing 322 shares, as reported in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.28649,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.309128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eye On Growth: Gabrielle Sulzberger Adds $229K Of Eli Lilly Stock To Portfolio - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/42114566/eye-on-growth-gabrielle-sulzberger-adds-229k-of-eli-lilly-stock-to-portfolio",
    "time_published": "20241121T150251",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "On November 20, Gabrielle Sulzberger, Director at Eli Lilly LLY executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: In a significant move reported in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999346"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.276988,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.352223",
        "ticker_sentiment_score": "0.122393",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/11/21/is-now-good-time-to-buy-the-dip-in-eli-lilly-stock/",
    "time_published": "20241121T150000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798070%2Fgetty-investing-time-to-sell.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.101365,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.720567",
        "ticker_sentiment_score": "0.170397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.045827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "-0.022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.090645",
        "ticker_sentiment_score": "0.007484",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View",
    "url": "https://www.zacks.com/stock/news/2374304/pharma-stock-roundup-eu-nod-for-pfes-hympavzi-nvs-ups-sales-view",
    "time_published": "20241122T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.169194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.17879",
        "ticker_sentiment_score": "0.136826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "-0.128118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.17879",
        "ticker_sentiment_score": "0.131993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "-0.128118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.139626",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock",
    "url": "https://www.zacks.com/stock/news/2374141/novo-nordisk-plunges-25-in-3-months-how-to-play-the-stock",
    "time_published": "20241122T162800",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.262262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "0.094098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.178297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.178297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.495692",
        "ticker_sentiment_score": "0.339054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VKTX Stock Loses Over $1B in a Month: How to Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2373925/vktx-stock-loses-over-1b-in-a-month-how-to-play-the-stock",
    "time_published": "20241122T141800",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "The plunge in Viking Therapeutics' share price can be attributed to the rising competition in the sector to secure a position in the booming obesity market.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.247119",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.111386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.113033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.177933",
        "ticker_sentiment_score": "0.177852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.059917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.130936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.065377",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investing in Pharma Stocks? Check These 3 Things First",
    "url": "https://www.fool.com/investing/2024/11/22/investing-in-pharma-stocks-check-these-3-things/",
    "time_published": "20241122T141500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The world of pharmacenutical stocks has a lot to offer investors. With their resilience in the face of economic issues and frequently in the face of market fluctuations as well, pharma stocks can serve as an anchor for your portfolio.But it's a tricky category to invest in if you aren't sure what ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798355/two-older-investors-smile-while-looking-at-papers.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.172582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.068227",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?",
    "url": "https://www.fool.com/investing/2024/11/23/israel-englander-increased-his-stake-in-eli-lilly/",
    "time_published": "20241123T150000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "After flying high during the first half of the year, pharmaceutical giant Eli Lilly ( NYSE: LLY ) has lost some momentum. the company's shares are down by 11% since June 1. However, the healthcare leader still has plenty of fans on Wall Street, including Israel Englander, the billionaire owner of ...",
    "banner_image": "https://media.ycharts.com/charts/e4c555ac8bf9ea4de226fccc39314a2b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.159713,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.513775",
        "ticker_sentiment_score": "0.301534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Need to Invest in This Unstoppable Vanguard ETF Today to Grow Your Portfolio to $1 Million or More by Retirement",
    "url": "https://www.fool.com/investing/2024/11/23/heres-how-much-you-would-need-to-invest-in-this-un/",
    "time_published": "20241123T140000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Investing in growth stocks can be a great strategy for building up your portfolio. But picking the best ones to buy is not necessarily easy. It wasn't all that long ago that metaverse stocks were all the hype on Wall Street. Nowadays, it's artificial intelligence stocks that people are rushing ...",
    "banner_image": "https://media.ycharts.com/charts/ea63597a351539e8c4e532836fd579f2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.28867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.133039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.133039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.133039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.133039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Chip Giant Broadcom Be the Next $1 Trillion Company?",
    "url": "https://www.fool.com/investing/2024/11/23/will-chip-giant-broadcom-be-the-next-1-trillion/",
    "time_published": "20241123T113000",
    "authors": [
      "Keithen Drury"
    ],
    "summary": "Worldwide, there are currently nine companies with market capitalizations of $1 trillion or higher. Taiwan Semiconductor Manufacturing ( NYSE: TSM ) fluctuates between crossing that threshold based on daily trading, so the true figure is more like 10 companies.",
    "banner_image": "https://media.ycharts.com/charts/58a91834ac274263fb3c8f4ba33f90ab.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.222203,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181591",
        "ticker_sentiment_score": "0.19914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.218544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.680214",
        "ticker_sentiment_score": "0.282188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.052025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.186264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.181591",
        "ticker_sentiment_score": "0.19914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Incredible Growth Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/11/23/2-incredible-growth-stocks-to-buy-with-1000-right/",
    "time_published": "20241123T111500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "It's always a great time to invest in quality businesses that can prime your portfolio for long-term growth. It's important to be selective with the companies that you add to your portfolio and ensure that you only put cash into investments that align with your overall investment priorities, risk ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798436/getty-happy-smiling-person-looking-at-phone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999499"
      }
    ],
    "overall_sentiment_score": 0.198794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.104081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.242544",
        "ticker_sentiment_score": "0.061408",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( LLY )  - Analyzing Eli Lilly's Short Interest - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/11/42172012/lly-analyzing-eli-lillys-short-interest",
    "time_published": "20241125T184520",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly's LLY short percent of float has risen 8.33% since its last report. The company recently reported that it has 6.62 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732560317_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.28994,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.147012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "url": "https://www.zacks.com/stock/news/2374611/jj-seeks-fda-nod-for-subcutaneous-tremfya-as-induction-regimen-in-uc",
    "time_published": "20241125T140800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.260148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.243306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.274495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.200519",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst",
    "url": "https://www.fool.com/investing/2024/11/25/billionaire-ken-griffin-invested-93-million-of-cit/",
    "time_published": "20241125T092100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics ( NASDAQ: VKTX ) .",
    "banner_image": "https://g.foolcdn.com/editorial/images/798754/a-person-delivering-a-presentation-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.155695,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.101306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.173002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.521812",
        "ticker_sentiment_score": "0.226384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "-0.124002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/signals/24/11/42204656/tradepulse-power-inflow-alert-eli-lilly-company-climbs-over-22-points-after-alert",
    "time_published": "20241126T234500",
    "authors": [
      "Finit"
    ],
    "summary": "STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAY Today, at 10:21 AM on November 26th, a significant trading signal occurred for Eli Lilly & Company LLY as it demonstrated a Power Inflow at a price of $784.63.",
    "banner_image": "https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/26210820/Screen-Shot-2024-11-26-at-4.07.45-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.284853,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.207687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study",
    "url": "https://www.zacks.com/stock/news/2375622/sava-stock-plunges-84-on-alzheimers-drug-failure-in-late-stage-study",
    "time_published": "20241126T184200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": -0.041151,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.03996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.033843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.03996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "-0.095929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Is Rising Tuesday: What's Going On? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/movers/24/11/42190210/eli-lilly-stock-is-rising-tuesday-whats-going-on",
    "time_published": "20241126T141151",
    "authors": [],
    "summary": "Eli Lilly And Co LLY shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid. What Happened: The government has proposed a new rule to expand access to medications for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/26/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.15343,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.483888",
        "ticker_sentiment_score": "0.28018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs",
    "url": "https://www.zacks.com/stock/news/2376034/lly-nvo-stock-up-as-biden-proposes-medicare-cover-for-obesity-drugs",
    "time_published": "20241127T144600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.17319,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "0.277599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.172955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.141827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.172955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.465599",
        "ticker_sentiment_score": "0.310952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study",
    "url": "https://www.zacks.com/stock/news/2376009/alec-stock-tanks-as-alzheimers-drug-fails-in-mid-stage-study",
    "time_published": "20241127T144200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.090101,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.050025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.0385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.085652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.640683",
        "ticker_sentiment_score": "0.054661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.050025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2375772/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20241127T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.261648,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.125983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/11/27/the-ultimate-pharmaceutical-stock-to-buy-with-1000/",
    "time_published": "20241127T093500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will continue with them no matter what the economy is doing.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799115%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.29368,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.066832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.506433",
        "ticker_sentiment_score": "0.244769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
    "url": "https://www.fool.com/investing/2024/11/27/why-amgens-success-is-a-win-for-eli-lilly/",
    "time_published": "20241127T085700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Shares of Amgen ( NASDAQ: AMGN ) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799133/investor-doing-stuff-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.048263,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.11535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.746902",
        "ticker_sentiment_score": "0.067079",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer",
    "url": "https://www.zacks.com/stock/news/2376729/ec-approves-nvs-kisqali-for-a-broad-population-in-early-breast-cancer",
    "time_published": "20241128T170200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128988,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.113494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.080623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Incyte  ( INCY )  Up 2.1% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2376668/why-is-incyte-incy-up-21-since-last-earnings-report",
    "time_published": "20241128T163138",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default153.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.157134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "0.044257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGNX",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.087589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.464763",
        "ticker_sentiment_score": "0.165386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.009861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.151301",
        "ticker_sentiment_score": "0.045723",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/11/28/down-more-than-20-from-its-high-is-now-the-time-to/",
    "time_published": "20241128T123000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling. And now the stock is down over 20% from its 52-week high of $972.53.",
    "banner_image": "https://media.ycharts.com/charts/16e9c72348f9238aea15e6856da93554.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.265617,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.796043",
        "ticker_sentiment_score": "0.510565",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.187319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/42248288/bristol-myers-squibb-files-lawsuit-against-us-agency-for-overreach-in-340b-drug-pricing-program",
    "time_published": "20241129T173743",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Bristol-Myers Squibb Co BMY filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration ( HRSA ) and the U.S. Department of Health and Human Services ( HHS ) , alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.236406,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "-0.214064",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.337427",
        "ticker_sentiment_score": "-0.297406",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "-0.419214",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Why Is Lilly  ( LLY )  Down 5% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2377213/why-is-lilly-lly-down-5-since-last-earnings-report",
    "time_published": "20241129T163154",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default29.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.100519,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.282827",
        "ticker_sentiment_score": "0.095376",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Eli Lilly's Latest Options Trends - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42244892/behind-the-scenes-of-eli-lillys-latest-options-trends",
    "time_published": "20241129T144611",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 8 unusual trades. Delving into the details, we found 12% of traders were bullish, while 75% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732891568_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.098515,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.702434",
        "ticker_sentiment_score": "-0.148011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "-0.009331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2376930/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241129T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default95.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.240016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.132235",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum - Viking Therapeutics  ( NASDAQ:VKTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/42243781/viking-therapeutics-stock-on-brink-of-death-cross-as-weight-loss-hype-loses-momentum",
    "time_published": "20241129T134249",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Viking Therapeutics Inc. VKTX is nearing a pivotal moment as its stock hovers just above a potential death cross. This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.009983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.271002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.412861",
        "ticker_sentiment_score": "-0.020222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.271002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Does Billionaire Israel Englander Know Something Wall Street Doesn't? The Billionaire Investor Just Sold 8.1 Million Shares of Walmart Stock.",
    "url": "https://www.fool.com/investing/2024/11/29/does-billionaire-israel-englander-know-something-w/",
    "time_published": "20241129T133000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Israel Englander's Millennium Management reduced its stake in Walmart by 69% last quarter.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799017%2Fgettyimages-1428386188.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.230385,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.096027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGT",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.232612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.096027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.096027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.096027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.197385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.817006",
        "ticker_sentiment_score": "0.42999",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/11/30/down-123-at-one-point-in-a-single-trading-session/",
    "time_published": "20241130T112000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The market didn't appreciate Amgen's ( NASDAQ: AMGN ) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.And, with shares of certain direct competitors, ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799310/concerned-investor-with-two-people-in-background.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.1415,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.25178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.260004",
        "ticker_sentiment_score": "0.150928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.09004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Unstoppable Vanguard ETF Will Beat the S&P 500 Again in 2025",
    "url": "https://www.fool.com/investing/2024/12/01/prediction-vanguard-etf-beat-sp-500-again-in-2025/",
    "time_published": "20241201T083700",
    "authors": [
      "Anthony Di Pizio"
    ],
    "summary": "This exchange-traded fund holds big positions in top-performing growth stocks like Nvidia.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799391%2Fa-sculpture-of-a-golden-bull-standing-on-a-laptop-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.229365,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.091971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.056106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.075966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.078967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.078967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.075966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.075966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.075966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.091971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Macy's Multimillion-Dollar Error",
    "url": "https://www.fool.com/investing/2024/12/02/macys-multimillion-dollar-error/",
    "time_published": "20241202T202100",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We also talk about snack foods, AI, Netflix's strategy on live events, and more.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799332/mfm_25.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.101808,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "-0.037889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.199542",
        "ticker_sentiment_score": "0.064627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.015512",
        "ticker_sentiment_score": "0.061922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.14918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.060954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.030365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAG",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "-0.038679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.015512",
        "ticker_sentiment_score": "-0.041586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "M",
        "relevance_score": "0.069719",
        "ticker_sentiment_score": "-0.008077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TPL",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.067641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UVV",
        "relevance_score": "0.015512",
        "ticker_sentiment_score": "0.070343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.030365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMAX",
        "relevance_score": "0.015512",
        "ticker_sentiment_score": "0.015037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "-0.038679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "0.010303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.015512",
        "ticker_sentiment_score": "-0.015528",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "-0.038941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.007756",
        "ticker_sentiment_score": "-0.037889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42270074/weight-loss-medicines-such-as-wegovy-and-zepbound-show-promise-in-reducing-alcohol-use",
    "time_published": "20241202T160116",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence of alcohol use disorder.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/02/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.014316,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Momentum Stocks & ETFs Are Crushing the Market",
    "url": "https://www.zacks.com/stock/news/2378525/why-momentum-stocks-etfs-are-crushing-the-market",
    "time_published": "20241203T223400",
    "authors": [
      "Neena Mishra"
    ],
    "summary": "The momentum factor has been a standout performer this year, but which ETF should you buy?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default52.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.133068,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.119811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.119811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.061002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.177454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.119811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.073864",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance",
    "time_published": "20241203T141616",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Amgen's MariTide challenges Lilly and Novo but falls short on efficacy and side effect profiles. Obesity market leaders Lilly and Novo strengthen dominance with advanced drugs nearing approval, eclipsing Amgen's MariTide. Benzinga shares with you top insiders news",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.203705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.624172",
        "ticker_sentiment_score": "0.29196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.150974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.128612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.071417",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/24/12/42291660/defiance-etfs-introduces-leveraged-etf-to-capture-novo-nordisk-momentum-riding-high-on-weight-loss-medications",
    "time_published": "20241203T141516",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Defiance ETFs introduced NVOX, the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S NVO. The ETF offers retail investors double the daily long exposure to Novo Nordisk's stock price changes without requiring a margin account, presenting an ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/ozempic-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      }
    ],
    "overall_sentiment_score": 0.113485,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "-0.195133",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.512596",
        "ticker_sentiment_score": "0.112952",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
    "url": "https://www.zacks.com/stock/news/2378129/jj-seeks-fda-approval-for-tremfya-for-psoriasis-in-kids",
    "time_published": "20241203T135800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.270878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.221839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.172527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.109865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.088801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  technical analysis - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42320619/stock-of-the-day-where-will-the-eli-lilly-rally-end",
    "time_published": "20241204T164739",
    "authors": [
      "Mark Putrino"
    ],
    "summary": "'Sell at former peaks' is an old Wall Street expression. The chart of Eli Lilly shows that this can be good advice. Benzinga shares with you top insiders news Shares of Eli Lilly and Company LLY are trading higher on Wednesday.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04114441/12-1024x573.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.115947,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.519739",
        "ticker_sentiment_score": "0.337733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.167406",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Decoding Eli Lilly's Options Activity: What's the Big Picture? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42317374/decoding-eli-lillys-options-activity-whats-the-big-picture",
    "time_published": "20241204T150203",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1733324520_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.12124,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "0.096938",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss? - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42316929/eli-lillys-zepbound-vs-novo-nordisks-wegovy-which-shows-greater-weight-loss",
    "time_published": "20241204T144749",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co LLY revealed topline data from the SURMOUNT-5 phase 3b trial evaluating the efficacy and safety of Zepbound ( tirzepatide ) compared with Novo Nordisk A/S' NVO Wegovy ( semaglutide ) in adults with obesity, or overweight with at least one of the following ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/04/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.019444,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "-0.060184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.00813",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money' - LandBridge  ( NYSE:LB ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42313103/jim-cramer-this-energy-stock-is-a-winner-navitas-semiconductor-is-losing-a-lot-of-money",
    "time_published": "20241204T130607",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Jim Cramer says LandBridge is a \"winner.\" Navitas Semiconductor is \"losing a lot of money,\" says Cramer. Benzinga shares with you top insiders news On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Navitas Semiconductor Corporation NVTS is \"losing a lot of money.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/04/Nvidia-ed-Eli-Lilly-in-caduta-libera--ma.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.115351,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.130458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVTS",
        "relevance_score": "0.575055",
        "ticker_sentiment_score": "-0.291071",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.575055",
        "ticker_sentiment_score": "0.179264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LB",
        "relevance_score": "0.661658",
        "ticker_sentiment_score": "0.207016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.122083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Got a Bundle of Good News: Time to Buy?",
    "url": "https://www.fool.com/investing/2024/12/04/eli-lilly-just-got-multiple-good-news-time-to-buy/",
    "time_published": "20241204T121000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The magic isn't over for Eli Lilly ( NYSE: LLY ) . Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth. In fact, the drugmaker recently received some welcome news that jolted its stock price.The ...",
    "banner_image": "https://media.ycharts.com/charts/113bfec7c110430bdc4e44e43050e287.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.168048,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.580595",
        "ticker_sentiment_score": "0.279756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.038355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.02698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
    "url": "https://www.zacks.com/stock/news/2378613/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
    "time_published": "20241204T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.127337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.08904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.063471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
    "url": "https://www.zacks.com/stock/news/2378618/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
    "time_published": "20241204T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.069712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42349122/how-much-did-americans-overspend-on-weight-loss-medications-in-2024-goodrx-reveals",
    "time_published": "20241205T192206",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "GoodRx Holdings GDRX, a prescription savings platform in the U.S., has released its latest Weight Loss Medications Tracker, revealing a sharp increase in the use of popular weight loss drugs like Eli Lilly And Co's LLY Mounjaro and Zepbound, and Novo Nordisk A/S' NVO Ozempic and Wegovy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/05/Eli-Lilly-and-Company-Zepbound-Vials.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.18441,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.147915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GDRX",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.226039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.142537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2379380/pfizer-stock-falls-8-in-a-month-should-you-buy-the-dip",
    "time_published": "20241205T133000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.065336,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.074164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.074854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "-0.061694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.462953",
        "ticker_sentiment_score": "0.149125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
    "url": "https://www.zacks.com/stock/news/2379302/llys-zepbound-outshines-nvos-wegovy-in-head-to-head-obesity-study",
    "time_published": "20241205T113200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095653,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.541766",
        "ticker_sentiment_score": "0.056698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.172449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.019104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.081093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.004847",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?",
    "url": "https://www.fool.com/investing/2024/12/05/healthcare-stock-favorite-of-billionaire-buy-lly/",
    "time_published": "20241205T103200",
    "authors": [
      "James Brumley"
    ],
    "summary": "Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.",
    "banner_image": "https://media.ycharts.com/charts/67ab82d1e1ac14a9612625c544122276.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.196331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.063746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.063746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.486544",
        "ticker_sentiment_score": "0.260501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "-0.005972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.032464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "-0.006386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "-0.006386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-fa",
    "time_published": "20241206T184205",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Eli Lilly And Co LLY announced a $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility to address the rising demand for diabetes, obesity, and pipeline medicines.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/06/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.240921,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.66906",
        "ticker_sentiment_score": "0.196079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand",
    "url": "https://www.zacks.com/stock/news/2380315/eli-lilly-to-invest-3b-in-wisconsin-plant-to-meet-obesity-drug-demand",
    "time_published": "20241206T153400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.151255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.591019",
        "ticker_sentiment_score": "0.197123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.163539",
        "ticker_sentiment_score": "0.085956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.101003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.269181",
        "ticker_sentiment_score": "0.143479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.061988",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study",
    "url": "https://www.zacks.com/stock/news/2380023/how-to-play-lly-stock-as-zepbound-beats-nvos-wegovy-in-obesity-study",
    "time_published": "20241206T130100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.166682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.163676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.142491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.002902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.017445",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street",
    "url": "https://www.fool.com/investing/2024/12/06/billionaire-izzy-englander-buying-obesity-stock/",
    "time_published": "20241206T104700",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Most of Israel \"Izzy\" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd draw based on the top holdings of the billionaire's Millennium Management hedge fund.However, Englander's interest isn't limited to tech stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799927/scales-with-tape-measure.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.25031,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.627119",
        "ticker_sentiment_score": "0.343359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.132164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Growth Stocks to Buy in December",
    "url": "https://www.fool.com/investing/2024/12/07/3-no-brainer-growth-stocks-to-buy-in-december/",
    "time_published": "20241207T114600",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800044/excited-investor-looks-at-financial-charts-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.190917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.1895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.013156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.136836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.",
    "url": "https://www.fool.com/investing/2024/12/07/could-eli-lilly-beat-rivals-in-the-billion-dollar/",
    "time_published": "20241207T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) has produced a wide variety of treatments for various illnesses throughout its 145-year history. But this big pharma company truly took center stage over the past year or so, with the launches of two drugs that have been prescribed for a billion-dollar indication: weight ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800023%2Fgettyimages-1070239362.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.02647,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.073164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.022887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.306416",
        "ticker_sentiment_score": "0.006752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
    "url": "https://www.zacks.com/research-daily/2380721/top-stock-reports-for-eli-lilly-abbvie-gilead-sciences",
    "time_published": "20241209T201500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.216563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.206166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.263231",
        "ticker_sentiment_score": "0.206527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.096893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOSL",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.15323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.316183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRT",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.107017",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown - Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown",
    "time_published": "20241209T184413",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup. Leqembi ( lecanemab ) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/09/Biogen---logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.144371,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.245526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.593484",
        "ticker_sentiment_score": "0.088337",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns - Bioage Labs  ( NASDAQ:BIOA ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42387175/just-two-months-after-ipo-bioage-labs-stops-eli-lilly-collaborated-obesity-trial-on-safety-concer",
    "time_published": "20241209T124122",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, BioAge Labs Inc. BIOA announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co's LLY Chorus clinical development organization.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/09/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.080534,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOA",
        "relevance_score": "0.390396",
        "ticker_sentiment_score": "0.200442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now",
    "url": "https://www.fool.com/investing/2024/12/09/eli-lilly-stock-just-got-even-sweeter-heres-why-it/",
    "time_published": "20241209T095900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "According to a sneak peek of the data from one of Eli Lilly's ( NYSE: LLY ) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, ( NYSE: NVO ) and it isn't the first time.Here's why the stock ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800087/two-pharmacists-chat-in-the-pharmacy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.201159,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.240261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.328642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics",
    "url": "https://www.zacks.com/stock/news/2380599/the-zacks-analyst-blog-eli-lilly-novo-nordisks-amgen-and-viking-therapeutics",
    "time_published": "20241209T065100",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.171024,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.395492",
        "ticker_sentiment_score": "0.148572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.048132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.002878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.157896",
        "ticker_sentiment_score": "0.010733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42421676/eli-lilly-15b-buyback-faces-stiff-resistance-on-the-charts",
    "time_published": "20241210T185901",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co LLY is making headlines with its $15 billion share buyback plan and a 15% dividend boost. Yet, as the Indianapolis-based pharma giant enjoys the success of blockbuster drugs like Mounjaro and Zepbound, its stock is sending mixed technical signals ahead of its next move.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10130853/Screenshot-2024-12-10-at-11.34.59-PM.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.225082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.260146",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Eli Lilly Stock On Tuesday? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42418886/whats-going-on-with-eli-lilly-stock-on-tuesday-2",
    "time_published": "20241210T165206",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Eli Lilly And Co LLY announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma ( CLL/SLL ) previously treated with a covalent BTK inhibitor.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/10/Indianapolis---Circa-November-2021-Eli-L.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160935,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.30569",
        "ticker_sentiment_score": "-0.130143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2381397/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241210T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default230.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.233056,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.526867",
        "ticker_sentiment_score": "0.122362",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%",
    "url": "https://www.zacks.com/stock/news/2381320/lilly-announces-new-15b-stock-buyback-plan-ups-dividend-by-15",
    "time_published": "20241210T123600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.225736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.627549",
        "ticker_sentiment_score": "0.320451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.156758",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.192183",
        "ticker_sentiment_score": "0.094419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15% - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/news/buybacks/24/12/42408839/as-eli-lilly-shares-gain-over-35-ytd-drugmaker-announces-15b-share-buyback-program-and-boosts-divid",
    "time_published": "20241210T113427",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "Eli Lilly and Company LLY has announced a significant $15 billion share repurchase program. This decision follows the completion of a previous $5 billion buyback initiative in the fourth quarter of 2024.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10061101/Screenshot-2024-12-10-at-4.40.33%E2%80%AFPM-1024x387.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.229388,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.53784",
        "ticker_sentiment_score": "0.142837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.011388",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
    "url": "https://www.zacks.com/stock/news/2381245/the-zacks-analyst-blog-highlights-eli-lilly-abbvie-gilead-sciences-air-t-and-fossil-group",
    "time_published": "20241210T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.206635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.119414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.124977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.096533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOSL",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.073565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.223654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRT",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "url": "https://www.fool.com/investing/2024/12/10/warning-this-skyrocketing-stock-has-a-hidden-risk/",
    "time_published": "20241210T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800265%2Fgettyimages-1213513544.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.240307,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.408672",
        "ticker_sentiment_score": "0.305699",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.154177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.15404",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.298985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Slides as Market Rises: Facts to Know Before You Trade",
    "url": "https://www.zacks.com/stock/news/2382413/eli-lilly-lly-stock-slides-as-market-rises-facts-to-know-before-you-trade",
    "time_published": "20241211T224521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.206893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.315282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42442160/eli-lillys-investigational-cancer-drug-cuts-risk-of-death-by-38-in-breast-cancer-patients",
    "time_published": "20241211T162834",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Eli Lilly And Co LLY announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive ( ER+ ) , human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/xrdDAE9HpS4rJc10373-j6447302046727189944.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.002445,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "-0.115761",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42438837/eli-lilly-unusual-options-activity",
    "time_published": "20241211T144750",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1733928467_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.147499,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.548363",
        "ticker_sentiment_score": "0.02029",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/news/24/12/42475461/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-this-much-today",
    "time_published": "20241212T234519",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly LLY has outperformed the market over the past 10 years by 15.66% on an annualized basis producing an average annual return of 27.25%. Currently, Eli Lilly has a market capitalization of $742.84 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734047115_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.373286",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42467660/novo-nordisks-ozempic-label-expansion-snags-approval-from-european-drug-regulators-advisory-panel",
    "time_published": "20241212T173659",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S' NVO Ozempic ( once-weekly subcutaneous semaglutide ) label to reflect data from the FLOW kidney outcomes trial.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/12/IMG-5322-1-768x512-copy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.062889,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.274903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GDRX",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.274903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.512093",
        "ticker_sentiment_score": "0.144377",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42462469/telehealth-firm-ro-partners-with-eli-lilly-to-boost-access-to-obesity-drug-zepbound",
    "time_published": "20241212T143844",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Telehealth firm Ro has partnered with Eli Lilly And Co LLY to enhance patient access to Zepbound ( tirzepatide ) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/12/Eli-Lilly-and-Company-Zepbound-Vials.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.228115,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.101101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.140015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study",
    "url": "https://www.zacks.com/stock/news/2382613/eli-lilly-reports-positive-data-from-late-stage-breast-cancer-study",
    "time_published": "20241212T133900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.094086,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.025177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "-0.093383",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks to Keep an Eye on After Dividend Hike Announcement",
    "url": "https://www.zacks.com/stock/news/2382603/3-stocks-to-keep-an-eye-on-after-dividend-hike-announcement",
    "time_published": "20241212T132400",
    "authors": [
      "Ritujay Ghosh"
    ],
    "summary": "Stocks like SYK, LLY and AES recently announced dividend hikes.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/50121.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.140043,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.299857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.532696",
        "ticker_sentiment_score": "0.201414",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025",
    "url": "https://www.fool.com/investing/2024/12/12/eli-lilly-stock-could-have-a-huge-growth-catalyst/",
    "time_published": "20241212T124500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.Although it may seem like it has hit a peak given the ...",
    "banner_image": "https://media.ycharts.com/charts/64978daad199bbddd8941c1621e58d28.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.24078,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.532043",
        "ticker_sentiment_score": "0.28204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond",
    "url": "https://www.fool.com/investing/2024/12/12/2-no-brainer-growth-stocks-to-buy-and-hold-through/",
    "time_published": "20241212T090700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The stock market performed well in 2024 despite lingering economic issues and geopolitical instability. The bull run remains in full swing, and although investors can't predict what will happen in 2025, it is still worth investing in stocks.",
    "banner_image": "https://media.ycharts.com/charts/c1b1c866178cea5ae70d876bdd093ac1.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.281597,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VEEV",
        "relevance_score": "0.532941",
        "ticker_sentiment_score": "0.18484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.28387",
        "ticker_sentiment_score": "0.43665",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares - iShares U.S. Pharmaceutical ETF  ( ARCA:IHE ) , iShares U.S. Healthcare ETF  ( ARCA:IYH ) ",
    "url": "https://www.benzinga.com/news/24/12/42481606/eli-lilly-stock-soars-34-42-ytd-a-1000-investment-outpaces-returns-from-these-etfs-holding-mounjaro-maker-sh",
    "time_published": "20241213T122817",
    "authors": [
      "Pooja Rajkumari"
    ],
    "summary": "Eli Lilly And Co LLY has achieved a year-to-date ( YTD ) increase of 32.11% as of Friday, according to Benzinga Pro. This surge has had varied effects on several ETFs that hold significant stakes in the pharmaceutical giant.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/13/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972476"
      }
    ],
    "overall_sentiment_score": 0.225312,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.902881",
        "ticker_sentiment_score": "0.197896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HKHC",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "-0.118306",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca\u00ae  ( pirtobrutinib )  in Mainland China - Eli Lilly  ( NYSE:LLY ) , Innovent Biologics  ( OTC:IVBIY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/n42500486/innovent-and-lilly-expand-collaboration-through-agreement-on-commercialization-rights-for-jaypirca",
    "time_published": "20241215T235500",
    "authors": [
      "PRNewswire"
    ],
    "summary": "SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ( \"Innovent\" ) ( HKEX: 01801 ) , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219165,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.400202",
        "ticker_sentiment_score": "0.317847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.024622",
        "ticker_sentiment_score": "0.044694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.024622",
        "ticker_sentiment_score": "0.235617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.060776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.024622",
        "ticker_sentiment_score": "0.044694",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious",
    "url": "https://www.fool.com/investing/2024/12/15/2-brand-new-reasons-to-buy-eli-lilly-stock-right-n/",
    "time_published": "20241215T190500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly ( NYSE: LLY ) is always providing investors with additional reasons to consider buying its stock.On the other hand, the nature of its industry means that there will often be solid new reasons ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800833/three-investors-gather-around-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.165127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.486544",
        "ticker_sentiment_score": "0.236983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.029069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Did Eli Lilly Just Say \"Checkmate\" to Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/12/15/did-eli-lilly-just-say-checkmate-to-novo-nordisk/",
    "time_published": "20241215T131700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) and Novo Nordisk ( NYSE: NVO ) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.In recent years, these two healthcare leaders have also been butting ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800234/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.224978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.410716",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.306447",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Weight Loss Stocks That Are Screaming Buys in December",
    "url": "https://www.fool.com/investing/2024/12/15/2-weight-loss-stocks-that-are-screaming-buys-in-de/",
    "time_published": "20241215T114000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.There are a pair of businesses that are particularly appealing on the basis of ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800835/3-investors-gather-around-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.196095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.043179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/12/15/3-unstoppable-stocks-to-buy-right-now/",
    "time_published": "20241215T110700",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter category. Here's why they think AstraZeneca ( NASDAQ: AZN ) , Eli Lilly ( NYSE: LLY ) , and ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800812/smiling-person-with-cup-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.255103,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "-0.032449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.321273",
        "ticker_sentiment_score": "0.135827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.159379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.290746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2384030/abbvs-acquisition-spree-continues-buy-sell-or-hold-the-stock",
    "time_published": "20241216T151700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.252571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.06785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.06785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.669807",
        "ticker_sentiment_score": "0.39222",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "url": "https://www.zacks.com/stock/news/2383727/ema-panel-endorses-lillys-omvoh-for-expanded-use-in-crohns-disease",
    "time_published": "20241216T122300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.295927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.292425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.129758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Moves -0.05%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2384847/eli-lilly-lly-stock-moves--005-what-you-should-know",
    "time_published": "20241217T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $778.62, indicating a -0.05% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default220.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.16329,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.531019",
        "ticker_sentiment_score": "0.197889",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Peering Into Eli Lilly's Recent Short Interest - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/12/42539354/peering-into-eli-lillys-recent-short-interest",
    "time_published": "20241217T203014",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Eli Lilly's LLY short percent of float has fallen 10.39% since its last report. The company recently reported that it has 5.84 million shares sold short, which is 0.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.15 days to cover ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734467410_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264456,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.077712",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVS vs. LLY: Which Stock Should Value Investors Buy Now?",
    "url": "https://www.zacks.com/stock/news/2384736/nvs-vs-lly-which-stock-should-value-investors-buy-now",
    "time_published": "20241217T164008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default263.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.491197,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.694939",
        "ticker_sentiment_score": "0.580707",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark",
    "url": "https://www.zacks.com/stock/news/2384653/nvo-to-invest-12b-in-new-rare-disease-drugs-facility-in-denmark",
    "time_published": "20241217T150900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.193425,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "-0.019148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.248851",
        "ticker_sentiment_score": "0.192697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.689798",
        "ticker_sentiment_score": "0.290526",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.200273",
        "ticker_sentiment_score": "0.095737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Big Drug Stocks That May Continue to Outperform in 2025",
    "url": "https://www.zacks.com/stock/news/2384649/4-big-drug-stocks-that-may-continue-to-outperform-in-2025",
    "time_published": "20241217T150300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.196045,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.083643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.057058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.141608",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Eli Lilly's Latest Options Trends - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42532345/behind-the-scenes-of-eli-lillys-latest-options-trends",
    "time_published": "20241217T150053",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734447650_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.069456,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.689185",
        "ticker_sentiment_score": "0.037815",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Who's Next To Join Tesla, Broadcom In $1 Trillion Club? Over 50% Say The World's Biggest Retailer - Broadcom  ( NASDAQ:AVGO ) , JPMorgan Chase  ( NYSE:JPM ) ",
    "url": "https://www.benzinga.com/trading-ideas/24/12/42561975/whos-next-to-join-tesla-broadcom-in-1-trillion-club-over-50-say-the-worlds-biggest-retailer",
    "time_published": "20241218T193642",
    "authors": [
      "Chris Katje"
    ],
    "summary": "The list of companies that have market capitalizations greater than $1 trillion continues to grow with Broadcom Inc AVGO recently joining the club after its quarterly financial results sparked a rally in shares. A Benzinga poll asks readers which company could be next to join the elusive club.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output-1024x765.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.261548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.170695",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.380978",
        "ticker_sentiment_score": "0.23785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.179548",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.196344",
        "ticker_sentiment_score": "0.108172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.112433",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.180059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug",
    "url": "https://www.fool.com/investing/2024/12/18/ozempic-dethroned-a-head-to-head-study-confirms-th/",
    "time_published": "20241218T111500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes ( Wegovy is the equivalent version, which is approved for weight loss ) , many people have been using it for years to lose weight, and it has been highly ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801006/a-physician-using-a-scale-to-measure-a-persons-weight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.204437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "-0.011118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.202644",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.396086",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout",
    "url": "https://www.fool.com/investing/2024/12/18/eli-lilly-is-putting-dividend-growth-stocks-to-sha/",
    "time_published": "20241218T101100",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake. A long streak doesn't necessarily make a dividend stock a good long-term buy. After all, those increases may only be modest, for the sake of keeping the streak going.",
    "banner_image": "https://media.ycharts.com/charts/ce4c8f5241378e109533c345e91598be.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.184714,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.656158",
        "ticker_sentiment_score": "0.463853",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.102247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.102247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "-0.102096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",
    "url": "https://www.zacks.com/stock/news/2385668/merck-enters-obesity-space-buys-rights-to-hansohs-oral-glp-1-drug",
    "time_published": "20241219T132400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.176309,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "-0.044179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.202224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.141057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.07801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "-0.064976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.07801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why VKTX Stock Plummeted 18% on Wednesday",
    "url": "https://www.zacks.com/stock/news/2385620/heres-why-vktx-stock-plummeted-18-on-wednesday",
    "time_published": "20241219T124100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.199464,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.167373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.165505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.273705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.134173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.142539",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?",
    "url": "https://www.fool.com/investing/2024/12/19/these-2-stocks-just-declared-dividend-raises-that/",
    "time_published": "20241219T102600",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital.Yet there is a clutch of companies at the top of the industry not only ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801021/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.142019,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.243376",
        "ticker_sentiment_score": "0.146772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.147516",
        "ticker_sentiment_score": "0.173688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is Huge News for Eli Lilly Investors",
    "url": "https://www.fool.com/investing/2024/12/19/this-is-huge-news-for-eli-lilly-investors/",
    "time_published": "20241219T094400",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly just gave investors several reasons to cheer.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801177%2Fgettyimages-2024514092.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.145922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.676093",
        "ticker_sentiment_score": "0.211409",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.138198",
        "ticker_sentiment_score": "0.085567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138198",
        "ticker_sentiment_score": "0.152936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up",
    "url": "https://www.fool.com/investing/2024/12/20/novo-nordisk-destroyed-lilly-and-viking-stocks-up/",
    "time_published": "20241220T172025",
    "authors": [
      "Rich Smith"
    ],
    "summary": "Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801777%2Fpackage-of-weight-loss-drug-next-to-a-barbell.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.051323,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.302429",
        "ticker_sentiment_score": "-0.057461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "-0.037888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.56296",
        "ticker_sentiment_score": "0.076628",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List",
    "url": "https://www.zacks.com/stock/news/2386395/lly-stock-up-as-fda-removes-mounjaro-zepbound-from-shortage-list",
    "time_published": "20241220T150500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.014591,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.402045",
        "ticker_sentiment_score": "0.086551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.034179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.038834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.03281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.082355",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges",
    "time_published": "20241220T115816",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Novo Nordisk A/S NVO stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/20/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": -0.021391,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "-0.062662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.418689",
        "ticker_sentiment_score": "-0.141769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves",
    "url": "https://www.fool.com/investing/2024/12/21/2-dividend-growth-stocks-israel-englander-loves/",
    "time_published": "20241221T134300",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts. Furthermore, the pursuit of dividends need not come at the expense of other investment styles.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800238/person-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.364472,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.231208",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.370882",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
    "url": "https://www.fool.com/investing/2024/12/21/is-now-a-good-time-to-buy-the-dip-eli-lilly-stock/",
    "time_published": "20241221T095500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801652%2Fgettyimages-1166581794-2.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.120666,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.714306",
        "ticker_sentiment_score": "0.203421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.042571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.042571",
        "ticker_sentiment_score": "0.063573",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more",
    "time_published": "20241222T195134",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/22/Healthcare--Opioid-Epidemic-And-Drug-Abu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.363138,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ELAN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.345107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.262117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.396574",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.344367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.217986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.249624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.345107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Merck the Next Big Weight-Loss Stock?",
    "url": "https://www.fool.com/investing/2024/12/22/is-merck-the-next-big-weight-loss-stock/",
    "time_published": "20241222T114500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Watch out, Eli Lilly and Novo Nordisk. Merck ( NYSE: MRK ) is hungrily looking to take a bite out of the weight-loss drugs market.Amidst an evolving field of competitors, the big pharma is committing a hearty chunk of cash in hopes of becoming a contender.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801609/investor-holds-glasses-while-considering-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.274202,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.117125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year",
    "url": "https://www.fool.com/investing/2024/12/22/3-stocks-that-could-join-the-trillion-dollar-marke/",
    "time_published": "20241222T103400",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "Believe it or not, there are now nine publicly traded U.S. companies worth $1 trillion or more.They are Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, Tesla, Broadcom, and Taiwan Semiconductor. Berkshire Hathaway was briefly a member of the group, but its market cap has dipped ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801486%2Fbull-market-rising-stock-charts-financial-newspaper-quotes-invest-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.292996,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.079569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.044635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRBA",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.148591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.223947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/health-care/24/12/42637278/eli-lillys-zepbound-receives-fda-approval-for-obesity-linked-sleep-apnea-drug",
    "time_published": "20241222T044826",
    "authors": [
      "Ananya Gairola"
    ],
    "summary": "On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.'s LLY weight loss drug Zepbound for treating sleep apnea What Happened: The FDA's decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/21033911/Screenshot-2024-12-21-at-2.09.01%E2%80%AFPM-1024x374.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.211058,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.230364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "-0.171031",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Is Rising Monday: What's Going On? - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/movers/24/12/42658865/eli-lilly-stock-is-rising-monday-whats-going-on",
    "time_published": "20241223T195748",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Eli Lilly and Company LLY shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23132849/tydh-1024x527.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.170942,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.771935",
        "ticker_sentiment_score": "0.23082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.106541",
        "ticker_sentiment_score": "0.118926",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III",
    "url": "https://www.zacks.com/stock/news/2386953/nvo-stock-plunges-as-obesity-drug-cagrisema-misses-target-in-phase-iii",
    "time_published": "20241223T150000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.077059,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.281692",
        "ticker_sentiment_score": "0.161712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.107487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.411549",
        "ticker_sentiment_score": "0.075997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Eli Lilly or Novo Nordisk?",
    "url": "https://www.fool.com/investing/2024/12/23/better-buy-eli-lilly-or-novo-nordisk/",
    "time_published": "20241223T143041",
    "authors": [
      "Neil Rozenbaum"
    ],
    "summary": "Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801942/gettyimages-1665778558.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.232887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.885652",
        "ticker_sentiment_score": "0.545189",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.885652",
        "ticker_sentiment_score": "0.545189",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2386790/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241223T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default36.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.233292,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.532696",
        "ticker_sentiment_score": "0.119931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
    "url": "https://www.zacks.com/stock/news/2386725/lillys-zepbound-receives-fda-approval-for-sleep-apnea",
    "time_published": "20241223T131600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.129827,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.498479",
        "ticker_sentiment_score": "0.230669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.202358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.286082",
        "ticker_sentiment_score": "0.097459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.193078",
        "ticker_sentiment_score": "0.071825",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
    "url": "https://www.zacks.com/stock/news/2386648/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
    "time_published": "20241223T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default117.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.20659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.043671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.070203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Does This News From the FDA Make Eli Lilly a Buy for 2025?",
    "url": "https://www.fool.com/investing/2024/12/23/does-this-news-from-fda-make-eli-lilly-2025-buy/",
    "time_published": "20241223T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly ( NYSE: LLY ) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801727%2Fgettyimages-1178121483.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.05347,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.764396",
        "ticker_sentiment_score": "0.18574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "-0.057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2387721/eli-lilly-lly-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20241224T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $795.67, indicating a -0.08% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.208313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.663374",
        "ticker_sentiment_score": "0.349009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?",
    "url": "https://www.zacks.com/stock/news/2387354/novo-nordisk-stock-plunges-18-in-a-week-what-should-investors-do",
    "time_published": "20241224T134600",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.223501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.16594",
        "ticker_sentiment_score": "0.029716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.176553",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.176553",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.355125",
        "ticker_sentiment_score": "0.269359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Company News for Dec 24, 2024",
    "url": "https://www.zacks.com/stock/news/2387299/company-news-for-dec-24-2024",
    "time_published": "20241224T123400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The Article Are: ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4b/786.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.139975,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.470812",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.361288",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.526426",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.239395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "-0.359622",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
    "url": "https://www.zacks.com/stock/news/2387264/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
    "time_published": "20241224T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.270903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.049759",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Musk Tests Mounjaro, Ozempic, Wegovy, Says One Weight-Loss Drug 'Seems To Have Fewer Side Effects And Be More Effective' - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/trading-ideas/24/12/42692809/musk-tests-mounjaro-ozempic-wegovy-which-weight-loss-drug-won-him-over",
    "time_published": "20241226T192552",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Elon Musk shared a social media post that may point to a recent weight loss. The post shared Musk's personal history with weight-loss drugs, including the one he currently prefers.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/26/Why-It-Matters.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.307732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.044146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "0.114936",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.",
    "url": "https://www.fool.com/investing/2024/12/26/better-buy-eli-lilly-vs-novo-nordisk-the-answer-is/",
    "time_published": "20241226T151500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801921%2Fgettyimages-2025836701-2.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.179568,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.598368",
        "ticker_sentiment_score": "0.456767",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.394236",
        "ticker_sentiment_score": "0.39924",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "0.098935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY",
    "url": "https://www.zacks.com/stock/news/2388207/pharma-stock-roundup-nvos-obesity-study-failure-fda-nod-to-pfe-lly",
    "time_published": "20241226T141100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.038399,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.230017",
        "ticker_sentiment_score": "0.05037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "-0.1171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.004254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.027877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.13066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.027877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.004254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.032887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/12/26/down-19-in-1-day-is-novo-nordisk-stock-still-a-buy/",
    "time_published": "20241226T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's ( NYSE: NVO ) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.So what's the real story here?",
    "banner_image": "https://g.foolcdn.com/editorial/images/802000/concerned-investor-with-two-people-in-background.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.004823,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.108194",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.384397",
        "ticker_sentiment_score": "0.040511",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be Amazon's Next Big Acquisition",
    "url": "https://www.fool.com/investing/2024/12/27/prediction-this-will-be-amazons-next-big-buyout/",
    "time_published": "20241227T100700",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802093%2Fpharmacy-customer-1419247648.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.173893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.076691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.727912",
        "ticker_sentiment_score": "0.339633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.045687",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.436759",
        "ticker_sentiment_score": "0.356928",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.069846",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades",
    "url": "https://www.fool.com/investing/2024/12/28/2-pharmaceutical-growth-stocks-to-buy-now-and-hold/",
    "time_published": "20241228T110500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801970/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.307975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.402135",
        "ticker_sentiment_score": "0.478989",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.28029",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/government/regulations/24/12/42712897/elon-musk-admits-to-using-weight-loss-medication-criticized-by-rfk-jr-says-he-prefers-moun",
    "time_published": "20241228T052534",
    "authors": [
      "Anan Ashraf"
    ],
    "summary": "The world's richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. What Happened: Musk on Christmas posted a picture of himself donning the Santa Claus costume with the caption \"Ozempic Santa.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/28/Los-Angeles--Usa--April-13--2024-Elon-Mu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.067972,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "-0.173981",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.028855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders",
    "url": "https://www.fool.com/investing/2024/12/29/billionaire-philippe-laffont-is-selling-artificial/",
    "time_published": "20241229T103900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors. Every three months, the regulator has everyone with more than $100 million under management share their trading details with ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/802136/investor-looking-for-stocks-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.252065,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.40638",
        "ticker_sentiment_score": "0.329117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.170332",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.36472",
        "ticker_sentiment_score": "0.238109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/12/29/is-eli-lilly-stock-a-buy/",
    "time_published": "20241229T093500",
    "authors": [
      "Geoffrey Seiler"
    ],
    "summary": "While Novo Nordisk's ( NYSE: NVO ) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself \"Ozempic Santa,\" he ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802194%2Fgettyimages-2025836701.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.155107,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.133395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.048913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Eli Lilly  ( LLY )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2389673/why-eli-lilly-lly-dipped-more-than-broader-market-today",
    "time_published": "20241230T224524",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.120073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.196969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J Trading Near 52-Week Low: Should You Sell the Stock?",
    "url": "https://www.zacks.com/stock/news/2389562/jj-trading-near-52-week-low-should-you-sell-the-stock",
    "time_published": "20241230T155000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.103889,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.158421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.066777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.066777",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?",
    "url": "https://www.fool.com/investing/2024/12/30/will-this-major-pharma-stock-split-stock-2025/",
    "time_published": "20241230T093000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801858%2Fgettyimages-1335027284.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.09837,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.16563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.106063",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.077015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.053473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.094",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday - Applied Mat  ( NASDAQ:AMAT ) , Adobe  ( NASDAQ:ADBE ) ",
    "url": "https://www.benzinga.com/24/12/42747345/marjorie-taylor-green-went-christmas-shopping-for-stocks-heres-what-she-bought-before-holiday",
    "time_published": "20241231T184627",
    "authors": [
      "Chris Katje"
    ],
    "summary": "Rep. Marjorie Taylor Greene ( R-Ga. ) disclosed recent purchases of several stocks on Christmas Eve, according to Benzinga Government Trades. Here's a look at what the far-right politician bought. What Happened: Greene has been an active trader of stocks while in Congress, based on her ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/31/Congresswoman-Marjorie-Taylor-Greene-Spe.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.188505,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.061679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAT",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.306371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.224383",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.224383",
        "ticker_sentiment_score": "0.133528",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42742430/eli-lilly-unusual-options-activity",
    "time_published": "20241231T151539",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 22 unusual trades. Delving into the details, we found 45% of traders were bullish, while 31% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1735658136_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.138254,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.708432",
        "ticker_sentiment_score": "0.061702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  }
]